[go: up one dir, main page]

US20180319798A1 - 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor - Google Patents

1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor Download PDF

Info

Publication number
US20180319798A1
US20180319798A1 US16/045,594 US201816045594A US2018319798A1 US 20180319798 A1 US20180319798 A1 US 20180319798A1 US 201816045594 A US201816045594 A US 201816045594A US 2018319798 A1 US2018319798 A1 US 2018319798A1
Authority
US
United States
Prior art keywords
group
pharmaceutically acceptable
atom
compound
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/045,594
Inventor
Susumu Miyazaki
Yuki Bessho
Kaoru Adachi
Seiji KAWASHITA
Hirotaka Isoshima
Kengo OSHITA
Shunichi Fukuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44506987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20180319798(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to US16/045,594 priority Critical patent/US20180319798A1/en
Publication of US20180319798A1 publication Critical patent/US20180319798A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative useful as an anti-HIV agent, a pharmaceutically acceptable salt thereof, and a solvate thereof.
  • the present invention relates to a pharmaceutical composition comprising the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier; an anti-HIV agent, an HIV integrase inhibitor and the like, comprising the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient; an anti-HIV agent comprising a combination of the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, and one or more kinds of other anti-HIV active substances; and the like.
  • HIV Human Immunodeficiency Virus (type 1) belonging to retrovirus is a causative virus of AIDS (Acquired Immunodeficiency Syndrome).
  • HIV targets CD4 positive cell groups such as helper T cell, macrophage and dendritic cell and destroys these immunocompetent cells to cause immunodeficiency.
  • CD4 positive cell groups such as helper T cell, macrophage and dendritic cell and destroys these immunocompetent cells to cause immunodeficiency.
  • a medicament that eradicates HIV in a living organism or suppresses its growth is effective for the prophylaxis or treatment of AIDS.
  • HIV possesses a bimolecular RNA gene in a shell, which is covered with an envelope protein.
  • the RNA codes for several enzymes (protease, reverse transcriptase, integrase) characteristic of the virus and the like.
  • protease is present inside and outside the shell.
  • DNA is transcribed by reverse transcriptase, and a full length double stranded DNA is produced.
  • the DNA moves into the nucleus of the host cell and is incorporated by integrase into the DNA of the host cell.
  • the incorporated DNA is converted to an mRNA by polymerase of the host cell, from which mRNA various proteins necessary for forming a virus are synthesized by HIV protease and the like, and a virus particle is finally formed, which then undergoes budding and its release.
  • zidovudine, didanosine, lamivudine and the like have been already on the market as reverse transcriptase inhibitors, and indinavir, nelfinavir and the like as protease inhibitors.
  • a multiple drug combination therapy using these medicaments in combination (to be also referred to as HAART (highly active antiretroviral therapy)) is also used.
  • 3 agent combination therapy using two agents from reverse transcriptase inhibitors zidovudine and lamivudine, or tenofovir and emtricitabine
  • efavirenz non-nucleic acid reverse transcriptase inhibitor
  • protease inhibitor lopinavir, fosamprenavir or atazanavir
  • an anti-HIV agent is effective for the prophylaxis or treatment of AIDS, and particularly a compound having an integrase inhibitory activity can be an effective anti-HIV agent.
  • the present invention aims at provision of a compound having an anti-HIV activity, particularly a compound having an integrase inhibitory activity.
  • the present inventors have conducted intensive studies in an attempt to find a compound having an anti-HIV action, particularly a compound having an integrase inhibitory action, and completed the present invention.
  • the present invention provides the following.
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
  • R A1 and R A2 are the same or different and each is
  • R A1 and R A2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
  • R A3 and R A4 are the same or different and each is
  • R A3 and R A4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B,
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B, or
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B, or
  • R a and R b form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B,
  • the compound of the present invention can be medicaments effective for the prophylaxis or treatment of HIV infections or AIDS, as anti-HIV agents, having an HIV integrase inhibitory activity.
  • anti-HIV agents having an HIV integrase inhibitory activity.
  • other anti-HIV agent(s) such as protease inhibitor, reverse transcriptase inhibitor and the like, they can be more effective anti-HIV agents.
  • having high inhibitory activity specific for integrase they can be medicaments safe for human body with a fewer side effects.
  • halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • the “C 1-6 alkyl group” is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. Specific examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a hexyl group and the like.
  • the “C 1-6 alkoxy group” is a straight chain or branched chain alkoxy group having 1 to 6 carbon atoms, preferably a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms. Specific examples include a methoxy group, an ethoxy group, a propoxy group, an isopropyloxy group, a butoxy group, an isobutyloxy group, a tert-butyloxy group, a pentyloxy group, a hexyloxy group and the like.
  • C 1-6 alkoxy-C 1-6 alkyl group is that wherein the alkoxy moiety is the “C 1-6 alkoxy group” defined above, and the alkyl moiety is the “C 1-6 alkyl group” defined above.
  • Preferred is a C 1-6 alkoxy-C 1-6 alkyl group wherein the alkoxy moiety is a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms, and the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.
  • Examples of the C 1-6 alkoxy-C 1-6 alkyl group include a methoxymethyl group, a methoxyethyl group, a methoxypropyl group, a methoxybutyl group, a methoxypentyl group, a methoxyhexyl group, an ethoxymethyl group, an ethoxyethyl group, an ethoxypropyl group, an ethoxybutyl group, an ethoxypentyl group, an ethoxyhexyl group, a propoxymethyl group, a propoxyethyl group, a propoxypropyl group, a propoxybutyl group, a propoxypentyl group, a propoxyhexyl group, a butoxymethyl group, a butoxyethyl group, a butoxypropyl group, a butoxybutyl group, a butoxypentyl group, a butoxyhexyl group, a butoxy
  • C 1-6 alkoxy-C 1-6 alkoxy group is that wherein the C 1-6 alkoxy moiety is the “C 1-6 alkoxy group” defined above, preferably a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms.
  • Examples thereof include a methoxymethoxy group, a methoxyethoxy group, a methoxypropoxy group, a methoxybutoxy group, a methoxypentyloxy group, a methoxyhexyloxy group, an ethoxymethoxy group, an ethoxyethoxy group, an ethoxypropoxy group, an ethoxybutoxy group, an ethoxypentyloxy group, an ethoxyhexyloxy group, a propoxymethoxy group, a propoxyethoxy group, a propoxypropoxy group, a propoxybutoxy group, a propoxypentyloxy group, a propoxyhexyloxy group, a butoxymethoxy group, a butoxyethoxy group, a butoxypropoxy group, a butoxybutoxy group, a butoxypentyloxy group, a butoxyhexyloxy group, a pentyloxymethoxy group, a pen
  • C 1-6 alkyl-carbonyl group is an alkyl-carbonyl group wherein the C 1-6 alkyl moiety is the “C 1-6 alkyl group” defined above, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.
  • Examples thereof include a methylcarbonyl group, an ethylcarbonyl group, a propylcarbonyl group, an isopropylcarbonyl group, a butylcarbonyl group, an isobutylcarbonyl group, a sec-butylcarbonyl group, a tert-butylcarbonyl group, a pentylcarbonyl group, an isopentylcarbonyl group, a 1,1-dimethylpropylcarbonyl group, hexylcarbonyl group and the like.
  • C 1-6 alkyl-sulfonyl group is an alkyl-sulfonyl group wherein the C 1-6 alkyl moiety is the “C 1-6 alkyl group” defined above, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.
  • Examples thereof include a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, an isopentylsulfonyl group, a 1,1-dimethylpropylsulfonyl group, a hexylsulfonyl group and the like.
  • the “C 3-8 cycloalkyl group” is a saturated cycloalkyl group having 3 to 8 carbon atoms, preferably 3 to 5 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group and the like.
  • the “C 3-8 cycloalkane” is saturated cycloalkane having 3 to 8 carbon atoms, preferably 3 to 5 carbon atoms, and examples thereof include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
  • hetero ring means a saturated or unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, or a fused ring of the hetero rings, or a fused ring of a carbon ring selected from benzene, cyclopentane and cyclohexane, and the hetero ring.
  • saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom examples include a 4- to 7-membered saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
  • azetidine pyrrolidine, tetrahydrofuran, tetrahydrothiophene, imidazolidine, pyrazolidine, 1,3-dioxolane, 1,3-oxathioran, oxazolidine, thiazolidine, piperidine, piperazine, tetrahydropyran, tetrahydrothiopyran, dioxane, morpholine, thiomorpholine and the like.
  • Examples of the above-mentioned “unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom” include a 4- to 7-membered unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
  • pyrroline furan, thiophene, imidazole, imidazoline, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,4-triazole, 1,2,3-triazole, tetrazole, 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-thiadiazole, furazan, pyridine, pyrimidine, 3,4-dihydropyrimidine, pyridazine, pyrazine, 1,3,5-triazine, pyrazoline, oxazoline, isooxazoline, thiazoline, isothiazoline, pyran and the like.
  • fused ring of the hetero rings or fused ring of a carbon ring selected from benzene, cyclopentane and cyclohexane, and the hetero ring
  • indole isoindole, benzimidazole, indazole, benzothiazole, benzofuran, isobenzofuran, indolizine, quinoline, isoquinoline, 1,2-dihydroquinoline, quinazoline, quinoxaline, cinnoline, phthalazine, quinolizidine, purine, pteridine, indoline, isoindoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoline, 1,3-benzodioxolane, 3,4-methylenedioxypyridine, 4,5-ethylenedioxypyrimidine, chromene, chromane, isochromane, 1,2,4-benzotri
  • the “saturated monocyclic hetero ring” formed by R a and R b together with the nitrogen atom bonded thereto means a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 7-membered (e.g., 4- to 6-membered) saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 (e.g., 1 to 3, preferably 1) hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and the like.
  • saturated monocyclic hetero ring examples include those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, beside carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which contain, beside carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • the saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the following group B.
  • the “saturated monocyclic hetero ring” formed by R 2 and R 3 or R 4 and R 5 , together with the carbon atom bonded thereto means a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 5- to 7-membered (e.g., 6-membered) saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 (e.g., 1 to 3, preferably 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
  • saturated monocyclic hetero ring examples include those similar to the saturated monocyclic hetero rings exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”.
  • the “saturated monocyclic hetero ring” formed by R A1 and R A2 together with the nitrogen atom bonded thereto means a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 6-membered saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like.
  • saturated monocyclic hetero ring examples include those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which optionally contain, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • the saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 substituents selected from the following group B.
  • the “hetero ring” formed by R A3 and R A4 together with the nitrogen atom bonded thereto means a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 6-membered (e.g., 5-membered) monocyclic hetero ring, a 8- to 10-membered (e.g., 9-membered) fused cyclic hetero ring and the like, optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • hetero ring examples include those exemplified as the above-mentioned “hetero ring”, which optionally contain, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • the hetero ring is optionally substituted by 1 or 2 oxo groups.
  • the “saturated monocyclic heterocyclic group” for R 1 means a saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 5- or 6-membered saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
  • saturated monocyclic heterocyclic group examples include groups derived from those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which optionally contain, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like.
  • Examples thereof include a pyrrolidinyl group, a tetrahydrofuryl (e.g., 3-tetrahydrofuryl) group, a tetrahydrothienyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1,3-dioxolanyl group, a 1,3-oxathioranyl group, an oxazolidinyl group, a thiazolidinyl group, a piperidinyl group, a piperazinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a dioxanyl group, a morpholinyl group, a thiomorpholinyl group and the like.
  • a pyrrolidinyl group e.g., 3-tetrahydrofuryl
  • a tetrahydrothienyl group an imidazolidinyl
  • the “group A” includes the following substituents (a) to (i).
  • R A1 and R A2 are the same or different and each is
  • R A1 and R A2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
  • R A3 and R A4 are the same or different and each is
  • R A3 and R A4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
  • C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A is that wherein the “C 1-6 alkyl group” defined above is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from “group A” defined above, and includes an unsubstituted C 1-6 alkyl group.
  • the “group B” includes the following substituents (a) to (e).
  • the “C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B” is that wherein the “C 1-6 alkyl group” defined above is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the “group B” defined above, and includes an unsubstituted C 1-6 alkyl group.
  • the “saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 substituents selected from group B” for R a and R b , or R A1 and R A2 means that the “saturated monocyclic hetero ring” defined above which is formed by R a and R b , or R A1 and R A2 together with the nitrogen atom bonded thereto is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the “group B” defined above, and includes an unsubstituted saturated monocyclic hetero ring.
  • 1 to 5 e.g., 1 to 3, preferably 1 to 3
  • R 1 is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
  • R 1 is a C 1-6 alkyl group.
  • R 1 is a C 1-6 alkyl group substituted by a C 3-8 cycloalkyl group.
  • R 1 is a C 3-8 cycloalkyl group.
  • R 1 is (1) a C 1-6 alkyl group optionally substituted by the same or different 1 to 3 C 3-8 cycloalkyl groups,
  • a tetrahydrofuryl e.g., 3-tetrahydrofuryl
  • R 2 , R 3 , R 4 and R 5 are the same or different and each is
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B,
  • R 2 , R 3 , R 4 and R 5 one of R 2 , R 3 , R 4 and R 5 is —CO—NR a R b
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B.
  • one of R 2 , R 3 , R 4 and R 5 is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A.
  • R 2 , R 3 , R 4 and R 5 are respectively shown below.
  • R a and R b are the same or different and each is
  • R 3 more preferred are a hydrogen atom, a methyl group and a methoxymethyl group.
  • R 5 preferred are a hydrogen atom and a C 1-6 alkyl group optionally substituted by one substituent selected from a C 1-6 alkoxy group and a C 1-6 alkoxy-C 1-6 alkoxy group.
  • R 5 more preferred are a hydrogen atom and a methyl group or an ethyl group, which is optionally substituted by one substituent selected from a methoxy group and a methoxyethoxy group.
  • R 2 and R 3 , or R 4 and R 5 optionally form, together with the carbon atom bonded thereto, i) C 3-8 cycloalkane or ii) a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • R 2 and R 3 As the ring formed by R 2 and R 3 , or R 4 and R 5 together with the carbon atom bonded thereto, more preferred are cyclopropane and tetrahydropyran.
  • R 2 , R 3 , R 4 and R 5 are not hydrogen atoms at the same time.
  • R 6 preferred is a halogen atom.
  • R 6 are a methyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, a fluorine atom, a chlorine atom, a bromine atom and a cyclopropyl group.
  • Y preferred is CH.
  • Y is a nitrogen atom.
  • n is an integer of 1 to 5, and when m is an integer of 2 to 5, the above-mentioned R 6 may be the same or different.
  • n preferred is 1 to 3.
  • n more preferred is 1 or 2.
  • n is an integer of 1 to 3.
  • n preferred is 1.
  • R 11 those exemplified as the preferable embodiments of R 1 in the above-mentioned formula (I), which are within the scope of R 11 , are preferable.
  • R 21 , R 31 , R 41 and R 51 are the same or different and each is
  • R 21 preferred is a hydrogen atom.
  • R 21 is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A. More preferred is a C 1-6 alkyl group.
  • R 21 examples include those exemplified as the preferable embodiments of R 2 in the above-mentioned formula (I), which are within the scope of R 21 .
  • R 31 preferred is a hydrogen atom.
  • R 31 examples include those exemplified as the preferable embodiments of R 3 in the above-mentioned formula (I), which are within the scope of R 31 .
  • R 41 preferred is a hydrogen atom.
  • R 41 is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A. More preferred is a C 1-6 alkyl group.
  • R 41 examples include those exemplified as the preferable embodiments of R 4 in the above-mentioned formula (I), those contained within the scope of R 41 .
  • R 51 preferred is a hydrogen atom.
  • R 51 is those exemplified as the preferable embodiments of R 5 in the above-mentioned formula (I), which are within the scope of R 51 .
  • R 21 , R 31 , R 41 and R 51 are not hydrogen atoms at the same time.
  • R 61 is a halogen atom.
  • R 61 preferred are a fluorine atom and a chlorine atom.
  • R 62 is a hydrogen atom or a halogen atom.
  • R 62 preferred are a hydrogen atom, a fluorine atom and a bromine atom.
  • R 12 is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
  • R 12 those exemplified as the preferable embodiments of R 1 in the above-mentioned formula (I), which are within the scope of R 12 , are preferable.
  • R 22 , R 32 , R 42 and R 52 are the same or different and each is
  • R a and R b are the same or different and each is
  • R a and R b optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
  • R 22 preferred is a hydrogen atom.
  • R 22 are those exemplified as the preferable embodiments of R 2 in the above-mentioned formula (I), which are within the scope of R 22 .
  • R 32 preferred is a hydrogen atom.
  • R 32 are those exemplified as the preferable embodiments of R 3 in the above-mentioned formula (I), which are within the scope of R 32 .
  • R 42 preferred is —CO—NR a R b
  • R 42 are those exemplified as the preferable embodiments of R 4 in the above-mentioned formula (I), which are within the scope of R 42 .
  • R 52 preferred is a C 1-6 alkyl group.
  • R 52 is those exemplified as the preferable embodiments of R 5 in the above-mentioned formula (I), which are within the scope of R 52 .
  • R 22 , R 32 , R 42 and R 52 are not hydrogen atoms at the same time.
  • R 63 is a halogen atom.
  • R 63 preferred is a fluorine atom.
  • R 64 is a hydrogen atom or a halogen atom.
  • R 64 preferred are a hydrogen atom and a fluorine atom.
  • a pharmaceutically acceptable salt of the “compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2]” may be any salt as long as it forms an atoxic salt with the compound of the present invention.
  • examples thereof include a salt with an inorganic acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, a salt with an amino acid and the like.
  • Examples of the salt with an inorganic acid include salts with hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like.
  • Examples of the salt with an organic acid include salts with oxalic acid, malonic acid, maleic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
  • Examples of the salt with an inorganic base include sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt and the like.
  • Examples of the salt with an organic base include salts with methylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine, guanidine, pyridine, picoline, choline, cinchonine, meglumine and the like.
  • Examples of the salt with an amino acid include salts with lysine, arginine, aspartic acid, glutamic acid and the like.
  • Each salt can be obtained by reacting a compound represented by the formula [I], the formula [I-1] and the formula [I-2] with an inorganic base, an organic base, an inorganic acid, an organic acid or an amino acid according to a method known per se.
  • salts with hydrochloric acid e.g., 1 hydrochloride, 2 hydrochloride
  • salts with hydrobromic acid e.g., 1 hydrobromide, 2 hydrobromide
  • sodium salts with hydrochloric acid e.g., 1 hydrochloride, 2 hydrochloride
  • hydrobromic acid e.g., 1 hydrobromide, 2 hydrobromide
  • sodium salts with hydrochloric acid e.g., 1 hydrochloride, 2 hydrochloride
  • hydrobromic acid e.g., 1 hydrobromide, 2 hydrobromide
  • the “solvate” is a compound represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, with which a molecule of a solvent is coordinated, and also encompasses hydrates (also referred to as water-containing compound).
  • the solvate is preferably a pharmaceutically acceptable solvate, such as a 1 hydrate, a 1 ⁇ 2 hydrate, a 2 hydrate, a 1 hydrate of sodium salt, a 1 methanolate, a 1 ethanolate, a 1 acetonitrilate, a 2 ⁇ 3 ethanolate of 2 hydrochloride of the compound represented by the formula [I], the formula [I-1] and the formula [I-2] and the like.
  • a solvate of a compound represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof can be obtained according to a method known per se.
  • the compound of the present invention one isolated and purified from various isomers, by-products, metabolites or prodrugs is preferable, and one having a purity of not less than 90% is preferable and one having a purity of not less than 95% is more preferable.
  • the compounds represented by the formula [I], the formula [I-1] and the formula [I-2] may be crystal or amorphous.
  • a compound represented by the formula [I], the formula [I-1] and the formula [I-2] may be labeled with an isotope (e.g., 3 H, 14 C, 35 S etc.).
  • compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof, which is substantially purified, is preferable. More preferred is compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof, which has been purified to a purity of not less than 80%.
  • a prodrug of a compound represented by the formula [I], the formula [I-1] and the formula [I-2] can also be a useful medicament.
  • a “prodrug” is a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which restores to the original compound to show its inherent efficacy after administration to the body by, for example, hydrolysis, solvolysis or decomposition under physiological conditions. It includes a complex and a salt, not involving a covalent bond.
  • the prodrug is utilized, for example, for improving absorption by oral administration or targeting of a target site.
  • Examples of the site to be modified include highly reactive functional groups in the compound of the present invention, such as hydroxyl group, carboxyl group, amino group and the like.
  • hydroxyl-modifying group examples include acetyl group, propionyl group, isobutyryl group, pivaloyl group, palmitoyl group, benzoyl group, 4-methylbenzoyl group, dimethylcarbamoyl group, dimethylaminomethylcarbonyl group, sulfo group, alanyl group, fumaryl group and the like.
  • a sodium salt of 3-carboxybenzoyl group, 2-carboxyethylcarbonyl group and the like can also be used.
  • carboxyl-modifying group examples include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pivaloyloxymethyl group, carboxymethyl group, dimethylaminomethyl group, 1-(acetyloxy) ethyl group, 1-(ethoxycarbonyloxy)ethyl group, 1-(isopropyloxycarbonyloxy)ethyl group, 1-(cyclohexyloxycarbonyloxy) ethyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, benzyl group, phenyl group, o-tolyl group, morpholinoethyl group, N,N-diethylcarbamoylmethyl group, phthalidyl group and the like.
  • amino-modifying group examples include hexylcarbamoyl group, 3-methylthio-1-(acetylamino)propylcarbonyl group, 1-sulfo-1-(3-ethoxy-4-hydroxyphenyl)methyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group and the like.
  • compositions examples include oral preparations such as tablet, capsule, granule, powder, troche, syrup, emulsion, suspension and the like, and parenteral agents such as external preparation, suppository, injection, eye drop, transnasal agent, pulmonary preparation and the like.
  • the pharmaceutical composition of the present invention (e.g., an anti-HIV composition, a pharmaceutical composition for HIV integrase inhibitory etc.) is produced by appropriately admixing a suitable amount of a compound represented by the formula [I], the formula [I-1] or the formula [I-2] of the present invention or a salt thereof, or a solvate thereof with at least one kind of a pharmaceutically acceptable carrier according to a method known per se in the technical field of pharmaceutical preparations.
  • the content of the compound represented by the formula [I], the formula [I-1] or the formula [I-2] of the present invention or a salt thereof, or a solvate thereof in the pharmaceutical composition varies depending on the dosage form, the dose and the like, and the like. It is, for example, 0.1 to 100 wt % of the whole composition.
  • “pharmaceutically acceptable carrier” examples include various organic or inorganic carrier substances conventionally used as preparation materials such as excipient, disintegrant, binder, fluidizer, lubricant and the like for solid dosage forms, and solvent, solubilizing agent, suspending agent, isotonicity agent, buffering agent, soothing agent and the like for liquid preparations. Where necessary, additives such as preservative, antioxidant, colorant, sweetening agent and the like are used.
  • excipient examples include lactose, sucrose, D-mannitol, D-solbitol, cornstarch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethyl starch, low-substituted hydroxypropylcellulose, gum arabic and the like.
  • disintegrant examples include carmellose, carmellose calcium, carmellose sodium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose and the like.
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, crystalline cellulose, sucrose, dextrin, starch, gelatin, carmellose sodium, gum arabic and the like.
  • fluidizer examples include light anhydrous silicic acid, magnesium stearate and the like.
  • lubricant examples include magnesium stearate, calcium stearate, talc and the like.
  • solvent examples include purified water, ethanol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
  • Examples of the “solubilizing agent” include propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate and the like.
  • suspending agent examples include benzalkonium chloride, carmellose, hydroxypropylcellulose, propylene glycol, povidone, methylcellulose, glycerol monostearate and the like.
  • isotonicity agent examples include glucose, D-sorbitol, sodium chloride, D-mannitol and the like.
  • buffering agent examples include sodium hydrogen phosphate, sodium acetate, sodium carbonate, sodium citrate and the like.
  • Examples of the “soothing agent” include benzyl alcohol and the like.
  • preservative examples include ethyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sorbic acid and the like.
  • antioxidant examples include sodium sulfite, ascorbic acid and the like.
  • colorant examples include food colors (e.g., Food Color Red No. 2 or 3, Food Color yellow 4 or 5 etc.), ⁇ -carotene and the like.
  • sweetening agent examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame and the like.
  • the pharmaceutical composition of the present invention can be administered not only to human but also to mammals other than human (e.g., mouse, rat, hamster, guinea pig, rabbit, cat, dog, swine, bovine, horse, sheep, monkey etc.) orally or parenterally (e.g., topical, rectal, intravenous administration etc.). While the dose varies depending on the subject of administration, disease, symptom, dosage form, administration route and the like, for example, the dose for oral administration to an adult patient (body weight: about 60 kg) is generally within the scope of about 1 mg to 1 g per day, based on the compound of the present invention as an active ingredient. The amount can be administered in one to several portions.
  • mammals other than human e.g., mouse, rat, hamster, guinea pig, rabbit, cat, dog, swine, bovine, horse, sheep, monkey etc.
  • parenterally e.g., topical, rectal, intravenous administration etc.
  • the compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof inhibits HIV integrase, and can be used as an active ingredient of a therapeutic agent or prophylactic agent for HIV infection.
  • HIV integrase means to specifically inhibit the function as HIV integrase to eliminate or attenuate the activity thereof. For example, it means to specifically inhibit the function of HIV integrase under the conditions of the below-mentioned Experimental Example 1.
  • HIV integrase inhibitor preferred is a “human HIV integrase inhibitor”.
  • the compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof can be used in combination (hereinafter to be referred to as combination use) with other single or plural medicaments (hereinafter to be also referred to as a concomitant drug) by a conventional method generally employed in the medicament field.
  • the administration frequency of the compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2], or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a concomitant drug is not limited, and they may be administered as a combined agent to the subject of administration, or the two may be administered simultaneously or at certain time intervals. In addition, they may be used as a medicament in the form of a kit containing the pharmaceutical composition of the present invention and a concomitant drug.
  • the dose of the concomitant drug may be determined according to the dosage used clinically, and can be appropriately determined depending on the subject of administration, disease, symptom, dosage form, administration route, administration time, combination and the like.
  • the administration form of the concomitant drug is not particularly limited, and the compound of the present invention or a salt thereof, or a solvate thereof and the concomitant drug need only be combined.
  • An anti-HIV agent is generally required to sustain its effect for a long time, so that can be effective not only for temporal suppression of viral growth but also prohibition of viral re-growth. This means that a prolonged administration is necessary and that a high single dose may be frequently inevitable to sustain effect for a longer period through the night. Such prolonged and high dose administration increases the risk of causing side effects.
  • one of the preferable embodiments of the compound of the present invention is such compound permitting high absorption by oral administration, and such compound capable of maintaining blood concentration of the administered compound for an extended period of time.
  • preferable embodiments of the compound of the present invention are a compound having fine pharmacological activity (e.g., a compound having strong HIV integrase inhibitory activity, a compound having high anti-HIV activity), a compound having fine bioavailability (e.g., a compound having high cellular membrane permeability, a compound stable to metabolic enzyme, a compound with low binding ability to protein and the like), a compound having an anti-HIV activity against HIV having G140S/Q148H mutation, and the like.
  • a compound having fine pharmacological activity e.g., a compound having strong HIV integrase inhibitory activity, a compound having high anti-HIV activity
  • a compound having fine bioavailability e.g., a compound having high cellular membrane permeability, a compound stable to metabolic enzyme, a compound with low binding ability to protein and the like
  • a compound having an anti-HIV activity against HIV having G140S/Q148H mutation e.g., a compound having strong
  • a compound having high pharmacological activity (concretely, IC 50 of HIV integrase inhibitory activity is less than 0.1 ⁇ M, preferably less than 0.01 ⁇ M) and high oral absorption, whose blood concentration is maintained for a long time after administration, is more preferable.
  • dose and/or frequency of administration of the compound of the present invention to human are/is expected to be decreased.
  • Preferable administration frequency is not more than twice a day, more preferably, not more than once a day (e.g., once a day, once in two days, etc.).
  • the compound of the present invention can be used for the improvement of viremia due to HIV and/or maintenance of improved condition thereof, prophylaxis and treatment of virus infections, particularly, an HIV infection and/or maintenance of improved condition thereof.
  • a decrease in the virus level or HIV RNA level in the body, particularly in blood can be used.
  • the “prophylaxis of HIV infection” includes administration of a medicament to a person with suspected or possible HIV infection (infection due to transfusion, infection from mother to child), and the like.
  • prophylaxis of AIDS is meant, for example, administration of a medicament to an individual who tested HIV positive but has not yet developed the disease state of AIDS; administration of a medicament to an individual who shows an improved disease state of AIDS after treatment but who carries HIV still to be eradicated and whose relapse of AIDS is concerned; administration of a medicament before infection with HIV out of a fear of possible infection; and the like.
  • the “other anti-HIV agents” and “other anti-HIV active substances” to be used for a multiple drug combination therapy include an anti-HIV antibody or other antibody, an HIV vaccine or other vaccine, immunostimulants such as interferon, interferon agonist and the like, a ribozyme against HIV, an HIV antisense drug, an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, an HIV integrase inhibitor, an inhibitor of attachment between a receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus (CCR5 antagonist and the like), a DNA polymerase inhibitor or DNA synthesis inhibitor, a medicament acting on HIVp24, an HIV fusion inhibitor, an IL-2 agonist or antagonist, a TNF- ⁇ antagonist, an ⁇ -glucosidase inhibitor, a purine nucleoside phosphorylase inhibitor, an apoptosis agonist or inhibitor, a cholinesterase inhibitor, an immunomodulator and the like.
  • HIV reverse transcriptase inhibitor examples include Retrovir® (zidovudine), Epivir® (lamivudine), Zerit® (sanilvudine), Videx® (didanosine), Hivid® (zalcitabine), Ziagen® (abacavir sulfate), Viramune® (nevirapine), Stocrin® (efavirenz), Rescriptor® (delavirdine mesylate), Combivir® (zidovudine+lamivudine), Trizivir® (abacavir sulfate+lamivudine+zidovudine), Coactinon® (emivirine), Phosphonovir®, Coviracil®, alovudine (3′-fluoro-3′-deoxythymidine), Thiovir (thiophosphonoformic acid), Capravirin (5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyri)
  • HIV protease inhibitor examples include Crixivan® (indinavir sulfate ethanolate), saquinavir, Invirase® (saquinavir mesylate), Norvir® (ritonavir), Viracept® (nelfinavir mesylate), lopinavir, Prozei® (amprenavir), Kaletra® (ritonavir+lopinavir), mozenavir dimesylate ([4R-(4 ⁇ ,5 ⁇ ,6 ⁇ )]-1,3-bis[(3-aminophenyl)methyl]-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate), tipranavir (3′-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenylethyl-6-propyl-2H-pyran
  • the HIV integrase inhibitor is exemplified by S-1360, L-870810 and the like
  • the DNA polymerase inhibitor or DNA synthesis inhibitor is exemplified by Foscavir®, ACH-126443 (L-2′,3′-didehydro-dideoxy-5-fluorocytidine), entecavir ((1S,3S,4S)-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine), calanolide A ([10R-(10 ⁇ ,11 ⁇ ,12 ⁇ )]-11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-2H,6H,10H-benzo[1,2-b:3,4-b′:5,6-b′′]tripyran-2-one), calanolide B, NSC-674447 (1,1′-azobisformamide), Iscador (viscum alubm extract), Rubitecan and the like, the HIV antis
  • Neurotropin® Lidakol®, Ancer 20®, Ampligen®, Anticort®, Inactivin®, PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL immunotherapy, ACTG protocol 080 therapy, CD4- ⁇ gene therapy), SCA binding protein, RBC-CD4 complex, Motexafin gadolinium, GEM-92, CNI-1493, ( ⁇ )-FTC, Ushercell, D2S, BufferGel®, VivaGel®, Glyminox vaginal gel, sodium lauryl sulfate, 2F5, 2F5/2G12, VRX-496, Ad5gag2, BG-777, IGIV-C, BILR-255 and the like are exemplified.
  • the compound of the present invention can be combined with one or more (e.g., 1 or 2) kinds of other anti-HIV active substances (to be also referred to as other anti-HIV agents), and used as an anti-HIV agent and the like for the prophylaxis or treatment of HIV infection.
  • other anti-HIV agents e.g., 1 or 2
  • other anti-HIV active substances e.g., 1 or 2
  • the combination of medicaments include a combination of a group consisting of efavirenz, tenofovir, emtricitabine, indinavir, nelfinavir, atazanavir, ritonavir+indinavir, ritonavir+lopinavir, ritonavir+saquinavir, didanosine+lamivudine, zidovudine+didanosine, stavudine+didanosine, zidovudine+lamivudine, stavudine+lamivudine and tenofovir+emtricitabine, and the compound of the present invention (Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents.
  • Particularly preferred is a combined use of two agents with efavirenz, indinavir, nelfinavir, tenofovir, emtricitabine, zidovudine or lamivudine, and a combined use of three agents with zidovudine+lamivudine, tenofovir+lamivudine, tenofovir+zidovudine, tenofovir+efavirenz, tenofovir+nelfinavir, tenofovir+indinavir, tenofovir+emtricitabine, emtricitabine+lamivudine, emtricitabine+zidovudine, emtricitabine+efavirenz, emtricitabine+nelfinavir, emtricitabine+indinavir, nelfinavir+lamivudine, nelfinavir+zidovudine, nelfinavir
  • the compound of the present invention can be administered simultaneously with a medicament to be used in combination (hereinafter concomitant drug) or administered at certain time intervals.
  • a pharmaceutical composition comprising the compound of the present invention and a concomitant drug can be administered.
  • a pharmaceutical composition comprising the compound of the present invention and a pharmaceutical composition comprising a concomitant drug may be administered separately.
  • the administration route of the compound of the present invention and that of the concomitant drug may be the same or different.
  • the compound of the present invention can be administered once a day or several times a day in a single dose of 0.01 mg to 1 g, or may be administered at a smaller dose.
  • the concomitant drug can be administered at a dose generally used for the prevention or treatment of an HIV infection, for example, at a single dose of 0.01 mg to 0.3 g. Alternatively, it may be administered in a smaller dose.
  • the present invention is not limited to these production methods.
  • the order of reactions can be appropriately changed.
  • the reactions may be performed from a reasonable step or a reasonable substitution moiety.
  • an appropriate substituent conversion (conversion or further modification of substituent) step may be inserted between respective steps.
  • protection and deprotection may be appropriately performed.
  • reagents other than those exemplified below may be used as appropriate.
  • the starting compounds whose production methods are not described are commercially available or can be easily prepared by a combination of known synthesis reactions.
  • the compound obtained in each step can be purified by conventional methods such as distillation, recrystallization, column chromatography and the like. In some cases, the next step may be performed without isolation and purification.
  • room temperature means 1 to 40° C.
  • compound [I-1-6] which is compound [I-3-1] wherein Y is CH can be synthesized by the following method.
  • R 11a and R 11c are the same or different and each is a hydroxyl-protecting group such as an acetyl group, a benzyl group, a methyl group, an ethyl group, an isopropyl group, a trimethylsilyl group, a triethylsilyl group, a tert-butyldimethylsilyl group, a triisopropylsilyl group, a tert-butyldiphenylsilyl group and the like
  • R 11b is a carboxyl-protecting group such as a methyl group, an ethyl group, a benzyl group, a tert-butyl group and the like
  • X 11a is a halogen atom such as a chlorine atom, a bromine atom and the like, and other symbols are each as described above.
  • Compound [I-1-2] can be obtained by introducing a protecting group into the carboxyl group of compound [I-1-1] according to a known method.
  • compound [I-1-2] when R 11b is a methyl group, compound [I-1-2] can be obtained by reacting compound [I-1-1] with trimethylsilyldiazomethane at a low temperature to room temperature in a single or mixed solvent such as tetrahydrofuran (THF), toluene, methanol, ethanol and the like.
  • a single or mixed solvent such as tetrahydrofuran (THF), toluene, methanol, ethanol and the like.
  • Compound [I-1-3] can be obtained by introducing a halogen atom X 11a into compound [I-1-2] according to a known method.
  • compound [I-1-3] can be obtained by reacting compound [I-1-2] with a bromination reagent (e.g., bromine, trimethylphenylammonium tribromide etc.) at room temperature to under heating in a solvent such as chloroform, methylene chloride, acetic acid and the like.
  • a bromination reagent e.g., bromine, trimethylphenylammonium tribromide etc.
  • Compound [I-1-4] can be obtained by introducing a protecting group into a hydroxyl group of compound [I-1-3] according to a known method.
  • compound [I-1-4] can be obtained by reacting compound [I-1-3] with benzyl halide (e.g., benzyl chloride, benzyl bromide etc.) at room temperature to under heating in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, sodium hydrogen phosphate, cesium carbonate, sodium hydride, potassium t-butoxide, lithiumdiisopropylamide (LDA) and the like in a solvent such as N,N-dimethylformamide (DMF), dimethylacetamide (DMA), acetonitrile, 1,2-dimethoxyethane, THF, toluene and the like.
  • benzyl halide e.g., benzyl chloride, benzyl bromide etc.
  • a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate,
  • Compound [I-1-6] can be obtained by subjecting compound [I-1-4] to a coupling reaction with compound [I-1-5] in the presence of a palladium catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0), tetrakis(triphenylphosphine)palladium(0) and bis(triphenylphosphine)palladium(II) dichloride etc.) at room temperature to under heating in a solvent such as DMF, DMA, acetonitrile, toluene, 1,4-dioxane and the like.
  • a ligand e.g., tri(2-furyl)phosphine, tributylphosphine etc.
  • a ligand e.g., tri(2-furyl)phosphine, tributylphosphine etc.
  • compound [I-1-5] wherein n is 1 can be obtained in the same manner as in step 1R-2 and step 1R-3 of the below-mentioned Reference Example 1.
  • compound [I-2-9] which is compound [I-3-1] wherein Y is a nitrogen atom and R 13b is an ethyl group can be synthesized by the following method.
  • R 12a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like
  • R 12b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, and other symbols are each as described above.
  • Compound [I-2-3] can be obtained by reacting compound [I-2-1] with compound [I-2-2] at ⁇ 78° C. to room temperature conditions in a solvent such as DMF, DMA, dimethyl sulfoxide (DMSO), THF, toluene and the like, in the presence of a base such as sodium hydride, lithiumdiisopropylamide (LDA), lithium hexamethyldisilazide (LHMDS) and the like.
  • a solvent such as DMF, DMA, dimethyl sulfoxide (DMSO), THF, toluene and the like
  • a base such as sodium hydride, lithiumdiisopropylamide (LDA), lithium hexamethyldisilazide (LHMDS) and the like.
  • Compound [I-2-4] can be obtained by reacting Compound [I-2-3] with N,N-dimethylformamidedimethylacetal at room temperature to under heating in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like.
  • a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like.
  • Compound [I-2-6] can be obtained by adding a base such as sodium hydride, LDA, LHMDS and the like to a solution of Compound [I-2-4] dissolved in a solvent such as DMF, DMA, DMSO, THF, toluene and the like at -78° C. to room temperature, reacting the compound with compound [I-2-5] and treating same with triethylamine, diisopropylethylamine or the like.
  • a base such as sodium hydride, LDA, LHMDS and the like
  • a solvent such as DMF, DMA, DMSO, THF, toluene and the like
  • Compound [I-2-7] can be obtained by removing the carboxyl-protecting group R 12b of compound [I-2-6] by a known method.
  • the protecting group is a tert-butyl group
  • compound [I-2-7] can be obtained by stirring compound [I-2-6] at a low temperature to under heating in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF, methanol, ethanol, 2-propanol, DMSO, DMF, DMA, acetonitrile, water and the like in the presence of acid such as p-toluenesulfonic acid, methanesulfonic acid, boron trifluoride, boron trichloride, boron tribromide, aluminum trichloride, hydrochloric acid, hydrogen bromide, phosphoric acid,
  • Compound [I-2-9] can be obtained by converting compound [I-2-7] to acid chloride by a known method, and further reacting the compound with compound [I-2-8].
  • compound [I-2-9] can be obtained by converting compound [I-2-7] to acid chloride with a chlorinating agent such as oxalyl chloride, thionyl chloride, phosphorus trichloride and the like at a low temperature to room temperature in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF and the like in the presence of a catalytic amount of DMF where necessary, and reacting the compound with compound [I-2-8].
  • a chlorinating agent such as oxalyl chloride, thionyl chloride, phosphorus trichloride and the like at a low temperature to room temperature in a single or
  • a compound represented by the above-mentioned formula [I] can be synthesized by the following method.
  • R 13a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like
  • R 13b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like
  • R 13c is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, and other symbols are each as described above.
  • Compound [I-3-3] can be obtained by reacting compound [I-3-1] with compound [I-3-2], wherein amino-protecting group R 13c is removed in advance according to a known method at room temperature to under heating in a single or mixed solvent of chloroform, dichloromethane, DMF, DMA, DMSO, acetonitrile, 1,2-dimethoxyethane, THF, toluene, water and the like, and cyclizing the compound in the presence of a base such as triethylamine, diisopropylamine, diisopropylethylamine, diazabicycloundecene, sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like.
  • a base such as triethylamine, diisopropylamine, diisopropylethylamine, diazabicycloundecene, sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like.
  • the cyclization reaction can also be performed in the presence of acid such as acetic acid, p-toluenesulfonic acid, methanesulfonic acid, boron trifluoride, boron trichloride, boron tribromide, hydrochloric acid, hydrogen bromide, phosphoric acid, sulfuric acid and the like.
  • acid such as acetic acid, p-toluenesulfonic acid, methanesulfonic acid, boron trifluoride, boron trichloride, boron tribromide, hydrochloric acid, hydrogen bromide, phosphoric acid, sulfuric acid and the like.
  • Compound [I] can be obtained by removing the hydroxyl-protecting group R 13a of compound [I-3-3] by a known method.
  • the protecting group is a benzyl group
  • compound [I] can be obtained by stirring compound [I-3-3] at a low temperature to room temperature in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, methanol, ethanol, 2-propanol, THF, 1,4-dioxane, acetonitrile, water and the like, in the presence of acid such as hydrochloric acid, sulfuric acid, hydrogen bromide, phosphoric acid, acetic acid, trifluoroacetic acid and the like.
  • the acid may be used as a solvent.
  • Compound [I-3-2] in the above-mentioned production method I-3 (corresponding to the following compound [I-4-3]) can be synthesized by the following method.
  • R 14a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, and other symbols are each as described above.
  • Compound [I-4-1] obtainable from a commercially available compound by a known method is reacted with phthalimide at a low temperature to under heating in a single or mixed solvent of THF, methylene chloride, chloroform, DMF, ethyl acetate, toluene and the like in the presence of a phosphorus reagent such as triphenylphosphine, diphenyl(2-pyridyl)phosphine, tributylphosphine, tri-tert-butylphosphine and the like and an azo compound such as diisopropylazodicarboxylate, diethylazodicarboxylate, N,N,N′,N′-tetramethylazodicarboxamide, 1,1′-(azodicarbonyl)dipiperidine and the like, and the obtained compound is further treated with hydrazine to remove a phthaloyl group to give amine compound [I-4-2].
  • Compound [I-4-2] is reacted with a ketone compound or aldehyde compound at a low temperature to room temperature in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like, and the mixture is stirred in the presence of a reducing agent such as sodium borohydride, sodium triacetoxyborohydride and the like to introduce substituent R 1 into the amino group of compound [I-4-2], whereby compound [I-4-3] can be obtained.
  • a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like
  • a compound which is compound [I-3-2] wherein particularly R 2 and R 3 are each a hydrogen atom, one of R 4 and R 5 is a carboxyl group or —CO—NR a R b wherein R a and R b are as described above, and the other is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, can be synthesized by the following method.
  • R 15a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like
  • R 15b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like
  • R 15c is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, and other symbols are each as described above.
  • Compound [I-5-2] can be obtained by oxidizing the hydroxyl group of compound [I-5-1] obtainable from a commercially available compound by a known method, to a aldehyde group by a chromium oxide-pyridine complex (e.g., pyridinium chlorochromate, pyridinium dichromate and the like), a metal oxidant (e.g., chromium oxide, silver carbonate, manganese dioxide and the like), by DMSO oxidization using various DMSO activators such as oxalyl chloride, trifluoroacetic anhydride, acetic anhydride, dicyclohexylcarbodiimide (DCC), sulfur trioxide-pyridine complex and the like, Dess-Martin oxidization and the like according to a known method.
  • a chromium oxide-pyridine complex e.g., pyridinium chlorochromate, pyridinium dichromate and the like
  • Compound [I-5-3] can be obtained by subjecting the aldehyde group of compound [I-5-2] to a reductive amination under similar conditions as in production method I-4, step 2.
  • the obtained compound [I-5-3] is cyclized by the above-mentioned method, and the carboxyl-protecting group R 15b is removed by a known method and, where necessary, the resulting compound is reacted with an amine compound by a known method to give the object compound.
  • compound [II-1-6] which is compound [I] wherein Y is CH can be synthesized by the following method.
  • R 21a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like
  • R 21b is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like
  • X 21a is a leaving group such as a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom and the like), p-toluenesulfonyloxy group (OTs), methanesulfonyloxy group (OMs), trifluoromethanesulfonyloxy group (OTf
  • Compound [II-1-3] can be obtained by converting compound [II-1-1] to acid chloride by a known method at a low temperature to under heating, reacting the acid chloride with compound [II-1-2], removing the amino-protecting group R 21b , and stirring the mixture in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, diisopropylethylamine, sodium hydrogen phosphate, cesium carbonate and the like.
  • a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, diisopropylethylamine, sodium hydrogen phosphate, cesium carbonate and the like.
  • Compound [II-1-2] can be obtained by a method similar to that of Production method I-4.
  • Compound [II-1-4] can be obtained by introducing leaving group X 21a into compound [II-1-3] by a known method.
  • the bromine atom is introduced into compound [II-1-3] by a method similar to that in production method I-1, step 2 to give compound [II-1-4].
  • a compound which is compound [I] wherein particularly R 2 and R 3 are each a hydrogen atom, and one of R 4 and R 5 is a methyl group substituted by —NR A3 R A4 wherein R A3 and A4 are as described above, and the other is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, can be synthesized by the following method.
  • R 22a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like
  • R 22b is a C 1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A
  • R 22a and R 22d are the same or different, and each is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, and other symbols are each as described above.
  • the hydroxyl group of compound [II-2-1] is oxidized, by a known method to give aldehyde group, whereby compound [II-2-2] can be obtained.
  • the known method is the same as the one indicated for, for example, the production method I-5, step 1.
  • Compound [II-2-3] can be obtained by subjecting compound [II-2-2] to reductive amination by the same method as in the production method I-5, step 2.
  • Compound [II-2-4] can be obtained from compound [II-2-3] by the same method as in production method II-1, step 1 to step 3.
  • the hydroxyl-protecting group R 22c of compound [II-2-4] is removed by a known method, and the hydroxyl group is appropriately subjected to substituent conversion to a leaving group (OTs, OMs, OTf etc.).
  • a leaving group OTs, OMs, OTf etc.
  • step 1 After reaction with potassium phthalimide, and the phthaloyl group is removed by a method similar to production method I-4, step 1 to give compound [II-2-5].
  • the obtained compound [II-2-5] is subjected to an appropriately combination of removal of hydroxyl-protecting group R 22d by a method similar to production method I-3, step 2, and modification of amino group of compound [II-2-5] by a known method to give the object compound.
  • compound [III-1-9] which is compound [I] wherein Y is a nitrogen atom can be synthesized by the following method.
  • R 31a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like
  • R 31b and R 31c are the same or different and each is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, and other symbols are each as described above.
  • Compound [III-1-3] can be obtained by reacting compound [III-1-1] with compound [III-1-2] by a method similar to production method I-2, step 3.
  • Compound [III-1-4] can be obtained by removing the carboxyl-protecting group R 31b of compound [III-1-3] by a method similar to production method I-2, step 4.
  • Compound [III-1-5] can be obtained by reacting compound [III-1-4] with compound [I-2-8] by a method similar to production method I-2, step 5.
  • Compound [III-1-6] can be obtained by removing the carboxyl-protecting group R 31c of compound [III-1-5] by a known method.
  • Compound [III-1-7] can be obtained by converting compound [III-1-6] to acid chloride by a method similar to production method I-2, step 5, and reacting the acid chloride with compound [I-3-2] in a solvent such as hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF and the like in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, diisopropylethylamine, sodium hydrogen phosphate, cesium carbonate and the like.
  • a solvent such as hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF and the like
  • a base such as potassium acetate, potassium carbon
  • Compound [III-1-8] can be obtained by removing the amino-protecting group R 13c of compound [III-1-7] by a known method, and performing cyclization by a method similar to a cyclization reaction of production method II-1, step 1 in the presence of a base.
  • Compound [III-1-9] can be obtained by removing the hydroxyl-protecting group R 31a of compound [III-1-8] by a known method.
  • the protecting group is a benzyl group
  • step 2 can be used.
  • the obtained solid was dissolved in dimethylformamide (54 mL), potassium carbonate (7.1 g) and benzyl bromide (5.6 mL) were added, and the mixture was stirred at 80° C. for 40 min. The mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated and 1N aqueous hydrochloric acid solution was added to the obtained residue. The mixture was extracted twice with ethyl acetate. The combined ethyl acetate layer was washed with saturated brine, dried, and concentrated.
  • step 1R-2 To a solution of the compound (3.2 g) obtained in step 1R-2 in THF (50 mL) was added dropwise 1.6M n-butyllithium/hexane solution (8.1 mL) at ⁇ 78° C. and the mixture was stirred for 10 min. Tributyltin chloride (3.5 mL) was added, and the mixture was stirred at ⁇ 78° C. for 30 min and at room temperature for 30 min. Ice-cold water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated to give the object compound (6.2 g) described in the above-mentioned scheme as a crude product.
  • Tributyltin chloride 3.5 mL
  • Ice-cold water was added and the mixture was extracted with ethyl acetate.
  • the organic layer was washed with saturated brine, dried, and concentrated to give the object compound (6.2 g) described in the above-menti
  • step 1R-1 In the same manner as in step 1R-1 except that 3-benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (15.0 g) was ethylated with iodoethane, the object compound (10.97 g) described in the above-mentioned scheme was obtained.
  • step 1R-4 the object compound (1.0 g) described in the above-mentioned scheme was obtained from the compound (1.2 g) obtained in step 2R-1.
  • step 3R-1 To a solution of the compound (32.3 g) obtained in step 3R-1 in THF (300 mL) was added a Lawesson reagent (48.7 g), and the mixture was stirred at 50° C. overnight and allowed to cool. The reaction mixture was poured into a stirred saturated aqueous sodium hydrogen carbonate solution by small portions, and the mixture was stirred at room temperature for 30 min. The mixture was extracted twice with ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, and concentrated. To the residue was added 4N hydrochloric acid/dioxane solution (300 mL), and the mixture was stirred at room temperature for 1 hr.
  • a Lawesson reagent 48.7 g
  • the precipitated salt was collected by filtration, and dissolved in water (200 mL), and the solution was neutralized with sodium hydrogen carbonate and extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated. To the residue was added ethyl acetate/hexane (1:4) solution and the mixture was slurry washed. The residue was collected by filtration, and dried to give the object compound (15.78 g) described in the above-mentioned scheme.
  • step 1-2 Compound (56 mg) obtained in step 1-2 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 1 hr. The reaction solution was concentrated, ethyl acetate was added and the mixture was concentrated. Ethyl acetate, 4N hydrochloric acid/ethyl acetate solution, and hexane were added to allow crystallization to give the object compound (28 mg) described in the above-mentioned scheme.
  • step 2-8 The compound (155 mg) obtained in step 2-8 was dissolved in trifluoroacetic acid solution (1.0 mL), and the mixture was stirred at room temperature for 30 min. The mixture was concentrated, chloroform was added, and the mixture was 25 concentrated. This operation was performed twice. Toluene (5 mL), diisopropylethylamine (395 ⁇ L) and the compound (200 mg) obtained in step 2-5 were added, and the mixture was stirred at room temperature for 30 min. Toluene (5 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (100 ⁇ L) were added, and the mixture was stirred at 120° C. for 1 hr.
  • reaction mixture was allowed to cool to room temperature, acetic acid (1.0 mL) was added, and the mixture was further stirred at 110° C. for 1 hr. 2N Aqueous hydrochloric acid solution (30 mL) was added, and the mixture was extracted with ethyl acetate (60 mL). The organic layer was dried and concentrated, toluene was added, and this operation was repeated twice to give the object compound (263 mg) described in the above-mentioned scheme.
  • step 2-10 The compound (25.0 mg) obtained in step 2-10 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stirred at room temperature for 30 min. The reaction solution was concentrated, chloroform was added, and the mixture was concentrated. 4N Hydrochloric acid/ethyl acetate solution was added, and the mixture was concentrated. Crystallization from ethyl acetate-hexane gave the object compound (17.2 mg) described in the above-mentioned scheme.
  • step 3-1 To a solution of the compound (2.8 g) obtained in step 3-1 in methanol (100 mL) was added a 7.5% palladium-carbon catalyst (1.4 g), and the mixture was stirred at room temperature for 17 hr under a hydrogen atmosphere and moderate pressure (0.4 MPa). The reaction mixture was filtered through celite and concentrated to give the object compound (2.05 g) described in the above-mentioned scheme.
  • the obtained solid was dissolved in ethanol (30 mL)-toluene (30 mL), hydrazine monohydrate (1.6 mL) was added, and the mixture was stirred at 80° C. for 40 min. The mixture was allowed to cool to room temperature, the solid was filtered off, and the filtrate was concentrated. Toluene was added to the residue, and the precipitated solid was filtered off. The filtrate was concentrated to give the object compound (1.3 g) described in the above-mentioned scheme.
  • step 3-4 To a solution of the compound (150 mg) obtained in step 3-4 in chloroform (4 mL) were added acetone (70 ⁇ L), acetic acid (54 ⁇ L) and sodium triacetoxyborohydride (200 mg) under ice-cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred. The chloroform layer was washed with saturated brine, dried, and concentrated to give the object compound (156 mg) described in the above-mentioned scheme.
  • step 2-9 and step 2-11 the object compound (17.0 mg) described in the above-mentioned scheme was obtained from the compound (156 mg) obtained in step 3-5.
  • a known method was used for removal of the amino-protecting group (benzyloxycarbonyl group) of the compound obtained in step 3-5 according to the protecting group.
  • step 2-9 and step 2-11 the object compound (10.8 mg) described in the above-mentioned scheme was obtained from the compound (19.0 mg) obtained in step 4-1.
  • step 3-3 the object compound (1.0 g) described in the above-mentioned scheme was obtained from (S)-2-hydroxy-1-methylethylcarbamic acid tert-butyl ester (1.4 g).
  • step 4-1 the object compound (180 mg) described in the above-mentioned scheme was obtained from the compound (190 mg) obtained in step 5-1.
  • step 2-9 and step 2-11 the object compound (27.5 mg) described in the above-mentioned scheme was obtained from the compound (30.0 mg) obtained in step 5-2.
  • step 3-3 to step 3-5 the object compound (105 mg) described in the above-mentioned scheme was obtained from (R)-2-hydroxy-1-methylethylcarbamic acid tert-butyl ester (2.0 g).
  • step 2-9 and step 2-11 the object compound (16.6 mg) described in the above-mentioned scheme was obtained from the compound (105 mg) obtained in step 6-1.
  • a known method was used for removal of the amino-protecting group (benzyloxycarbonyl group) of the compound obtained in step 6-1 according to the protecting group.
  • 2-Amino-2-methyl-1,3-propanediol (20.0 g) was suspended in tetrahydrofuran (400 mL), and di-tert-butyl dicarbonate (41.6 g) was added. The mixture was stirred at room temperature for 3 hr and concentrated. Dimethylformamide (200 mL) was added to dissolve the concentrate again, imidazole (13.0 g) and tert-butylchlorodimethylsilane (29.3 g) were added, and the mixture was stirred at room temperature for 15 hr. Water (500 mL) was added, and the mixture was extracted with ethyl acetate (800 mL).
  • step 7-4 To the compound (9.65 g) obtained in step 7-4 was added 4N hydrochloric acid/ethyl acetate solution (100 mL), and the mixture was stirred at room temperature for 30 min. This was concentrated, ethanol (400 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL) were added, and the mixture was stirred at room temperature for 18 hr. The insoluble material was filtered off, and the filtrate was concentrated. Water (100 mL) was added, and the mixture was extracted twice with chloroform (200 mL, 100 mL).
  • step 7-14 The compound (5.6 mg) obtained in step 7-14 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated, chloroform was added, and the mixture was concentrated. 4N Hydrochloric acid/ethyl acetate solution was added, and the mixture was concentrated. Crystallization from ethyl acetate-hexane gave the object compound (3.2 mg) described in the above-mentioned scheme.
  • step 8-1 To a solution of the compound (4.49 g) obtained in step 8-1 in dioxane (5 mL) was added 4N hydrochloric acid/dioxane solution (20 mL) with stirring, and the mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated, ethyl acetate/hexane (1:4) solution was added and the mixture was slurry washed. The residue was collected by filtration, and dried to give the object compound (3.30 g) described in the above-mentioned scheme.
  • step 8-5 To the compound (18 mg) obtained in step 8-5 was added 4N hydrochloric acid/dioxane solution (1 mL), and the mixture was left standing at room temperature for 1.5 hr.
  • the reaction mixture was concentrated, 2-propanol (6 mL), water (0.6 mL) and saturated aqueous sodium hydrogen carbonate solution (0.6 mL) were added, and the mixture was stirred with heating at 100° C. for 4 hr.
  • the mixture was allowed to cool to room temperature once, left standing overnight, and stirred again with heating at 100° C. for 8 hr.
  • saturated brine To the reaction mixture was added saturated brine, and the mixture was extracted with ethyl acetate, dried and concentrated.
  • step 8-6 The compound (10 mg) obtained in step 8-6 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 50 min. Trifluoroacetic acid solution was concentrated, 4N hydrochloric acid/dioxane solution was added and the mixture was concentrated. Toluene was added and the mixture was concentrated. The obtained residue was crystallized from ethyl acetate (0.5 mL)-hexane (2 mL) to give the object compound (4.7 mg) described in the above-mentioned scheme.
  • step 2-11 the object compound (18.0 mg) described in the above-mentioned scheme was obtained from ((S)-2-ethylamino-3-methoxypropyl)carbamic acid benzyl ester (80 mg) obtainable from a commercially available compound by a known method.
  • step 2-11 the object compound (10.7 mg) described in the above-mentioned scheme was obtained from ((S)-2-cyclopropylmethylamino-3-methoxypropyl)carbamic acid benzyl ester (36 mg) obtainable from a commercially available compound by a known method.
  • step 2-11 the object compound (32.0 mg) described in the above-mentioned scheme was obtained from ((S)-2-cyclopropylmethylamino-3-ethoxypropyl)carbamic acid benzyl ester (295 mg) obtainable from a commercially available compound by a known method.
  • step 2-11 the object compound (35.0 mg) described in the above-mentioned scheme was obtained from ((S)-3-ethoxy-2-isopropylaminopropyl)carbamic acid benzyl ester (230 mg) obtainable from a commercially available compound by a known method.
  • step 2-11 the object compound (37.0 mg) described in the above-mentioned scheme was obtained from ((S)-3-ethoxy-2-ethylaminopropyl)carbamic acid benzyl ester (250 mg) obtainable from a commercially available compound by a known method.
  • step 2-11 the object compound (32.9 mg) described in the above-mentioned scheme was obtained from ((1S,2S)-2-ethylamino-3-methoxy-1-methylpropyl)carbamic acid benzyl ester (51 mg) obtainable from a commercially available compound by a known method.
  • step 2-9 and step 2-11 the object compound (6.2 mg) described in the above-mentioned scheme was obtained from [(R)-2-isopropylamino-1-((2-methoxyethoxy)methyl)ethyl]carbamic acid tert-butyl ester (19.3 mg) obtainable from a commercially available compound by a known method.
  • step 2-9 and step 2-11 the object compound (10.7 mg) described in the above-mentioned scheme was obtained from [(R)-2-cyclopropylamino-1-((2-methoxyethoxy)methyl)ethyl]carbamic acid tert-butyl ester (16 mg) obtainable from a commercially available compound by a known method.
  • step 2-9 to step 2-11 the object compound (39 mg) described in the above-mentioned scheme was obtained from (R)-2-tert-butoxycarbonylamino-3-ethylamino-2-methylpropionic acid methyl ester (60 mg) obtainable from a commercially available compound by a known method.
  • step 340-1 To a solution of the compound (2.39 g) obtained in step 340-1 in toluene (12 mL) were added tetrabutylammonium hydrogen sulfate (76 mg), 50% aqueous sodium hydroxide solution (8 mL) and methyl sulfate (922 ⁇ L) under ice-cooling, and the mixture was stirred at room temperature for 90 min. Ice water was added, and the mixture was extracted with toluene. The organic layer was washed with saturated brine, dried, and concentrated.
  • tetrabutylammonium hydrogen sulfate 76 mg
  • 50% aqueous sodium hydroxide solution 8 mL
  • methyl sulfate 922 ⁇ L
  • the obtained solid was dissolved in ethanol (60 mL)-toluene (60 mL), hydrazine monohydrate (2.05 mL) was added, and the mixture was stirred at 80° C. for 4 hr. The mixture was allowed to cool to room temperature, the solid was filtered off, and the filtrate was concentrated. Toluene was added to the residue, and the precipitated solid was filtered off. The filtrate was concentrated to give the object compound (1.54 g) described in the above-mentioned scheme.
  • step 340-2 To a solution of the compound (187 mg) obtained in step 340-2 in chloroform (3 mL) were added acetone (76 ⁇ L), acetic acid (59 ⁇ L) and sodium triacetoxyborohydride (218 mg) under ice-cooling, and the mixture was stirred at room temperature for 5 hr. The reaction mixture was diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution was added and the mixture was stirred. The chloroform layer was dried and concentrated to give the object compound (190 mg) described in the above-mentioned scheme.
  • step 340-3 The compound (190 mg) obtained in step 340-3 was dissolved in trifluoroacetic acid (2.0 mL), and the mixture was stood at room temperature for 20 min. Trifluoroacetic acid solution was concentrated, tetrahydrofuran (1.58 mL) and diisopropylethylamine (636 ⁇ L) were added to give a solution. To a solution of the compound (75 mg) obtained in step 2-5 in tetrahydrofuran (500 ⁇ L) was added the above-mentioned solution (634 ⁇ L), and the mixture was stirred at room temperature for 15 min.
  • step 340-4 The compound (72 mg) obtained in step 340-4 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 4 hr. Trifluoroacetic acid solution was concentrated, toluene was added and the mixture was concentrated. Ethyl acetate, 4N hydrochloric acid/ethyl acetate solution, and hexane were added to allow crystallization to give the object compound (65 mg) described in the above-mentioned scheme.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

Description

    TECHNICAL FIELD
  • The present invention relates to a novel 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative useful as an anti-HIV agent, a pharmaceutically acceptable salt thereof, and a solvate thereof. In addition, the present invention relates to a pharmaceutical composition comprising the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier; an anti-HIV agent, an HIV integrase inhibitor and the like, comprising the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient; an anti-HIV agent comprising a combination of the derivative or a pharmaceutically acceptable salt thereof, or a solvate thereof, and one or more kinds of other anti-HIV active substances; and the like.
    • BACKGROUND ART
  • HIV (Human Immunodeficiency Virus (type 1)) belonging to retrovirus is a causative virus of AIDS (Acquired Immunodeficiency Syndrome).
  • HIV targets CD4 positive cell groups such as helper T cell, macrophage and dendritic cell and destroys these immunocompetent cells to cause immunodeficiency.
  • Accordingly, a medicament that eradicates HIV in a living organism or suppresses its growth is effective for the prophylaxis or treatment of AIDS.
  • HIV possesses a bimolecular RNA gene in a shell, which is covered with an envelope protein. The RNA codes for several enzymes (protease, reverse transcriptase, integrase) characteristic of the virus and the like. Translated reverse transcriptase and integrase are present in the shell, and protease is present inside and outside the shell.
  • HIV contacts and invades a host cell, causes uncoating, and releases a complex of RNA and integrase and the like into the cytoplasm. From the RNA, DNA is transcribed by reverse transcriptase, and a full length double stranded DNA is produced. The DNA moves into the nucleus of the host cell and is incorporated by integrase into the DNA of the host cell. The incorporated DNA is converted to an mRNA by polymerase of the host cell, from which mRNA various proteins necessary for forming a virus are synthesized by HIV protease and the like, and a virus particle is finally formed, which then undergoes budding and its release.
  • These virus specific enzymes are considered to be essential for the growth of HIV. These enzymes are drawing attention as the target of the development of antiviral agents, and several anti-HIV agents have been already developed.
  • For example, zidovudine, didanosine, lamivudine and the like have been already on the market as reverse transcriptase inhibitors, and indinavir, nelfinavir and the like as protease inhibitors.
  • In addition, a multiple drug combination therapy using these medicaments in combination (to be also referred to as HAART (highly active antiretroviral therapy)) is also used. For example, 3 agent combination therapy using two agents from reverse transcriptase inhibitors (zidovudine and lamivudine, or tenofovir and emtricitabine), and a non-nucleic acid reverse transcriptase inhibitor (efavirenz), or a protease inhibitor (lopinavir, fosamprenavir or atazanavir) in combination with ritonavir, and the like is used in clinical practice, and such multiple drug combination therapy is becoming the mainstream of the AIDS treatment.
  • However, some of these medicaments are known to cause side effects such as liver function failure, central nervous disorders (e.g., vertigo), and the like. In addition, acquisition of resistance to a medicament causes a problem. Even worse, emergence of an HIV that shows multiple drug resistance in a multiple drug combination therapy has been known.
  • Under the circumstances, a further development of a novel medicament, particularly a development of an anti-HIV agent based on a new mechanism, has been desired, wherein a development of an anti-HIV agent having an integrase inhibitory activity is expected, because an integrase characteristic of retrovirus is an essential enzyme for the growth of HIV.
    • SUMMARY OF THE INVENTION Problems to be Solved by the Invention
  • From the findings obtained from pharmacological studies and clinical results heretofore, an anti-HIV agent is effective for the prophylaxis or treatment of AIDS, and particularly a compound having an integrase inhibitory activity can be an effective anti-HIV agent.
  • Therefore, the present invention aims at provision of a compound having an anti-HIV activity, particularly a compound having an integrase inhibitory activity.
    • Means of Solving the Problems
  • The present inventors have conducted intensive studies in an attempt to find a compound having an anti-HIV action, particularly a compound having an integrase inhibitory action, and completed the present invention.
  • More specifically, the present invention provides the following.
    • [1] A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof (sometimes to be abbreviated as “the compound of the present invention” in the present specification):
  • Figure US20180319798A1-20181108-C00002
  • wherein
    • R1 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group,
    • (2) a C3-8 cycloalkyl group, or
    • (3) a saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom,
    • R2, R3, R4 and R5 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
    • (4) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group A, or
    • (5) a cyano group, or
    • R2 and R3, or R4 and R5 optionally form, together with the carbon atom bonded thereto,
    • i) C3-8 cycloalkane, or
    • ii) a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom,
    • wherein R2, R3, R4 and R5 are not hydrogen atoms at the same time,
    • R6 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 halogen atoms,
    • (2) a C1-6 alkoxy group,
    • (3) a halogen atom, or
    • (4) a C3-8 cycloalkyl group,
    • Y is
    • (1) CH, or
    • (2) a nitrogen atom,
    • m is an integer of 1 to 5, and when m is an integer of 2 to 5, then each R6 may be the same or different, and
    • n is an integer of 1 to 3,
    • group A:
    • (a) —CO—NRA1RA2
  • wherein RA1 and RA2 are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • RA1 and RA2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
    • (b) a hydroxyl group,
    • (c) a C1-6 alkoxy group,
    • (d) a C1-6 alkoxy-C1-6 alkoxy group,
    • (e) a cyano group,
    • (f) —NRA3RA4
  • wherein RA3 and RA4 are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group,
      • (iii) a C1-6 alkyl-carbonyl group, or
      • (iv) a C1-6 alkyl-sulfonyl group, or
  • RA3 and RA4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
    • (g) a carboxyl group,
    • (h) a C1-6 alkyl-sulfonyl group, and
    • (i) a C1-6 alkyl-carbonyl group; group B:
    • (a) a hydroxyl group,
    • (b) a C1-6 alkoxy group,
    • (c) a C1-6 alkoxy-C1-6 alkyl group
    • (d) a C3-8 cycloalkyl group, and
    • (e) an oxo group.
    • [2] The compound of the above-mentioned [1], wherein R1 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [3] The compound of the above-mentioned [2], wherein R1 is a C1-6 alkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [4] The compound of the above-mentioned [2], wherein R1 is a C1-6 alkyl group substituted by a C3-8 cycloalkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [5] The compound of the above-mentioned [1], wherein R1 is a C3-8 cycloalkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [6] The compound of the above-mentioned [1], wherein one of R2, R3, R4 and R5 is —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [7] The compound of the above-mentioned [1], wherein one of R2, R3, R4 and R5 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [8] The compound of the above-mentioned [1], wherein R6 is a halogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [9] The compound of the above-mentioned [1], wherein Y is CH, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [10] The compound of the above-mentioned [1], wherein Y is a nitrogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [11] The compound of the above-mentioned [1], wherein m is 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [12] The compound of the above-mentioned [1], wherein n is 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [13] The compound of the above-mentioned [1], which is represented by the following formula [I-1], or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00003
  • wherein
    • R11 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group, or
    • (2) a C3-8 cycloalkyl group, R21, R31, R41 and R51 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B, or
    • (3) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, wherein R21, R31, R41 and R51 are not hydrogen atoms at the same time,
    • R61 is a halogen atom, and
    • R62 is a hydrogen atom or a halogen atom.
    • [14] The compound of the above-mentioned [13], wherein R21 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, and
    • R31, R41 and R51 are each a hydrogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [15] The compound of the above-mentioned [13], wherein R21 is a C1-6 alkyl group, and
    • R31, R41 and R51 are each a hydrogen atom,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [16] The compound of the above-mentioned [13], wherein R41 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, and
    • R21, R31 and R51 are each a hydrogen atom,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [17] The compound of the above-mentioned [13], wherein R21 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A,
    • R41 is a C1-6 alkyl group, and
    • R31 and R51 are each a hydrogen atom,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [18] The compound of the above-mentioned [1], which is represented by the following formula [I-2], or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00004
  • wherein
    • R12 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group,
    • R22, R32, R42 and R52 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B, or
    • (3) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, wherein R22, R32, R42 and R52 are not hydrogen atoms at the same time,
    • R63 is a halogen atom, and
    • R64 is a hydrogen atom or a halogen atom.
    • [19] The compound of the above-mentioned [18], wherein R42 is —CO—NRaRb
  • wherein Ra and Rb form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B,
    • R52 is a C1-6 alkyl group, and
    • R22 and R32 is a hydrogen atom,
    • or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    • [20] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00005
    • [21] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00006
    • [22] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00007
    • [23] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00008
    • [24] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00009
    • [25] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00010
    • [26] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00011
    • [27] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00012
    • [28] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00013
    • [29] The compound of the above-mentioned [1], which is represented by the formula, or a pharmaceutically acceptable salt thereof, or a solvate thereof:
  • Figure US20180319798A1-20181108-C00014
    • [30] A pharmaceutical composition comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
    • [31] An anti-HIV agent comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.
    • [32] An HIV integrase inhibitor comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.
    • [33] An anti-HIV agent comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, in combination with one or more other kinds of anti-HIV active substances.
    • [34] Use of the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, for the production of an anti-HIV agent.
    • [35] Use of the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, for the production of an HIV integrase inhibitor.
    • [36] A method for the prophylaxis or treatment of an HIV infectious disease in a mammal, which comprises administering an effective amount of the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
    • [37] The method of the above-mentioned [36], which further comprises administering an effective amount of one or more other kinds of anti-HIV active substances to the mammal.
    • [38] A method for inhibiting HIV integrase in a mammal, which comprises administering an effective amount of the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
    • [39] An anti-HIV composition comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
    • [40] A pharmaceutical composition for inhibiting HIV integrase, comprising the compound of any one of the above-mentioned [1] to [29] or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
    • [41] A commercial package comprising the pharmaceutical composition of the above-mentioned [30] and a written matter associated therewith, which states that the pharmaceutical composition can or should be used for treating HIV.
    • [42] A kit comprising the pharmaceutical composition of the above-mentioned [30] and a written matter associated therewith, which states that the pharmaceutical composition can or should be used for treating HIV.
    Effect of the Invention
  • The compound of the present invention can be medicaments effective for the prophylaxis or treatment of HIV infections or AIDS, as anti-HIV agents, having an HIV integrase inhibitory activity. In addition, by a combined use with other anti-HIV agent(s) such as protease inhibitor, reverse transcriptase inhibitor and the like, they can be more effective anti-HIV agents. Furthermore, having high inhibitory activity specific for integrase, they can be medicaments safe for human body with a fewer side effects.
    • DESCRIPTION OF EMBODIMENTS
  • The definitions of respective substituents and respective moieties used in the present specification are as follows.
  • The “halogen atom” is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • The “C1-6 alkyl group” is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. Specific examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isopentyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a hexyl group and the like.
  • The “C1-6 alkoxy group” is a straight chain or branched chain alkoxy group having 1 to 6 carbon atoms, preferably a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms. Specific examples include a methoxy group, an ethoxy group, a propoxy group, an isopropyloxy group, a butoxy group, an isobutyloxy group, a tert-butyloxy group, a pentyloxy group, a hexyloxy group and the like.
  • The “C1-6 alkoxy-C1-6 alkyl group” is that wherein the alkoxy moiety is the “C1-6 alkoxy group” defined above, and the alkyl moiety is the “C1-6 alkyl group” defined above. Preferred is a C1-6 alkoxy-C1-6 alkyl group wherein the alkoxy moiety is a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms, and the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. Examples of the C1-6 alkoxy-C1-6 alkyl group include a methoxymethyl group, a methoxyethyl group, a methoxypropyl group, a methoxybutyl group, a methoxypentyl group, a methoxyhexyl group, an ethoxymethyl group, an ethoxyethyl group, an ethoxypropyl group, an ethoxybutyl group, an ethoxypentyl group, an ethoxyhexyl group, a propoxymethyl group, a propoxyethyl group, a propoxypropyl group, a propoxybutyl group, a propoxypentyl group, a propoxyhexyl group, a butoxymethyl group, a butoxyethyl group, a butoxypropyl group, a butoxybutyl group, a butoxypentyl group, a butoxyhexyl group, a pentyloxymethyl group, a pentyloxyethyl group, a pentyloxypropyl group, a pentyloxybutyl group, a pentyloxypentyl group, a pentyloxyhexyl group, a hexyloxymethyl group, a hexyloxyethyl group, a hexyloxypropyl group, a hexyloxybutyl group, a hexyloxypentyl group, a hexyloxyhexyl group and the like.
  • The “C1-6 alkoxy-C1-6 alkoxy group” is that wherein the C1-6 alkoxy moiety is the “C1-6 alkoxy group” defined above, preferably a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms. Examples thereof include a methoxymethoxy group, a methoxyethoxy group, a methoxypropoxy group, a methoxybutoxy group, a methoxypentyloxy group, a methoxyhexyloxy group, an ethoxymethoxy group, an ethoxyethoxy group, an ethoxypropoxy group, an ethoxybutoxy group, an ethoxypentyloxy group, an ethoxyhexyloxy group, a propoxymethoxy group, a propoxyethoxy group, a propoxypropoxy group, a propoxybutoxy group, a propoxypentyloxy group, a propoxyhexyloxy group, a butoxymethoxy group, a butoxyethoxy group, a butoxypropoxy group, a butoxybutoxy group, a butoxypentyloxy group, a butoxyhexyloxy group, a pentyloxymethoxy group, a pentyloxyethoxy group, a pentyloxypropoxy group, a pentyloxybutoxy group, a pentyloxypentyloxy group, a pentyloxyhexyloxy group, a hexyloxymethoxy group, a hexyloxyethoxy group, a hexyloxypropoxy group, a hexyloxybutoxy group, a hexyloxypentyloxy group, a hexyloxyhexyloxy group and the like.
  • The “C1-6 alkyl-carbonyl group” is an alkyl-carbonyl group wherein the C1-6 alkyl moiety is the “C1-6 alkyl group” defined above, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. Examples thereof include a methylcarbonyl group, an ethylcarbonyl group, a propylcarbonyl group, an isopropylcarbonyl group, a butylcarbonyl group, an isobutylcarbonyl group, a sec-butylcarbonyl group, a tert-butylcarbonyl group, a pentylcarbonyl group, an isopentylcarbonyl group, a 1,1-dimethylpropylcarbonyl group, hexylcarbonyl group and the like.
  • The “C1-6 alkyl-sulfonyl group” is an alkyl-sulfonyl group wherein the C1-6 alkyl moiety is the “C1-6 alkyl group” defined above, preferably a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. Examples thereof include a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, a pentylsulfonyl group, an isopentylsulfonyl group, a 1,1-dimethylpropylsulfonyl group, a hexylsulfonyl group and the like.
  • The “C3-8 cycloalkyl group” is a saturated cycloalkyl group having 3 to 8 carbon atoms, preferably 3 to 5 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group and the like.
  • The “C3-8 cycloalkane” is saturated cycloalkane having 3 to 8 carbon atoms, preferably 3 to 5 carbon atoms, and examples thereof include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like.
  • The “hetero ring” means a saturated or unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, or a fused ring of the hetero rings, or a fused ring of a carbon ring selected from benzene, cyclopentane and cyclohexane, and the hetero ring.
  • Examples of the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom” include a 4- to 7-membered saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like. Specific examples thereof include azetidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, imidazolidine, pyrazolidine, 1,3-dioxolane, 1,3-oxathioran, oxazolidine, thiazolidine, piperidine, piperazine, tetrahydropyran, tetrahydrothiopyran, dioxane, morpholine, thiomorpholine and the like.
  • Examples of the above-mentioned “unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom” include a 4- to 7-membered unsaturated (including partially unsaturated and completely unsaturated) monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like. Specific examples thereof include pyrroline, furan, thiophene, imidazole, imidazoline, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,4-triazole, 1,2,3-triazole, tetrazole, 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-thiadiazole, furazan, pyridine, pyrimidine, 3,4-dihydropyrimidine, pyridazine, pyrazine, 1,3,5-triazine, pyrazoline, oxazoline, isooxazoline, thiazoline, isothiazoline, pyran and the like.
  • Examples of the above-mentioned “fused ring of the hetero rings, or fused ring of a carbon ring selected from benzene, cyclopentane and cyclohexane, and the hetero ring” include indole, isoindole, benzimidazole, indazole, benzothiazole, benzofuran, isobenzofuran, indolizine, quinoline, isoquinoline, 1,2-dihydroquinoline, quinazoline, quinoxaline, cinnoline, phthalazine, quinolizidine, purine, pteridine, indoline, isoindoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoline, 1,3-benzodioxolane, 3,4-methylenedioxypyridine, 4,5-ethylenedioxypyrimidine, chromene, chromane, isochromane, 1,2,4-benzotriazine and the like.
  • The “saturated monocyclic hetero ring” formed by Ra and Rb together with the nitrogen atom bonded thereto means a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 7-membered (e.g., 4- to 6-membered) saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 (e.g., 1 to 3, preferably 1) hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, and the like. Specific examples of the saturated monocyclic hetero ring include those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, beside carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which contain, beside carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • The saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the following group B.
  • The “saturated monocyclic hetero ring” formed by R2 and R3 or R4 and R5, together with the carbon atom bonded thereto means a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 5- to 7-membered (e.g., 6-membered) saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 (e.g., 1 to 3, preferably 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like. Specific examples of the saturated monocyclic hetero ring include those similar to the saturated monocyclic hetero rings exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”.
  • The “saturated monocyclic hetero ring” formed by RA1 and RA2 together with the nitrogen atom bonded thereto means a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 6-membered saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like. Specific examples of the saturated monocyclic hetero ring include those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which optionally contain, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • The saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 substituents selected from the following group B.
  • The “hetero ring” formed by RA3 and RA4 together with the nitrogen atom bonded thereto means a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 4- to 6-membered (e.g., 5-membered) monocyclic hetero ring, a 8- to 10-membered (e.g., 9-membered) fused cyclic hetero ring and the like, optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Specific examples of the hetero ring include those exemplified as the above-mentioned “hetero ring”, which optionally contain, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • The hetero ring is optionally substituted by 1 or 2 oxo groups.
  • The “saturated monocyclic heterocyclic group” for R1 means a saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and examples thereof include a 5- or 6-membered saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like. Specific examples of the saturated monocyclic heterocyclic group include groups derived from those exemplified as the above-mentioned “saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom”, which optionally contain, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like. Examples thereof include a pyrrolidinyl group, a tetrahydrofuryl (e.g., 3-tetrahydrofuryl) group, a tetrahydrothienyl group, an imidazolidinyl group, a pyrazolidinyl group, a 1,3-dioxolanyl group, a 1,3-oxathioranyl group, an oxazolidinyl group, a thiazolidinyl group, a piperidinyl group, a piperazinyl group, a tetrahydropyranyl group, a tetrahydrothiopyranyl group, a dioxanyl group, a morpholinyl group, a thiomorpholinyl group and the like.
  • The “group A” includes the following substituents (a) to (i).
    • (a) —CO—NRA1RA2
  • wherein RA1 and RA2 are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • RA1 and RA2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
    • (b) a hydroxyl group,
    • (c) a C1-6 alkoxy group,
    • (d) a C1-6 alkoxy-C1-6 alkoxy group,
    • (e) a cyano group,
    • (f) —NRA3RA4
  • wherein RA3 and RA4 are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group,
      • (iii) a C1-6 alkyl-carbonyl group, or
      • (iv) a C1-6 alkyl-sulfonyl group, or
  • RA3 and RA4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
    • (g) a carboxyl group,
    • (h) a C1-6 alkyl-sulfonyl group, and
    • (i) a C1-6 alkyl-carbonyl group.
  • The “C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A” is that wherein the “C1-6 alkyl group” defined above is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from “group A” defined above, and includes an unsubstituted C1-6 alkyl group.
  • The “group B” includes the following substituents (a) to (e).
    • (a) a hydroxyl group,
    • (b) a C1-6 alkoxy group,
    • (c) a C1-6 alkoxy-C1-6 alkyl group,
    • (d) a C3-8 cycloalkyl group, and
    • (e) an oxo group.
  • The “C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B” is that wherein the “C1-6 alkyl group” defined above is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the “group B” defined above, and includes an unsubstituted C1-6 alkyl group.
  • The “saturated monocyclic hetero ring is optionally substituted by the same or different 1 to 5 substituents selected from group B” for Ra and Rb, or RA1 and RA2 means that the “saturated monocyclic hetero ring” defined above which is formed by Ra and Rb, or RA1 and RA2 together with the nitrogen atom bonded thereto is optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from the “group B” defined above, and includes an unsubstituted saturated monocyclic hetero ring.
  • In the above-mentioned formula [I], preferable groups are as described below.
  • R1 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group,
    • (2) a C3-8 cycloalkyl group, or
    • (3) a saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • Preferable embodiment of R1 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group.
  • More preferable embodiment of R1 is a C1-6 alkyl group.
  • A different, more preferable embodiment of R1 is a C1-6 alkyl group substituted by a C3-8 cycloalkyl group.
  • A different, preferable embodiment of R1 is a C3-8 cycloalkyl group.
  • Further different preferable embodiments of R1 are (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 3 C3-8 cycloalkyl groups,
    • (2) a C3-8 cycloalkyl group,
    • (3) a 5- or 6-membered saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like.
  • Of these, preferred are a methyl group, a cyclopropylmethyl group, an ethyl group, a 1-cyclopropylethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a tetrahydrofuryl (e.g., 3-tetrahydrofuryl) group and the like.
  • R2, R3, R4 and R5 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B,
    • (4) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A, or
    • (5) a cyano group.
  • In a preferable embodiment of R2, R3, R4 and R5, one of R2, R3, R4 and R5 is —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B.
  • In another preferable embodiment of R2, R3, R4 and R5, one of R2, R3, R4 and R5 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A.
  • Further preferable embodiments of R2, R3, R4 and R5 are respectively shown below.
  • As R2, preferred are
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom, and
      • (ii) a C1-6 alkyl group, or
      • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a 4- to 7-membered (e.g., 4- to 6-membered) saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 (e.g., 1 to 3, preferably 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom,
    • (4) a C1-6 alkyl group optionally substituted by the same or different 1 to 3 (e.g., 1) substituents selected from
      • (a) —CO—NRA1RA2
        • wherein RA1 and RA2 are the same or different and each is
          • (i) a hydrogen atom, or
          • (ii) a C1-6 alkyl group,
      • (b) a hydroxyl group,
      • (c) a C1-6 alkoxy group,
      • (d) a C1-6 alkoxy-C1-6 alkoxy group,
      • (e) a cyano group,
      • (f) —NRA3RA4
        • wherein RA3 and RA4 are the same or different and each is
          • (i) a hydrogen atom,
          • (ii) a C1-6 alkyl group,
          • (iii) a C1-6 alkyl-carbonyl group, or
          • (iv) a C1-6 alkyl-sulfonyl group, and
      • (g) a carboxyl group, and
    • (5) a cyano group.
  • As R2, more preferred are
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb
      • wherein Ra and Rb are the same or different and each is
        • (i) a hydrogen atom,
        • (ii) a methyl group,
        • (ii′) an ethyl group,
        • (ii″) an isopropyl group, or
        • (ii′″) a tert-butyl group, or
      • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring selected from azetidine, pyrrolidine and morpholine,
    • (4) a methyl group, an ethyl group, a propyl group, or an isopropyl group, which is optionally substituted by the same or different 1 to 3 (e.g., 1) substituents selected from
      • (a) —CO—NRA1RA2
        • wherein RA1 and RA2 are the same or different and each is
          • (i) a hydrogen atom, or
          • (ii) a methyl group,
      • (b) a hydroxyl group,
      • (c) a methoxy group,
      • (c′) an ethoxy group,
      • (c″) an isopropoxy group,
      • (d) a methoxyethoxy group,
      • (e) a cyano group,
      • (f) —NRA3RA4
        • wherein RA3 and RA4 are the same or different and each is a hydrogen atom, a methyl group, a methylcarbonyl group, an isopropylcarbonyl group, a tert-butylcarbonyl group, a 1,1-dimethylpropylcarbonyl group or a methylsulfonyl group, and
      • (g) a carboxyl group, and
    • (5) a cyano group.
  • As R3, preferred are
    • (1) a hydrogen atom, and
    • (2) a C1-6 alkyl group optionally substituted by a C1-6 alkoxy group.
  • As R3, more preferred are a hydrogen atom, a methyl group and a methoxymethyl group.
  • As R4, preferred are
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb
      • wherein Ra and Rb are the same or different and each is
        • (i) a hydrogen atom,
        • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from a C1-6 alkoxy group and a C3-8 cycloalkyl group, or
        • (iii) a C3-8 cycloalkyl group, or
      • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring which is a 4- to 7-membered (e.g., 4- to 6-membered) saturated monocyclic hetero ring which is optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 (e.g., 1 to 3, preferably 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents selected from (a) a hydroxyl group, (b) a C1-6 alkoxy group, (c) a C1-6 alkoxy-C1-6 alkyl group and (d) an oxo group,
    • (4) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) substituents
      • (a) —CO—NRA1RA2
        • wherein RA1 and RA2 are the same or different and each is selected from
          • (i) a hydrogen atom,
          • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 (e.g., 1 to 3, preferably 1) C1-6 alkoxy groups, or
          • (iii) a C3-8 cycloalkyl group, or
        • RA1 and RA2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring which is a 4- to 6-membered saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 (e.g., 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by a C1-6 alkoxy group,
      • (b) a hydroxyl group,
      • (c) a C1-6 alkoxy group,
      • (d) a C1-6 alkoxy-C1-6 alkoxy group,
      • (e) a cyano group,
      • (f) —NRA3RA4
        • wherein RA3 and RA4 are the same or different and each is
          • (i) a hydrogen atom,
          • (ii) a C1-6 alkyl group,
          • (iii) a C1-6 alkyl-carbonyl group, or
          • (iv) a C1-6 alkyl-sulfonyl group, or
        • RA3 and RA4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring which is a 4- to 7-membered (e.g., 6-membered) monocyclic hetero ring, or a 8- to 10-membered (e.g., 9-membered) fused cyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
      • (g) a carboxyl group,
      • (h) a C1-6 alkyl-sulfonyl group, and
      • (i) a C1-6 alkyl-carbonyl group, and
    • (5) a cyano group.
  • As R4, more preferred are
    • (1) a hydrogen atom,
    • (2) a carboxyl group,
    • (3) —CO—NRaRb
      • wherein Ra and Rb are the same or different and each is
        • (i) a hydrogen atom,
        • (ii) a methyl group, an ethyl group, an isopropyl group or an isobutyl group, which is optionally substituted by the same or different one substituent selected from a methoxy group and a cyclopropyl group, or
        • (iii) a cyclopropyl group, or
      • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring selected from azetidine, pyrrolidine, piperidine and morpholine, which is optionally substituted by one substituent selected from a hydroxyl group, a methoxy group, a methoxymethyl group and an oxo group,
    • (4) a methyl group, an ethyl group, a propyl group, an isopropyl group or a tert-butyl group, which is optionally substituted by one or two substituents selected from
      • (a) —CO—NRA1RA2
        • wherein RA1 and RA2 are the same or different and each is
          • (i) a hydrogen atom,
          • (ii) a methyl group, an ethyl group, an isopropyl group or an isobutyl group, which is optionally substituted by a methoxy group, or
          • (iii) a cyclopropyl group, or
        • RA1 and RA2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring selected from azetidine, piperidine and morpholine, and optionally substituted by a methoxy group,
      • (b) a hydroxyl group,
      • (c) a methoxy group,
      • (c′) an ethoxy group,
      • (c″) a propoxy group,
      • (c′″) an isopropoxy group,
      • (c″″) a butoxy group,
      • (d) a methoxyethoxy group,
      • (d′) an ethoxyethoxy group,
      • (d″) a methoxypropoxy group,
      • (d′″) a methoxyisopropoxy group,
      • (d″″) an isopropoxyethoxy group,
      • (e) a cyano group,
      • (f) —NRA3RA4
        • wherein RA3 and RA4 are the same or different and each is a hydrogen atom, a methyl group, an ethyl group, an isopropyl group, a methylcarbonyl group, an ethylcarbonyl group, an isopropylcarbonyl group, a methylsulfonyl group or a tert-butylsulfonyl group, or
        • RA3 and RA4 optionally form, together with the nitrogen atom bonded thereto, pyrazole, triazole (e.g., 1,2,4-triazole), tetrazole, oxazolidine or isoindoline, which is optionally substituted by 1 or 2 oxo groups,
      • (g) a carboxyl group,
      • (h) a methylsulfonyl group, and
      • (i) a methylcarbonyl group, and
    • (5) a cyano group.
  • As R5, preferred are a hydrogen atom and a C1-6 alkyl group optionally substituted by one substituent selected from a C1-6 alkoxy group and a C1-6 alkoxy-C1-6 alkoxy group.
  • As R5, more preferred are a hydrogen atom and a methyl group or an ethyl group, which is optionally substituted by one substituent selected from a methoxy group and a methoxyethoxy group.
  • R2 and R3, or R4 and R5 optionally form, together with the carbon atom bonded thereto, i) C3-8 cycloalkane or ii) a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • As the ring formed by R2 and R3, or R4 and R5 together with the carbon atom bonded thereto, preferred are
    • i) C3-8 cycloalkane, and
    • ii) a 5- to 7-membered (e.g., 6-membered) saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 (e.g., 1 to 3, preferably 1) hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
  • As the ring formed by R2 and R3, or R4 and R5 together with the carbon atom bonded thereto, more preferred are cyclopropane and tetrahydropyran.
  • Here, R2, R3, R4 and R5 are not hydrogen atoms at the same time.
  • R6 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 (e.g., 1 to 3) halogen atoms,
    • (2) a C1-6 alkoxy group,
    • (3) a halogen atom, or
    • (4) a C3-8 cycloalkyl group.
  • As R6, preferred is a halogen atom.
  • Other preferable embodiments of R6 are a methyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, a fluorine atom, a chlorine atom, a bromine atom and a cyclopropyl group.
  • Y is
    • (1) CH, or
    • (2) a nitrogen atom.
  • As Y, preferred is CH.
  • Other preferable embodiment of Y is a nitrogen atom.
  • m is an integer of 1 to 5, and when m is an integer of 2 to 5, the above-mentioned R6 may be the same or different.
  • As m, preferred is 1 to 3.
  • As m, more preferred is 1 or 2.
  • n is an integer of 1 to 3.
  • As n, preferred is 1.
  • In the above-mentioned formula [I-1], preferable groups are as described below.
  • R11 is
    • (1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group, or
    • (2) a C3-8 cycloalkyl group.
  • As R11, those exemplified as the preferable embodiments of R1 in the above-mentioned formula (I), which are within the scope of R11, are preferable.
  • R21, R31, R41 and R51 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) —CO—NRaRb
      • wherein Ra and Rb are the same or different and each is
        • (i) a hydrogen atom,
        • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, and
        • (iii) a C3-8 cycloalkyl group, or
      • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
    • (3) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A.
  • As R21, preferred is a hydrogen atom.
  • Other preferable embodiment of R21 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A. More preferred is a C1-6 alkyl group.
  • Examples of yet other preferable embodiment of R21 include those exemplified as the preferable embodiments of R2 in the above-mentioned formula (I), which are within the scope of R21.
  • As R31, preferred is a hydrogen atom.
  • Examples of other preferable embodiment of R31 include those exemplified as the preferable embodiments of R3 in the above-mentioned formula (I), which are within the scope of R31.
  • As R41, preferred is a hydrogen atom.
  • Other preferable embodiment of R41 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A. More preferred is a C1-6 alkyl group.
  • Examples of yet other preferable embodiment of R41 include those exemplified as the preferable embodiments of R4 in the above-mentioned formula (I), those contained within the scope of R41.
  • As R51, preferred is a hydrogen atom.
  • Other preferable embodiments of R51 are those exemplified as the preferable embodiments of R5 in the above-mentioned formula (I), which are within the scope of R51.
  • Here, R21, R31, R41 and R51 are not hydrogen atoms at the same time.
  • R61 is a halogen atom.
  • As R61, preferred are a fluorine atom and a chlorine atom.
  • R62 is a hydrogen atom or a halogen atom.
  • As R62, preferred are a hydrogen atom, a fluorine atom and a bromine atom.
  • In the above-mentioned formula [I-2], preferable groups are as described below.
  • R12 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
      • (i) a C3-8 cycloalkyl group, and
      • (ii) a C1-6 alkoxy group.
  • As R12, those exemplified as the preferable embodiments of R1 in the above-mentioned formula (I), which are within the scope of R12, are preferable.
  • R22, R32, R42 and R52 are the same or different and each is
    • (1) a hydrogen atom,
    • (2) —CO—NRaRb
  • wherein Ra and Rb are the same or different and each is
      • (i) a hydrogen atom,
      • (ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
      • (iii) a C3-8 cycloalkyl group, or
  • Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, or
    • (3) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group A.
  • As R22, preferred is a hydrogen atom.
  • Other preferable embodiments of R22 are those exemplified as the preferable embodiments of R2 in the above-mentioned formula (I), which are within the scope of R22.
  • As R32, preferred is a hydrogen atom.
  • Other preferable embodiments of R32 are those exemplified as the preferable embodiments of R3 in the above-mentioned formula (I), which are within the scope of R32.
  • As R42, preferred is —CO—NRaRb
      • wherein Ra and Rb form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B.
  • Other preferable embodiments of R42 are those exemplified as the preferable embodiments of R4 in the above-mentioned formula (I), which are within the scope of R42.
  • As R52, preferred is a C1-6 alkyl group.
  • Other preferable embodiments of R52 are those exemplified as the preferable embodiments of R5 in the above-mentioned formula (I), which are within the scope of R52.
  • Here, R22, R32, R42 and R52 are not hydrogen atoms at the same time.
  • R63 is a halogen atom.
  • As R63, preferred is a fluorine atom.
  • R64 is a hydrogen atom or a halogen atom.
  • As R64, preferred are a hydrogen atom and a fluorine atom.
  • As the compound of the present invention, compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2], and compounds described in the following Examples are preferable.
  • A pharmaceutically acceptable salt of the “compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2]” (hereinafter to be also referred to as the compound of the present invention) may be any salt as long as it forms an atoxic salt with the compound of the present invention. Examples thereof include a salt with an inorganic acid, a salt with an organic acid, a salt with an inorganic base, a salt with an organic base, a salt with an amino acid and the like.
  • Examples of the salt with an inorganic acid include salts with hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like.
  • Examples of the salt with an organic acid include salts with oxalic acid, malonic acid, maleic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
  • Examples of the salt with an inorganic base include sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt and the like.
  • Examples of the salt with an organic base include salts with methylamine, diethylamine, trimethylamine, triethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, dicyclohexylamine, N,N′-dibenzylethylenediamine, guanidine, pyridine, picoline, choline, cinchonine, meglumine and the like.
  • Examples of the salt with an amino acid include salts with lysine, arginine, aspartic acid, glutamic acid and the like.
  • Each salt can be obtained by reacting a compound represented by the formula [I], the formula [I-1] and the formula [I-2] with an inorganic base, an organic base, an inorganic acid, an organic acid or an amino acid according to a method known per se.
  • In the present invention, as the pharmaceutically acceptable salt of the compounds represented by the formula [I], the formula [I-1] and the formula [I-2], preferred are salts with hydrochloric acid (e.g., 1 hydrochloride, 2 hydrochloride), salts with hydrobromic acid (e.g., 1 hydrobromide, 2 hydrobromide), and sodium salt.
  • The “solvate” is a compound represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, with which a molecule of a solvent is coordinated, and also encompasses hydrates (also referred to as water-containing compound). The solvate is preferably a pharmaceutically acceptable solvate, such as a 1 hydrate, a ½ hydrate, a 2 hydrate, a 1 hydrate of sodium salt, a 1 methanolate, a 1 ethanolate, a 1 acetonitrilate, a ⅔ ethanolate of 2 hydrochloride of the compound represented by the formula [I], the formula [I-1] and the formula [I-2] and the like.
  • A solvate of a compound represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof can be obtained according to a method known per se.
  • In addition, there can be various isomers of compounds represented by the above-mentioned formulas [I], [I-1] and [I-2]. For example, when E form and Z form are present as geometric isomers, and when an asymmetric carbon atom is present, enantiomers and diastereomers are present as stereo isomers based on them. In addition, when axial chirality is present, stereo isomers based thereon are present. Where necessary, tautomers can be present. Accordingly, all of such isomers and mixtures thereof are encompassed in the scope of the present invention. As the compound of the present invention, one isolated and purified from various isomers, by-products, metabolites or prodrugs is preferable, and one having a purity of not less than 90% is preferable and one having a purity of not less than 95% is more preferable.
  • In addition, the compounds represented by the formula [I], the formula [I-1] and the formula [I-2] may be crystal or amorphous.
  • In addition, a compound represented by the formula [I], the formula [I-1] and the formula [I-2] may be labeled with an isotope (e.g., 3H, 14C, 35S etc.).
  • As the compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof, compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof, which is substantially purified, is preferable. More preferred is compounds represented by the formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof, which has been purified to a purity of not less than 80%.
  • In the present invention, a prodrug of a compound represented by the formula [I], the formula [I-1] and the formula [I-2] can also be a useful medicament.
  • A “prodrug” is a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which restores to the original compound to show its inherent efficacy after administration to the body by, for example, hydrolysis, solvolysis or decomposition under physiological conditions. It includes a complex and a salt, not involving a covalent bond.
  • The prodrug is utilized, for example, for improving absorption by oral administration or targeting of a target site.
  • Examples of the site to be modified include highly reactive functional groups in the compound of the present invention, such as hydroxyl group, carboxyl group, amino group and the like.
  • Examples of the hydroxyl-modifying group include acetyl group, propionyl group, isobutyryl group, pivaloyl group, palmitoyl group, benzoyl group, 4-methylbenzoyl group, dimethylcarbamoyl group, dimethylaminomethylcarbonyl group, sulfo group, alanyl group, fumaryl group and the like. In addition, a sodium salt of 3-carboxybenzoyl group, 2-carboxyethylcarbonyl group and the like can also be used.
  • Examples of the carboxyl-modifying group include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pivaloyloxymethyl group, carboxymethyl group, dimethylaminomethyl group, 1-(acetyloxy) ethyl group, 1-(ethoxycarbonyloxy)ethyl group, 1-(isopropyloxycarbonyloxy)ethyl group, 1-(cyclohexyloxycarbonyloxy) ethyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group, benzyl group, phenyl group, o-tolyl group, morpholinoethyl group, N,N-diethylcarbamoylmethyl group, phthalidyl group and the like.
  • Examples of the amino-modifying group include hexylcarbamoyl group, 3-methylthio-1-(acetylamino)propylcarbonyl group, 1-sulfo-1-(3-ethoxy-4-hydroxyphenyl)methyl group, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl group and the like.
  • Examples of the “pharmaceutical composition” include oral preparations such as tablet, capsule, granule, powder, troche, syrup, emulsion, suspension and the like, and parenteral agents such as external preparation, suppository, injection, eye drop, transnasal agent, pulmonary preparation and the like.
  • The pharmaceutical composition of the present invention (e.g., an anti-HIV composition, a pharmaceutical composition for HIV integrase inhibitory etc.) is produced by appropriately admixing a suitable amount of a compound represented by the formula [I], the formula [I-1] or the formula [I-2] of the present invention or a salt thereof, or a solvate thereof with at least one kind of a pharmaceutically acceptable carrier according to a method known per se in the technical field of pharmaceutical preparations. The content of the compound represented by the formula [I], the formula [I-1] or the formula [I-2] of the present invention or a salt thereof, or a solvate thereof in the pharmaceutical composition varies depending on the dosage form, the dose and the like, and the like. It is, for example, 0.1 to 100 wt % of the whole composition.
  • Examples of the “pharmaceutically acceptable carrier” include various organic or inorganic carrier substances conventionally used as preparation materials such as excipient, disintegrant, binder, fluidizer, lubricant and the like for solid dosage forms, and solvent, solubilizing agent, suspending agent, isotonicity agent, buffering agent, soothing agent and the like for liquid preparations. Where necessary, additives such as preservative, antioxidant, colorant, sweetening agent and the like are used.
  • Examples of the “excipient” include lactose, sucrose, D-mannitol, D-solbitol, cornstarch, dextrin, microcrystalline cellulose, crystalline cellulose, carmellose, carmellose calcium, sodium carboxymethyl starch, low-substituted hydroxypropylcellulose, gum arabic and the like.
  • Examples of the “disintegrant” include carmellose, carmellose calcium, carmellose sodium, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, crystalline cellulose and the like.
  • Examples of the “binder” include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, crystalline cellulose, sucrose, dextrin, starch, gelatin, carmellose sodium, gum arabic and the like.
  • Examples of the “fluidizer” include light anhydrous silicic acid, magnesium stearate and the like.
  • Examples of the “lubricant” include magnesium stearate, calcium stearate, talc and the like.
  • Examples of the “solvent” include purified water, ethanol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
  • Examples of the “solubilizing agent” include propylene glycol, D-mannitol, benzyl benzoate, ethanol, triethanolamine, sodium carbonate, sodium citrate and the like.
  • Examples of the “suspending agent” include benzalkonium chloride, carmellose, hydroxypropylcellulose, propylene glycol, povidone, methylcellulose, glycerol monostearate and the like.
  • Examples of the “isotonicity agent” include glucose, D-sorbitol, sodium chloride, D-mannitol and the like.
  • Examples of the “buffering agent” include sodium hydrogen phosphate, sodium acetate, sodium carbonate, sodium citrate and the like.
  • Examples of the “soothing agent” include benzyl alcohol and the like.
  • Examples of the “preservative” include ethyl parahydroxybenzoate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, sorbic acid and the like.
  • Examples of the “antioxidant” include sodium sulfite, ascorbic acid and the like.
  • Examples of the “colorant” include food colors (e.g., Food Color Red No. 2 or 3, Food Color yellow 4 or 5 etc.), β-carotene and the like.
  • Examples of the “sweetening agent” include saccharin sodium, dipotassium glycyrrhizinate, aspartame and the like.
  • The pharmaceutical composition of the present invention can be administered not only to human but also to mammals other than human (e.g., mouse, rat, hamster, guinea pig, rabbit, cat, dog, swine, bovine, horse, sheep, monkey etc.) orally or parenterally (e.g., topical, rectal, intravenous administration etc.). While the dose varies depending on the subject of administration, disease, symptom, dosage form, administration route and the like, for example, the dose for oral administration to an adult patient (body weight: about 60 kg) is generally within the scope of about 1 mg to 1 g per day, based on the compound of the present invention as an active ingredient. The amount can be administered in one to several portions.
  • The compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof inhibits HIV integrase, and can be used as an active ingredient of a therapeutic agent or prophylactic agent for HIV infection.
  • To “inhibit HIV integrase” means to specifically inhibit the function as HIV integrase to eliminate or attenuate the activity thereof. For example, it means to specifically inhibit the function of HIV integrase under the conditions of the below-mentioned Experimental Example 1. As the “inhibition of HIV integrase”, preferred is “inhibition of human HIV integrase”. As the “HIV integrase inhibitor”, preferred is a “human HIV integrase inhibitor”.
  • The compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2] or a pharmaceutically acceptable salt thereof, or a solvate thereof can be used in combination (hereinafter to be referred to as combination use) with other single or plural medicaments (hereinafter to be also referred to as a concomitant drug) by a conventional method generally employed in the medicament field.
  • The administration frequency of the compounds represented by the above-mentioned formula [I], the formula [I-1] and the formula [I-2], or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a concomitant drug is not limited, and they may be administered as a combined agent to the subject of administration, or the two may be administered simultaneously or at certain time intervals. In addition, they may be used as a medicament in the form of a kit containing the pharmaceutical composition of the present invention and a concomitant drug. The dose of the concomitant drug may be determined according to the dosage used clinically, and can be appropriately determined depending on the subject of administration, disease, symptom, dosage form, administration route, administration time, combination and the like. The administration form of the concomitant drug is not particularly limited, and the compound of the present invention or a salt thereof, or a solvate thereof and the concomitant drug need only be combined.
  • An anti-HIV agent is generally required to sustain its effect for a long time, so that can be effective not only for temporal suppression of viral growth but also prohibition of viral re-growth. This means that a prolonged administration is necessary and that a high single dose may be frequently inevitable to sustain effect for a longer period through the night. Such prolonged and high dose administration increases the risk of causing side effects.
  • In view of this, one of the preferable embodiments of the compound of the present invention is such compound permitting high absorption by oral administration, and such compound capable of maintaining blood concentration of the administered compound for an extended period of time.
  • In addition to the above-mentioned, preferable embodiments of the compound of the present invention are a compound having fine pharmacological activity (e.g., a compound having strong HIV integrase inhibitory activity, a compound having high anti-HIV activity), a compound having fine bioavailability (e.g., a compound having high cellular membrane permeability, a compound stable to metabolic enzyme, a compound with low binding ability to protein and the like), a compound having an anti-HIV activity against HIV having G140S/Q148H mutation, and the like.
  • Of the compounds of the present invention, a compound having high pharmacological activity (concretely, IC50 of HIV integrase inhibitory activity is less than 0.1 μM, preferably less than 0.01 μM) and high oral absorption, whose blood concentration is maintained for a long time after administration, is more preferable.
  • Using the above-mentioned compound, dose and/or frequency of administration of the compound of the present invention to human are/is expected to be decreased. Preferable administration frequency is not more than twice a day, more preferably, not more than once a day (e.g., once a day, once in two days, etc.).
  • The compound of the present invention can be used for the improvement of viremia due to HIV and/or maintenance of improved condition thereof, prophylaxis and treatment of virus infections, particularly, an HIV infection and/or maintenance of improved condition thereof.
  • As an index of the “treatment”, “improvement” or “effect”, a decrease in the virus level or HIV RNA level in the body, particularly in blood, can be used.
  • The “prophylaxis of HIV infection” includes administration of a medicament to a person with suspected or possible HIV infection (infection due to transfusion, infection from mother to child), and the like.
  • By the “prophylaxis of AIDS” is meant, for example, administration of a medicament to an individual who tested HIV positive but has not yet developed the disease state of AIDS; administration of a medicament to an individual who shows an improved disease state of AIDS after treatment but who carries HIV still to be eradicated and whose relapse of AIDS is worried; administration of a medicament before infection with HIV out of a fear of possible infection; and the like.
  • Examples of the “other anti-HIV agents” and “other anti-HIV active substances” to be used for a multiple drug combination therapy include an anti-HIV antibody or other antibody, an HIV vaccine or other vaccine, immunostimulants such as interferon, interferon agonist and the like, a ribozyme against HIV, an HIV antisense drug, an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, an HIV integrase inhibitor, an inhibitor of attachment between a receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus (CCR5 antagonist and the like), a DNA polymerase inhibitor or DNA synthesis inhibitor, a medicament acting on HIVp24, an HIV fusion inhibitor, an IL-2 agonist or antagonist, a TNF-α antagonist, an α-glucosidase inhibitor, a purine nucleoside phosphorylase inhibitor, an apoptosis agonist or inhibitor, a cholinesterase inhibitor, an immunomodulator and the like.
  • Specific examples of the HIV reverse transcriptase inhibitor include Retrovir® (zidovudine), Epivir® (lamivudine), Zerit® (sanilvudine), Videx® (didanosine), Hivid® (zalcitabine), Ziagen® (abacavir sulfate), Viramune® (nevirapine), Stocrin® (efavirenz), Rescriptor® (delavirdine mesylate), Combivir® (zidovudine+lamivudine), Trizivir® (abacavir sulfate+lamivudine+zidovudine), Coactinon® (emivirine), Phosphonovir®, Coviracil®, alovudine (3′-fluoro-3′-deoxythymidine), Thiovir (thiophosphonoformic acid), Capravirin (5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyridylmethyl) imidazole-2-methanol carbamic acid), Tenofovir disoproxil fumarate ((R)-[[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid bis(isopropoxycarbonyloxymethyl)ester fumarate), DPC-083 ((4S)-6-chloro-4-[(1E)-cyclopropylethenyl]-3,4-dihydro-4-trifluoromethyl-2(1H)-quinazolinone), DPC-961 ((4S)-6-chloro-4-(cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)-2(1H)-quinazolinone), DAPD ((−)-β-D-2,6-diaminopurine dioxolane), Immunocal, MSK-055, MSA-254, MSH-143, NV-01, TMC-120, DPC-817, GS-7340, TMC-125, SPD-754, D-A4FC, capravirine, UC-781, emtricitabine, alovudine, Phosphazid, BCH-10618, DPC-083, Etravirine, BCH-13520, MIV-210, Abacavir sulfate/lamivudine, GS-7340, GW-5634, GW-695634, TMC-278 and the like, wherein ® means a registered trademark (hereinafter the same) and the names of other medicaments are general names.
  • Specific examples of the HIV protease inhibitor include Crixivan® (indinavir sulfate ethanolate), saquinavir, Invirase® (saquinavir mesylate), Norvir® (ritonavir), Viracept® (nelfinavir mesylate), lopinavir, Prozei® (amprenavir), Kaletra® (ritonavir+lopinavir), mozenavir dimesylate ([4R-(4α,5α,6β)]-1,3-bis[(3-aminophenyl)methyl]-hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one dimethanesulfonate), tipranavir (3′-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenylethyl-6-propyl-2H-pyran-3-yl]propyl]-5-(trifluoromethyl)-2-pyridinesulfonamide), lasinavir (N-[5(S)-(tert-butoxycarbonylamino)-4(S)-hydroxy-6-phenyl-2(R)-(2,3,4-trimethoxybenzyl)hexanoyl]-L-valine 2-methoxyethylenamide), KNI-272 ((R)—N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-N-1(R)-2-N-(isoquinolin-5-yloxyacetyl)amino-3-methylthiopropanoyl]amino-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide), GW-433908, TMC-126, DPC-681, buckminsterfullerene, MK-944A (MK944 (N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-[4-(2-benzo[b]furanylmethyl)-2(S)-(tert-butylcarbamoyl)piperazin-1-yl]pentanamide)+indinavir sulfate), JE-2147 ([2(S)-oxo-4-phenylmethyl-3(S)-[(2-methyl-3-oxy)phenylcarbonylamino]-1-oxabutyl]-4-[(2-methylphenyl)methylamino]carbonyl-4(R)-5,5-dimethyl-1,3-thiazole), BMS-232632 (dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedicarboxylate), DMP-850 ((4R,5S,6S,7R)-1-(3-amino-1H-indazol-5-ylmethyl)-4,7-dibenzyl-3-butyl-5,6-dihydroxyperhydro-1,3-diazepin-2-one), DMP-851, RO-0334649, Nar-DG-35, R-944, VX-385, TMC-114, Tipranavir, Fosamprenavir sodium, Fosamprenavir calcium, Darunavir, GW-0385, R-944, RO-033-4649, AG-1859 and the like.
  • The HIV integrase inhibitor is exemplified by S-1360, L-870810 and the like, the DNA polymerase inhibitor or DNA synthesis inhibitor is exemplified by Foscavir®, ACH-126443 (L-2′,3′-didehydro-dideoxy-5-fluorocytidine), entecavir ((1S,3S,4S)-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine), calanolide A ([10R-(10α,11β,12α)]-11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-2H,6H,10H-benzo[1,2-b:3,4-b′:5,6-b″]tripyran-2-one), calanolide B, NSC-674447 (1,1′-azobisformamide), Iscador (viscum alubm extract), Rubitecan and the like, the HIV antisense drug is exemplified by HGTV-43, GEM-92 and the like, the anti-HIV antibody or other antibody is exemplified by NM-01, PRO-367, KD-247, Cytolin®, TNX-355 (CD4 antibody), AGT-1, PRO-140 (CCR5 antibody), Anti-CTLA-4MAb and the like, the HIV vaccine or other vaccine is exemplified by ALVAC®, AIDSVAX®, Remune®, HIV gp41 vaccine, HIV gp120 vaccine, HIV gp140 vaccine, HIV gp160 vaccine, HIV p17 vaccine, HIV p24 vaccine, HIV p55 vaccine, AlphaVax Vector System, canarypox gp160 vaccine, AntiTat, MVA-F6 Nef vaccine, HIV rev vaccine, C4-V3 peptide, p2249f, VIR-201, HGP-30W, TBC-3B, PARTICLE-3B, Antiferon (interferon-α vaccine) and the like, the interferon or interferon agonist is exemplified by Sumiferon®, MultiFeron®, interferon-τ, Reticulose, human leukocyte interferon α and the like, the CCR5 antagonist is exemplified by SCH-351125 and the like, the medicament acting on HIV p24 is exemplified by GPG-NH2 (glycyl-prolyl-glycinamide) and the like, the HIV fusion inhibitor is exemplified by FP-21399 (1,4-bis[3-[(2,4-dichlorophenyl)carbonylamino]-2-oxo-5,8-disodium sulfonyl]naphthyl-2,5-dimethoxyphenyl-1,4-dihydrazone), T-1249, Synthetic Polymeric Construction No3, pentafuside, FP-21399, PRO-542, Enfuvirtide and the like, the IL-2 agonist or antagonist is exemplified by interleukin-2, Imunace®, Proleukin®, Multikine®, Ontak® and the like, the TNF-α antagonist is exemplified by Thalomid® (thalidomide), Remicade® (infliximab), curdlan sulfate and the like, the α-glucosidase inhibitor is exemplified by Bucast® and the like, the purine nucleoside phosphorylase inhibitor is exemplified by peldesine (2-amino-4-oxo-3H,5H-7-[(3-pyridyl)methyl]pyrrolo[3,2-d]pyrimidine) and the like, the apoptosis agonist or inhibitor is exemplified by Arkin Z®, Panavir®, Coenzyme Q10 (2-deca(3-methyl-2-butenylene)-5,6-dimethoxy-3-methyl-p-benzoquinone) and the like, the cholinesterase inhibitor is exemplified by Cognex® and the like, and the immunomodulator is exemplified by Imunox®, Prokine®, Met-enkephalin (6-de-L-arginine-7-de-L-arginine-8-de-L-valinamide-adrenorphin), WF-10 (10-fold dilute tetrachlorodecaoxide solution), Perthon, PRO-542, SCH-D, UK-427857, AMD-070, AK-602, TK-303 (Elvitegravir) and the like.
  • In addition, Neurotropin®, Lidakol®, Ancer 20®, Ampligen®, Anticort®, Inactivin®, PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL immunotherapy, ACTG protocol 080 therapy, CD4-ζ gene therapy), SCA binding protein, RBC-CD4 complex, Motexafin gadolinium, GEM-92, CNI-1493, (±)-FTC, Ushercell, D2S, BufferGel®, VivaGel®, Glyminox vaginal gel, sodium lauryl sulfate, 2F5, 2F5/2G12, VRX-496, Ad5gag2, BG-777, IGIV-C, BILR-255 and the like are exemplified.
  • The compound of the present invention can be combined with one or more (e.g., 1 or 2) kinds of other anti-HIV active substances (to be also referred to as other anti-HIV agents), and used as an anti-HIV agent and the like for the prophylaxis or treatment of HIV infection. As the “other anti-HIV agents” and “other anti-HIV active substances” to be used for a multiple drug combination therapy with the compound of the present invention, preferred are an HIV reverse transcriptase inhibitor and an HIV protease inhibitor. Two or three, or even a greater number of medicaments can be used in combination, wherein a combination of medicaments having different action mechanisms is one of the preferable embodiments. In addition, selection of medicaments free of side effect duplication is preferable.
  • Specific examples of the combination of medicaments include a combination of a group consisting of efavirenz, tenofovir, emtricitabine, indinavir, nelfinavir, atazanavir, ritonavir+indinavir, ritonavir+lopinavir, ritonavir+saquinavir, didanosine+lamivudine, zidovudine+didanosine, stavudine+didanosine, zidovudine+lamivudine, stavudine+lamivudine and tenofovir+emtricitabine, and the compound of the present invention (Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Aug. 13, 2001). Particularly preferred is a combined use of two agents with efavirenz, indinavir, nelfinavir, tenofovir, emtricitabine, zidovudine or lamivudine, and a combined use of three agents with zidovudine+lamivudine, tenofovir+lamivudine, tenofovir+zidovudine, tenofovir+efavirenz, tenofovir+nelfinavir, tenofovir+indinavir, tenofovir+emtricitabine, emtricitabine+lamivudine, emtricitabine+zidovudine, emtricitabine+efavirenz, emtricitabine+nelfinavir, emtricitabine+indinavir, nelfinavir+lamivudine, nelfinavir+zidovudine, nelfinavir+efavirenz, nelfinavir+indinavir, efavirenz+lamivudine, efavirenz+zidovudine or efavirenz+indinavir.
  • In the case of combined administration, the compound of the present invention can be administered simultaneously with a medicament to be used in combination (hereinafter concomitant drug) or administered at certain time intervals. In the case of combined administration, a pharmaceutical composition comprising the compound of the present invention and a concomitant drug can be administered. Alternatively, a pharmaceutical composition comprising the compound of the present invention and a pharmaceutical composition comprising a concomitant drug may be administered separately. The administration route of the compound of the present invention and that of the concomitant drug may be the same or different.
  • In the case of a combined administration, the compound of the present invention can be administered once a day or several times a day in a single dose of 0.01 mg to 1 g, or may be administered at a smaller dose. The concomitant drug can be administered at a dose generally used for the prevention or treatment of an HIV infection, for example, at a single dose of 0.01 mg to 0.3 g. Alternatively, it may be administered in a smaller dose.
  • Now, production methods of the compound of the present invention are specifically explained. However, the present invention is not limited to these production methods. For production of the compound of the present invention, the order of reactions can be appropriately changed. The reactions may be performed from a reasonable step or a reasonable substitution moiety. In addition, an appropriate substituent conversion (conversion or further modification of substituent) step may be inserted between respective steps. When a reactive functional group is present, protection and deprotection may be appropriately performed. Furthermore, to promote the progress of reactions, reagents other than those exemplified below may be used as appropriate. The starting compounds whose production methods are not described are commercially available or can be easily prepared by a combination of known synthesis reactions. The compound obtained in each step can be purified by conventional methods such as distillation, recrystallization, column chromatography and the like. In some cases, the next step may be performed without isolation and purification.
  • In the following production methods, the “room temperature” means 1 to 40° C.
    • Production Method I Production Method I-1
  • Of compounds [I-3-1] in the below-mentioned production method I-3, compound [I-1-6] which is compound [I-3-1] wherein Y is CH can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00015
  • wherein R11a and R11c are the same or different and each is a hydroxyl-protecting group such as an acetyl group, a benzyl group, a methyl group, an ethyl group, an isopropyl group, a trimethylsilyl group, a triethylsilyl group, a tert-butyldimethylsilyl group, a triisopropylsilyl group, a tert-butyldiphenylsilyl group and the like, R11b is a carboxyl-protecting group such as a methyl group, an ethyl group, a benzyl group, a tert-butyl group and the like, X11a is a halogen atom such as a chlorine atom, a bromine atom and the like, and other symbols are each as described above.
    • Step 1
  • Compound [I-1-2] can be obtained by introducing a protecting group into the carboxyl group of compound [I-1-1] according to a known method.
  • For example, when R11b is a methyl group, compound [I-1-2] can be obtained by reacting compound [I-1-1] with trimethylsilyldiazomethane at a low temperature to room temperature in a single or mixed solvent such as tetrahydrofuran (THF), toluene, methanol, ethanol and the like.
    • Step 2
  • Compound [I-1-3] can be obtained by introducing a halogen atom X11a into compound [I-1-2] according to a known method.
  • For example, when X11a is a bromine atom, compound [I-1-3] can be obtained by reacting compound [I-1-2] with a bromination reagent (e.g., bromine, trimethylphenylammonium tribromide etc.) at room temperature to under heating in a solvent such as chloroform, methylene chloride, acetic acid and the like.
    • Step 3
  • Compound [I-1-4] can be obtained by introducing a protecting group into a hydroxyl group of compound [I-1-3] according to a known method.
  • For example, when R11c is a benzyl group, compound [I-1-4] can be obtained by reacting compound [I-1-3] with benzyl halide (e.g., benzyl chloride, benzyl bromide etc.) at room temperature to under heating in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, sodium hydrogen phosphate, cesium carbonate, sodium hydride, potassium t-butoxide, lithiumdiisopropylamide (LDA) and the like in a solvent such as N,N-dimethylformamide (DMF), dimethylacetamide (DMA), acetonitrile, 1,2-dimethoxyethane, THF, toluene and the like.
    • Step 4
  • Compound [I-1-6] can be obtained by subjecting compound [I-1-4] to a coupling reaction with compound [I-1-5] in the presence of a palladium catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0), tetrakis(triphenylphosphine)palladium(0) and bis(triphenylphosphine)palladium(II) dichloride etc.) at room temperature to under heating in a solvent such as DMF, DMA, acetonitrile, toluene, 1,4-dioxane and the like. For preferable progress of the reaction, a ligand (e.g., tri(2-furyl)phosphine, tributylphosphine etc.) may be further added.
  • For example, compound [I-1-5] wherein n is 1 can be obtained in the same manner as in step 1R-2 and step 1R-3 of the below-mentioned Reference Example 1.
    • Production Method I-2
  • Of compounds [I-3-1] in the below-mentioned production method I-3, compound [I-2-9] which is compound [I-3-1] wherein Y is a nitrogen atom and R13b is an ethyl group can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00016
  • wherein R12a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, R12b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, and other symbols are each as described above.
    • Step 1
  • Compound [I-2-3] can be obtained by reacting compound [I-2-1] with compound [I-2-2] at −78° C. to room temperature conditions in a solvent such as DMF, DMA, dimethyl sulfoxide (DMSO), THF, toluene and the like, in the presence of a base such as sodium hydride, lithiumdiisopropylamide (LDA), lithium hexamethyldisilazide (LHMDS) and the like.
    • Step 2
  • Compound [I-2-4] can be obtained by reacting Compound [I-2-3] with N,N-dimethylformamidedimethylacetal at room temperature to under heating in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like.
    • Step 3
  • Compound [I-2-6] can be obtained by adding a base such as sodium hydride, LDA, LHMDS and the like to a solution of Compound [I-2-4] dissolved in a solvent such as DMF, DMA, DMSO, THF, toluene and the like at -78° C. to room temperature, reacting the compound with compound [I-2-5] and treating same with triethylamine, diisopropylethylamine or the like.
    • Step 4
  • Compound [I-2-7] can be obtained by removing the carboxyl-protecting group R12b of compound [I-2-6] by a known method. For example, when the protecting group is a tert-butyl group, compound [I-2-7] can be obtained by stirring compound [I-2-6] at a low temperature to under heating in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF, methanol, ethanol, 2-propanol, DMSO, DMF, DMA, acetonitrile, water and the like in the presence of acid such as p-toluenesulfonic acid, methanesulfonic acid, boron trifluoride, boron trichloride, boron tribromide, aluminum trichloride, hydrochloric acid, hydrogen bromide, phosphoric acid, sulfuric acid, acetic acid, trifluoroacetic acid and the like.
    • Step 5
  • Compound [I-2-9] can be obtained by converting compound [I-2-7] to acid chloride by a known method, and further reacting the compound with compound [I-2-8]. Specifically, compound [I-2-9] can be obtained by converting compound [I-2-7] to acid chloride with a chlorinating agent such as oxalyl chloride, thionyl chloride, phosphorus trichloride and the like at a low temperature to room temperature in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF and the like in the presence of a catalytic amount of DMF where necessary, and reacting the compound with compound [I-2-8].
    • Production Method I-3
  • A compound represented by the above-mentioned formula [I] can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00017
  • wherein R13a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, R13b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, R13c is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, and other symbols are each as described above.
    • Step 1
  • Compound [I-3-3] can be obtained by reacting compound [I-3-1] with compound [I-3-2], wherein amino-protecting group R13c is removed in advance according to a known method at room temperature to under heating in a single or mixed solvent of chloroform, dichloromethane, DMF, DMA, DMSO, acetonitrile, 1,2-dimethoxyethane, THF, toluene, water and the like, and cyclizing the compound in the presence of a base such as triethylamine, diisopropylamine, diisopropylethylamine, diazabicycloundecene, sodium carbonate, potassium carbonate, sodium hydrogen carbonate and the like. The cyclization reaction can also be performed in the presence of acid such as acetic acid, p-toluenesulfonic acid, methanesulfonic acid, boron trifluoride, boron trichloride, boron tribromide, hydrochloric acid, hydrogen bromide, phosphoric acid, sulfuric acid and the like.
    • Step 2
  • Compound [I] can be obtained by removing the hydroxyl-protecting group R13a of compound [I-3-3] by a known method. For example, when the protecting group is a benzyl group, compound [I] can be obtained by stirring compound [I-3-3] at a low temperature to room temperature in a single or mixed solvent of hexane, chloroform, methylene chloride, ethyl acetate, toluene, methanol, ethanol, 2-propanol, THF, 1,4-dioxane, acetonitrile, water and the like, in the presence of acid such as hydrochloric acid, sulfuric acid, hydrogen bromide, phosphoric acid, acetic acid, trifluoroacetic acid and the like. The acid may be used as a solvent.
    • Production Method I-4
  • Compound [I-3-2] in the above-mentioned production method I-3 (corresponding to the following compound [I-4-3]) can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00018
  • wherein R14a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, and other symbols are each as described above.
    • Step 1
  • Compound [I-4-1] obtainable from a commercially available compound by a known method is reacted with phthalimide at a low temperature to under heating in a single or mixed solvent of THF, methylene chloride, chloroform, DMF, ethyl acetate, toluene and the like in the presence of a phosphorus reagent such as triphenylphosphine, diphenyl(2-pyridyl)phosphine, tributylphosphine, tri-tert-butylphosphine and the like and an azo compound such as diisopropylazodicarboxylate, diethylazodicarboxylate, N,N,N′,N′-tetramethylazodicarboxamide, 1,1′-(azodicarbonyl)dipiperidine and the like, and the obtained compound is further treated with hydrazine to remove a phthaloyl group to give amine compound [I-4-2].
    • Step 2
  • Compound [I-4-2] is reacted with a ketone compound or aldehyde compound at a low temperature to room temperature in a solvent such as DMF, acetonitrile, THF, chloroform, ethyl acetate, methylene chloride, toluene and the like, and the mixture is stirred in the presence of a reducing agent such as sodium borohydride, sodium triacetoxyborohydride and the like to introduce substituent R1 into the amino group of compound [I-4-2], whereby compound [I-4-3] can be obtained.
    • Production Method I-5
  • Of compounds [I-3-2] in the above production method I-3, a compound, which is compound [I-3-2] wherein particularly R2 and R3 are each a hydrogen atom, one of R4 and R5 is a carboxyl group or —CO—NRaRb wherein Ra and Rb are as described above, and the other is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00019
  • wherein R15a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, R15b is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, R15c is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, and other symbols are each as described above.
    • Step 1
  • Compound [I-5-2] can be obtained by oxidizing the hydroxyl group of compound [I-5-1] obtainable from a commercially available compound by a known method, to a aldehyde group by a chromium oxide-pyridine complex (e.g., pyridinium chlorochromate, pyridinium dichromate and the like), a metal oxidant (e.g., chromium oxide, silver carbonate, manganese dioxide and the like), by DMSO oxidization using various DMSO activators such as oxalyl chloride, trifluoroacetic anhydride, acetic anhydride, dicyclohexylcarbodiimide (DCC), sulfur trioxide-pyridine complex and the like, Dess-Martin oxidization and the like according to a known method.
    • Step 2
  • Compound [I-5-3] can be obtained by subjecting the aldehyde group of compound [I-5-2] to a reductive amination under similar conditions as in production method I-4, step 2. The obtained compound [I-5-3] is cyclized by the above-mentioned method, and the carboxyl-protecting group R15b is removed by a known method and, where necessary, the resulting compound is reacted with an amine compound by a known method to give the object compound.
  • Production method II
    • Production Method II-1
  • Of the compounds represented by the above-mentioned formula [I], compound [II-1-6], which is compound [I] wherein Y is CH can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00020
  • wherein R21a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, R21b is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, X21a is a leaving group such as a halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, iodine atom and the like), p-toluenesulfonyloxy group (OTs), methanesulfonyloxy group (OMs), trifluoromethanesulfonyloxy group (OTf) and the like, and other symbols are each as described above.
    • Step 1
  • Compound [II-1-3] can be obtained by converting compound [II-1-1] to acid chloride by a known method at a low temperature to under heating, reacting the acid chloride with compound [II-1-2], removing the amino-protecting group R21b, and stirring the mixture in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, diisopropylethylamine, sodium hydrogen phosphate, cesium carbonate and the like.
  • Compound [II-1-2] can be obtained by a method similar to that of Production method I-4.
    • Step 2
  • Compound [II-1-4] can be obtained by introducing leaving group X21a into compound [II-1-3] by a known method.
  • For example, when the leaving group X21a is a bromine atom, the bromine atom is introduced into compound [II-1-3] by a method similar to that in production method I-1, step 2 to give compound [II-1-4].
    • Step 3
  • Compound [II-1-4] is reacted with compound [II-1-5] by a method similar to that of production method I-1, step 4, and the hydroxyl-protecting group R21a is removed by a method similar to that of production method I-3, step 2, whereby compound [II-1-6] can be obtained.
    • Production Method I-2
  • Of the compounds represented by the above-mentioned formula [I], a compound, which is compound [I] wherein particularly R2 and R3 are each a hydrogen atom, and one of R4 and R5 is a methyl group substituted by —NRA3RA4 wherein RA3 and A4 are as described above, and the other is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00021
  • wherein R22a is an amino-protecting group such as benzyloxycarbonyl group, tert-butoxycarbonyl group, benzyl group and the like, R22b is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the aforementioned group A, R22a and R22d are the same or different, and each is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, and other symbols are each as described above.
    • Step 1
  • The hydroxyl group of compound [II-2-1] is oxidized, by a known method to give aldehyde group, whereby compound [II-2-2] can be obtained. The known method is the same as the one indicated for, for example, the production method I-5, step 1.
    • Step 2
  • Compound [II-2-3] can be obtained by subjecting compound [II-2-2] to reductive amination by the same method as in the production method I-5, step 2.
    • Step 3
  • Compound [II-2-4] can be obtained from compound [II-2-3] by the same method as in production method II-1, step 1 to step 3.
    • Step 4
  • The hydroxyl-protecting group R22c of compound [II-2-4] is removed by a known method, and the hydroxyl group is appropriately subjected to substituent conversion to a leaving group (OTs, OMs, OTf etc.). After reaction with potassium phthalimide, and the phthaloyl group is removed by a method similar to production method I-4, step 1 to give compound [II-2-5]. The obtained compound [II-2-5] is subjected to an appropriately combination of removal of hydroxyl-protecting group R22d by a method similar to production method I-3, step 2, and modification of amino group of compound [II-2-5] by a known method to give the object compound.
    • Production Method III
  • Of compounds represented by the above-mentioned formula [I], compound [III-1-9], which is compound [I] wherein Y is a nitrogen atom can be synthesized by the following method.
  • Figure US20180319798A1-20181108-C00022
    Figure US20180319798A1-20181108-C00023
  • wherein R31a is a hydroxyl-protecting group such as acetyl group, benzyl group, methyl group, ethyl group, isopropyl group, trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, triisopropylsilyl group, tert-butyldiphenylsilyl group and the like, R31b and R31c are the same or different and each is a carboxyl-protecting group such as methyl group, ethyl group, benzyl group, tert-butyl group and the like, and other symbols are each as described above.
    • Step 1
  • Compound [III-1-3] can be obtained by reacting compound [III-1-1] with compound [III-1-2] by a method similar to production method I-2, step 3.
    • Step 2
  • Compound [III-1-4] can be obtained by removing the carboxyl-protecting group R31b of compound [III-1-3] by a method similar to production method I-2, step 4.
    • Step 3
  • Compound [III-1-5] can be obtained by reacting compound [III-1-4] with compound [I-2-8] by a method similar to production method I-2, step 5.
    • Step 4
  • Compound [III-1-6] can be obtained by removing the carboxyl-protecting group R31c of compound [III-1-5] by a known method.
    • Step 5
  • Compound [III-1-7] can be obtained by converting compound [III-1-6] to acid chloride by a method similar to production method I-2, step 5, and reacting the acid chloride with compound [I-3-2] in a solvent such as hexane, chloroform, methylene chloride, ethyl acetate, toluene, 1,2-dimethoxyethane, 1,4-dioxane, THF and the like in the presence of a base such as potassium acetate, potassium carbonate, potassium hydrogen carbonate, sodium hydrogen carbonate, potassium phosphate, triethylamine, diisopropylethylamine, sodium hydrogen phosphate, cesium carbonate and the like.
    • Step 6
  • Compound [III-1-8] can be obtained by removing the amino-protecting group R13c of compound [III-1-7] by a known method, and performing cyclization by a method similar to a cyclization reaction of production method II-1, step 1 in the presence of a base.
    • Step 7
  • Compound [III-1-9] can be obtained by removing the hydroxyl-protecting group R31a of compound [III-1-8] by a known method. For example, when the protecting group is a benzyl group, a method similar to production method I-3, step 2 can be used.
    • EXAMPLES
  • Now, the production methods of the compound of the present invention are specifically explained by referring to Examples, which are not to be construed as limitative.
  • The abbreviations used in the Examples mean the following.
    • Bn: benzyl group
    • Boc: tert-butoxycarbonyl group
    • Et: ethyl group
    • Me: methyl group
    • Ms: methanesulfonyl group
    • TBS: tert-butyldimethylsilyl group
    • TFA: trifluoroacetic acid
    • THP: tetrahydropyranyl group
    • Z: benzyloxycarbonyl group
  • In addition, the following 1H-NMR values were measured by resolution 400 MHz.
    • Reference Example 1 Step 1R-1
  • Figure US20180319798A1-20181108-C00024
  • 3-benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (11.43 g) was suspended in methanol (20 mL)-tetrahydrofuran (80 mL), 2M (trimethylsilyl)diazomethane/hexane solution (46.4 mL) was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 1.5 hr. The solvent was evaporated under reduced pressure and the obtained residue was dissolved in chloroform (80 mL). Thereto was added bromine (23 mL) and the mixture was stirred for 2 days at 75° C. The mixture was allowed to cool to room temperature, hexane was added and the precipitated solid was collected by filtration. The obtained solid was dissolved in dimethylformamide (54 mL), potassium carbonate (7.1 g) and benzyl bromide (5.6 mL) were added, and the mixture was stirred at 80° C. for 40 min. The mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated and 1N aqueous hydrochloric acid solution was added to the obtained residue. The mixture was extracted twice with ethyl acetate. The combined ethyl acetate layer was washed with saturated brine, dried, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:20-1:4), the eluate was concentrated, and the precipitated crystals were collected by filtration to give the object compound (7.65 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.11 (s, 1H), 7.49-7.44 (m, 2H), 7.40-7.32 (m, 3H), 5.32 (s, 2H), 3.89 (s, 3H).
    • Step 1R-2
  • Figure US20180319798A1-20181108-C00025
  • To a solution of 2-bromothiazole-5-carbaldehyde (14 g) in THF (300 mL) was added dropwise 1M (4-fluorophenyl)magnesium bromide/THF solution (80 mL) at −78° C., and the mixture was stirred for 1 hr. Saturated aqueous ammonium chloride solution was added, and the mixture was allowed to cool to room temperature, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated. Trifluoroacetic acid (100 mL) and triethylsilane (58 mL) were added to the obtained residue, and the mixture was stirred for 100 min at 75° C. The mixture was allowed to cool to room temperature and concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:50-1:9) to give the object compound (16.8 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.31-7.29 (m, 1H), 7.21-7.14 (m, 2H), 7.05-6.98 (m, 2H), 4.07 (s, 2H).
    • Step 1R-3
  • Figure US20180319798A1-20181108-C00026
  • To a solution of the compound (3.2 g) obtained in step 1R-2 in THF (50 mL) was added dropwise 1.6M n-butyllithium/hexane solution (8.1 mL) at −78° C. and the mixture was stirred for 10 min. Tributyltin chloride (3.5 mL) was added, and the mixture was stirred at −78° C. for 30 min and at room temperature for 30 min. Ice-cold water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated to give the object compound (6.2 g) described in the above-mentioned scheme as a crude product.
  • 1H-NMR (THF) δ: 7.76-7.74 (m, 1H), 7.25-7.21 (m, 2H), 7.03-6.97 (m, 2H), 4.19 (s, 2H), 1.65-1.56 (m, 6H), 1.40-1.28 (m, 6H), 1.20-1.13 (m, 6H), 0.91-0.85 (m, 9H).
    • Step 1R-4
  • Figure US20180319798A1-20181108-C00027
  • Under an argon stream, tris(dibenzylideneacetone)dipalladium(0) (84 mg) and tri(2-furyl)phosphine (85 mg) were suspended in toluene (1.5 mL), and the suspension was stirred at room temperature for 15 min. The compound (890 mg) obtained in step 1R-3 and the compound (310 mg) obtained in step 1R-1 were added, and the mixture was stirred at 80° C. for 1 hr. The obtained reaction mixture was filtered through celite, and concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:20-1:4) to give the object compound (190 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.91 (s, 1H), 7.62-7.61 (m, 1H), 7.51-7.45 (m, 2H), 7.40-7.32 (m, 3H), 7.25-7.19 (m, 2H), 7.04-6.97 (m, 2H), 5.37 (s, 2H), 4.19 (s, 2H), 3.91 (s, 3H).
    • Reference Example 2 Step 2R-1
  • Figure US20180319798A1-20181108-C00028
  • In the same manner as in step 1R-1 except that 3-benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (15.0 g) was ethylated with iodoethane, the object compound (10.97 g) described in the above-mentioned scheme was obtained.
  • 1H-NMR (CDCl3) δ: 8.11 (s, 1H), 7.50-7.46 (m, 2H), 7.40-7.32 (m, 3H), 5.31 (s, 2H), 4.36 (q, 2H, J=7.2 Hz), 1.33 (t, 3H, J=7.2 Hz).
    • Step 2R-2
  • Figure US20180319798A1-20181108-C00029
  • In the same manner as in step 1R-4, the object compound (1.0 g) described in the above-mentioned scheme was obtained from the compound (1.2 g) obtained in step 2R-1.
  • 1H-NMR (CDCl3) δ: 8.91 (s, 1H), 7.62-7.61 (m, 1H), 7.51-7.47 (m, 2H), 7.39-7.31 (m, 3H), 7.25-7.20 (m, 2H), 7.04-6.97 (m, 2H), 5.37 (s, 2H), 4.38 (q, 2H, J=7.2 Hz), 4.19 (s, 2H), 1.34 (t, 3H, J=7.2 Hz).
    • Reference Example 3
  • Figure US20180319798A1-20181108-C00030
    • Step 3R-1
  • To a solution of 4-fluorophenylacetic acid (25 g) and tert-butyl carbazate (22.5 g) in DMF (200 mL) were added 1-hydroxybenzotriazole hydrate (HOBT.HZO (27.3 g)) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl (34.1 g)), and the mixture was stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred for a while and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, and is concentrated to give the object compound (32.3 g) described in the above-mentioned scheme as a crude product.
    • Step 3R-2
  • Figure US20180319798A1-20181108-C00031
  • To a solution of the compound (32.3 g) obtained in step 3R-1 in THF (300 mL) was added a Lawesson reagent (48.7 g), and the mixture was stirred at 50° C. overnight and allowed to cool. The reaction mixture was poured into a stirred saturated aqueous sodium hydrogen carbonate solution by small portions, and the mixture was stirred at room temperature for 30 min. The mixture was extracted twice with ethyl acetate, and the organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over magnesium sulfate, and concentrated. To the residue was added 4N hydrochloric acid/dioxane solution (300 mL), and the mixture was stirred at room temperature for 1 hr. The precipitated salt was collected by filtration, and dissolved in water (200 mL), and the solution was neutralized with sodium hydrogen carbonate and extracted twice with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated. To the residue was added ethyl acetate/hexane (1:4) solution and the mixture was slurry washed. The residue was collected by filtration, and dried to give the object compound (15.78 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.27-8.03 (br m, 1H), 7.26-7.20 (m, 2H), 7.10-7.03 (m, 2H), 4.88-4.75 (br m, 2H), 4.08 (s, 2H).
    • Example 1 Step 1-1
  • Figure US20180319798A1-20181108-C00032
  • To a solution of (S)-2-ethylamino-3-methoxypropylcarbamic acid benzyl ester (76 mg) in methanol (10 mL) was added a 7.5% palladium-carbon catalyst (100 mg), and the reaction mixture was stirred under a moderate-pressure (0.4 MPa) in a hydrogen atmosphere at room temperature for 3 hr. The reaction mixture was filtered through celite, trifluoroacetic acid (1 mL) was added and the mixture was concentrated to give the object compound (133 mg) described in the above-mentioned scheme as a crude product.
    • Step 1-2
  • Figure US20180319798A1-20181108-C00033
  • To a solution of the compound (55 mg) obtained in step 1-1 in tetrahydrofuran (1.5 mL) was added diisopropylethylamine (160 μL), and the mixture was stirred for 10 min. A solution of the compound (46 mg) obtained in Reference Example 2 in tetrahydrofuran (1 mL) was added, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, toluene (4 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (200 μL) were added, and the mixture was stirred at 110° C. for 15 min. Acetic acid (500 μL) was added, and the mixture was stirred at 110° C. for 1 hr. The reaction mixture was allowed to cool to room temperature, and diluted with ethyl acetate. The mixture was washed with 5% aqueous potassium hydrogen sulfate solution, dried and concentrated, and the concentrate was purified by silica gel thin layer chromatography (ethyl acetate:methanol=20:1) to give the object compound (56 mg) described in the above-mentioned scheme.
    • Step 1-3
  • Figure US20180319798A1-20181108-C00034
  • Compound (56 mg) obtained in step 1-2 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 1 hr. The reaction solution was concentrated, ethyl acetate was added and the mixture was concentrated. Ethyl acetate, 4N hydrochloric acid/ethyl acetate solution, and hexane were added to allow crystallization to give the object compound (28 mg) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-d6) δ: 12.30 (br s, 1H), 8.64 (s, 1H), 7.66 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.57 (d, 1H, J=13.5 Hz), 4.39 (dd, 1H, J=13.5, 3.9 Hz), 4.19 (s, 2H), 4.12-4.10 (m 1H), 3.87-3.80 (m, 1H), 3.53-3.44 (m, 2H), 3.27-3.22 (m, 1H), 3.20 (s, 3H), 1.18 (t, 3H, J=7.1 Hz).
    • Example 2 Step 2-1
  • Figure US20180319798A1-20181108-C00035
  • Under nitrogen, a solution of 1M lithium bis(trimethylsilyl)amide-THF/ethylbenzene (100 mL) in THF (100 mL) was cooled to −70° C., and tert-butyl acetate (13.5 mL) was added dropwise under stirring. After stirring for 15 min, benzyloxyacetyl chloride (7.52 mL) was added dropwise. After stirring for 1 hr, 2N aqueous hydrochloric acid solution was added to the reaction mixture until its pH reached 3 and the mixture was allowed to warm to room temperature. The mixture was extracted with ethyl acetate, and the organic layer was washed with 2N aqueous hydrochloric acid solution and saturated brine, dried over sodium sulfate and concentrated. The above operation was repeated, and the both were combined to give the object compound (40.3 g) described in the above-mentioned scheme as a crude product.
    • Step 2-2
  • Figure US20180319798A1-20181108-C00036
  • To a solution of the compound (38 g) obtained in step 2-1 in toluene (80 mL) was added dimethylformamidedimethylacetal (38 mL), and the mixture was stirred at 100° C. for 1 hr. The mixture was allowed to cool, and concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:2-ethyl acetate) to give the object compound (11.3 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.66 (s, 1H), 7.40-7.13 (m, 5H), 4.60 (s, 2H), 4.42 (s, 2H), 3.40-2.65 (m, 6H), 1.45 (s, 9H).
    • Step 2-3
  • Figure US20180319798A1-20181108-C00037
  • Under nitrogen, a solution of 1M lithium bis(trimethylsilyl)amide-THF/ethylbenzene (42.5 mL) in THF (150 mL) was cooled to −70° C., and a solution of the compound (11.3 g) obtained in step 2-2 in THF (50 mL) was added dropwise over 3 min under stirring. After stirring for 20 min, ethyl chloroglyoxylate (4.75 mL) was added at once. After stirring for 25 min, saturated aqueous potassium hydrogen sulfate solution and ethyl acetate were added and the mixture was allowed to warm to room temperature. The organic layer was separated, washed with saturated brine, dried over sodium sulfate, and concentrated. Toluene was added to the residue, and the mixture was concentrated once. Toluene (100 mL) and triethylamine (10 mL) were added and the mixture was stirred at room temperature. One hour later, the mixture was concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:6-1:3) to give the object compound (6.03 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.39 (s, 1H), 7.51-7.47 (m, 2H), 7.39-7.30 (m, 3H), 5.32 (s, 2H), 4.34 (q, 2H, J=7.2 Hz), 1.57 (s, 9H), 1.31 (t, 3H, J=7.2 Hz).
    • Step 2-4
  • Figure US20180319798A1-20181108-C00038
  • To a solution of the compound (18.7 g) obtained in step 2-3 in ethyl acetate (20 mL) was added 4N hydrochloric acid/ethyl acetate (200 mL) under stirring, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was added hexane (1 L), the mixture was stirred for a while, and the crystals were collected by filtration, and dried to give the object compound (11.1 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 13.03 (s, 1H), 8.80 (s, 1H), 7.47-7.43 (m, 2H), 7.41-7.35 (m, 3H), 5.38 (s, 2H), 4.40 (q, 2H, J=7.2 Hz), 1.35 (t, 3H, J=7.2 Hz).
    • Step 2-5
  • Figure US20180319798A1-20181108-C00039
  • To a solution of the compound (6 g) obtained in step 2-4 in toluene (80 mL) were added oxalyl chloride (3.27 mL) and dimethylformamide (0.04 mL) under stirring, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, chloroform (100 ml) and the compound (5.22 g) obtained in Reference Example 3 were added, and the mixture was stirred at room temperature overnight. 5% Aqueous potassium hydrogen sulfate solution was added, and the mixture was extracted twice with chloroform. The organic layer was washed with 5% aqueous potassium hydrogen sulfate solution and saturated brine, dried over magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:4-1:3), ethyl acetate/hexane (1:3) solution was added, and the mixture was slurry washed. The residue was collected by filtration, and dried to give the object compound (6.348 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.07 (s, 1H), 7.49-7.44 (m, 2H), 7.39-7.28 (m, 5H), 7.07-7.00 (m, 2H), 5.35 (s, 2H), 4.46 (s, 2H), 4.39 (q, 2H, J=7.1 Hz), 1.34 (t, 3H, J=7.1 Hz).
    • Step 2-6
  • Figure US20180319798A1-20181108-C00040
  • To a solution of (R)-2-tert-butoxycarbonylamino-3-hydroxy-2-methylpropionic acid (5.00 g) in dimethylformamide (50 mL) were added potassium carbonate (6.31 g) and iodomethane (2.84 mL), and the mixture was stirred at room temperature for 3 hr. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (150 mL). The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (100 mL), dried and concentrated to give the object compound (5.06 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.29 (br s, 1H), 3.99 (dd, 1H, J=11.6, 6.0 Hz), 3.83-3.73 (m, 1H), 3.78 (s, 3H), 3.23 (br s, 1H), 1.48 (s, 3H), 1.45 (s, 9H).
    • Step 2-7
  • Figure US20180319798A1-20181108-C00041
  • To a solution of the compound (2.50 g) obtained in step 2-6 in dimethyl sulfoxide (25 mL) were added triethylamine (2.25 mL) and a pyridine-sulfur trioxide complex (2.62 g), and the mixture was stirred at room temperature for 1 hr. 1N Aqueous hydrochloric acid solution (100 mL) was added, and the mixture was extracted with ethyl acetate (200 mL). The organic layer was washed successively with 1N aqueous hydrochloric acid solution (100 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL), dried and concentrated to give the object compound (1.22 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.57 (s, 1H), 5.63 (br s, 1H), 3.81 (s, 3H), 1.57 (s, 3H), 1.45 (s, 9H).
    • Step 2-8
  • Figure US20180319798A1-20181108-C00042
  • To a solution of the compound (660 mg) obtained in step 2-7 in chloroform (7.0 mL) were added isopropylamine (368 μL), acetic acid (245 μL) and sodium triacetoxyborohydride (955 mg), and the mixture was stirred at room temperature for 18 hr. Saturated aqueous sodium hydrogen carbonate solution (30 mL) and chloroform (50 mL) were added and the mixture was partitioned. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (30 mL), dried and concentrated. The concentrate was purified by silica gel column chromatography (chloroform:methanol=10:1) to give the object compound (764 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.74 (br s, 1H), 3.74 (s, 3H), 2.89 (br s, 2H), 2.73 (sep, 1H, J=6.2 Hz), 1.52 (s, 3H), 1.44 (s, 9H), 1.02 (d, 3H, J=6.2 Hz), 1.02 (d, 3H, J=6.2 Hz).
    • Step 2-9
  • Figure US20180319798A1-20181108-C00043
  • The compound (155 mg) obtained in step 2-8 was dissolved in trifluoroacetic acid solution (1.0 mL), and the mixture was stirred at room temperature for 30 min. The mixture was concentrated, chloroform was added, and the mixture was 25 concentrated. This operation was performed twice. Toluene (5 mL), diisopropylethylamine (395 μL) and the compound (200 mg) obtained in step 2-5 were added, and the mixture was stirred at room temperature for 30 min. Toluene (5 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (100 μL) were added, and the mixture was stirred at 120° C. for 1 hr. The reaction mixture was allowed to cool to room temperature, acetic acid (1.0 mL) was added, and the mixture was further stirred at 110° C. for 1 hr. 2N Aqueous hydrochloric acid solution (30 mL) was added, and the mixture was extracted with ethyl acetate (60 mL). The organic layer was dried and concentrated, toluene was added, and this operation was repeated twice to give the object compound (263 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.87 (s, 1H), 7.59 (d, 2H, J=7.0 Hz), 7.41-7.13 (m, 4H), 7.08-6.98 (m, 3H), 5.46 (d, 1H, J=10.0 Hz), 5.23 (d, 1H, J=10.0 Hz), 4.86 (sep, 1H, J=6.3 Hz), 4.44 (s, 2H), 3.85 (d, 1H, J=13.5 Hz), 3.44 (d, 1H, J=13.5 Hz), 1.96 (s, 3H), 1.14 (d, 3H, J=6.3 Hz), 1.12 (d, 3H, J=6.3 Hz).
    • Step 2-10
  • Figure US20180319798A1-20181108-C00044
  • To a solution of the compound (40.0 mg) obtained in step 2-9, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (28.0 mg) and 1-hydroxybenzotriazole hydrate (22.0 mg) in dimethylformamide (400 μL) was added azetidine (20 μL), and the mixture was stirred at room temperature for 18 hr. Saturated aqueous sodium hydrogen carbonate solution (10 mL) was added, and the mixture was extracted with ethyl acetate (25 mL). The organic layer was washed successively with 1N aqueous hydrochloric acid solution (10 mL) and saturated aqueous sodium hydrogen carbonate solution (10 mL), dried and concentrated. The concentrate was purified by silica gel thin layer chromatography (chloroform:methanol=15:1) to give the object compound (26.7 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.99 (s, 1H), 7.64-7.58 (m, 2H), 7.36-7.27 (m, 5H), 7.07-6.99 (m, 2H), 5.53 (d, 1H, J=10.0 Hz), 5.39 (d, 1H, J=10.0 Hz), 4.82 (sep, 1H, J=6.7 Hz), 4.46 (s, 2H), 4.10-3.92 (m, 2H), 3.97 (d, 1H, J=13.4 Hz), 3.75-3.66 (m, 1H), 3.61-3.51 (m, 1H), 3.27 (d, 1H, J=13.4 Hz), 2.19-2.05 (m, 2H), 1.97 (s, 3H), 1.15 (d, 6H, J=6.7 Hz).
    • Step 2-11
  • Figure US20180319798A1-20181108-C00045
  • The compound (25.0 mg) obtained in step 2-10 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stirred at room temperature for 30 min. The reaction solution was concentrated, chloroform was added, and the mixture was concentrated. 4N Hydrochloric acid/ethyl acetate solution was added, and the mixture was concentrated. Crystallization from ethyl acetate-hexane gave the object compound (17.2 mg) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-d6) δ: 12.91 (br s, 1H), 8.71 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.70 (sep, 1H, J=6.7 Hz), 4.48 (s, 2H), 4.29-4.18 (br m, 1H), 4.02 (d, 1H, J=13.9 Hz), 3.90-3.81 (br m, 2H), 3.80-3.72 (br m, 1H), 3.71 (d, 1H, J=13.9 Hz), 2.16-2.04 (br m, 2H), 1.99 (s, 3H), 1.16 (d, 3H, J=6.7 Hz), 1.14 (d, 3H, J=6.7 Hz).
    • Example 3 Step 3-1
  • Figure US20180319798A1-20181108-C00046
  • To a solution of (R)-1-benzyloxymethyl-2-hydroxyethylcarbamic acid tert-butyl ester (5.0 g) and 2,6-di-tert-butylpyridine (8.0 mL) in chloroform (50 mL) were added iodomethane (1.33 mL) and silver(I) trifluoromethanesulfonate (6.85 g) under ice-cooling, and the mixture was stirred for 30 min, and further stirred at room temperature for 1 hr. The reaction suspension was filtered through celite, and concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:20-1:4) to give the object compound (2.8 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.38-7.27 (m, 5H), 4.97-4.85 (m, 1H), 4.53 (s, 15 2H), 4.00-3.81 (m, 1H), 3.59 (dd, 1H, J=9.4, 4.2 Hz), 3.51 (dd, 1H, J=9.4, 5.8 Hz), 3.51 (dd, 1H, J=9.4, 4.4 Hz), 3.44 (dd, 1H, J=9.4, 6.0 Hz), 3.34 (s, 3H), 1.44 (s, 9H).
    • Step 3-2
  • Figure US20180319798A1-20181108-C00047
  • To a solution of the compound (2.8 g) obtained in step 3-1 in methanol (100 mL) was added a 7.5% palladium-carbon catalyst (1.4 g), and the mixture was stirred at room temperature for 17 hr under a hydrogen atmosphere and moderate pressure (0.4 MPa). The reaction mixture was filtered through celite and concentrated to give the object compound (2.05 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.22-5.10 (m, 1H), 3.84-3.64 (m, 3H), 3.60-3.49 (m, 2H), 3.37 (s, 3H), 2.73-2.55 (m, 1H), 1.45 (s, 9H).
    • Step 3-3
  • Figure US20180319798A1-20181108-C00048
  • To a solution of the compound (1.6 g) obtained in step 3-2, phthalimide (1.38 g) and triphenylphosphine (2.47 g) in tetrahydrofuran (20 mL) was added dropwise 2.2M diethyl azodicarboxylate/toluene solution (4.3 mL) under ice-cooling, and the mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:10-1:2). The obtained solid was dissolved in ethanol (30 mL)-toluene (30 mL), hydrazine monohydrate (1.6 mL) was added, and the mixture was stirred at 80° C. for 40 min. The mixture was allowed to cool to room temperature, the solid was filtered off, and the filtrate was concentrated. Toluene was added to the residue, and the precipitated solid was filtered off. The filtrate was concentrated to give the object compound (1.3 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.08-4.89 (m, 1H), 3.71-3.63 (m, 1H), 3.50 (dd, 1H, J=9.5, 3.7 Hz), 3.40 (dd, 1H, J=9.5, 5.1 Hz), 3.35 (s, 3H), 2.84 (dd, 1H, J=13.0, 6.0 Hz), 2.80 (dd, 1H, 25 J=13.0, 6.0 Hz), 1.45 (s, 9H).
    • Step 3-4
  • Figure US20180319798A1-20181108-C00049
  • To a solution of the compound (0.8 g) obtained in step 3-3 in dioxane (8 mL) was added saturated aqueous sodium hydrogen carbonate solution (2 mL), benzyl chloroformate (0.84 mL) was added dropwise under ice-cooling, and the mixture was stirred for 40 min, and at room temperature for 10 min. Water (15 mL) was added, and the mixture was extracted with ethyl acetate. The extract was dried, and concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:10-1:2). To the obtained solid was added 4N hydrochloric acid/dioxane solution (5 mL), and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, and the residue was dissolved in chloroform. Saturated aqueous sodium hydrogen carbonate solution (2 mL) was added, and the mixture was stirred. The mixture was extracted with chloroform, and the organic layer was dried and concentrated to give the object compound (639 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.39-7.28 (m, 5H), 5.27-5.20 (m, 1H), 5.10 (s, 2H), 3.41-3.24 (m, 3H), 3.35 (s, 3H), 3.18-3.01 (m, 2H), 1.39 (br s, 2H).
    • Step 3-5
  • Figure US20180319798A1-20181108-C00050
  • To a solution of the compound (150 mg) obtained in step 3-4 in chloroform (4 mL) were added acetone (70 μL), acetic acid (54 μL) and sodium triacetoxyborohydride (200 mg) under ice-cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was stirred. The chloroform layer was washed with saturated brine, dried, and concentrated to give the object compound (156 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.39-7.28 (m, 5H), 5.39-5.29 (m, 1H), 5.10 (s, 2H), 3.42-3.28 (m, 3H), 3.33 (s, 3H), 3.22-3.14 (m, 1H), 2.96-2.82 (m, 2H), 1.04 (d, 3H, J=6.8 Hz), 1.02 (d, 3H, J=6.8 Hz).
    • Step 3-6
  • Figure US20180319798A1-20181108-C00051
  • In the same manner as in step 2-9 and step 2-11, the object compound (17.0 mg) described in the above-mentioned scheme was obtained from the compound (156 mg) obtained in step 3-5. For removal of the amino-protecting group (benzyloxycarbonyl group) of the compound obtained in step 3-5, a known method was used according to the protecting group.
  • 1H-NMR (DMSO-d6) δ: 8.84 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.14 (m, 2H), 4.66 (d, 1H, J=13.2 Hz), 4.47 (sep, 1H, J=6.7 Hz), 4.47 (s, 2H), 4.34 (dd, 1H, J=13.5, 3.7 Hz), 4.22-4.17 (m, 1H), 3.49 (dd, 1H, J=10.6, 4.3 Hz), 3.39 (dd, 1H, J=10.6, 7.5 Hz), 3.21 (s, 3H), 1.30 (d, 3H, J=6.7 Hz), 1.28 (d, 3H, J=6.7 Hz).
    • Example 4 Step 4-1
  • Figure US20180319798A1-20181108-C00052
  • To a solution of (R)-1-aminomethyl-2-methoxyethylcarbamic acid tert-butyl ester (1.0 g) produced from (S)-1-benzyloxymethyl-2-hydroxyethylcarbamic acid tert-butyl ester in the same manner as in Example 3, step 3-1 to step 3-3 in chloroform (15 mL) were added acetone (432 μL) and acetic acid (337 μL) under ice-cooling, sodium triacetoxyborohydride (1.25 g) was added at room temperature, and the mixture was stirred at room temperature for 14 hr. To the reaction mixture was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted 3 times with chloroform. The combined chloroform layer was dried, and concentrated, and the concentrate was purified by silica gel column chromatography (chloroform:methanol=50:1-7:1) to give the object compound (1.12 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.09-4.90 (m, 1H), 3.81-3.69 (m, 1H), 3.49 (dd, 1H, J=9.5, 4.0 Hz), 3.43-3.37 (m, 1H), 3.34 (s, 3H), 2.82-2.68 (m, 3H), 1.45 (s, 9H), 1.04 (d, 3H, J=6.4 Hz), 1.03 (d, 3H, J=6.4 Hz).
    • Step 4-2
  • Figure US20180319798A1-20181108-C00053
  • In the same manner as in step 2-9 and step 2-11 (known deprotection and condensation reactions may be omitted as necessary), the object compound (10.8 mg) described in the above-mentioned scheme was obtained from the compound (19.0 mg) obtained in step 4-1.
  • 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.80 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 5.01-4.93 (m, 1H), 4.77 (sep, 1H, J=6.7 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J=13.8, 4.1 Hz), 3.75 (dd, 1H, J=13.8, 1.3 Hz), 3.65-3.54 (m, 2H), 3.25 (s, 3H), 1.16 (d, 3H, J=6.7 Hz), 1.16 (d, 3H, J=6.7 Hz).
    • Example 5 Step 5-1
  • Figure US20180319798A1-20181108-C00054
  • In the same manner as in step 3-3, the object compound (1.0 g) described in the above-mentioned scheme was obtained from (S)-2-hydroxy-1-methylethylcarbamic acid tert-butyl ester (1.4 g).
  • 1H-NMR (CDCl3) δ: 4.68-4.49 (m, 1H), 3.71-3.58 (m, 1H), 2.74 (dd, 1H, J=13.0, 4.9 Hz), 2.62 (dd, 1H, J=13.0, 6.5 Hz), 1.45 (s, 9H), 1.12 (d, 3H, J=6.7 Hz).
    • Step 5-2
  • Figure US20180319798A1-20181108-C00055
  • In the same manner as in step 4-1, the object compound (180 mg) described in the above-mentioned scheme was obtained from the compound (190 mg) obtained in step 5-1.
  • 1H-NMR (CDCl3) δ: 4.91-4.66 (m, 1H), 3.81-3.66 (m, 1H), 2.81 (sep, 1H, J=6.4 Hz), 2.66 (dd, 1H, J=12.0, 4.9 Hz), 2.60 (dd, 1H, J=12.0, 6.7 Hz), 1.45 (s, 9H), 1.14 (d, 3H, J=6.6 Hz), 1.06 (d, 6H, J=6.4 Hz).
    • Step 5-3
  • Figure US20180319798A1-20181108-C00056
  • In the same manner as in step 2-9 and step 2-11, the object compound (27.5 mg) described in the above-mentioned scheme was obtained from the compound (30.0 mg) obtained in step 5-2.
  • 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.91 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.92 (ddd, 1H, J=6.8, 3.5, 2.2 Hz), 4.80 (t, 1H, J=6.8 Hz), 4.47 (s, 2H), 3.81 (dd, 1H, J=13.5, 3.5 Hz), 3.63 (dd, 1H, J=13.5, 2.2 Hz), 1.39 (d, 3H, J=6.8 Hz), 1.19 (d, 3H, J=6.8 Hz), 1.16 (d, 3H, J=6.8 Hz).
    • Example 6 Step 6-1
  • Figure US20180319798A1-20181108-C00057
  • In the same manner as in step 3-3 to step 3-5, the object compound (105 mg) described in the above-mentioned scheme was obtained from (R)-2-hydroxy-1-methylethylcarbamic acid tert-butyl ester (2.0 g).
  • 1H-NMR (CDCl3) δ: 7.40-7.28 (m, 5H), 5.28 (br s, 1H), 5.10 (s, 2H), 3.29-3.17 (m, 1H), 3.02-2.92 (m, 1H), 2.92-2.80 (m, 2H), 1.04 (d, 6H, J=6.3 Hz), 0.99 (d, 3H, J=6.0 Hz).
    • Step 6-2
  • Figure US20180319798A1-20181108-C00058
  • In the same manner as in step 2-9 and step 2-11 (known deprotection and condensation reactions may be omitted as necessary), the object compound (16.6 mg) described in the above-mentioned scheme was obtained from the compound (105 mg) obtained in step 6-1. For removal of the amino-protecting group (benzyloxycarbonyl group) of the compound obtained in step 6-1, a known method was used according to the protecting group.
  • 1H-NMR (DMSO-d6) δ: 12.54 (br s, 1H), 8.85 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.62-4.53 (m, 1H), 4.51-4.44 (m, 3H), 4.32 (dd, 1H, J=13.1, 3.4 Hz), 4.26-4.18 (m, 1H), 1.27 (d, 3H, J=6.7 Hz), 1.26 (d, 3H, J=6.7 Hz), 1.21 (d, 3H, J=6.5 Hz).
    • Example 7 Step 7-1
  • Figure US20180319798A1-20181108-C00059
  • 2-Amino-2-methyl-1,3-propanediol (20.0 g) was suspended in tetrahydrofuran (400 mL), and di-tert-butyl dicarbonate (41.6 g) was added. The mixture was stirred at room temperature for 3 hr and concentrated. Dimethylformamide (200 mL) was added to dissolve the concentrate again, imidazole (13.0 g) and tert-butylchlorodimethylsilane (29.3 g) were added, and the mixture was stirred at room temperature for 15 hr. Water (500 mL) was added, and the mixture was extracted with ethyl acetate (800 mL). The organic layer was washed with water (400 mL), dried, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:10) to give the object compound (35.9 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.13 (br s, 1H), 4.00 (br s, 1H), 3.77 (d, 1H, J=9.7 Hz), 3.70 (dd, 1H, J=11.4, 4.2 Hz), 3.61 (d, 1H, J=9.7 Hz), 3.55 (dd, 1H, J=11.4, 8.4 Hz), 1.44 (s, 9H), 1.19 (s, 3H) , 0.90 (s, 9H) , 0.07 (s, 6H).
    • Step 7-2
  • Figure US20180319798A1-20181108-C00060
  • To a solution of the compound (15.5 g) obtained in step 7-1 in dimethyl sulfoxide (120 mL) were added triethylamine (8.12 mL) and a sulfur trioxide-pyridine complex (11.9 g), and the mixture was stirred at room temperature for 3 hr. 1N Aqueous hydrochloric acid solution (300 mL) was added, and the mixture was extracted with ethyl acetate (700 mL). The organic layer was washed successively with 1N aqueous hydrochloric acid solution (150 mL) and saturated aqueous sodium hydrogen carbonate solution (200 mL), dried, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:20) to give the object compound (11.0 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.49 (s, 1H), 5.29 (br s, 1H), 3.86-3.71 (br m, 2H), 1.45 (s, 9H), 1.34 (s, 3H), 0.88 (s, 9H), 0.05 (s, 6H).
    • Step 7-3
  • Figure US20180319798A1-20181108-C00061
  • To a solution of the compound (11.0 g) obtained in step 7-2 in chloroform (110 mL) were added isopropylamine (4.46 mL), acetic acid (2.97 mL) and sodium triacetoxyborohydride (11.6 g), and the mixture was stirred at room temperature for 15 hr. The mixture was partitioned between saturated aqueous sodium hydrogen carbonate solution (150 mL) and chloroform (200 mL). The organic layer was washed twice with saturated aqueous sodium hydrogen carbonate solution (100 mL), dried, and concentrated. The concentrate was purified by silica gel column chromatography (chloroformmethanol=10:1) to give the object compound (14.1 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.43 (br s, 1H), 3.73 (d, 1H, J=9.6 Hz), 3.58 (d, 1H, J=9.6 Hz), 2.80-2.66 (m, 2H), 2.55 (d, 1H, J=11.6 Hz), 1.43 (s, 9H), 1.24 (s, 3H), 1.05 (br s, 6H), 0.89 (s, 9H), 0.05 (s, 6H).
    • Step 7-4
  • Figure US20180319798A1-20181108-C00062
  • To a solution of 3-benzyloxy-4-oxo-4H-pyran-2-carboxylic acid (5.00 g) in toluene (100 mL) were added triethylamine (3.40 mL) and thionyl chloride (1.78 mL) at 0° C., and the mixture was stirred at 0° C. for 30 min. The precipitated salt was filtered off, the filtrate was concentrated, and the concentrate was dissolved in tetrahydrofuran (40 mL). This tetrahydrofuran solution was added dropwise to a solution of the compound (10.3 g) obtained in step 7-3 and pyridine (30 mL) in tetrahydrofuran (60 mL) at 0° C., and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, toluene was added and the mixture was concentrated. This operation was performed twice. 1N Aqueous hydrochloric acid solution (150 mL) was added, and the mixture was extracted with ethyl acetate (250 mL). The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (100 mL), dried, and concentrated. The concentrate was purified by silica gel column chromatography (chloroformmethanol=50:1) to give the object compound (9.65 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.74-7.66 (m, 1H), 7.46-7.28 (m, 5H), 6.50-6.42 (m, 1H), 5.96 (br s, 1H), 5.28-5.14 (m, 2H), 4.02-3.33 (m, 5H), 1.47-1.37 (m, 9H), 1.29-1.00 (m, 9H), 0.95-0.83 (m, 9H), 0.13-0.03 (m, 6H).
    • Step 7-5
  • Figure US20180319798A1-20181108-C00063
  • To the compound (9.65 g) obtained in step 7-4 was added 4N hydrochloric acid/ethyl acetate solution (100 mL), and the mixture was stirred at room temperature for 30 min. This was concentrated, ethanol (400 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL) were added, and the mixture was stirred at room temperature for 18 hr. The insoluble material was filtered off, and the filtrate was concentrated. Water (100 mL) was added, and the mixture was extracted twice with chloroform (200 mL, 100 mL). The organic layer was dried, and concentrated, and the concentrate was purified by silica gel column chromatography (chloroform:methanol=30:1-20:1-10:1) to give the object compound (2.20 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.52 (d, 2H, J=7.9 Hz), 7.48 (d, 1H, J=7.9 Hz), 7.37-7.22 (m, 3H), 6.25 (d, 1H, J=7.9 Hz), 5.79 (br s, 1H), 5.20 (d, 1H, J=10.0 Hz), 5.17 (d, 1H, J=10.0 Hz), 4.85 (sep, 1H, J=6.5 Hz), 3.80 (d, 1H, J=12.1 Hz), 3.61 (d, 1H, J=12.1 Hz), 3.35 (d, 1H, J=14.2 Hz), 3.14 (d, 1H, J=14.2 Hz), 1.47 (s, 3H), 1.12 (d, 3H, J=6.5 Hz), 1.11 (d, 3H, J=6.5 Hz).
    • Step 7-6
  • Figure US20180319798A1-20181108-C00064
  • The compound (2.20 g) obtained in step 7-5, trimethylphenylammonium tribromide (3.48 g) and sodium hydrogen carbonate (1.04 g) were dissolved in 2:1 chloroform-methanol (60 mL), and the mixture was stirred at room temperature for 30 min. Saturated aqueous sodium hydrogen carbonate solution (100 mL) was added, and the mixture was extracted with chloroform (200 mL). The organic layer was washed successively with 1N aqueous hydrochloric acid solution (100 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL), dried, and concentrated to give the object compound (2.23 g) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-d6) δ: 8.22 (s, 1H), 7.53 (d, 2H, J=7.0 Hz), 7.41-7.27 (m, 3H), 5.48 (br s, 1H), 5.10 (d, 1H, J=10.2 Hz), 5.03 (d, 1H, J=10.2 Hz), 4.67 (sep, 1H, J=6.7 Hz), 3.66 (d, 1H, J=11.6 Hz), 3.59 (d, 1H, J=11.6 Hz), 3.56 (d, 1H, J=14.2 Hz), 3.45 (d, 1H, J=14.2 Hz), 1.48 (s, 3H), 1.11 (d, 6H, J=6.7 Hz).
    • Step 7-7
  • Figure US20180319798A1-20181108-C00065
  • To a solution of the compound (2.12 g) obtained in step 7-6 in chloroform (45 mL) were added 3,4-dihydro-2H-pyran (882 μL) and camphorsulfonic acid (56 mg), and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated, and the concentrate was purified by silica gel column chromatography (chloroform:methanol=30:1) to give the object compound (2.23 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.91-7.89 (m, 1H), 7.72-7.66 (m, 2H), 7.37-7.27 (m, 3H), 5.41-5.36 (m, 1H), 5.27-5.17 (m, 1H), 5.02-4.92 (m, 1H), 4.61-4.48 (m, 1H), 3.92-3.81 (m, 1H), 3.79-3.27 (m, 5H), 1.78-1.48 (m, 9H), 1.20-1.14 (m, 6H).
    • Step 7-8
  • Figure US20180319798A1-20181108-C00066
  • The compound (250 mg) obtained in step 7-7, tris(dibenzylideneacetone)dipalladium (44 mg), tri(2-furyl)phosphine (45 mg) and 5-(2,4-difluorobenzyl)-2-tributylstanylthiazole (835 mg) were dissolved in dioxane (5.0 mL), and the mixture was heated in a microwave apparatus at 110° C. for 40 min. This operation was performed twice using the same amounts, and the reaction mixtures were combined and concentrated. The concentrate was purified by silica gel column chromatography (chloroform:methanol=30:1) to give the object compound (682 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.78-8.74 (m, 1H), 7.72-7.67 (m, 2H), 7.60-7.56 (m, 1H), 7.37-7.17 (m, 4H), 6.86-6.71 (m, 2H), 5.52-5.46 (m, 1H), 5.34-5.25 (m, 1H), 5.03-4.93 (m, 1H), 4.62-4.53 (m, 1H), 4.20-4.14 (m, 2H), 4.02-3.87 (m, 1H), 3.77-3.43 (m, 5H), 3.36-3.26 (m, 1H), 1.78-1.42 (m, 8H), 1.21-1.13 (m, 6H).
    • Step 7-9
  • Figure US20180319798A1-20181108-C00067
  • The compound (682 mg) obtained in step 7-8 was dissolved in tetrahydrofuran-methanol-water (4:1:1, 6.0 mL). Acetic acid (2.0 mL) was added, and the mixture was stirred at 80° C. for 30 hr. The reaction mixture was concentrated, toluene was added, and the mixture was concentrated. This operation was performed twice, and the concentrate was purified by silica gel column chromatography (chloroformmethanol=40:1) to give the object compound (390 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.66 (s, 1H), 7.67-7.62 (m, 2H), 7.51 (s, 1H), 7.36-7.25 (m, 3H), 7.24-7.15 (m, 1H), 6.84-6.75 (m, 2H), 5.40 (d, 1H, J=9.7 Hz), 5.29 (d, 1H, J=9.7 Hz), 4.93 (sep, 1H, J=6.7 Hz), 4.14 (s, 2H), 3.86 (s, 2H), 3.51 (d, 1H, J=13.9 Hz), 3.25 (d, 1H, J=13.9 Hz), 1.65 (s, 3H), 1.16 (d, 3H, J=6.7 Hz), 1.15 (d, 3H, J=6.7 Hz).
    • Step 7-10
  • Figure US20180319798A1-20181108-C00068
  • To a solution of the compound (250 mg) obtained in step 7-9 in chloroform (5.0 mL) were added triethylamine (93 μL) and methanesulfonyl chloride (41 μL) at 0° C., and the mixture was stirred at 0° C. for 1 hr. Triethylamine (93 μL) and methanesulfonyl chloride (41 μL) were added, and the mixture was further stirred at 0° C. for 1 hr. Saturated aqueous sodium hydrogen carbonate solution (20 mL) was added, and the mixture was extracted with chloroform (40 mL). The organic layer was washed with 1N aqueous hydrochloric acid solution (20 mL), dried, and concentrated to give the object compound (295 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 7.68-7.61 (m, 4H), 7.40-7.20 (m, 4H), 6.92-6.82 (m, 2H), 5.45 (d, 1H, J=9.8 Hz), 5.32 (d, 1H, J=9.8 Hz), 4.98 (sep, 1H, J=6.8 Hz), 4.80 (br s, 1H), 4.50 (d, 1H, J=10.1 Hz), 4.19 (s, 2H), 3.58 (d, 1H, J=14.1 Hz), 3.37 (d, 1H, J=14.1 Hz), 3.20 (br s, 3H), 1.85 (s, 3H), 1.22 (d, 3H, J=6.8 Hz), 1.19 (d, 3H, J=6.8 Hz).
    • Step 7-11
  • Figure US20180319798A1-20181108-C00069
  • The compound (30 mg) obtained in step 7-10 and potassium phthalimide (26 mg) were dissolved in dimethylformamide (1.0 mL), and the mixture was heated in a microwave apparatus at 150° C. for 2 hr. This operation was performed two more times using the compound (115 mg) obtained in step 7-10, potassium phthalimide (100 mg) and dimethylformamide (4.0 mL), and all the reaction mixtures were combined. Water (30 mL) was added, and the mixture was extracted with ethyl acetate (60 mL). The organic layer was washed successively with 1N aqueous hydrochloric acid solution (30 mL) and saturated aqueous sodium hydrogen carbonate solution (30 mL), dried and concentrated. The concentrate was purified by silica gel column chromatography (chloroform:methanol=30:1) to give the object compound (277 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.45 (s, 1H), 7.91-7.58 (m, 7H), 7.40-7.14 (m, 4H), 6.85-6.76 (m, 2H), 5.60 (d, 1H, J=9.7 Hz), 5.31 (d, 1H, J=9.7 Hz), 5.07 (sep, 1H, J=6.7 Hz), 4.21 (d, 1H, J=14.4 Hz), 4.12 (s, 2H), 3.88 (d, 1H, J=14.4 Hz), 3.58 (d, 1H, J=13.9 Hz), 3.47 (d, 1H, J=13.9 Hz), 1.78 (s, 3H), 1.29 (d, 3H, J=6.7 Hz), 1.21 (d, 3H, J=6.7 Hz).
    • Step 7-12
  • Figure US20180319798A1-20181108-C00070
  • To a solution of the compound (277 mg) obtained in step 7-11 in 1:1 ethanol-toluene (6.0 mL) was added hydrazine monohydrate (60 μL), and the mixture was stirred at 80° C. for 3 hr. Furthermore, hydrazine monohydrate (60 μL) was added, and the mixture was stirred at 80° C. for 2 hr. The precipitate was filtered off, and the filtrate was concentrated, and the concentrate was purified by silica gel column chromatography (chloroform:methanol=30:1-20:1) to give the object compound (104 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.71 (s, 1H), 7.71-7.63 (m, 2H), 7.59 (s, 1H), 7.38-7.27 (m, 3H), 7.25-7.16 (m, 1H), 6.85-6.76 (m, 2H), 5.53 (d, 1H, J=9.7 Hz), 5.26 (d, 1H, J=9.7 Hz), 4.97 (sep, 1H, J=6.7 Hz), 4.18 (s, 2H), 3.51 (d, 1H, J=13.9 Hz), 3.32 (d, 1H, J=13.9 Hz), 3.05 (d, 1H, J=13.7 Hz), 2.98 (d, 1H, J=13.7 Hz), 1.67 (s, 3H), 1.20 (d, 3H, J=6.7 Hz), 1.18 (d, 3H, J=6.7 Hz).
    • Step 7-13
  • Figure US20180319798A1-20181108-C00071
  • To a solution of the compound (20.0 mg) obtained in step 7-12 in chloroform (400 μL) were added triethylamine (9.9 μL) and propionyl chloride (4.8 μL), and the mixture was stirred at room temperature for 1 hr. The obtained reaction mixture was directly purified by silica gel thin layer chromatography (chloroform:methanol=10:1) to give the object compound (14.2 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.58 (s, 1H), 7.64-7.59 (m, 2H), 7.52 (s, 1H), 7.36-7.27 (m, 3H), 7.25-7.17 (m, 1H), 6.86-6.78 (m, 2H), 6.21 (br s, 1H), 5.40 (d, 1H, J=9.7 Hz), 5.28 (d, 1H, J=9.7 Hz), 4.96 (sep, 1H, J=6.7 Hz), 4.15 (s, 2H), 3.76 (dd, 1H, J=14.7, 7.1 Hz), 3.55 (dd, 1H, J=14.7, 6.4 Hz), 3.39 (d, 1H, J=13.7 Hz), 3.35 (d, 1H, J=13.7 Hz), 2.28 (dt, 2H, J=14.5, 6.6 Hz), 1.61 (s, 3H), 1.17 (d, 3H, J=6.7 Hz), 1.16 (d, 3H, J=6.7 Hz), 1.14 (t, 3H, J=7.7 Hz).
    • Step 7-14
  • Figure US20180319798A1-20181108-C00072
  • To a solution of the compound (14.0 mg) obtained in step 7-13 in tetrahydrofuran (1.0 mL) were added excess amounts of iodomethane and potassium tert-butoxide at 0° C. (until disappearance of starting materials). The obtained reaction mixture was directly purified by silica gel thin layer chromatography (chloroform:methanol=15:1) to give the object compound (5.6 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.60 (s, 1H), 7.68-7.63 (m, 2H), 7.58 (s, 1H), 7.36-7.27 (m, 3H), 7.25-7.19 (m, 1H), 6.86-6.77 (m, 2H), 5.58 (d, 1H, J=10.0 Hz), 5.32 (d, 1H, J=10.0 Hz), 4.98 (sep, 1H, J=6.7 Hz), 4.28 (d, 1H, J=14.4 Hz), 4.19 (s, 2H), 3.47 (d, 1H, J=14.2 Hz), 3.32 (d, 1H, J=14.2 Hz), 3.12 (d, 1H, J=14.4 Hz), 2.54 (s, 3H), 2.37 (dq, 1H, J=15.5, 7.0 Hz), 2.30 (dq, 1H, J=15.5, 7.0 Hz), 1.69 (s, 3H), 1.21 (d, 3H, J=6.7 Hz), 1.17 (d, 3H, J=6.7 Hz), 1.15 (t, 3H, J=7.0 Hz).
    • Step 7-15
  • Figure US20180319798A1-20181108-C00073
  • The compound (5.6 mg) obtained in step 7-14 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated, chloroform was added, and the mixture was concentrated. 4N Hydrochloric acid/ethyl acetate solution was added, and the mixture was concentrated. Crystallization from ethyl acetate-hexane gave the object compound (3.2 mg) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-d6) δ: 13.18 (br s, 1H), 8.41 (s, 1H), 7.65 (s, 1H), 7.44 (td, 1H, J=8.8, 6.7 Hz), 7.25 (ddd, 1H, J=10.2, 9.3, 2.6 Hz), 7.07 (tdd, 1H, J=8.8, 2.6, 0.9 Hz), 4.80 (sep, 1H, J=6.7 Hz), 4.21 (s, 2H), 3.83 (d, 1H, J=14.1 Hz), 3.78 (d, 1H, J=13.7 Hz), 3.68 (d, 1H, J=13.7 Hz), 3.51 (d, 1H, J=14.1 Hz), 2.77 (s, 3H), 2.16-2.03 (m, 2H), 1.67 (s, 3H), 1.22 (d, 3H, J=6.7 Hz), 1.17 (d, 3H, J=6.7 Hz), 0.69 (t, 3H, J=7.3 Hz).
    • Example 8 Step 8-1
  • Figure US20180319798A1-20181108-C00074
  • Under nitrogen, a solution of 1.6M lithium hexamethyldisilazide-THF (11.73 mL) in THF (100 mL) was cooled to −78° C., and a solution of the compound (5 g) obtained in step 2-2 in THF (15 mL) was added dropwise over 2 min under stirring. After stirring for 13 min, tert-butyl chloroglyoxylate (3.58 mL) was added at once. After stirring for 25 min, saturated aqueous potassium hydrogen sulfate solution and ethyl acetate were added, and the mixture was allowed to warm to room temperature. The organic layer was separated, washed with saturated aqueous potassium hydrogen sulfate solution and saturated brine, dried over sodium sulfate, and concentrated. Toluene was added to the residue, and the mixture was concentrated once. Toluene (100 mL) and triethylamine (10 mL) were added and the mixture was stirred at room temperature, and concentrated 30 min later. The above-mentioned operation was repeated once more, and the both were combined and purified by silica gel column chromatography (ethyl acetate:hexane=1:9-1:6) to give the object compound (4.496 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.37 (s, 1H), 7.52-7.49 (m, 2H), 7.39-7.29 (m, 3H), 5.27 (s, 2H), 1.57 (s, 9H), 1.51 (s, 9H).
    • Step 8-2
  • Figure US20180319798A1-20181108-C00075
  • To a solution of the compound (4.49 g) obtained in step 8-1 in dioxane (5 mL) was added 4N hydrochloric acid/dioxane solution (20 mL) with stirring, and the mixture was stirred at room temperature for 20 min. The reaction mixture was concentrated, ethyl acetate/hexane (1:4) solution was added and the mixture was slurry washed. The residue was collected by filtration, and dried to give the object compound (3.30 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.78 (s, 1H), 7.48-7.44 (m, 2H), 7.41-7.34 (m, 3H), 5.34 (s, 2H), 1.54 (s, 9H).
    • Step 8-3
  • Figure US20180319798A1-20181108-C00076
  • To a solution of the compound (1 g) obtained in step 8-2 in toluene (20 mL)/chloroform (5 mL) were added oxalyl chloride (0.326 mL) and dimethylformamide (0.01 mL) under stirring, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, THF (20 mL) was added, and the mixture was cooled to −78° C. under nitrogen. Triethylamine (1.21 mL) and (2,4-difluorophenyl)thioacetic acid hydrazide (555 mg) were added, and the temperature of the mixture was raised slowly. After 25 min, ethyl acetate and water were added, and the mixture was warmed to room temperature. The mixture was extracted twice with ethyl acetate, and the organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated. To the residue was added acetic acid (20 mL), and the mixture was stirred at 100° C. for 2 hr. The mixture was allowed to cool to room temperature, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:9-1:4) to give the object compound (112 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.05 (s, 1H), 7.50-7.46 (m, 1H), 7.39-7.18 (m, 5H), 6.91-6.80 (m, 2H), 5.32 (s, 2H), 4.49 (s, 2H), 1.53 (s, 9H)
    • Step 8-4
  • Figure US20180319798A1-20181108-C00077
  • A solution of the compound (1.01 g) obtained in step 8-3 in formic acid (20 mL) was stirred at room temperature for 2 hr. The reaction mixture was concentrated, ethyl acetate/hexane (1:4) solution was added and the mixture was slurry washed. The crystals were collected by filtration. The mother liquor was concentrated, formic acid (20 mL) was added, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was concentrated, ethyl acetate/hexane (1:4) solution was added and the mixture was slurry washed. The crystals were collected by filtration. The both crystals were combined and dried to give the object compound (238 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.13 (s, 1H), 7.43-7.18 (m, 6H), 6.93-6.79 (m, 2H), 5.67 (s, 2H), 4.51 (s, 2H).
    • Step 8-5
  • Figure US20180319798A1-20181108-C00078
  • To a solution of the compound (69 mg) obtained in step 8-4 in N,N-dimethylformamide (1.5 mL) were added O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU) (86 mg), 1-hydroxy-7-azabenzotriazole (HOAt) (31 mg), triethylamine (1.1 mL) and [4-(isopropylaminomethyl)tetrahydropyran-4-yl]carbamic acid tert-butyl ester (49 mg) under ice-cooling, and the mixture was stirred at room temperature overnight. To the reaction mixture was added 5% aqueous potassium hydrogen sulfate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, dried, and concentrated. The concentrate was purified by silica gel thin layer chromatography (chloroform:methanol=10:1) to give the object compound (18 mg) described in the above-mentioned scheme.
    • Step 8-6
  • Figure US20180319798A1-20181108-C00079
  • To the compound (18 mg) obtained in step 8-5 was added 4N hydrochloric acid/dioxane solution (1 mL), and the mixture was left standing at room temperature for 1.5 hr. The reaction mixture was concentrated, 2-propanol (6 mL), water (0.6 mL) and saturated aqueous sodium hydrogen carbonate solution (0.6 mL) were added, and the mixture was stirred with heating at 100° C. for 4 hr. The mixture was allowed to cool to room temperature once, left standing overnight, and stirred again with heating at 100° C. for 8 hr. To the reaction mixture was added saturated brine, and the mixture was extracted with ethyl acetate, dried and concentrated. The concentrate was purified by silica gel thin layer chromatography (chloroform:methanol=10:1) to give the object compound (10 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 9.05 (s, 1H), 7.66-7.62 (m, 2H), 7.38-7.28 (m, 4H), 6.88-6.81 (m, 2H), 5.38 (s, 2H), 4.97 (sep, 1H, J=7.0 Hz), 4.47 (s, 2H), 4.11-4.04 (m, 2H), 3.74-3.65 (m, 2H), 3.55 (s, 2H), 2.45-2.36 (m, 2H), 2.01-1.94 (m, 2H), 1.22 (d, 6H, J=7.0 Hz).
    • Step 8-7
  • Figure US20180319798A1-20181108-C00080
  • The compound (10 mg) obtained in step 8-6 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 50 min. Trifluoroacetic acid solution was concentrated, 4N hydrochloric acid/dioxane solution was added and the mixture was concentrated. Toluene was added and the mixture was concentrated. The obtained residue was crystallized from ethyl acetate (0.5 mL)-hexane (2 mL) to give the object compound (4.7 mg) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-dd 5: 13.25 (br s, 1H), 8.88 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.09 (m, 1H), 4.83 (sep, 1H, J=6.9 Hz), 4.50 (s, 2H), 3.89-3.82 (m, 2H), 3.88 (br s, 2H), 3.80-3.73 (m, 2H), 2.31-2.22 (m, 2H), 2.01-1.94 (m, 2H), 1.23 (d, 6H, J=6.9 Hz).
    • Example 9
  • Figure US20180319798A1-20181108-C00081
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (18.0 mg) described in the above-mentioned scheme was obtained from ((S)-2-ethylamino-3-methoxypropyl)carbamic acid benzyl ester (80 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.64-12.34 (m, 1H), 8.83 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.64 (dd, 1H, J=13.4, 1.5 Hz), 4.47 (s, 2H), 4.42 (dd, 1H, J=13.4, 4.4 Hz), 4.17-4.11 (m, 1H), 3.86 (dq, 1H, J=14.0, 7.0 Hz), 3.54 (dd, 1H, J=10.4, 4.9 Hz), 3.50 (dd, 1H, J=10.4, 6.3 Hz), 3.27 (dq, 1H, J=14.0, 7.0 Hz), 3.22 (s, 3H), 1.20 (t, 3H, J=7.0 Hz).
    • Example 10
  • Figure US20180319798A1-20181108-C00082
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (10.7 mg) described in the above-mentioned scheme was obtained from ((S)-2-cyclopropylmethylamino-3-methoxypropyl)carbamic acid benzyl ester (36 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.46 (br s, 1H), 8.85 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.67 (dd, 1H, J=13.7, 1.6 Hz), 4.47 (s, 2H), 4.45 (dd, 1H, J=13.7, 3.9 Hz), 4.27-4.20 (m, 1H), 3.69 (dd, 1H, J=14.0, 7.0 Hz), 3.58 (dd, 1H, J=10.3, 4.8 Hz), 3.51 (dd, 1H, J=10.3, 6.5 Hz), 3.21 (dd, 1H, J=14.0, 7.0 Hz), 3.21 (s, 3H), 1.21-1.10 (m, 1H), 0.59-0.47 (m, 2H), 0.44-0.36 (m, 1H), 0.36-0.27 (m, 1H).
    • Example 11
  • Figure US20180319798A1-20181108-C00083
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (32.0 mg) described in the above-mentioned scheme was obtained from ((S)-2-cyclopropylmethylamino-3-ethoxypropyl)carbamic acid benzyl ester (295 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.84 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.15 (m, 2H), 4.67 (d, 1H, J=12.3 Hz), 4.46 (s, 2H), 4.46-4.42 (m, 1H), 4.22-4.19 (m, 2H), 3.67 (dd, 1H, J=14.2, 7.2 Hz), 3.61 (dd, 1H, J=10.4, 4.4 Hz), 3.55 (dd, 1H, J=10.4, 6.2 Hz), 3.40-3.32 (m, 2H), 3.21 (dd, 1H, J=14.2, 7.0 Hz), 0.94 (t, 3H, J=7.0 Hz), 0.54-0.46 (m, 2H), 0.41-0.37 (m, 1H), 0.33-0.27 (m, 1H).
    • Example 12
  • Figure US20180319798A1-20181108-C00084
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (35.0 mg) described in the above-mentioned scheme was obtained from ((S)-3-ethoxy-2-isopropylaminopropyl)carbamic acid benzyl ester (230 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.85 (s, 1H), 7.43-7.40 (m, 2H), 7.22-7.16 (m, 2H), 4.67, (d, 1H, J=11.9 Hz), 4.51-4.47 (m, 1H), 4.47 (s, 2H), 4.35 (dd, 1H, J=13.3, 3.9 Hz), 4.20-4.16 (m, 1H), 3.54 (dd, 1H, J=10.5, 4.1 Hz), 3.45-3.32 (m, 3H), 1.30 (d, 3H, J=4.6 Hz), 1.28 (d, 3H, J=4.6 Hz), 0.96 (t, 3H, J=7.0 Hz).
    • Example 13
  • Figure US20180319798A1-20181108-C00085
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (37.0 mg) described in the above-mentioned scheme was obtained from ((S)-3-ethoxy-2-ethylaminopropyl)carbamic acid benzyl ester (250 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.84 (s, 1H), 7.43-7.40 (m, 2H), 7.22-7.16 (m, 2H), 4.67, (dd, 1H, J=13.5, 1.5 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J=13.5, 4.2 Hz), 4.14-4.11 (m, 1H), 3.91-3.82 (m, 1H), 3.60-3.53 (m, 2H), 3.41-3.34 (m, 2H), 3.31-3.23 (m, 1H), 1.20 (t, 3H, J=7.2 Hz), 0.96 (t, 3H, J=7.0 Hz).
    • Example 14
  • Figure US20180319798A1-20181108-C00086
  • In the same manner as in step 2-9 (amino-protecting group was removed by a known method according to the protecting group) and step 2-11, the object compound (32.9 mg) described in the above-mentioned scheme was obtained from ((1S,2S)-2-ethylamino-3-methoxy-1-methylpropyl)carbamic acid benzyl ester (51 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.62 (s, 1H), 7.42-7.38 (m, 2H), 7.20-7.16 (m, 2H), 4.77-4.71 (m, 1H), 4.47 (s, 2H), 4.14 (q, 1H, J=4.0 Hz), 3.92-3.84 (m, 1H), 3.59 (d, 2H, J=4.4 Hz), 3.33-3.26 (m, 1H), 3.18 (s, 3H), 1.64 (d, 3H, J=6.5 Hz), 1.21 (t, 3H, J=7.1 Hz).
    • Example 15
  • Figure US20180319798A1-20181108-C00087
  • In the same manner as in step 2-9 and step 2-11, the object compound (6.2 mg) described in the above-mentioned scheme was obtained from [(R)-2-isopropylamino-1-((2-methoxyethoxy)methyl)ethyl]carbamic acid tert-butyl ester (19.3 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.82 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.99-4.91 (m, 1H), 4.77 (sep, 1H, J=6.7 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J=13.8, 4.1 Hz), 20 3.78-3.68 (m, 2H), 3.64 (dd, 1H, J=10.4, 7.7 Hz), 3.58-3.45 (m, 2H), 3.34 (t, 2H, J=4.5 Hz), 3.11 (s, 3H), 1.17 (d, 3H, J=6.7 Hz), 1.16 (d, 3H, J=6.7 Hz).
    • Example 16
  • Figure US20180319798A1-20181108-C00088
  • In the same manner as in step 2-9 and step 2-11, the object compound (10.7 mg) described in the above-mentioned scheme was obtained from [(R)-2-cyclopropylamino-1-((2-methoxyethoxy)methyl)ethyl]carbamic acid tert-butyl ester (16 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 8.81 (s, 1H), 7.45-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.92-4.84 (br m, 1H), 4.47 (s, 2H), 4.09-3.99 (m, 1H), 3.74-3.57 (m, 3H), 3.56-3.44 (m, 2H), 3.34 (t, 2H, J=4.6 Hz), 3.13 (s, 3H), 2.94-2.84 (m, 1H), 0.97-0.67 (m, 4H).
    • Example 17
  • Figure US20180319798A1-20181108-C00089
  • In the same manner as in step 2-9 to step 2-11, the object compound (39 mg) described in the above-mentioned scheme was obtained from (R)-2-tert-butoxycarbonylamino-3-ethylamino-2-methylpropionic acid methyl ester (60 mg) obtainable from a commercially available compound by a known method.
  • 1H-NMR (DMSO-d6) δ: 12.69 (m, 1H), 8.60 (s, 1H), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.12 (m, 2H), 4.20 (s, 2H), 4.18-4.13 (m, 1H), 4.01 (d, 1H, J=13.5 Hz), 3.89 (d, 1H, J=13.5 Hz), 3.87-3.80 (m, 2H), 3.67-3.61 (m, 1H), 3.54-3.44 (m, 2H), 2.12-2.04 (m, 2H), 1.91 (s, 3H), 1.10 (t, 3H, J=7.2 Hz).
    • Example 340 Step 340-1
  • Figure US20180319798A1-20181108-C00090
  • To a solution of L-threoninol (2.05 g) in chloroform (14 mL) were added di-tert-butyl dicarbonate (4.26 g) and saturated aqueous sodium hydrogen carbonate solution (10 mL) and the mixture was stirred at room temperature for 3 hr and left standing for 3 days. To the reaction mixture was added saturated brine, and the mixture was extracted with chloroform. The organic layer was dried, and concentrated. The obtained residue was dissolved in dimethylformamide (40 mL) and, under ice-cooling, imidazole (2.97 g) and tert-butylchlorodimethylsilane (1.49 g) were added, and the mixture was stirred at room temperature for 45 min. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated. The concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:10-1:3) to give the object compound (2.39 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 5.18 (d, 1H, J=8.2 Hz), 4.18-4.14 (m, 1H), 3.89 (dd, 1H, J=10.4, 3.3 Hz), 3.82 (dd, 1H, J=10.4, 2.6 Hz), 3.48-3.45 (m, 1H), 3.29 (s, 1H), 1.46 (s, 9H), 1.18 (d, 3H, J=6.2 Hz), 0.90 (s, 9H), 0.08 (s, 6H).
    • Step 340-2
  • Figure US20180319798A1-20181108-C00091
  • To a solution of the compound (2.39 g) obtained in step 340-1 in toluene (12 mL) were added tetrabutylammonium hydrogen sulfate (76 mg), 50% aqueous sodium hydroxide solution (8 mL) and methyl sulfate (922 μL) under ice-cooling, and the mixture was stirred at room temperature for 90 min. Ice water was added, and the mixture was extracted with toluene. The organic layer was washed with saturated brine, dried, and concentrated. The obtained residue was dissolved in tetrahydrofuran (20 mL), 1.0M tetrabutylammonium fluoride/tetrahydrofuran solution (8.16 mL) was added and the mixture was stirred at room temperature for 100 min. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried and concentrated. Toluene was added and the mixture was concentrated again. To a solution of the obtained residue in tetrahydrofuran (40 mL) were added phthalimide (1.85 g) and triphenylphosphine (3.30 g), 2.2M diethyl azodicarboxylate/toluene solution (5.05 mL) was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 90 min. The reaction mixture was concentrated, and the concentrate was purified by silica gel column chromatography (ethyl acetate:hexane=1:10-1:2). The obtained solid was dissolved in ethanol (60 mL)-toluene (60 mL), hydrazine monohydrate (2.05 mL) was added, and the mixture was stirred at 80° C. for 4 hr. The mixture was allowed to cool to room temperature, the solid was filtered off, and the filtrate was concentrated. Toluene was added to the residue, and the precipitated solid was filtered off. The filtrate was concentrated to give the object compound (1.54 g) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 4.82 (br s, 1H), 3.52-3.45 (m, 2H), 3.31 (s, 3H), 2.81 (dd, 2H, J=13.0, 6.0 Hz), 2.76 (dd, 2H, J=13.0, 7.1 Hz), 1.51 (br s, 2H), 1.15 (d, 3H, J=6.2 Hz).
    • Step 340-3
  • Figure US20180319798A1-20181108-C00092
  • To a solution of the compound (187 mg) obtained in step 340-2 in chloroform (3 mL) were added acetone (76 μL), acetic acid (59 μL) and sodium triacetoxyborohydride (218 mg) under ice-cooling, and the mixture was stirred at room temperature for 5 hr. The reaction mixture was diluted with chloroform, saturated aqueous sodium hydrogen carbonate solution was added and the mixture was stirred. The chloroform layer was dried and concentrated to give the object compound (190 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 4.84 (br s, 1H), 3.59-3.50 (m, 2H), 3.32 (s, 3H), 2.83-2.66 (m, 3H), 1.51 (br s, 1H), 1.14 (d, 3H, J=6.4 Hz), 1.04 (d, 3H, J=6.4 Hz), 1.04 (d, 3H, J=6.4 Hz).
    • Step 340-4
  • Figure US20180319798A1-20181108-C00093
  • The compound (190 mg) obtained in step 340-3 was dissolved in trifluoroacetic acid (2.0 mL), and the mixture was stood at room temperature for 20 min. Trifluoroacetic acid solution was concentrated, tetrahydrofuran (1.58 mL) and diisopropylethylamine (636 μL) were added to give a solution. To a solution of the compound (75 mg) obtained in step 2-5 in tetrahydrofuran (500 μL) was added the above-mentioned solution (634 μL), and the mixture was stirred at room temperature for 15 min. Toluene (6 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (250 μL) were added and the mixture was stirred at 100° C. for 20 min. Acetic acid (750 μL) was added and the mixture was stirred at 100° C. for 1 hr. The reaction mixture was allowed to cool to room temperature, 5% aqueous potassium hydrogen sulfate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried, and concentrated. The concentrate was purified by silica gel thin layer chromatography (ethyl acetate:methanol=15:1) to give the object compound (73 mg) described in the above-mentioned scheme.
  • 1H-NMR (CDCl3) δ: 8.65 (s, 1H), 7.65-7.62 (m, 2H), 7.35-7.25 (m, 5H), 7.04-6.98 (m, 2H), 5.51 (d, 1H, J=9.9 Hz), 5.24 (d, 1H, J=9.9 Hz), 4.94 (sep, 1H, J=6.8 Hz), 4.43 (s, 2H), 3.93-3.89 (m, 1H), 3.67 (dd, 1H, J=14.2, 3.9 Hz), 3.47 (dq, 1H, J=8.8, 6.0 Hz), 3.42 (dd, 1H, J=14.2, 1.5 Hz), 3.15 (s, 3H), 1.29 (d, 3H, J=6.0 Hz), 1.19 (d, 3H, J=6.8 Hz), 1.14 (d, 3H, J=6.8 Hz).
    • Step 340-5
  • Figure US20180319798A1-20181108-C00094
  • The compound (72 mg) obtained in step 340-4 was dissolved in trifluoroacetic acid (1.0 mL), and the mixture was stood at room temperature for 4 hr. Trifluoroacetic acid solution was concentrated, toluene was added and the mixture was concentrated. Ethyl acetate, 4N hydrochloric acid/ethyl acetate solution, and hexane were added to allow crystallization to give the object compound (65 mg) described in the above-mentioned scheme.
  • 1H-NMR (DMSO-D6) δ: 12.82 (br s, 1H), 8.72 (s, 1H), 7.44-7.41 (m, 2H), 7.21-7.17 (m, 2H), 4.77 (sep, 1H, J=6.6 Hz), 4.65 (ddd, 1H, J=8.2, 4.1, 0.9 Hz), 4.47 (s, 2H), 3.88 (dd, 1H, J=14.0, 4.1 Hz), 3.76 (dd, 1H, J=14.0, 0.9 Hz), 3.52 (dq, 1H, J=8.2, 6.2 Hz), 3.03 (s, 3H), 1.21 (d, 3H, J=6.2 Hz), 1.20 (d, 3H, J=6.6 Hz), 1.17 (d, 3H, J=6.6 Hz).
  • The compounds of Examples 18 to 465 shown in the following Tables were produced in the same manner as in the above-mentioned Examples 1 to 17 and 340, or by using other conventional methods where necessary. The structural formulas and property data of the compounds of Examples 18 to 465 are shown in the following Tables.
  • TABLE 1-1
    structural
    No. formula salt 1H-NMR
    18
    Figure US20180319798A1-20181108-C00095
         		— 1H-NMR (DMSO-d6) δ: 12.82 (s, 1H), 8.80 (s, 1H), 7.54 (td, 1H, J = 8.8, 6.7 Hz), 7.29 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.12 (tdd, 1H, J = 8.8, 2.6 0.9 Hz), 5.01-4.93 (br m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.9, 3.9 Hz), 3.75 (dd, 1H, J = 13.9, 1.4 Hz), 3.62 (dd, 1H, J = 10.2, 5.8 Hz), 3.57 (dd, 1H, J = 10.2, 7.7 Hz), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    19
    Figure US20180319798A1-20181108-C00096
         		— 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.58 (s, 1H), 7.64 (s, 1H), 7.45 (td, 1H, J = 8.8, 6.8 Hz), 7.24 (ddd, 1H, J = 10.6, 9.7, 2.9 Hz), 7.07 (tdd, 1H, J = 8.8, 2.9, 1.0 Hz), 4.75 (sep, 1H, J = 6.6 Hz), 4.69-4.59 (br m, 1H), 4.21 (s, 2H), 3.81 (dd, 1H, J = 13.5, 3.7 Hz), 3.72 (dd, 1H, J = 13.5,1.5 Hz), 3.67 (dd, 1H, J = 11.7, 5.3 Hz), 3.53 (dd, 1H, J = 11.7, 8.6 Hz), 1.16 (d, 3H, J = 6.6 Hz), 1.15 (d, 3H, J = 6.6 Hz).
    20
    Figure US20180319798A1-20181108-C00097
         		— 1H-NMR (DMSO-d6) δ: 13.11 (br s, 1H), 8.60 (s, 1H), 7.66 (s, 1H), 7.44 (td, 1H, J = 8.7, 6.7 Hz), 7.24 (ddd, 1H, J = 10.4, 9.3, 2.8 Hz), 7.07 (tdd, 1H, J = 8.7, 2.8, 0.9 Hz), 4.79 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.89 (d, 1H, J = 14.1 Hz), 3.79 (d, 1H, J = 14.1 Hz), 3.72 (d, 1H, J = 13.7 Hz), 3.63 (d, 1H, J = 13.7 Hz), 1.58 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
  • TABLE 1-2
    structural
    No. formula salt 1H-NMR
    21
    Figure US20180319798A1-20181108-C00098
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (s, 1H), 8.71 (s, 1H), 7.65 (s, 1H), 7.49-7.41 (m, 1H), 7.33-7.20 (m, 1H), 7.11-7.02 (m, 1H), 5.11-5.02 (m, 1H), 4.84-4.73 (m, 1H), 4.21 (s, 2H), 3.87-3.73 (m, 2H), 2.89-2.82 (m, 2H), 2.86 (s, 3H), 2.79 (s, 3H), 1.13 (d, 3H, J = 7.0 Hz), 1.13 (d, 3H, J = 6.7 Hz).
    22
    Figure US20180319798A1-20181108-C00099
         		— 1H-NMR (DMSO-d6) δ: 12.37 (s, 1H), 8.66 (s, 1H), 8.25 (q, 1H, J = 4.4 Hz), 7.64 (s, 1H), 7.45 (td, 1H, J = 8.6, 6.5 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.8 Hz), 7.07 (tdd, 1H, J = 8.6, 2.8, 0.9 Hz), 5.52-5.46 (br m, 1H), 4.69 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.02 (dd, 1H, J = 13.9, 2.1 Hz), 3.94 (dd, 1H, J = 13.9, 3.5 Hz), 2.61 (d, 3H, J = 4.4 Hz), 1.12 (d, 3H, J = 6.7 Hz), 1.03 (d, 3H, J = 6.7 Hz).
    23
    Figure US20180319798A1-20181108-C00100
         		— 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.75 (s. 1H), 7.65 (s, 1H), 7.46 (td, 1H, J = 8.8, 7.1 Hz), 7.24 (ddd, 1H, J = 10.6, 9.7, 2.4 Hz), 7.07 (tdd, 1H, J = 8.8, 2.4, 0.9 Hz), 5.71-5.66 (br m, 1H), 4.73 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.03 (dd, 1H, J = 13.5, 2.6 Hz), 3.95 (dd, 1H, J = 13.5, 4.0 Hz), 1.16 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
  • TABLE 1-3
    structural
    No. formula salt 1H-NMR
    24
    Figure US20180319798A1-20181108-C00101
         		— 1H-NMR (DMSO-d6) δ: 12.90 (br s, 1H), 8.59 (s, 1H), 7.66 (s, 1H), 7.44 (td, 1H, J = 9.0, 7.3 Hz), 7.24 (ddd, 1H, J = 10.8, 9.3, 2.4 Hz), 7.07 (tdd, 1H, J = 9.0, 2.4, 1.0 Hz), 4.72 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.05 (d, 2H, J = 13.2 Hz), 3.74 (d, 1H, J = 13.2 Hz), 1.92 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.14 (d, 3H, J = 6.7 Hz).
    25
    Figure US20180319798A1-20181108-C00102
         		— 1H-NMR (DMSO-d6) δ: 12.39 (s, 1H), 8.66 (s, 1H), 8.36 (t, 1H, J = 5.4 Hz), 7.64 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.6 Hz), 7.25 (ddd, 1H, J = 10.4, 9.3, 2.6 Hz), 7.07 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 5.50-5.43 (br m, 1H), 4.70 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.03 (dd, 1H, J = 13.9, 1.6 Hz), 3.95 (dd, 1H, J = 13.9, 3.7 Hz), 3.09 (qd, 2H, J = 7.4, 5.4 Hz), 1.13 (d, 3H, J = 6.7 Hz), 1.05 (d, 3H, J = 6.7 Hz), 1.02 (t, 3H, J = 7.4 Hz).
    26
    Figure US20180319798A1-20181108-C00103
         		— 1H-NMR (DMSO-d6) δ: 12.32 (br s, 1H), 8.71 (s, 1H), 7.63 (s, 1H), 7.46 (td, 1H, J = 8.7, 6.6 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.7, 2.6, 1.2 Hz), 6.05-6.00 (br m, 1H), 4.71 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.98 (dd, 1H, J = 14.4, 3.9 Hz), 3.80 (dd, 1H, J = 14.4, 1.4 Hz), 3.17 (s, 3H), 2.82 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 0.98 (d, 3H, J = 6.7 Hz).
  • TABLE 1-4
    structural
    No. formula salt 1H-NMR
    27
    Figure US20180319798A1-20181108-C00104
         		— 1H-NMR (DMSO-d6) δ: 12.80 (s. 1H), 8.50 (s, 1H), 8.13 (t, 1H, J = 5.4 Hz), 7.66 (s, 1H), 7.44 (td, 1H, J = 8.7, 6.7 Hz), 7.24 (ddd, 1H, J = 10.4, 9.3, 2.7 Hz), 7.07 (tdd, 1H, J = 8.7, 2.7, 0.9 Hz), 4.71 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.08 (d, 1H, J = 13.8 Hz), 3.78 (d, 1H, J = 13.8 Hz), 3.17-2.98 (m, 2H), 1.92 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz), 1.00 (t, 3H, J = 7.2 Hz).
    28
    Figure US20180319798A1-20181108-C00105
         		— 1H-NMR (DMSO-d6) δ: 12.85 (s, 1H), 8.42 (s, 1H), 7.66 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.7 Hz), 7.24 (ddd, 1H, J = 10.4, 9.7, 2.8 Hz), 7.07 (tdd, 1H, J = 8.7, 2.8, 0.9 Hz), 4.73 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.12 (d, 1H, J = 14.1 Hz), 3.79 (d, 1H, J = 14.1 Hz), 2.93 (br s, 6H), 1.97 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
    29
    Figure US20180319798A1-20181108-C00106
         		— 1H-NMR (DMSO-d6) δ: 12.78 (s, 1H), 8.51 (s, 1H), 8.05 (q, 1H, J = 4.2 Hz), 7.66 (s, 1H), 7.44 (td, 1H, J = 8.7, 6.6 Hz), 7.24 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.05 (d, 1H, J = 13.7 Hz), 3.78 (d, 1H, J = 13.7 Hz), 2.59 (d, 3H, J = 4.2 Hz), 1.92 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
  • TABLE 1-5
    structural
    No. formula salt 1H-NMR
    30
    Figure US20180319798A1-20181108-C00107
         		HCl 1H-NMR (DMSO-d6) δ: 13.17 (br s, 1H), 8.87 (s, 1H), 7.54 (td, 1H, J = 8.5, 6.9 Hz), 7.29 (ddd, 1H, J = 10.5, 9.3, 2.4 Hz), 7.11 (tdd, 1H, J = 8.5, 2.4, 1.2 Hz), 4.49 (s, 2H), 3.90 (s, 2H), 3.88-3.81 (m, 2H), 3.74-3.66 (m, 2H), 2.98 (ddt, 1H, J = 7.3, 6.9, 4.0 Hz), 2.28-2.19 (m, 2H), 1.98-1.91 (m, 2H), 0.93-0.80 (m, 4H).
    31
    Figure US20180319798A1-20181108-C00108
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.65 (s, 1H), 8.30 (d, 1H, J = 7.4 Hz), 7.64 (s, 1H), 7.45 (td, 1H, d = 8.6, 6.5 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.6, 2.6, 0.9 Hz), 5.46-5.41 (br m, 1H), 4.71 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.03 (dd, 1H, J = 14.0, 1.9 Hz), 3.95 (dd, 1H, J = 14.0, 3.6 Hz), 3.85-3.74 (m, 1H), 1.13 (d, 3H, J = 6.7 Hz), 1.09 (d, 3H, J = 6.7 Hz), 1.07 (d, 3H, J = 7.0 Hz), 1.05 (d, 3H, J = 7.0 Hz).
    32
    Figure US20180319798A1-20181108-C00109
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 3.68 (s, 1H), 8.31 (dd, 1H, J = 6.2, 5.7 Hz), 7.64 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.6 Hz), 7.24 (ddd, 1H, J = 10.4, 9.3, 2.8 Hz), 7.07 (tdd, 1H, J = 8.7, 2.8, 1.2 Hz), 5.51-5.46 (br m, 1H), 4.68 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.04 (dd, 1H, J = 14.1, 2.1 Hz), 3.94 (dd, 1H, J = 14.1, 3.6 Hz), 2.97 (ddd, 1H, J = 12.8, 6.6, 6.2 Hz), 2.78 (ddd, 1H, J = 12.8, 6.6, 5.7 Hz), 1.67 (sep, 1H, J = 6.5 Hz), 1.12 (d, 3H, J = 6.7 Hz), 1.04 (d, 3H, J = 6.7 Hz), 0.83 (d, 3H, J = 6.5 Hz), 0.82 (d, 3H, J = 6.5 Hz).
  • TABLE 1-6
    structural
    No. formula salt 1H-NMR
    33
    Figure US20180319798A1-20181108-C00110
         		— 1H-NMR (DMSO-d6) δ: 8.69 (s, 1H), 7.65 (sm 1H), 7.50-7.40 (m, 1H), 7.33-7.20 (m, 1H), 7.11-7.03 (m, 1H), 5.16-5.04 (m, 1H), 4.84-4.71 (m, 1H), 4.21 (s, 2H), 3.89-3.68 (m, 2H), 2.92-2.64 (m, 2H), 1.15 (t, 6H, J = 6.3 Hz).
    34
    Figure US20180319798A1-20181108-C00111
         		HCl 1H-NMR (DMSO-d6) δ: 12.64 (br s, 1H), 8.54 (s, 1H), 7.95-7.87 (m, 1H), 7.64 (s, 1H), 7.50-7.41 (m, 1H), 7.33-7.20 (m, 1H), 7.12-7.03 (m, 1H), 5.08-4.99 (m, 1H), 4.84-4.74 (m, 1H), 4.21 (s, 2H), 3.88-3.65 (m, 2H), 2.70-2.54 (m, 2H), 2.45 (d, 3H, J = 4.4 Hz), 1.17 (d, 3H, J = 6.5 Hz), 1.14 (d, 3H, J = 7.2 Hz).
    35
    Figure US20180319798A1-20181108-C00112
         		HCl 1H-NMR (DMSO-d6) δ: 8.58 (s, 1H), 7.65 (s, 1H), 7.49-7.38 (m, 2H), 7.28-7.19 (m, 1H), 7.11-7.03 (m, 1H), 7.00 (br s, 1H), 5.07-4.97 (m, 1H), 4.85-4.73 (m, 1H), 4.21 (s, 2H), 3.91-3.65 (m, 2H), 2.71-2.51 (m, 2H), 1.18 (d, 3H, J = 7.0 Hz), 1.15 (d, 3H, J = 7.2 Hz).
    36
    Figure US20180319798A1-20181108-C00113
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.46 (s, 1H), 7.85 (d, 1H, J = 7.7 Hz), 7.63 (s, 1H), 7.48-7.39 (m, 1H), 7.29-7.19 (m, 1H), 7.12-7.03 (m, 1H), 5.05-4.94 (m, 1H), 4.86-4.74 (m, 1H), 4.20 (s, 2H), 3.88-3.60 (m, 3H), 2.70-2.46 (m, 2H), 1.18 (d, 3H, J = 7.0 Hz), 1.15 (d, 3H, J = 7.2 Hz), 0.92 (d, 3H, J = 6.7 Hz), 0.69 (d, 3H, J = 6.7 Hz).
  • TABLE 1-7
    structural
    No. formula salt 1H-NMR
    37
    Figure US20180319798A1-20181108-C00114
         		HCl 1H-NMR (DMSO-d6) δ: 8.80 (s, 1H), 7.57-7.49 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.67 (dd, 1H, J = 13.2, 1.4 Hz), 4.51 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.34 (dd, 1H, J = 13.2, 3.5 Hz), 4.00-3.93 (m, 1H), 3.57 (dd, 1H, J = 11.5, 3.5 Hz), 3.36 (dd, 1H, J = 11.5, 8.1 Hz), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
    38
    Figure US20180319798A1-20181108-C00115
         		— 1H-NMR (DMSO-d6) δ: 12.97 (br s, 1H), 8.38 (s, 1H), 7.67 (s, 1H), 7.45 (td, 1H, J = 8.8, 6.6 Hz), 7.25 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.07 (tdd, 1H, J = 8.8, 2.6, 0.9 Hz), 4.75 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.03 (d, 1H, J = 13.9 Hz), 3.80 (d, 1H, J = 13.9 Hz), 3.56-3.35 (br m, 4H), 1.90 (s, 3H), 1.59-1.50 (br m, 2H), 1.49-1.40 (br m, 4H), 1.18 (d, 3H, J = 6.7 Hz), 1.14 (d, 3H, J = 6.7 Hz).
    39
    Figure US20180319798A1-20181108-C00116
         		— 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.52 (s, 1H), 7.66 (s, 1H), 7.45 (td, 1H, J = 8.8, 6.6 Hz), 7.24 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.8, 2.6, 0.9 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.11 (d, 1H, J = 13.9 Hz), 3.74 (d, 1H, J = 13.9 Hz), 3.64-3.54 (br m, 1H), 3.42-3.32 (br m, 1H), 3.32-3.22 (br m, 1H), 3.15-3.05 (br m, 1H), 2.00 (s, 3H), 1.94-1.82 (br m, 1H), 1.79-1.57 (br m, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.07 (d, 3H, J = 6.7 Hz).
  • TABLE 1-8
    structural
    No. formula salt 1H-NMR
    40
    Figure US20180319798A1-20181108-C00117
         		HCl 1H-NMR (DMSO-d6) δ: 12.92-12.53 (m, 1H), 8.44 (s, 1H), 7.97 (t, 1H, J = 6.3 Hz), 7.64 (s, 1H), 7.49-7.40 (m, 1H), 7.29-7.19 (m, 1H), 7.12-7.02 (m, 1H), 5.10-4.98 (m, 1H), 4.86-4.75 (m, 1H), 4.21 (s, 2H), 3.90-3.81 (m, 1H), 3.75-3.67 (m, 1H), 2.92-2.82 (m, 1H), 2.77-2.66 (m, 1H), 2.61-2.48 (m, 2H), 1.44-1.30 (m, 1H), 1.18 (d, 3H, J = 7.2 Hz), 1.15 (d, 3H, J = 7.2 Hz), 0.54 (d, 3H, J = 6.7 Hz), 0.50 (d, 3H, J = 7.2 Hz).
    41
    Figure US20180319798A1-20181108-C00118
         		HCl 1H-NMR (DMSO-d6) δ: 12.88-12.50 (m, 1H), 8.68 (s, 1H), 7.65 (s, 1H), 7.49-7.40 (m, 1H), 7.28-7.20 (m, 1H), 7.11-7.03 (m, 1H), 5.11-5.03 (m, 1H), 4.84-4.73 (m, 1H), 4.21 (s, 2H), 3.88-3.73 (m, 2H), 3.54-3.19 (m, 4H), 2.87 (d, 2H, J = 7.0 Hz), 1.59-1.43 (m, 2H), 1.42-1.29 (m, 4H), 1.13 (d, 3H, J = 6.7 Hz), 1.13 (d, 3H, J = 6.5 Hz).
    42
    Figure US20180319798A1-20181108-C00119
         		HCl 1H-NMR (DMSO-d6) δ: 12.45 (br s, 1H), 8.84 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.07 (m, 1H), 4.66 (dd, 1H, J = 13.4, 1.6 Hz), 4.49 (s, 2H), 4.47 (sep, 1H, J = 6.8 Hz), 4.35 (dd, 1H, J = 13.4, 3.7 Hz), 4.23-4.17 (m, 1H), 3.49 (dd, 1H, J = 10.2, 4.2 Hz), 3.39 (dd, 1H, J = 10.2, 7.4 Hz), 3.21 (s, 3H), 1.30 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz).
  • TABLE 1-9
    structural
    No. formula salt 1H-NMR
    43
    Figure US20180319798A1-20181108-C00120
         		HCl 1H-NMR (DMSO-d6) δ: 12.54 (br s, 1H), 8.83 (s, 1H), 7.57-7.49 (m, 1H), 7.32-7.25 (m, 1H), 7.14-7.07 (m, 1H), 4.65 (dd, 1H, J = 13.4, 1.4 Hz), 4.48 (s, 2H), 4.47 (dd, 1H, J = 13.4, 4.3 Hz), 4.10-4.04 (m, 1H), 3.80 (dd, 1H, J = 13.3, 8.0 Hz), 3.53 (dd, 1H, J = 10.4, 5.1 Hz), 3.49 (dd, 1H, J = 10.4, 6.3 Hz), 3.20 (s, 3H), 2.94 (dd, 1H, J = 13.3, 7.1 Hz), 2.08 (ddsep, 1H, J = 8.0, 7.1, 6.7 Hz), 0.95 (d, 3H, J = 6.7 Hz), 0.89 (d, 3H, J = 6.7 Hz).
    44
    Figure US20180319798A1-20181108-C00121
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.81 (s, 1H), 7.59-7.49 (m, 1H), 7.33-7.23 (m, 1H), 7.16-7.07 (m, 1H), 4.99-4.90 (m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 3.93-3.60 (m, 4H), 3.58-3.44 (m, 2H), 3.33 (t, 2H, J = 4.6 Hz), 3.11 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    45
    Figure US20180319798A1-20181108-C00122
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.80 (s, 1H), 7.59-7.50 (m, 1H), 7.35-7.24 (m, 1H), 7.16-7.07 (m, 1H), 4.97-4.86 (m, 1H), 4.49 (s, 2H), 4.06 (dd, 1H, J = 13.7, 4.2 Hz), 3.80-3.66 (m, 3H), 3.59-3.46 (m, 3H), 3.36-3.31 (m, 2H), 3.22 (dd, 1H, J = 7.1, 12.6 Hz), 3.11 (s, 3H), 2.00 (sept, 1H, J = 6.6 Hz), 0.91 (d, 6H, J = 6.6 Hz).
  • TABLE 1-10
    structural
    No. formula salt 1H-NMR
    46
    Figure US20180319798A1-20181108-C00123
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.81 (s, 1H), 7.59-7.49 (m, 1H), 7.33-7.23 (m, 1H), 7.16-7.07 (m, 1H), 4.99-4.90 (m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 3.93-3.60 (m, 4H), 3.58-3.44 (m, 2H), 3.33 (t, 2H, J = 4.6 Hz), 3.11 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    47
    Figure US20180319798A1-20181108-C00124
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.80 (s, 1H), 7.59-7.50 (m, 1H), 7.35-7.24 (m, 1H), 7.16-7.07 (m, 1H), 4.97-4.86 (m, 1H), 4.49 (s, 2H), 4.06 (dd, 1H, J = 13.7, 4.2 Hz), 3.80-3.66 (m, 3H), 3.59-3.46 (m, 3H), 3.36-3.31 (m, 2H), 3.22 (dd, 1H, J = 7.1, 12.6 Hz), 3.11 (s, 3H), 2.00 (sept, 1H, J = 6.6 Hz), 0.91 (d, 6H, J = 6.6 Hz).
    48
    Figure US20180319798A1-20181108-C00125
         		HCl 1H-NMR (DMSO-d6) δ: 12.55 (br s, 1H), 8.81 (s, 1H), 7.59-7.49 (m, 1H), 7.35-7.24 (m, 1H), 7.16-7.07 (m, 1H), 4.65 (d, 1H, J = 13.2 Hz), 4.53-4.45 (m, 1H), 4.48 (s, 2H), 4.09-4.01 (m, 1H), 3.80 (dd, 1H, J = 13.4, 7.9 Hz), 3.67-3.57 (m, 2H), 3.50-3.39 (m, 2H), 3.30-3.24 (m, 2H), 3.08 (s, 3H), 2.95 (dd, 1H, J = 13.4, 7.0 Hz), 2.14-2.01 (m, 1H), 0.95 (d, 3H, J = 6.5 Hz), 0.90 (d, 3H, J = 6.7 Hz).
    49
    Figure US20180319798A1-20181108-C00126
         		HCl 1H-NMR (DMSO-d6) δ: 12.73 (br s, 1H), 8.80 (s, 1H), 7.67 (s, 1H), 7.51-7.42 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.03 (m, 1H), 5.27-5.17 (m, 1H), 4.85-4.72 (m, 1H), 4.22 (s, 2H), 3.96-3.65 (m, 2H), 3.34-3.20 (m, 2H), 1.20 (d, 3H, J = 7.2 Hz), 1.14 (d, 3H, J = 7.0 Hz).
  • TABLE 1-11
    structural
    No. formula salt 1H-NMR
    50
    Figure US20180319798A1-20181108-C00127
         		HCl 1H-NMR (DMSO-d6) δ: 12.38 (s, 1H), 8.95 (s, 1H), 7.57-7.50 (m, 1H),7.32-7.25 (m, 1H), 7.14-7.08 (m, 1H), 5.00-4.91 (m, 2H), 4.73 (sep, 1H, J = 6.6 Hz), 4.52 (dd, 1H, J = 13.6, 3.9 Hz), 4.48 (s, 2H), 1.24 (d, 3H, J = 6.6 Hz), 1.13 (d, 3H, J = 6.6 Hz).
    51
    Figure US20180319798A1-20181108-C00128
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (s, 1H), 8.80 (s, 1H), 8.31 (q, 1H, J = 4.6 Hz), 7.57-7.49 (m, 1H), 7.33-7.24 (m, 1H), 7.14-7.07 (m, 1H), 4.76 (d, 1H, J = 14.2 Hz), 4.73 (sep, 1H, J = 6.8 Hz), 4.60 (d, 1H, J = 4.0 Hz), 4.54 (dd, 1H, J = 14.2, 4.0 Hz), 4.48 (s, 2H), 2.60 (d, 3H, J = 4.6 Hz), 1.21 (d, 3H, J = 6.8 Hz), 1.04 (d, 3H, J = 6.8 Hz).
    52
    Figure US20180319798A1-20181108-C00129
         		HCl 1H-NMR (DMSO-d6) δ: 12.95 (br s, 1H), 8.39 (s, 1H), 7.68 (s, 1H), 7.45 (td, 1H, J = 8.6, 6.7 Hz), 7.25 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.07 (tdd, 1H, J = 8.6, 2.6, 0.9 Hz), 4.75 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.02 (d, 1H, J = 14.4 Hz), 3.81 (d, 1H, J = 14.4 Hz), 3.60-3.41 (br m, 8H), 1.91 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    53
    Figure US20180319798A1-20181108-C00130
         		HCl 1H-NMR (DMSO-d6) δ: 12.57 (s, 1H), 8.81 (s, 1H), 7.57-7.49 (m, 1H), 7.32-7.25 (m, 1H), 7.14-7.07 (m, 1H), 5.17 (d, 1H, J = 3.0 Hz), 4.80 (d, 1H, J = 13.7 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.52-4.46 (m, 1H), 4.48 (s, 2H), 3.20 (s, 3H), 2.81 (s, 3H), 1.24 (d, 3H, J = 6.7 Hz), 1.00 (d, 3H, J = 6.7 Hz).
  • TABLE 1-12
    structural
    No. formula salt 1H-NMR
    54
    Figure US20180319798A1-20181108-C00131
         		HCl 1H-NMR (DMSO-d6) δ: 12.44 (br s, 1H), 8.81 (s, 1H), 7.59-7.48 (m, 1H), 7.34-7.23 (m, 1H), 7.16-7.06 (m, 1H), 4.69-4.61 (m, 1H), 4.53-4.43 (m, 1H), 4.48 (s, 2H), 4.36 (dd, 1H, J = 7.2, 13.4 Hz), 4.23-4.14 (m, 1H), 3.51-3.40 (m, 4H), 3.33-3.25 (m, 2H), 3.08 (s, 3H), 1.28 (d, 3H, J = 6.7 Hz), 1.29 (d, 3H, J = 6.5 Hz).
    55
    Figure US20180319798A1-20181108-C00132
         		HCl 1H-NMR (DMSO-d6) δ: 12.55 (br s, 1H), 8.81 (s, 1H), 7.59-7.49 (m, 1H), 7.35-7.24 (m, 1H), 7.16-7.07 (m, 1H), 4.65 (d, 1H, J = 13.2 Hz), 4.53-4.45 (m, 1H), 4.48 (s, 2H), 4.09-4.01 (m, 1H), 3.80 (dd, 1H, J = 13.4, 7.9 Hz), 3.67-3.57 (m, 2H), 3.50-3.39 (m, 2H), 3.30-3.24 (m, 2H), 3.08 (s, 3H), 2.95 (dd, 1H, J = 13.4, 7.0 Hz), 2.14-2.01 (m, 1H), 0.95 (d, 3H, J = 6.5 Hz), 0.90 (d, 3H, J = 6.7 Hz).
    56
    Figure US20180319798A1-20181108-C00133
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.65 (s, 1H), 7.65 (s, 1H), 7.49-7.42 (m, 1H), 7.28-7.21 (m, 1H), 7.10-7.04 (m, 1H), 4.93-4.87 (m, 1H), 4.77 (sep, 1H, J = 6.9 Hz), 4.21 (s, 2H), 3.82 (dd, 1H, J = 13.7, 4.0 Hz), 3.76-3.67 (m, 2H), 3.62 (dd, 1H, J = 10.5, 7.7 Hz), 3.56-3.45 (m, 2H), 3.35- 3.32 (m, 2H), 3.12 (s, 3H), 1.16 (d, 3H, J = 6.9 Hz), 1.15 (d, 3H, J = 6.9 Hz).
  • TABLE 1-13
    structural
    No. formula salt 1H-NMR
    57
    Figure US20180319798A1-20181108-C00134
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.64 (s, 1H), 7.65 (s, 1H), 7.49-7.42 (m, 1H), 7.28-7.21 (m, 1H), 7.10-7.04 (m, 1H), 4.90-4.82 (m, 1H), 4.21 (s, 2H), 4.04 (dd, 1H, J = 13.7, 4.4 Hz), 3.78-3.64 (m, 3H), 3.56-3.45 (m, 2H), 3.45-3.28 (m, 3H), 3.21 (dd, 1H, J = 13.3, 6.9 Hz), 3.11 (s, 3H), 2.05-1.94 (m, 1H), 0.91 (d, 6H, J = 6.4 Hz).
    58
    Figure US20180319798A1-20181108-C00135
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.63 (s, 1H), 7.64 (s, 1H), 7.49-7.41 (m, 1H), 7.28-7.20 (m, 1H), 7.11-7.04 (m, 1H), 4.62-4.55 (m, 1H), 4.46 (dd, 1H, J = 13.8, 4.4 Hz), 4.21 (s, 2H), 4.06-4.00 (m, 1H), 3.80 (dd, 1H, J = 13.4, 7.7 Hz), 3.64-3.54 (m, 2H), 3.50-3.40 (m, 2H), 3.33-3.24 (m, 2H), 3.10 (s, 3H), 2.94 (dd, 1H, J = 13.4, 7.1 Hz), 2.12-2.03 (m, 1H), 0.95 (d, 3H, J = 6.7 Hz), 0.89 (d, 3H, J = 6.7 Hz).
    59
    Figure US20180319798A1-20181108-C00136
         		HCl 1H-NMR (DMSO-d6) δ: 12.30 (br s, 1H), 8.62 (s, 1H), 7.64 (s, 1H), 7.50-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.03 (m, 1H), 4.62-4.55 (m, 1H), 4.48 (sep, 1H, J = 6.7 Hz), 4.36-4.31 (m, 1H), 4.21 (s, 2H), 4.19-4.14 (m, 1H), 3.58 (dd, 1H, J = 10.3, 4.1 Hz), 3.52-3.39 (m, 3H), 3.33-3.27 (m, 2H), 3.10 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
  • TABLE 1-14
    structural
    No. formula salt 1H-NMR
    60
    Figure US20180319798A1-20181108-C00137
         		HCl 1H-NMR (DMSO-d6) δ: 12.44 (br s, 1H), 8.81 (s, 1H), 7.59-7.48 (m, 1H), 7.34-7.23 (m, 1H), 7.16-7.06 (m, 1H), 4.69-4.61 (m, 1H), 4.53-4.43 (m, 1H), 4.48 (s, 2H), 4.36 (dd, 1H, J = 7.2, 13.4 Hz), 4.23-4.14 (m, 1H), 3.51-3.40 (m, 4H), 3.33-3.25 (m, 2H), 3.08 (s, 3H), 1.28 (d, 3H, J = 6.7 Hz), 1.29 (d, 3H, J = 6.5 Hz).
    61
    Figure US20180319798A1-20181108-C00138
         		HCl 1H-NMR (DMSO-d6) δ: 8.66 (s, 1H), 7.49-7.41 (m, 1H), 7.29-7.21 (m, 1H), 7.11-7.03 (m, 1H), 4.60 (dd, 1H, J = 13.4, 1.4 Hz), 4.47 (sep, 1H, J = 6.8 Hz), 4.33 (dd, 1H, J = 13.4, 3.7 Hz), 4.22 (s, 2H), 4.14-4.10 (m, 1H), 3.48 (dd, 1H, J = 10.3, 4.3 Hz), 3.36 (dd, 1H, J = 10.3, 7.7 Hz), 3.21 (s, 3H), 1.29 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz).
    62
    Figure US20180319798A1-20181108-C00139
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.65 (s, 1H), 7.65 (s, 1H), 7.50-7.41 (m, 1H), 7.30-7.21 (m, 1H), 7.11-7.03 (m, 1H), 4.59 (dd, 1H, J = 13.7, 1.2 Hz), 4.46 (dd, 1H, J = 13.7, 4.2 Hz), 4.21 (s, 2H), 4.08-4.01 (m, 1H), 3.80 (dd, 1H, J = 13.2, 7.9 Hz). 3.52 (dd, 1H, J = 10.4, 5.4 Hz), 3.48 (dd, 1H, J = 10.4, 6.4 Hz), 3.20 (s, 3H), 2.93 (dd, 1H, J = 13.2, 7.2 Hz), 2.08 (tt, 1H, J = 6.7, 6.7 Hz), 0.95 (d, 3H, J = 6.7 Hz), 0.89 (d, 3H, J = 6.7 Hz).
  • TABLE 1-15
    No. structural formula salt 1H-NMR
    63
    Figure US20180319798A1-20181108-C00140
         		HCl 1H-NMR (CDCl3) δ: 12.78 (br s, 1H), 9.36 (s, 1H), 7.38-7.30 (m, 1H), 6.92-6.84 (m, 2H), 4.58-4.51 (m, 1H), 4.48 (s, 2H), 4.05-3.98 (m, 1H), 3.76-3.63 (m, 3H), 3.51 (dd, 1H, J = 13.4, 7.9 Hz), 3.39 (s, 3H), 3.29 (dd, 1H, J = 13.4, 7.0 Hz), 2.09-1.99 (m, 1H), 1.00 (d, 3H, J = 6.7 Hz), 0.99 (d, 3H, J = 6.7 Hz).
    64
    Figure US20180319798A1-20181108-C00141
         		HCl 1H-NMR (DMSO-d6) δ: 9.03 (s, 1H), 7.59-7.51 (m, 1H), 7.33-7.25 (m, 1H), 7.16-7.08 (m, 1H), 5.66 (dd, 1H, J = 3.0, 1.9 Hz), 5.07 (dd, 1H, J = 13.8, 1.9 Hz), 4.78 (sep, 1H, J = 6.8 Hz), 4.61 (dd, 1H, J = 13.8, 3.0 Hz), 4.51 (s, 2H), 1.31 (d, 3H, J = 6.8 Hz), 1.24 (d, 3H, J = 6.8 Hz).
    65
    Figure US20180319798A1-20181108-C00142
         		HCl 1H-NMR (DMSO-d6) δ: 8.31 (s, 1H), 7.78-7.73 (m, 2H), 7.72-7.67 (m, 2H), 7.38 (td, 1H, J = 8.8, 6.8 Hz), 7.36 (s, 1H), 7.25 (ddd, 1H, J = 10.4, 9.0, 2.6 Hz), 7.08 (tdd, 1H, J = 8.8, 2.6, 0.9 Hz), 4.99-4.91 (br m, 1H), 4.80 (sep, 1H, J = 6.7 Hz), 4.13 (s, 2H), 4.04 (dd, 1H, J = 14.3, 4.6 Hz), 3.96 (dd, 1H, J = 13.9, 2.0 Hz), 3.89 (dd, 1H, J = 13.9, 4.0 Hz), 3.82 (dd, 1H, J = 14.3,9.3 Hz), 1.27 (d, 3H, J = 6.7 Hz), 1.19 (d, 3H, J = 6.7 Hz).
  • TABLE 1-16
    No. structural formula salt 1H-NMR
    66
    Figure US20180319798A1-20181108-C00143
         		2HCl 1H-NMR (DMSO-d6) δ: 12.56 (br s, 1H), 8.70 (s, 1H), 8.25-8.13 (br m, 2H), 7.66 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.7 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.08 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.95-4.86 (br m, 1H), 4.76 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 3.90 (dd, 1H, J = 13.8, 3.6 Hz), 3.84 (dd, 1H, J = 13.8, 1.9 Hz), 3.35-3.24 (br m, 1H), 3.22-3.09 (br m, 1H), 1.19 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz).
    67
    Figure US20180319798A1-20181108-C00144
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.39 (s, 1H), 8.05 (t, 1H, J = 6.0 Hz), 7.64 (s, 1H), 7.46 (td, 1H, J = 8.8, 7.0 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.08 (tdd, 1H, J = 8.8, 2.6, 0.9 Hz), 4.77 (sep, 1H, J = 6.7 Hz), 4.67-4.59 (br m, 1H), 4.21 (s, 2H), 3.84 (dd, 1H, J = 13.8, 3.8 Hz), 3.74 (dd, 1H, J = 13.8, 0.9 Hz), 3.41-3.27 (m, 2H), 1.66 (s, 3H), 1.19 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    68
    Figure US20180319798A1-20181108-C00145
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.36 (s, 1H), 7.97 (t, 1H, J = 6.0 Hz), 7.62 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.7 Hz), 7.25 (ddd, 1H, J = 10.4. 9.5, 2.6 Hz), 7.08 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.77 (sep, 1H, J = 6.7 Hz), 4.68-4.60 (br m, 1H), 4.21 (s, 2H), 3.84 (dd, 1H, J = 13.7, 3.9 Hz), 3.75 (dd, 1H, J = 13.7, 1.4 Hz), 3.40-3.29 (m, 2H), 1.96-1.86 (m, 2H), 1.19 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz), 0.78 (t, 3H, J = 7.5 Hz).
  • TABLE 1-17
    No. structural formula salt 1H-NMR
    69
    Figure US20180319798A1-20181108-C00146
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (s, 1H), 8.33 (s, 1H), 7.93 (t, 1H, J = 6.0 Hz), 7.61 (s, 1H), 7.43 (td, 1H, J = 8.7, 6.6 Hz), 7.25 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.78 (sep, 1H, J = 6.7 Hz), 4.69-4.61 (br m, 1H), 4.20 (s, 2H), 3.84 (dd, 1H, J = 13.7, 3.9 Hz), 3.74 (dd, 1H, J = 13.7, 1.4 Hz), 3.38-3.32 (m, 2H), 2.15 (sep, 1H, J = 6.7 Hz), 1.19 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz), 0.85 (d, 3H, J = 6.7 Hz), 0.73 (d, 3H, J = 6.7 Hz).
    70
    Figure US20180319798A1-20181108-C00147
         		HCl 1H-NMR (DMSO-d6) δ: 12.55 (br s, 1H), 8.75 (s, 1H), 7.58-7.50 (m, 1H), 7.34-7.24 (m, 1H), 7.16-7.07 (m, 1H), 4.49 (s, 2H), 4.43-4.30 (m, 3H), 4.03 (q, 1H, J = 7.8 Hz), 3.92-3.48 (m, 3H), 2.36-2.26 (m, 1H), 2.12-2.00 (m, 1H), 1.39 (s, 3H), 1.36 (s, 3H).
    71
    Figure US20180319798A1-20181108-C00148
         		HCl 1H-NMR (DMSO-d6) δ: 12.64 (br s, 1H), 8.49 (s, 1H), 8.04 (d, 1H, J = 3.9 Hz), 7.65 (s, 1H), 7.50-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.11-7.03 (m, 1H), 5.07-4.96 (m, 1H), 4.84-4.72 (m, 1H), 4.21 (s, 2H), 3.87-3.59 (m, 2H), 2.71-2.30 (m, 3H), 1.15 (t, 6H, J = 7.4 Hz), 0.55-0.35 (m, 2H), 0.24-0.06 (m, 2H).
  • TABLE 1-18
    No. sructural formula salt 1H-NMR
    72
    Figure US20180319798A1-20181108-C00149
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.70 (s, 1H), 7.65 (s, 1H), 7.49-7.39 (m, 1H), 7.29-7.19 (m, 1H), 7.11-7.00 (m, 1H), 5.14-5.01 (m, 1H), 4.86-4.71 (m, 1H), 4.21 (s, 2H), 3.91-3.67 (m, 2H), 3.51-3.22 (m, 8H), 2.91 (d, 2H, J = 6.5 Hz), 1.14 (d, 3H, J = 6.7 Hz), 1.13 (d, 3H, J = 6.7 Hz).
    73
    Figure US20180319798A1-20181108-C00150
         		HCl 1H-NMR (DMSO-d6) δ: 8.69 (s, 1.0H), 7.65 (s, 1.0H), 7.49-7.40 (m, 1.0H), 7.29-7.19 (m, 1.0H), 7.11-7.02 (m, 1.0H), 5.13-5.03 (m, 1.0H), 4.84-4.72 (m, 1.0H), 4.21 (s, 2.0H), 3.88-3.55 (m, 2.0H), 3.55-3.25 (m, 4.0H), 3.15 (s, 1.5H), 3.12 (s, 1.5H), 3.02-2.82 (m, 2.0H), 2.88 (s, 1.5H), 2.79 (s. 1.5H), 1.13 (d, 6.0H, J = 6.5 Hz).
    74
    Figure US20180319798A1-20181108-C00151
         		HCl 1H-NMR (DMSO-d6) δ: 8.85 (s, 1H), 7.57-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.62-4.56 (m, 1H), 4.53-4.30 (m, 3H), 4.49 (s, 2H), 2.69-2.45 (m, 2H), 1.30 (d, 3H, J = 7.2 Hz), 1.28 (d, 3H, J = 7.2 Hz).
    75
    Figure US20180319798A1-20181108-C00152
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (s, 1H), 8.80 (s, 1H), 7.57-7.49 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.57-4.46 (m, 2H), 4.48 (s, 2H), 4.45-4.34 (m, 2H), 2.84 (s, 3H), 2.83 (s, 3H), 2.81-2.54 (m, 2H), 1.28 (d, 3H, J = 6.8 Hz), 1.25 (d, 3H, J = 6.8 Hz).
  • TABLE 1-19
    No. structural formula salt 1H-NMR
    76
    Figure US20180319798A1-20181108-C00153
         		HCl 1H-NMR (DMSO-d6) δ: 12.81-12.55 (m, 1H), 8.70 (d, 1H, J = 3.7 Hz), 7.65 (s, 1H), 7.50-7.40 (m, 1H), 7.29-7.19 (m, 1H), 7.11-7.03 (m, 1H), 5.13-5.02 (m, 1H), 4.86-4.72 (m, 1H), 4.21 (s, 2H), 3.88-3.73 (m, 2H), 3.42-3.10 (m, 3H), 2.90-2.80 (m, 1H), 2.83 (s, 1.8H), 2.76 (s, 1.2H), 1.13 (d, 3H, J = 7.0 Hz), 1.12 (d, 3H, J = 6.7 Hz), 0.99 (t, 1.2H, J = 7.2 Hz), 0.93 (t 1.8H, J = 7.4 Hz).
    77
    Figure US20180319798A1-20181108-C00154
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.68 (s, 1H), 7.65 (s, 1H), 7.50-7.40 (m, 1H), 7.29-7.19 (m, 1H), 7.12-7.03 (m, 1H), 5.14-5.04 (m, 1H), 4.85-4.73 (m, 1H), 4.21 (s, 2H), 3.90-3.76 (m, 2H), 3.35-3.10 (m, 4H), 2.84 (d, 2H, J = 6.7 Hz), 1.13 (t, 6H, J = 6.7 Hz), 0.98 (t, 3H, J = 7.4 Hz), 0.94 (t, 3H, J = 7.4 Hz).
    78
    Figure US20180319798A1-20181108-C00155
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.57 (s, 1H), 7.65 (s, 1H), 7.45 (td, 1H, J = 8.7, 6.6 Hz), 7.36 (dd, 1H, J = 6.7, 6.1 Hz), 7.24 (ddd, 1H, J = 10.4, 9.5, 2.8 Hz), 7.07 (tdd, 1H, J = 8.7, 2.8, 0.9 Hz), 4.75 (sep, 1H, J = 6.7 Hz), 4.71-4.63 (br m, 1H), 4.21 (s, 2H), 3.85 (dd, 1H, J = 13.8, 4.1 Hz), 3.75 (dd, 1H, J = 13.8, 1.2 Hz), 3.38 (ddd. 1H, J = 14.1, 6.1, 5.6 Hz), 3.16 (ddd, 1H, J = 14.1, 9.0, 6.7 Hz), 2.89 (s, 3H), 1.21 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
  • TABLE 1-20
    No. structural formula salt 1H-NMR
    79
    Figure US20180319798A1-20181108-C00156
         		HCl 1H-NMR (DMSO-d6) δ: 8.94 (s, 1H), 7.70 (s, 1H), 7.47 (td, 1H, J = 8.6, 6.8 Hz), 7.25 (ddd, 1H, J = 10.1, 9.5, 2.6 Hz), 7.08 (tdd, 1H, J = 8.6, 2.6, 1.1 Hz), 6.30-6.25 (br m, 1H), 4.80 (sep, 1H, J = 6.8 Hz), 4.24 (dd, 1H, J = 14.1, 2.0 Hz), 4.23 (s, 2H), 4.02 (dd, 1H, J = 14.1, 3.5 Hz), 1.23 (d, 3H, J = 6.8 Hz), 1.16 (d, 3H, J = 6.8 Hz).
    80
    Figure US20180319798A1-20181108-C00157
         		HCl 1H-NMR (DMSO-d6) δ: 8.35 (s, 1H), 7.64 (s, 1H), 7.46 (td, 1H, J = 8.8, 7.1 Hz), 7.25 (ddd, 1H, J = 10.6, 9.5, 2.6 Hz), 7.08 (tdd, 1H, J = 8.8, 2.6, 1.3 Hz), 4.92-4.84 (br m, 1H), 4.78 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.87 (dd, 1H, J = 14.1, 4.4 Hz), 3.83 (dd, 1H, J = 14.1, 10.8 Hz), 3.71 (dd, 1H, J = 13.9, 1.1 Hz), 3.39 (dd, 1H, J = 13.9, 4.0 Hz), 2.90 (s, 3H), 1.77 (s, 3H), 1.19 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    81
    Figure US20180319798A1-20181108-C00158
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (s, 1H), 8.80 (s, 1H), 7.92 (q, 1H, J = 4.4 Hz), 7.57-7.50 (m, 1H), 7.33-7.26 (m, 1H), 7.15-7.08 (m, 1H), 4.53-4.30 (m, 4H), 4.49 (s, 2H), 2.56 (d, 3H, J = 4.4 Hz), 2.44-2.37 (m, 2H), 1.29 (d, 3H, J = 6.8 Hz), 1.27 (d, 3H, J = 6.8 Hz).
  • TABLE 1-21
    No. structural formula salt 1H-NMR
    82
    Figure US20180319798A1-20181108-C00159
         		HCl 1H-NMR (DMSO-d6) δ: 8.88 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.64 (d, 1H, J = 13.2 Hz), 4.54-4.41 (m, 3H), 4.49 (s, 2H), 3.12 (dd, 1H, J = 17.5, 7.0 Hz), 3.01 (dd, 1H, J = 17.5, 4.2 Hz), 1.31 (d, 3H, J = 6.8 Hz), 1.31 (d, 3H, d = 6.8 Hz).
    83
    Figure US20180319798A1-20181108-C00160
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.82 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.68-4.62 (m, 1H), 4.55-4.42 (m, 1H), 4.47 (s, 2H), 4.36 (dd, 1H, J = 13.1, 3.6 Hz), 4.23-4.13 (m, 1H), 3.52-3.39 (m, 4H), 3.32-3.25 (m, 2H), 3.09 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
    84
    Figure US20180319798A1-20181108-C00161
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.82 (s, 1H), 7.44-7.36 (m, 2H), 7.22-7.15 (m, 2H), 4.70-4.64 (m, 1H), 4.61-4.50 (m, 1H), 4.47 (s, 2H), 4.45-4.37 (m, 1H), 4.31-4.23 (m, 1H), 3.58-3.39 (m, 4H), 3.31-3.25 (m, 2H), 3.09 (s, 3H), 2.37-2.12 (m, 4H), 1.75-1.62 (m, 2H).
    85
    Figure US20180319798A1-20181108-C00162
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (s, 1H), 8.80 (s, 1H), 7.54 (td, 1H, J = 8.8, 6.7 Hz), 7.29 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.12 (tdd, 1H, J = 8.8, 2.6 0.9 Hz), 5.01-4.93 (br m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.9, 3.9 Hz), 3.75 (dd, 1H, J = 13.9, 1.4 Hz), 3.62 (dd, 1H, J = 10.2, 5.8 Hz), 3.57 (dd, 1H, J = 10.2, 7.7 Hz), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz). 1.16 (d, 3H. J = 6.7 Hz).
  • TABLE 1-22
    No. structural formula salt 1H-NMR
    86
    Figure US20180319798A1-20181108-C00163
         		HCl 1H-NMR (DMSO-d6) δ: 12.73 (br s, 1H), 8.82 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 5.00-4.84 (m, 2H), 4.49 (s. 2H), 3.98-3.87 (m, 2H), 3.74 (dd, 1H, J = 10.4, 6.0 Hz), 3.64 (dd, 1H, J = 10.4, 7.4 Hz), 3.58-3.46 (m, 2H), 3.34 (t, 2H, J = 4.6 Hz), 3.12 (s, 3H), 2.34-2.03 (m, 4H), 1.76-1.65 (m. 2H).
    87
    Figure US20180319798A1-20181108-C00164
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.80 (s, 1H), 7.59-7.49 (m, 1H), 7.35-7.24 (m, 1H), 7.16-7.07 (m, 1H), 5.01-4.93 (m, 1H), 4.77 (t, 1H, J = 6.7 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.7, 3.9 Hz), 3.75 (dd, 1H, J = 13.7, 2.5 Hz), 3.62 (dd, 1H, J = 10.2, 5.8 Hz), 3.57 (dd, 1H, J = 10.2, 7.7 Hz), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    88
    Figure US20180319798A1-20181108-C00165
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.80 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.15 (m, 2H), 5.01-4.94 (m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J = 13.7, 3.9 Hz), 3.75 (dd, 1H, J = 13.7, 1.6 Hz), 3.62 (dd, 1H, J = 10.4, 5.8 Hz), 3.57 (dd, 1H, J = 10.4, 7.7 Hz), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1,16 (d, 3H, J = 6.7 Hz).
    89
    Figure US20180319798A1-20181108-C00166
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (br s, 1H), 8.78 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.26 (m, 1H), 7.14-7.08 (m, 1H), 4.99-4.89 (m, 1H), 4.49 (s, 2H), 4.07 (dd, 1H, J = 13.7, 4.4 Hz), 3.74-3.56 (m, 4H), 3.44-3.33 (m, 1H), 3.25 (s, 3H), 1.14 (t, 3H, J = 7.2 Hz).
  • TABLE 1-23
    No. structural formula salt 1H-NMR
    90
    Figure US20180319798A1-20181108-C00167
         		HCl 1H-NMR (DMSO-d6) δ: 12.47 (s, 1H), 8.87 (s, 1H), 7.57-7.49 (m, 1H), 7.32-7.24 (m, 1H), 7.15-7.07 (m, 1H), 4.66 (dd, 1H, J = 13.5, 1.7 Hz), 4.53 (sep, 1H, J = 6.8 Hz), 4.49 (s, 2H), 4.35-4.28 (m, 1H), 4.14-4.07 (m, 1H), 3.62-3.47 (m, 2H), 1.81-1.51 (m, 2H), 1.29 (d, 6H, J = 6.8 Hz).
    91
    Figure US20180319798A1-20181108-C00168
         		HCl 1H-NMR (DMSO-d6) δ: 12.76-12.55 (br m, 1H), 8.61 (s, 1H), 7.61 (s, 1H), 7.25 (dd, 1H, J = 8.5, 6.9 Hz), 6.92 (dd, 1H, J = 11.3, 2.4 Hz), 6.73 (td, 1H, J = 8.5, 2.4 Hz), 4.94-4.86 (br m, 1H), 4.77 (sep, 1H, J = 6.9 Hz), 4.09 (s, 2H), 3.84-3.79 (m, 1H), 3.83 (s, 3H), 3.76-3.69 (m, 1H), 3.60 (dd, 1H, J = 10.5, 5.6 Hz), 3.54 (dd, 1H, J = 10.5, 7.7 Hz), 3.23 (s, 3H), 1.16 (d, 3H, J = 6.9 Hz), 1.15 (d, 3H, J = 6.9 Hz).
    92
    Figure US20180319798A1-20181108-C00169
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.81 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 5.02-4.85 (m, 2H), 4.47 (s, 2H), 3.98-3.87 (m, 2H), 3.65 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.5 Hz), 3.25 (s, 3H), 2.31-2.04 (m, 4H), 1.77-1.65 (m, 2H).
  • TABLE 1-24
    No. structural formula salt 1H-NMR
    93
    Figure US20180319798A1-20181108-C00170
         		HCl 1H-NMR (DMSO-d6) δ: 8.84 (s, 1H), 7.57-7.49 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.07 (m, 1H), 4.68 (d, 1H, J = 13.2 Hz), 4.60-4.49 (m, 1H), 4.48 (s, 2H), 4.41 (dd, 1H, J = 13.2, 3.7 Hz), 4.32-4.25 (m, 1H), 3.43 (dd, 1H, J = 10.4, 4.6 Hz), 3.39 (dd, 1H, J = 10.4, 6.8 Hz), 3.21 (s, 3H), 2.39-2.11 (m, 4H), 1.77-1.63 (m, 2H).
    94
    Figure US20180319798A1-20181108-C00171
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.60 (s, 1H), 7.67 (s, 1H), 7.45 (td, 1H, J = 8.2, 6.0 Hz), 7.24 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.07 (tdd, 1H, J = 8.2, 2.6, 0.9 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.22 (s, 2H), 4.19-4.14 (br m, 1H), 4.09 (d, 1H, J = 14.1 Hz), 4.00 (d, 1H, J = 14.1 Hz), 3.88-3.81 (br m, 2H), 3.74-3.69 (br m, 1H), 2.14-2.04 (br m, 2H), 1.94 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.13 (d, 3H, J = 6.7 Hz).
    95
    Figure US20180319798A1-20181108-C00172
         		HCl 1H-NMR (DMSO-d6) δ: 8.84 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.14 (m, 2H), 4.66 (d, 1H, J = 13.2 Hz), 4.47 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 4.34 (dd, 1H, J = 13.5, 3.7 Hz), 4.22-4.17 (m, 1H), 3.49 (dd, 1H, J = 10.6, 4.3 Hz), 3.39 (dd, 1H, J = 10.6, 7.5 Hz), 3.21 (s, 3H), 1.30 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
  • TABLE 1-25
    No. structural formula salt 1H-NMR
    96
    Figure US20180319798A1-20181108-C00173
         		HCl 1H-NMR (DMSO-d6) δ: 12.45 (br s, 1H), 8.84 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.07 (m, 1H), 4.66 (dd, 1H, J = 13.4, 1.6 Hz), 4.49 (s, 2H), 4.47 (sep, 1H, J = 6.8 Hz), 4.35 (dd, 1H, J = 13.4, 3.7 Hz), 4.23-4.17 (m, 1H), 3.49 (dd, 1H, J = 10.2, 4.2 Hz), 3.39 (dd, 1H, J = 10.2, 7.4 Hz), 3.21 (s, 3H), 1.30 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz).
    97
    Figure US20180319798A1-20181108-C00174
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (br s, 1H), 8.78 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.26 (m, 1H), 7.14-7.08 (m, 1H), 4.99-4.89 (m, 1H), 4.49 (s, 2H), 4.07 (dd, 1H, J = 13.7, 4.4 Hz), 3.74-3.56 (m, 4H), 3.44-3.33 (m, 1H), 3.25 (s, 3H), 1.14 (t, 3H, J = 7.2 Hz).
    98
    Figure US20180319798A1-20181108-C00175
         		HCl 1H-NMR (DMSO-d6) δ: 12.51 (br s, 1H), 8.84 (s, 1H), 7.58-7.49 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.71-4.64 (m, 1H), 4.60-4.46 (m, 3H), 4.41 (dd, 1H, J = 13.7, 3.9 Hz), 4.31-4.25 (m, 1H), 3.46-3.36 (m, 2H), 3.21 (s, 3H), 2.37-2.12 (m, 4H), 1.77-1.64 (m, 2H).
  • TABLE 1-26
    No. structural formula salt 1H-NMR
     99
    Figure US20180319798A1-20181108-C00176
         		HCl 1H-NMR (DMSO-d6) δ: 12.46 (br s, 1H), 8.84 (s, 1H), 7.57-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.56 (dd, 1H, J = 13.2, 1.6 Hz), 4.52-4.42 (m, 1H), 4.49 (s, 2H), 4.35 (dd, 1H, J = 13.2, 4.0 Hz), 4.23-4.17 (m, 1H), 3.49 (dd, 1H, J = 10.4, 4.3 Hz), 3.39 (dd, 1H, J = 10.4, 7.5 Hz), 3.21 (s, 3H), 1.30 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz).
    100
    Figure US20180319798A1-20181108-C00177
         		HCl 1H-NMR (DMSO-d6) δ: 12.56 (br s, 1H), 9.02 (s, 1H), 7.53 (td, 1H, J = 8.5, 6.4 Hz), 7.29 (ddd, 1H, J = 10.5, 9.7, 2.4 Hz), 7.12 (tdd, 1H, J = 8.5. 2.4, 1.2 Hz), 4.72 (s, 2H), 4.49 (s, 2H), 4.16-4.02 (br m, 1H), 3.82-3.78 (m, 2H), 3.74-3.66 (m, 2H), 2.21-2.13 (m, 2H), 1.64-1.58 (m, 2H), 1.43 (d, 6H, J = 6.4 Hz).
    101
    Figure US20180319798A1-20181108-C00178
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.66 (s, 1H), 7.66 (s, 1H), 7.51-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.11-7.03 (m, 1H), 5.45-5.34 (m, 1H), 4.83-4.70 (m, 1H), 4.21 (s, 2H), 3.95-3.85 (m, 2H), 3.81-3.59 (m, 2H), 3.05 (s, 3H), 1.20 (d, 3H, J = 6.7 Hz), 1.14 (d, 3H, J = 6.7 Hz).
  • TABLE 1-27
    No. structural formula salt 1H-NMR
    102
    Figure US20180319798A1-20181108-C00179
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.83 (s, 1H), 7.57-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.64 (dd, 1H, J = 13.7, 1.6 Hz), 4.49 (s, 2H), 4.43 (dd, 1H, J = 13.7, 4.1 Hz), 4.17-4.12 (m, 1H), 3.86 (dq, 1H, J = 13.4, 7.0 Hz), 3.54 (dd, 1H, J = 10.2, 5.1 Hz), 3.50 (dd, 1H, J = 10.2, 6.3 Hz), 3.27 (dq, 1H, J = 13.4, 7.0 Hz), 3.21 (s, 3H), 1.18 (t, 3H, J = 7.0 Hz).
    103
    Figure US20180319798A1-20181108-C00180
         		HCl 1H-NMR (DMSO-d6) δ: 8.61 (s, 1H), 7.70 (s, 1H), 7.36-7.29 (m, 2H), 7.18-7.11 (m, 2H), 4.80 (sep, 1H, J = 6.7 Hz), 4.20 (s, 2H), 3.74 (d, 1H, J = 13.7 Hz), 3.64 (d, 1H, J = 10.4 Hz), 3.64 (d, 1H, J = 13.7 Hz), 3.58 (d, 1H, J = 10.4 Hz), 3.24 (s, 3H), 1.63 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
    104
    Figure US20180319798A1-20181108-C00181
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.53 (s, 1H), 8.14 (q, 1H, J = 4.4 Hz), 7.69 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.70 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.09 (d, 1H, J = 13.9 Hz), 3.77 (d, 1H, J = 13.9 Hz), 2.60 (d, 3H, J = 4.4 Hz), 1.93 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.09 (d, 3H, J = 6.7 Hz).
  • TABLE 1-28
    No. structural formula salt 1H-NMR
    105
    Figure US20180319798A1-20181108-C00182
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.52 (s, 1H), 8.18 (t, 1H, J = 5.2 Hz), 7.68 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.71 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.11 (d, 1H, J = 13.9 Hz), 3.78 (d, 1H, J = 13.9 Hz), 3.18-2.98 (m, 2H), 1.92 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz), 1.00 (t, 3H, J = 7.2 Hz).
    106
    Figure US20180319798A1-20181108-C00183
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.50 (s, 1H), 8.07 (d, 1H, J = 7.4 Hz), 7.68 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.72 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.16 (d, 1H, J = 14.1 Hz), 3.81 (sep, 1H, J = 6.7 Hz), 3.79 (d, 1H, J = 14.1 Hz), 1.93 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz), 1.07 (d, 3H, J = 6.7 Hz), 1.06 (d, 3H, J = 6.7 Hz).
    107
    Figure US20180319798A1-20181108-C00184
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (s, 1H), 8.43 (s, 1H), 7.69 (s, 1H), 7.37-7.29 (m, 2H), 7.19-7.11 (m, 2H), 4.73 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.12 (d, 1H, J = 14.1 Hz), 3.79 (d, 1H, J = 14.1 Hz), 2.93 (s, 6H), 1.98 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
  • TABLE 1-29
    No. structural formula salt 1H-NMR
    108
    Figure US20180319798A1-20181108-C00185
         		HCl 1H-NMR (DMSO-d6) δ: 12.96 (br s, 1H), 8.39 (s, 1H), 7.69 (s, 1H), 7.37-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.75 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.03 (d, 1H, J = 14.4 Hz), 3.80 (d, 1H, J = 14.4 Hz), 3.56-3.37 (br m, 4H), 1.90 (s, 3H), 1.59-1.50 (br m, 2H), 1.50-1.41 (br m, 4H), 1.18 (d, 3H, J = 6.7 Hz), 1.14 (d, 3H, J = 6.7 Hz).
    109
    Figure US20180319798A1-20181108-C00186
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.54 (s, 1H), 7.69 (s, 1H), 7.37-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.70 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.12 (d, 1H, J = 14.1 Hz), 3.75 (d, 1H, J = 14.1 Hz), 3.65-3.53 (br m, 1H), 3.43-3.33 (br m, 1H), 3.33-3.23 (br m, 1H), 3.16-3.05 (br m, 1H), 2.01 (s, 3H), 1.94-1.84 (br m, 1H), 1.81-1.56 (br m, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
    110
    Figure US20180319798A1-20181108-C00187
         		HCl 1H-NMR (DMSO-d6) δ: 13.12 (s, 1H), 8.63 (s, 1H), 7.69 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.79 (sep, 1H, J = 6.7 Hz), 4.20 (s, 2H), 3.74 (d, 1H, J = 10.2 Hz), 3.73 (d, 1H, J = 13.9 Hz), 3.66 (d, 1H, J = 10.2 Hz), 3.65 (d, 1H, J = 13.9 Hz), 3.54-3.42 (m, 2H), 3.38-3.30 (m, 2H), 3.11 (s, 3H), 1.63 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
  • TABLE 1-30
    No. structural formula salt 1H-NMR
    111
    Figure US20180319798A1-20181108-C00188
         		HCl 1H-NMR (DMSO-d6) δ: 13.14 (s, 1H), 8.63 (s, 1H), 7.69 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.79 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.72 (d, 1H, J = 13.7 Hz), 3.64 (d, 1H, J = 13.7 Hz), 3.61 (s, 2H), 1.59 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
    112
    Figure US20180319798A1-20181108-C00189
         		HCl 1H-NMR (DMSO-d6) δ: 12.87 (br s, 1H), 8.61 (s, 1H), 7.70 (s, 1H), 7.37-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.73 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.06 (d, 1H, J = 13.7 Hz), 3.80 (d, 1H, J = 13.7 Hz), 1.98 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.14 (d, 3H, J = 6.7 Hz).
    113
    Figure US20180319798A1-20181108-C00190
         		HCl 1H-NMR (DMSO-d6) δ: 12.64-12.34 (m, 1H), 8.83 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.64 (dd, 1H, J = 13.4, 1.5 Hz), 4.47 (s, 2H), 4.42 (dd, 1H, J = 13.4, 4.4 Hz), 4.17-4.11 (m, 1H), 3.86 (dq, 1H, J = 14.0, 7.0 Hz), 3.54 (dd, 1H, J = 10.4, 4.9 Hz), 3.50 (dd, 1H, J = 10.4, 6.3 Hz), 3.27 (dq, 1H, J = 14.0, 7.0 Hz), 3.22 (s, 3H), 1.20 (t, 3H, J = 7.0 Hz).
  • TABLE 1-31
    No. structural formula salt 1H-NMR
    114
    Figure US20180319798A1-20181108-C00191
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.83 (s, 1H), 7.57-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.64 (dd, 1H, J = 13.7, 1.6 Hz), 4.49 (s, 2H), 4.43 (dd, 1H, J = 13.7, 4.1 Hz), 4.17-4.12 (m, 1H), 3.86 (dq, 1H, J = 13.4, 7.0 Hz), 3.54 (dd, 1H, J = 10.2, 5.1 Hz), 3.50 (dd, 1H, J = 10.2, 6.3 Hz), 3.27 (dq, 1H, J = 13.4, 7.0 Hz), 3.21 (s, 3H), 1.18 (t, 3H, J = 7.0 Hz).
    115
    Figure US20180319798A1-20181108-C00192
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (br s, 1H), 8.79 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.61 (dd, 1H, J = 13.6, 1.6 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J = 13.6, 4.2 Hz), 3.86-3.80 (m, 1H), 3.62 (dd, 1H, J = 11.5, 3.8 Hz), 3.52 (dd, 1H, J = 11.5, 7.1 Hz), 2.95-2.88 (m, 1H), 1.03-0.94 (m, 1H), 0.90-0.83 (m, 1H), 0.83-0.72 (m, 2H).
    116
    Figure US20180319798A1-20181108-C00193
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.79 (s, 1H), 7.46-7.38 (m, 2H), 7.24-7.15 (m, 2H), 5.02-4.90 (m, 1H), 4.47 (s, 2H), 4.12 (dd, 1H, J = 13.7, 3.9 Hz), 3.87-3.79 (m, 1H), 3.73-3.58 (m, 2H), 3.45 (dd, 1H, J = 14.0, 7.3 Hz), 3.31 (dd, 1H, J = 14.0, 6.8 Hz), 3.26 (s, 3H), 1.15- 1.03 (m, 1H), 0.58-0.46 (m, 2H), 0.39-0.26 (m, 2H).
  • TABLE 1-32
    No. structural formula salt 1H-NMR
    117
    Figure US20180319798A1-20181108-C00194
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.79 (s, 1H), 7.59-7.50 (m, 1H), 7.33-7.26 (m, 1H), 7.15-7.08 (m, 1H), 4.99-4.92 (m, 1H), 4.49 (s, 2H), 4.12 (dd, 1H, J = 13.8, 4.3 Hz), 3.87-3.80 (m, 1H), 3.69 (dd, 1H, J = 10.4, 5.6 Hz), 3.62 (dd, 1H, J = 10.4, 7.9 Hz), 3.45 (dd, 1H, J = 13.8, 7.3 Hz), 3.31 (dd, 1H, J = 13.9, 7.0 Hz), 3.26 (s, 3H), 1.14-1.03 (m, 1H), 0.57-0.46 (m, 2H), 0.39-0.27 (m, 2H).
    118
    Figure US20180319798A1-20181108-C00195
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (s, 1H), 8.80 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.96-4.89 (m, 1H), 4.47 (s, 2H), 4.11 (dd, 1H, J = 13.7, 4.2 Hz), 3.84 (dd, 1H, J = 13.7, 1.2 Hz), 3.78 (dd, 1H, J = 10.5, 5.6 Hz), 3.70 (dd, 1H, J = 10.5, 7.7 Hz), 3.59-3.39 (m, 3H), 3.37-3.29 (m, 3H), 3.10 (s, 3H), 1.13-1.04 (m, 1H), 0.58-0.46 (m, 2H), 0.38-0.27 (m, 2H).
    119
    Figure US20180319798A1-20181108-C00196
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.80 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.16-7.08 (m, 1H), 4.97-4.89 (m, 1H), 4.49 (s, 2H), 4.12 (dd, 1H, J = 13.7, 4.4 Hz), 3.84 (dd, 1H, J = 13.7, 1.2 Hz), 3.78 (dd, 1H, J = 10.5, 5.6 Hz), 3.70 (dd, 1H, J = 10.5, 7.7 Hz), 3.59-3.40 (m, 3H), 3.37-3.29 (m, 3H), 3.10 (s, 3H), 1.14-1.04 (m, 1H), 0.58-0.47 (m, 2H), 0.38-0.27 (m, 2H).
  • TABLE 1-33
    No. structural formula salt 1H-NMR
    120
    Figure US20180319798A1-20181108-C00197
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.82 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.65 (d, 1H, J = 12.5 Hz), 4.55-4.42 (m, 1H), 4.47 (s, 2H), 4.36 (dd, 1H, J = 13.1, 3.6 Hz), 4.23-4.13 (m, 1H), 3.52-3.39 (m, 4H), 3.32-3.25 (m, 2H), 3.09 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
    121
    Figure US20180319798A1-20181108-C00198
         		HCl 1H-NMR (DMSO-d6) δ: 13.10 (br s, 1H), 8.58 (s, 1H), 7.66 (s, 1H), 7.44 (td, 1H, J = 8.7, 6.7 Hz), 7.23 (ddd, 1H, J = 10.4, 9.5, 2.6 Hz), 7.06 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.78 (sep, 1H, J = 6.7 Hz), 4.20 (s, 2H), 3.73 (d, 1H, J = 13.9 Hz), 3.63 (d, 1H, J = 13.9 Hz), 3.63 (d, 1H, J = 10.2 Hz), 3.56 (d, 1H, J = 10.2 Hz), 3.22 (s, 3H), 1.61 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    122
    Figure US20180319798A1-20181108-C00199
         		HCl 1H-NMR (DMSO-d6) δ: 13.12 (br s, 1H), 8.62 (s, 1H), 7.67 (s, 1H), 7.45 (td, 1H, J = 8.8, 7.0 Hz), 7.25 (ddd, 1H, J = 10.4, 9.3, 2.6 Hz), 7.07 (tdd, 1H, J = 8.8, 2.6, 1.0 Hz), 4.79 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.78-3.70 (m, 2H), 3.66 (d, 1H, J = 10.2 Hz), 3.65 (d, 1H, J = 13.9 Hz), 3.54-3.42 (m, 2H), 3.37-3.29 (m, 2H), 3.11 (s, 3H), 1.63 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
  • TABLE 1-34
    No. structural formula salt 1H-NMR
    123
    Figure US20180319798A1-20181108-C00200
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (s, 1H), 8.82 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.93-4.86 (m, 1H), 4.47 (s, 2H), 4.19 (dd, 1H, J = 13.7, 4.2 Hz), 3.82 (dd, 1H, J = 10.4, 5.6 Hz), 3.78-3.70 (m, 2H), 3.58-3.47 (m, 2H), 3.42 (d, 1H, J = 13.4 Hz), 3.35-3.31 (m, 2H), 3.23 (d, 1H, J = 13.4 Hz), 3.11 (s, 3H), 0.98 (s, 9H).
    124
    Figure US20180319798A1-20181108-C00201
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.80 (s, 1H), 7.57-7.50 (m, 1H), 7.32-7.24 (m, 1H), 7.14-7.07 (m, 1H), 4.92-4.85 (m, 1H), 4.48 (s, 2H), 4.18 (dd, 1H, J = 13.7, 4.2 Hz), 3.81 (dd, 1H, J = 10.6, 5.7 Hz), 3.76-3.69 (m, 2H), 3.56-3.46 (m, 2H), 3.41 (d, 1H, J = 13.4 Hz), 3.34-3.30 (m, 2H), 3.22 (d, 1H, J = 13.4 Hz), 3.09 (s, 3H), 0.97 (s, 9H).
    125
    Figure US20180319798A1-20181108-C00202
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.79 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.96-4.88 (m, 1H), 4.49 (s, 2H), 4.07 (dd, 1H, J = 13.6, 4.3 Hz), 3.79-3.59 (m, 4H), 3.57-3.45 (m, 2H), 3.45-3.36 (m, 1H), 3.33 (t, 2H, J = 4.6 Hz), 3.10 (s, 3H), 1.15 (t, 3H, J = 7.2 Hz).
  • TABLE 1-35
    No. structural formula salt 1H-NMR
    126
    Figure US20180319798A1-20181108-C00203
         		HCl 1H-NMR (DMSO-d6) δ: 12.47 (br s, 1H), 8.83 (s, 1H), 7.56-7.49 (m, 1H), 7.32-7.24 (m, 1H), 7.14-7.07 (m, 1H), 4.66 (dd, 1H, J = 13.4, 1.6 Hz), 4.48 (s, 2H), 4.44 (dd, 1H, J = 13.4, 4.2 Hz), 4.25-4.20 (m, 1H), 3.68 (dd, 1H, J = 14.0, 7.0 Hz), 3.57 (dd, 1H, J = 10.2, 4.6 Hz), 3.50 (dd, 1H, J = 10.2, 6.5 Hz), 3.20 (dd, 1H, J = 14.0, 7.0 Hz), 3.20 (s, 3H), 1.20-1.09 (m, 1H), 0.58-0.46 (m, 2H), 0.43-0.35 (m, 1H), 0.35-0.27 (m, 1H).
    127
    Figure US20180319798A1-20181108-C00204
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.79 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.96-4.88 (m, 1H), 4.49 (s, 2H), 4.07 (dd, 1H, J = 13.6, 4.3 Hz), 3.79-3.59 (m, 4H), 3.57-3.45 (m, 2H), 3.45-3.36 (m, 1H), 3.33 (t, 2H, J = 4.6 Hz), 3.10 (s, 3H), 1.15 (t, 3H, J = 7.2 Hz).
    128
    Figure US20180319798A1-20181108-C00205
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.80 (s, 1H), 7.44-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.95-4.88 (m, 1H), 4.47 (s, 2H), 4.07 (dd, 1H, J = 13.6, 4.3 Hz), 3.78-3.60 (m, 4H), 3.57-3.46 (m, 2H), 3.43-3.37 (m, 1H), 3.33 (t, 2H, J = 4.6 Hz), 3.10 (s, 3H), 1.15 (t, 3H, J = 7.2 Hz).
  • TABLE 1-36
    No. structural formula salt 1H-NMR
    129
    Figure US20180319798A1-20181108-C00206
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (s, 1H), 8.83 (s, 1H), 7.59-7.49 (m, 1H), 7.34-7.25 (m, 1H), 7.16-7.07 (m, 1H), 4.70-4.55 (m, 2H), 4.49 (s, 2H), 4.03-3.97 (br m, 1H), 3.95 (d, 1H, J = 13.4 Hz), 3.66-3.59 (m, 2H), 3.47-3.41 (m, 2H), 3.27- 3.22 (m, 2H), 3.07 (s, 3H), 2.85 (d, 1H, J = 13.4 Hz), 0.98 (s, 9H).
    130
    Figure US20180319798A1-20181108-C00207
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (s, 1H), 8.80 (s, 1H), 7.59-7.49 (m, 1H), 7.34-7.25 (m, 1H), 7.15-7.07 (m, 1H), 4.68-4.59 (m, 1H), 4.48 (s, 2H), 4.43 (dd, 1H, J = 13.4, 4.2 Hz), 4.17-4.09 (m, 1H), 3.86 (td, 1H, J = 13.9, 7.0 Hz), 3.67- 3.56 (m, 2H), 3.52-3.41 (m, 2H), 3.34-3.22 (m, 3H), 3.09 (s, 3H), 1.20 (t, 3H, J = 7.0 Hz).
    131
    Figure US20180319798A1-20181108-C00208
         		HCl 1H-NMR (DMSO-d6) δ: 12.97-12.84 (br m, 1H), 8.76 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.92-4.85 (br m, 1H), 4.48 (s, 2H), 3.98-3.84 (m, 2H), 3.67 (dd, 1H, J = 10.1, 5.6 Hz), 3.59 (dd, 1H, J = 10.1, 7.7 Hz), 3.28 (s, 3H), 1.48 (s, 9H).
  • TABLE 1-37
    No. structural formula salt 1H-NMR
    132
    Figure US20180319798A1-20181108-C00209
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.90 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.97-4.88 (m, 1H), 4.84-4.74 (m, 1H), 4.49 (s, 2H), 3.81 (dd, 1H, J = 13.5, 3.7 Hz), 3.63 (dd, 1H, J = 13.5, 2.2 Hz), 1.39 (d, 3H, J = 6.6 Hz), 1.19 (d, 3H, J = 6.8 Hz), 1.16 (d, 3H, J = 6.8 Hz).
    133
    Figure US20180319798A1-20181108-C00210
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (s, 1H), 8.80 (s, 1H), 7.57-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.67 (d, 1H, J = 13.1 Hz), 4.51 (sep, 1H, J = 6.8 Hz), 4.49 (s, 2H), 4.34 (dd, 1H, J = 13.1, 3.7 Hz), 4.00-3.93 (m, 1H), 3.57 (dd, 1H, J = 11.4, 3.7 Hz), 3.37 (dd, 1H, J = 11.4, 8.3 Hz), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
    134
    Figure US20180319798A1-20181108-C00211
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (br s, 1H), 8.83-8.80 (m, 1H), 7.59-7.50 (m, 1H), 7.33-7.24 (m, 1H), 7.16-7.08 (m, 1H), 5.01-4.90 (br m, 1H), 4.60-4.50 (m, 1H), 4.49 (s, 2H) 3.87-3.63 (m, 4H), 3.57-3.46 (m, 2H), 3.35-3.30 (m, 2H), 3.12-3.10 (m, 3H), 1.59-1.48 (m, 2H), 1.15 (d, 3H, J = 6.7 Hz), 0.91-0.78 (m, 3H).
  • TABLE 1-38
    No. structural formula salt 1H-NMR
    135
    Figure US20180319798A1-20181108-C00212
         		HCl 1H-NMR (DMSO-d6) δ: 12.89 (br s, 1H), 8.81 (s, 1H), 7.59-7.50 (m, 1H), 7.34-7.25 (m, 1H), 7.16-7.06 (m, 1H), 5.03-4.92 (br m, 1H), 4.59-4.50 (m, 1H), 4.49 (s, 2H), 3.73-3.54 (m, 4H), 3.26-3.23 (m, 3H), 1.61-1.45 (m, 2H), 1.15 (d, 3H, J = 6.7 Hz), 0.91-0.80 (m, 3H).
    136
    Figure US20180319798A1-20181108-C00213
         		HCl 1H-NMR (DMSO-d6) δ: 12.96 (br s, 1H), 8.82 (s, 1H), 7.59-7.49 (m, 1H), 7.35-7.24 (m, 1H), 7.17-7.06 (m, 1H), 5.04-4.91 (m, 1H), 4.49 (s, 2H), 4.30-3.57 (m, 5H), 3.27-3.22 (m, 3H), 1.87-1.69 (m, 1H), 1.17 (d, 3H, J = 6.8 Hz), 0.97-0.79 (m, 6H).
    137
    Figure US20180319798A1-20181108-C00214
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.71 (s, 1H), 8.23-8.17 (m, 1H), 7.58-7.50 (m, 1H), 7.33-7.26 (m, 1H), 7.15-7.08 (m, 1H), 4.58 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.43 (dd, 1H, J = 13.0, 1.3 Hz), 4.31 (dd, 1H, J = 13.0, 3.0 Hz), 3.97-3.91 (m, 1H), 3.45-3.36 (m, 1H), 2.97-2.86 (m, 1H), 1.80 (s, 3H), 1.34 (d, 3H, J = 6.7 Hz), 1.27 (d, 3H, J = 6.7 Hz).
    138
    Figure US20180319798A1-20181108-C00215
         		HCl 1H-NMR (DMSO-d6) δ: 12.49 (br s, 1H), 8.72 (s, 1H), 7.88-7.83 (m, 1H), 7.57-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.57 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.38-4.28 (m, 2H), 3.99-3.92 (m, 1H), 3.38-3.29 (m, 1H), 3.04-2.95 (m, 1H), 1.38 (d, 3H, J = 6.7 Hz), 1.29 (d, 3H, J = 6.7 Hz), 1.08 (s, 9H).
  • TABLE 1-39
    No. structural formula salt 1H-NMR
    139
    Figure US20180319798A1-20181108-C00216
         		HCl 1H-NMR (DMSO-d6) δ: 13.18 (br s, 1H), 8.47 (s, 1H), 7.67 (s, 1H), 7.46 (td, 1H, J = 8.8, 6.6 Hz), 7.25 (ddd, 1H, J = 10.4, 9.3, 2.6 Hz), 7.08 (tdd, 1H, J = 8.8, 2.6, 0.9 Hz), 4.79 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 3.79 (d, 1H, J = 13.9 Hz), 3.74 (d, 1H, J = 14.6 Hz), 3.68 (d, 1H, J = 13.9 Hz), 3.57 (d, 1H, J = 14.6 Hz), 2.75 (s, 3H), 1.81 (s, 3H), 1.67 (s, 3H), 1.22 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
    140
    Figure US20180319798A1-20181108-C00217
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.71 (s, 1H), 8.22-8.17 (m, 1H), 7.57-7.50 (m, 1H), 7.33-7.26 (m, 1H), 7.15-7.08 (m, 1H), 4.58 (sep, 1H, J = 6.8 Hz), 4.49 (s, 2H), 4.43 (d, 1H, J = 13.0 Hz), 4.30 (dd, 1H, J = 13.0, 3.0 Hz), 3.98-3.91 (m, 1H), 2.96-2.86 (m, 1H), 2.56-2.50 (m, 1H), 1.80 (s, 3H), 1.34 (d, 3H, J = 6.8 Hz), 1.27 (d, 3H, J = 6.8 Hz).
    141
    Figure US20180319798A1-20181108-C00218
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (s, 1H), 8.82 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.99-4.91 (m, 1H), 4.77 (sep, 1H, J = 6.8 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J = 13.8, 4.1 Hz), 3.75 (dd, 1H, J = 13.8, 1.7 Hz), 3.66 (dd, 1H, J = 10.4, 6.0 Hz), 3.59 (dd, 1H, J = 10.4, 7.5 Hz), 3.50-3.34 (m, 2H), 1.17 (d, 3H, J = 6.8 Hz), 1.16 (d, 3H, J = 6.8 Hz), 1.02 (t, 3H, J = 7.1 Hz).
  • TABLE 1-40
    No. structural formula salt 1H-NMR
    142
    Figure US20180319798A1-20181108-C00219
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.81 (s, 1H), 7.58-7.51 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.07 (m, 1H), 4.98-4.91 (m, 1H), 4.77 (sep, 1H, J = 6.8 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.78-3.73 (m, 1H), 3.69-3.56 (m, 2H), 3.50-3.34 (m, 2H), 1.17 (d, 3H, J = 6.8 Hz), 1.16 (d, 3H, J = 6.8 Hz), 1.02 (t, 3H, J = 7.1 Hz).
    143
    Figure US20180319798A1-20181108-C00220
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.80 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.99-4.92 (m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 3.84 (dd, 1H, J = 13.8, 4.1 Hz), 3.79-3.68 (m, 2H), 3.65 (dd, 1H, J = 10.4, 7.9 Hz), 3.56-3.44 (m, 2H), 3.38-3.34 (m, 2H), 3.30-3.22 (m, 2H), 1.17 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz), 0.91 (t, 3H, J = 7.0 Hz).
    144
    Figure US20180319798A1-20181108-C00221
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.81 (s, 1H), 7.52-7.38 (m, 2H), 7.26-7.21 (m, 1H), 5.00-4.94 (m, 1H), 4.77 (sep, 1H, J = 6.9 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (dd, 1H, J = 13.7, 1.2 Hz), 3.66-3.54 (m, 2H), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.9 Hz), 1.16 (d, 3H, J = 6.9 Hz).
  • TABLE 1-41
    No. structural formula salt 1H-NMR
    145
    Figure US20180319798A1-20181108-C00222
         		HCl 1H-NMR (DMSO-d6) δ: 12.45 (br s, 1H), 8.85 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.71-4.65 (m, 1H), 4.49 (s, 2H), 4.38-4.27 (m, 2H), 4.17-4.11 (m, 1H), 3.50 (dd, 1H, J = 10.5, 4.1 Hz), 3.39 (dd, 1H, J = 10.5, 7.7 Hz), 3.20 (s, 3H), 1.78-1.59 (m, 2H), 1.25 (d, 3H, J = 6.8 Hz), 0.86 (t, 3H, J = 7.4 Hz).
    146
    Figure US20180319798A1-20181108-C00223
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.83 (s, 1H), 7.57-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.65 (dd, 1H, J = 13.5, 1.1 Hz), 4.49 (s, 2H), 4.38 (dd, 1H, J = 13.5, 4.1 Hz), 4.15-4.03 (m, 2H), 3.50 (dd, 1H, J = 10.1, 4.2 Hz), 3.42 (dd, 1H, J = 10.1, 7.1 Hz), 3.20 (s, 3H), 1.83-1.73 (m, 1H), 1.63-1.53 (m, 1H), 1.33 (d, 3H, J = 6.8 Hz), 0.91 (t, 3H, J = 7.4 Hz).
    147
    Figure US20180319798A1-20181108-C00224
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.81 (s, 1H), 7.59-7.49 (m, 1H), 7.33-7.25 (m, 1H), 7.16-7.08 (m, 1H), 5.05-4.86 (br m, 1H), 4.60-4.50 (m, 1H), 4.49 (s, 2H), 3.87-3.56 (m, 4H), 3.25-3.25 (m, 3H), 1.54-1.50 (m, 2H), 1.15 (d, 3H, J = 6.5 Hz), 0.91-0.80 (m, 3H).
  • TABLE 1-42
    No. structural formula salt 1H-NMR
    148
    Figure US20180319798A1-20181108-C00225
         		HCl 1H-NMR (DMSO-d6) δ: 12.87 (br s, 1H), 8.81 (s, 1H), 7.58-7.52 (m, 1H), 7.32-7.27 (m, 1H), 7.16-7.07 (m, 1H), 5.05-4.90 (m, 1H), 4.49 (s, 2H), 4.32-4.20 (m, 1H), 3.90-3.57 (m, 4H), 3.26-3.24 (m, 3H), 1.87-1.69 (m, 1H), 1.19-1.10 (m, 3H), 0.97-0.79 (m, 6H).
    149
    Figure US20180319798A1-20181108-C00226
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.90 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.97-4.88 (m, 1H), 4.84-4.74 (m, 1H), 4.49 (s, 2H), 3.81 (dd, 1H, J = 13.5, 3.7 Hz), 3.63 (dd, 1H, J = 13.5, 2.2 Hz), 1.39 (d, 3H, J = 6.6 Hz), 1.19 (d, 3H, J = 6.8 Hz), 1.16 (d, 3H, J = 6.8 Hz).
    150
    Figure US20180319798A1-20181108-C00227
         		HCl 1H-NMR (DMSO-d6) δ: 12.44 (br s, 1H), 8.85 (s, 1H), 7.53-7.37 (m, 2H), 7.26-7.19 (m, 1H), 4.66 (dd, 1H, J = 13.5, 1.5 Hz), 4.51-4.43 (m, 1H), 4.49 (s, 2H), 4.38-4.32 (m, 1H), 4.23-4.17 (m, 1H), 3.49 (dd, 1H, J = 10.4, 4.4 Hz), 3.39 (dd, 1H, J = 10.4, 7.5 Hz), 3.22 (s, 3H), 1.30 (d, 3H, J = 6.6 Hz), 1.29 (d, 3H, J = 6.8 Hz).
  • TABLE 1-43
    No. structural formula salt 1H-NMR
    151
    Figure US20180319798A1-20181108-C00228
         		HCl 1H-NMR (DMSO-d6) δ: 12.86-12.34 (m, 1H), 8.68 (s, 1H), 7.66 (s, 1H), 7.49-7.39 (m, 1H), 7.29-7.20 (m, 1H), 7.11-7.02 (m, 1H), 5.12-5.03 (m, 1H), 4.84-4.70 (m, 1H), 4.21 (s, 2H), 3.82-3.55 (m, 2H), 3.15-2.96 (m, 2H), 2.08 (s, 3H), 1.17-1.09 (m, 6H).
    152
    Figure US20180319798A1-20181108-C00229
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.43 (s, 1H), 7.68 (s, 1H), 7.50-7.41 (m, 1H), 7.29-7.20 (m, 1H), 7.11-7.03 (m, 1H), 4.24-4.16 (m, 1H), 4.22 (s, 2H), 3.91 (d, 1H, J = 13.9 Hz), 3.07 (s, 3H), 2.89 (s, 6H), 1.92 (s, 3H).
    153
    Figure US20180319798A1-20181108-C00230
         		HCl 1H-NMR (DMSO-d6) δ: 12.64 (br s, 1H), 8.53 (s, 1H), 8.34-8.23 (m, 1H), 7.68 (s, 1H),7.50-7.40 (m, 1H), 7.30-7.20 (m, 1H), 7.13-7.02 (m, 1H) 4.23 (s, 2H), 4.12 (d, 1H, J = 14.1 Hz), 4.01 (d, 1H, J = 14.1 Hz), 3.17-2.97 (m, 2H), 3.03 (s, 3H), 1.87 (s, 3H), 0.99 (t, 3H, J = 7.4 Hz).
    154
    Figure US20180319798A1-20181108-C00231
         		HCl 1H-NMR (DMSO-d6) δ: 12.32 (s, 1H), 8.79 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.60 (d, 1H, J = 13.0 Hz), 4.55 (sep, 1H, J = 6.8 Hz), 4.48 (s, 2H), 4.35 (dd, 1H, J = 13.0, 3.0 Hz), 4.27-4.20 (m, 1H), 3.26 (dd, 1H, J = 13.7, 10.5 Hz), 2.99 (dd, 1H, J = 13.7, 3.0 Hz), 2.87 (s, 3H), 2.84 (s, 3H), 1.30 (d, 6H, J = 6.8 Hz).
  • TABLE 1-44
    No. structural formula salt 1H-NMR
    155
    Figure US20180319798A1-20181108-C00232
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.82 (s, 1H), 7.52-7.37 (m, 2H), 7.27-7.20 (m, 1H), 4.99-4.91 (m, 1H), 4.77 (sep, 1H, J = 6.9 Hz), 4.49 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.79-3.69 (m, 2H), 3.64 (dd, 1H, J = 10.5, 7.7 Hz), 3.58-3.45 (m, 2H), 3.34 (t, 2H, J = 4.6 Hz), 3.11 (s, 3H), 1.17 (d, 3H, J = 6.9 Hz), 1.16 (d, 3H, J = 6.9 Hz).
    156
    Figure US20180319798A1-20181108-C00233
         		HCl 1H-NMR (DMSO-d6) δ: 8.84 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.62-4.53 (m, 1H), 4.51-4.45 (m, 3H), 4.32 (dd, 1H, J = 13.1, 3.4 Hz), 4.26-4.18 (m, 1H), 1.27 (d, 3H, J = 6.9 Hz), 1.26 (d, 3H, J = 6.9 Hz), 1.21 (d, 3H, J = 6.4 Hz).
    157
    Figure US20180319798A1-20181108-C00234
         		HCl 1H-NMR (DMSO-d6) δ: 12.96 (s, 1H), 8.56 (s, 1H), 7.53-7.19 (m, 3H), 4.80-4.66 (m, 1H), 4.50 (s, 2H), 4.15 (d, 1H, J = 14.3 Hz), 3.82 (d, 1H, J = 14.3 Hz), 3.09-2.83 (m, 6H), 2.04 (s, 3H), 1.18 (d, 3H, J = 7.1 Hz), 1.11 (d, 3H, J = 7.1 Hz).
    158
    Figure US20180319798A1-20181108-C00235
         		HCl 1H-NMR (DMSO-d6) δ: 12.35 (s, 1H), 8.75 (s, 1H), 7.57-7.49 (m, 2H), 7.32-7.25 (m, 1H), 7.15- 7.08 (m, 1H), 4.61-4.53 (m, 2H), 4.49 (s, 2H), 4.40-4.33 (m, 1H), 4.00-3.93 (m, 1H), 3.21-3.12 (m, 1H), 3.02-2.92 (m, 1H), 2.90 (s, 3H), 1.30 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
  • TABLE 1-45
    structural
    No. formula salt 1H-NMR
    159
    Figure US20180319798A1-20181108-C00236
         		HCl 1H-NMR (DMSO-d6) δ: 12.39 (br s, 1H), 8.83 (s, 1H), 7.58-7.49 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.56 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.42-4.28 (m, 2H), 4.26-4.18 (m, 1H), 3.41-3.36 (m, 2H), 3.04 (s, 3H), 2.83 (t, 1H, J = 6.7 Hz), 1.34 (d, 3H, J = 6.7 Hz), 1.29 (d, 3H, J = 6.7 Hz), 1.00 (d, 3H, J = 6.7 Hz), 0.99 (d, 3H, J = 6.7 Hz).
    160
    Figure US20180319798A1-20181108-C00237
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.53 (s, 1H), 8.12-8.02 (m, 1H), 7.67 (s, 1H), 7.49-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.02 (m, 1H), 4.22 (s, 2H), 4.07 (d, 1H, J = 14.1 Hz), 3.99 (d, 1H, J = 14.1 Hz), 3.03 (s, 3H), 2.60 (d, 3H, J = 4.6 Hz), 1.86 (s, 3H).
    161
    Figure US20180319798A1-20181108-C00238
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (br s, 1H), 8.41 (s, 1H), 7.66 (s, 1H), 7.50-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.03 (m, 1H), 4.22 (s, 2H), 4.17 (d, 1H, J = 13.9 Hz), 3.91 (d, 1H, J = 13.9 Hz), 3.46-3.17 (m, 2H), 3.06 (s, 3H), 2.84 (s, 3H), 1.90 (s, 3H), 0.99 (t, 3H, J = 7.4 Hz).
    162
    Figure US20180319798A1-20181108-C00239
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.52 (s, 1H), 8.31-8.22 (m, 1H), 7.67 (s, 1H), 7.50-7.39 (m, 1H), 7.31-7.19 (m, 1H), 7.13-7.03 (m, 1H), 4.22 (s, 2H), 4.14 (d, 1H, J = 13.7 Hz), 3.99 (d, 1H, J = 13.7 Hz), 3.66-3.28 (m, 2H), 3.15-3.00 (m, 2H), 1.89 (s, 3H), 1.11 (t, 3H, J = 7.4 Hz), 0.99 (t, 3H, J = 7.4 Hz).
  • TABLE 1-46
    structural
    No. formula salt 1H-NMR
    163
    Figure US20180319798A1-20181108-C00240
         		HCl 1H-NMR (DMSO-d6) δ: 12.34 (br s, 1H), 8.78 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.55 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 4.43 (d, 1H, J = 12.4 Hz), 4.38-4.27 (m, 1H), 4.25-4.17 (m, 1H), 3.44 (dd, 1H, J = 13.3, 10.0 Hz), 3.34-3.28 (m, 1H), 3.00 (s, 3H), 1.99 (s, 3H), 1.33 (d, 3H, J = 6.7 Hz), 1.29 (d, 3H, J = 6.7 Hz).
    164
    Figure US20180319798A1-20181108-C00241
         		HCl 1H-NMR (DMSO-d6) δ: 8.71 (s, 1H), 7.66 (s, 1H), 7.49-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.03 (m, 1H), 5.06-4.95 (m, 1H), 4.21 (s, 2H), 4.04 (dd, 1H, J = 13.4, 3.5 Hz), 3.68-3.60 (m, 1H), 2.97-2.88 (m, 1H), 2.88-2.82 (m, 2H), 2.87 (s, 3H), 2.79 (s, 3H), 0.96-0.83 (m, 2H), 0.83-0.72 (m, 1H), 0.67-0.55 (m, 1H).
    165
    Figure US20180319798A1-20181108-C00242
         		HCl 1H-NMR (DMSO-d6) δ: 8.52 (s, 1H), 7.99 (t, 1H, J = 4.9 Hz), 7.65 (s, 1H), 7.49-7.40 (m, 1H), 7.29-7.20 (m, 1H), 7.12-7.03 (m, 1H), 5.00-4.89 (m, 1H), 4.21 (s, 2H), 4.03 (dd, 1H, J = 13.9, 3.9 Hz), 3.58-3.50 (m, 1H), 3.03-2.83 (m, 3H), 2.56 (d, 2H, J = 7.4 Hz), 1.01-0.71 (m, 4H), 0.80 (t, 3H, J = 7.2 Hz).
    166
    Figure US20180319798A1-20181108-C00243
         		HCl 1H-NMR (DMSO-d6) δ: 8.81 (s, 1H), 7.47-7.36 (m, 2H), 7.23-7.12 (m, 2H), 5.04-4.91 (m, 1H), 4.60-4.49 (m, 1H), 4.47 (s, 2H), 3.88-3.54 (m, 4H), 3.27-3.23 (m, 3H), 1.61-1.46 (m, 2H), 1.15 (d, 3H, J = 6.4 Hz), 0.91-0.80 (m, 3H).
  • TABLE 1-47
    structural
    No. formula salt 1H-NMR
    167
    Figure US20180319798A1-20181108-C00244
         		HCl 1H-NMR (DMSO-d6) δ: 8.81 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.14 (m, 2H), 5.02-4.92 (m, 1H), 4.60-4.49 (m, 1H), 4.47 (s, 2H), 3.89-3.54 (m, 4H), 3.27-3.23 (m, 3H), 1.59-1.47 (m, 2H), 1.15 (d, 3H, J = 6.4 Hz), 0.91-0.80 (m, 3H).
    168
    Figure US20180319798A1-20181108-C00245
         		HCl 1H-NMR (DMSO-d6) δ: 8.66 (s, 1H), 7.65 (s, 1H), 7.49-7.40 (m, 1H), 7.30-7.20 (m, 1H), 7.12-7.02 (m, 1H), 4.64-4.56 (m, 1H), 4.47 (sep, 1H, J = 6.7 Hz), 4.33 (dd, 1H, J = 13.3, 3.6 Hz), 4.24-4.14 (m, 3H), 3.48 (dd, 1H, J = 10.2, 4.2 Hz), 3.36 (dd, 1H, J = 10.2, 7.7 Hz), 3.21 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 1.28 (d, 3H, J = 6.7 Hz).
    169
    Figure US20180319798A1-20181108-C00246
         		HCl 1H-NMR (DMSO-d6) δ: 12.96 (br s, 1H), 8.55 (s, 1H), 7.54 (td, 1H, J = 8.6, 6.6 Hz), 7.29 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.11 (tdd, 1H, J = 8.6, 2.6, 0.9 Hz), 4.73 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.15 (d, 1H, J = 14.4 Hz), 3.82 (d, 1H, J = 14.4 Hz), 2.95 (br s, 6H), 2.03 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
    170
    Figure US20180319798A1-20181108-C00247
         		HCl 1H-NMR (DMSO-d6) δ: 12.91 (br s, 1H), 8.64 (s, 1H), 7.54 (td, 1H, J = 8.8, 6.6 Hz), 7.29 (ddd, 1H, J = 10.4, 9.5, 2.8 Hz), 7.12 (tdd, 1H, J = 8.8, 2.8, 1.2 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.14 (d, 1H, J = 14.1 Hz), 3.77 (d, 1H, J = 14.1 Hz), 3.71-3.50 (br m, 2H), 3.36-3.24 (br m, 1H), 3.21-3.08 (br m, 1H), 2.06 (s, 3H), 1.97-1.86 (br m, 1H), 1.83-1.59 (br m, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
  • TABLE 1-48
    structural
    No. formula salt 1H-NMR
    171
    Figure US20180319798A1-20181108-C00248
         		HCl 1H-NMR (DMSO-d6) δ: 12.96 (br s, 1H), 8.55 (s, 1H), 7.54 (td, 1H, J = 8.6, 6.6 Hz), 7.29 (ddd, 1H, J = 10.2, 9.3, 2.6 Hz), 7.11 (tdd, 1H, J = 8.6, 2.6, 0.9 Hz), 4.73 (sep, 1H, J = 6.7 Hz), 4.49 (s. 2H), 4.15 (d, 1H, J = 14.4 Hz), 3.82 (d, 1H, J = 14.4 Hz), 2.95 (br s, 6H), 2.03 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
    172
    Figure US20180319798A1-20181108-C00249
         		HCl 1H-NMR (DMSO-d6) δ: 12.91 (br s, 1H), 8.64 (s, 1H), 7.54 (td, 1H, J = 8.8, 6.6 Hz), 7.29 (ddd, 1H, J = 10.4, 9.5, 2.8 Hz), 7.12 (tdd, 1H, J = 8.8, 2.8, 1.2 Hz), 4.70 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.14 (d, 1H, J = 14.1 Hz), 3.77 (d, 1H, J = 14.1 Hz), 3.71-3.50 (br m, 2H), 3.36-3.24 (br m, 1H), 3.21-3.08 (br m, 1H), 2.06 (s, 3H), 1.97-1.86 (br m, 1H), 1.83-1.59 (br m, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
    173
    Figure US20180319798A1-20181108-C00250
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (br s, 1H), 8.62 (s, 1H), 8.19 (t, 1H, J = 5.2 Hz), 7.54 (td, 1H, J = 8.7, 6.6 Hz), 7.29 (ddd, 1H, J = 10.4, 9.3, 2.6 Hz), 7.12 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.71 (sep, 1H, J = 6.7 Hz), 4.50 (s, 2H), 4.11 (d, 1H, J = 13.9 Hz), 3.80 (d, 1H, J = 13.9 Hz), 3.18-2.98 (m, 2H), 1.96 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz), 1.00 (t, 3H, J = 7.2 Hz).
  • TABLE 1-49
    structural
    No. formula salt 1H-NMR
    174
    Figure US20180319798A1-20181108-C00251
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (br s, 1H), 8.62 (s, 1H), 8.19 (t, 1H, J = 5.2 Hz), 7.54 (td, 1H, J = 8.7, 6.6 Hz), 7.29 (ddd, 1H, J = 10.4, 9.3, 2.6 Hz), 7.12 (tdd, 1H, J = 8.7, 2.6, 0.9 Hz), 4.71 (sep, 1H, J = 6.7 Hz), 4.50 (s, 2H), 4.11 (d, 1H, J = 13.9 Hz), 3.80 (d, 1H, J = 13.9 Hz), 3.18-2.98 (m, 2H), 1.96 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz), 1.00 (t, 3H, J = 7.2 Hz).
    175
    Figure US20180319798A1-20181108-C00252
         		HCl 1H-NMR (DMSO-d6) δ: 8.43 (s, 1H), 7.42-7.37 (m, 2H), 7.21-7.15 (m, 2H), 4.76 (sep, 1H, J = 6.9 Hz), 4.46 (s, 2H), 3.66 (s, 2H), 1.66-1.61 (m, 2H), 1.13-1.18 (m, 2H), 1.16 (d, 6H, J = 6.9 Hz).
    176
    Figure US20180319798A1-20181108-C00253
         		HCl 1H-NMR (DMSO-d6) δ: 8.67 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.47 (s, 2H), 4.31 (s, 2H), 4.15 (sep, 1H, J = 6.9 Hz), 1.35-1.29 (m, 2H), 1.32 (d, 6H, J = 6.9 Hz), 1.07-1.02 (m, 2H).
    177
    Figure US20180319798A1-20181108-C00254
         		HCl 1H-NMR (DMSO-d6) δ: 12.95 (s, 1H), 8.55 (s, 1H), 7.44-7.36 (m, 2H), 7.21-7.15 (m, 2H), 4.73 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.15 (d, 1H, J = 14.1 Hz), 3.82 (d, 1H, J = 14.1 Hz), 3.07-2.81 (br m, 6H), 2.04 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
  • TABLE 1-50
    structural
    No. formula salt 1H-NMR
    178
    Figure US20180319798A1-20181108-C00255
         		HCl 1H-NMR (DMSO-d6) δ: 12.87 (s, 1H), 8.55 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.48 (s, 2H), 4.15 (d, 1H, J = 13.9 Hz), 3.85 (d, 1H, J = 13.9 Hz), 2.95-2.83 (m, 1H), 2.89 (s, 6H), 1.97 (s, 3H), 0.95-0.80 (m, 2H), 0.76-0.62 (m, 2H).
    179
    Figure US20180319798A1-20181108-C00256
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (s, 1H), 8.65 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.70 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.14 (d, 1H, J = 13.9 Hz), 3.77 (d, 1H, J = 13.9 Hz), 3.72-3.62 (br m, 1H), 3.36-3.23 (br m, 2H), 3.20-3.09 (br m, 1H), 2.06 (s, 3H), 1.98-1.84 (br m, 1H), 1.83-1.59 (br m, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
    180
    Figure US20180319798A1-20181108-C00257
         		HCl 1H-NMR (DMSO-d6) δ: 12.92 (s, 1H), 8.62 (s, 1H), 8.17 (t, 1H, J = 5.2 Hz), 7.44-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.71 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.10 (d, 1H, J = 13.9 Hz), 3.80 (d, 1H, J = 13.9 Hz), 3.18-2.99 (m, 2H), 1.96 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz), 1.01 (t, 3H, J = 7.2 Hz).
    181
    Figure US20180319798A1-20181108-C00258
         		HCl 1H-NMR (DMSO-d6) δ: 12.98 (br s, 1H), 8.59 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.47 (s, 2H), 4.32 (d, 1H, J = 14.4 Hz), 3.82 (d, 1H, J = 14.4 Hz), 2.90 (s, 6H), 2.03 (s, 3H), 1.45 (s, 9H).
  • TABLE 1-51
    structural
    No. formula salt 1H-NMR
    182
    Figure US20180319798A1-20181108-C00259
         		HCl 1H-NMR (DMSO-d6) δ: 8.91 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.55 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 4.43-4.29 (m, 2H), 4.26-4.19 (m, 1H), 3.47 (dd, 1H, J = 13.3, 4.0 Hz), 3.28 (dd, 1H, J = 13.3, 10.0 Hz), 3.12 (s, 3H), 1.35 (d, 3H, J = 6.7 Hz), 1.30 (d, 3H, J = 6.7 Hz), 1.20 (s, 9H).
    183
    Figure US20180319798A1-20181108-C00260
         		HCl 1H-NMR (DMSO-d6) δ: 8.92 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.55 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 4.38-4.33 (m, 2H), 4.22-4.16 (m, 1H), 3.47 (dd, 1H, J = 13.5, 3.5 Hz), 3.28 (dd, 1H, J = 13.5, 10.0 Hz), 3.12 (s, 3H), 1.65-1.57 (m, 2H), 1.35 (d, 3H, J = 6.7 Hz), 1.30 (d, 3H, J = 6.7 Hz), 1.17 (s, 3H), 1.16 (s, 3H), 0.79 (t, 3H, J = 7.5 Hz).
    184
    Figure US20180319798A1-20181108-C00261
         		HCl 1H-NMR (DMSO-d6) δ: 12.41 (br s, 1H), 8.90 (s, 1H), 7.58-7.50 (m, 1H), 7.32-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.56 (sep, 1H, J = 6.6 Hz), 4.49 (s, 2H), 4.41-4.29 (m, 2H), 4.27-4.18 (m, 1H), 3.48-3.44 (m, 1H), 3.29 (dd, 1H, J = 13.5, 10.0 Hz), 3.12 (s, 3H), 1.35 (d, 3H, J = 6.7 Hz), 1.30 (d, 3H, J = 6.7 Hz), 1.20 (s, 9H).
    185
    Figure US20180319798A1-20181108-C00262
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (br s, 1H), 8.63 (s, 1H), 8.12 (q, 1H, J = 4.4 Hz), 7.45-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.70 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.08 (d, 1H, J = 13.9 Hz), 3.80 (d, 1H, J = 13.9 Hz), 2.59 (d, 3H, J = 4.4 Hz), 1.97 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.09 (d, 3H, J = 6.7 Hz).
  • TABLE 1-52
    structural
    No. formula salt 1H-NMR
    186
    Figure US20180319798A1-20181108-C00263
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (br s, 1H), 8.64 (s, 1H), 8.09 (t, 1H, J = 6.0 Hz), 7.43-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.69 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.14 (d, 1H, J = 13.9 Hz), 3.79 (d, 1H, J = 13.9 Hz), 3.10-3.01 (m, 1H), 2.71-2.62 (m, 1H), 1.97 (s, 3H), 1.75-1.61 (m, 1H), 1.15 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz), 0.79 (d, 6H, J = 6.7 Hz).
    187
    Figure US20180319798A1-20181108-C00264
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.62 (s, 1H), 8.19 (t, 1H, J = 5.2 Hz), 7.45-7.36 (m, 2H), 7.22-7.15 (m, 2H), 4.48 (s, 2H), 4.00 (d, 1H, J = 13.7 Hz), 3.96 (d, 1H, J = 13.7 Hz), 3.11-3.02 (m, 2H), 2.88 (sep, 1H, J = 3.9 Hz), 1.92 (s, 3H), 0.98 (t, 3H, J = 7.0 Hz), 0.96-0.89 (m, 1H), 0.85-0.69 (m, 2H), 0.65-0.56 (m, 1H).
    188
    Figure US20180319798A1-20181108-C00265
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (br s, 1H), 8.69 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.48 (s, 2H), 4.32 (d, 1H, J = 13.9 Hz), 3.77 (d, 1H, J = 13.9 Hz), 3.44-3.23 (br m, 4H), 2.01 (s, 3H), 1.92-1.54 (br m, 4H), 1.44 (s, 9H).
    189
    Figure US20180319798A1-20181108-C00266
         		HCl 1H-NMR (DMSO-d6) δ: 12.98 (br s, 1H), 8.59 (s, 1H), 8.19 (t, 1H, J = 7.0 Hz), 7.44-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.48 (s, 2H), 4.23 (d, 1H, J = 13.7 Hz), 3.83 (d, 1H, J = 13.7 Hz), 3.10 (dq, 2H, J = 7.0, 7.0 Hz), 1.94 (s, 3H), 1.45 (s, 9H), 1.02 (t, 3H, J = 7.0 Hz).
  • TABLE 1-53
    structural
    No. formula salt 1H-NMR
    190
    Figure US20180319798A1-20181108-C00267
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (br s, 1H), 8.62 (s, 1H), 8.10 (q, 1H, J = 4.4 Hz), 7.53 (td, 1H, J = 8.6, 6.5 Hz), 7.28 (ddd, 1H, J = 10.2, 9.5, 2.6 Hz), 7.11 (tdd, 1H, J = 8.6, 2.6, 1.1 Hz), 4.69 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.06 (d, 1H, J = 13.9 Hz), 3.78 (d, 1H, J = 13.9 Hz), 2.58 (d, 3H, J = 4.4 Hz), 1.95 (s, 3H), 1.13 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
    191
    Figure US20180319798A1-20181108-C00268
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (br s, 1H), 8.62 (s, 1H), 8.10 (q, 1H, J = 4.4 Hz), 7.53 (td, 1H, J = 8.6, 6.5 Hz), 7.28 (ddd, 1H, J = 10.2, 9.5, 2.6 Hz), 7.11 (tdd, 1H, J = 8.6, 2.6, 1.1 Hz), 4.69 (sep, 1H, J = 6.7 Hz), 4.49 (s, 2H), 4.06 (d, 1H, J = 13.9 Hz), 3.78 (d, 1H, J = 13.9 Hz), 2.58 (d, 3H, J = 4.4 Hz), 1.95 (s, 3H), 1.13 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
    192
    Figure US20180319798A1-20181108-C00269
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (br s, 1H), 8.82 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.77 (sep, 1H, J = 6.9 Hz), 4.63-4.59 (m, 1H), 4.47 (s, 2H), 3.89-3.82 (m, 2H), 1.27 (d, 3H, J = 6.9 Hz), 1.19 (d, 3H, J = 6.9 Hz), 0.96 (s, 9H).
    193
    Figure US20180319798A1-20181108-C00270
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (br s, 1H), 8.82 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.77 (sep, 1H, J = 6.9 Hz), 4.63-4.59 (m, 1H), 4.47 (s, 2H), 3.89-3.83 (m, 2H), 1.28 (d, 3H, J = 6.9 Hz), 1.19 (d, 3H, J = 6.9 Hz), 0.96 (s, 9H).
  • TABLE 1-54
    structural
    No. formula salt 1H-NMR
    194
    Figure US20180319798A1-20181108-C00271
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (br s, 1H), 8.90 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.79-4.79 (sep, 1H, J = 6.7 Hz), 4.50-4.43 (m, 1H), 4.47 (s, 2H), 3.86-3.78 (m, 2H), 2.03-1.92 (m, 1H), 1.20 (d, 3H, J = 6.7 Hz), 1.18 (d, 3H, J = 6.7 Hz), 1.04 (d, 3H, J = 6.7 Hz), 0.69 (d, 3H, J = 6.7 Hz).
    195
    Figure US20180319798A1-20181108-C00272
         		HCl 1H-NMR (DMSO-d6) δ: 12.49 (br s, 1H), 8.85 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.68 (dd, 1H, J = 13.5, 1.3 Hz), 4.61-4.49 (m, 1H), 4.47 (s, 2H), 4.41 (dd, 1H, J = 13.5, 4.0 Hz), 4.31-4.25 (m, 1H), 3.43 (dd, 1H, J = 10.6, 5.0 Hz), 3.39 (dd, 1H, J = 10.6, 6.8 Hz), 3.21 (s, 3H), 2.38-2.11 (m, 4H), 1.77-1.64 (m, 2H).
    196
    Figure US20180319798A1-20181108-C00273
         		HCl 1H-NMR (DMSO-d6) δ: 12.49 (br s, 1H), 8.85 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.65 (dd, 1H, J = 13.7, 1.5 Hz), 4.47 (s, 2H), 4.44-4.34 (m, 2H), 4.20-4.13 (m, 1H), 3.47 (dd, 1H, J = 10.4, 4.6 Hz), 3.41 (dd, 1H, J = 10.4, 7.3 Hz), 3.21 (s, 3H), 1.95-1.72 (m, 6H), 1.63-1.49 (m, 2H).
    197
    Figure US20180319798A1-20181108-C00274
         		HCl 1H-NMR (DMSO-d6) δ: 13.29 (br s, 1H), 8.52 (s, 1H), 7.60-7.50 (m, 1H), 7.36-7.25 (m, 1H), 7.17-7.08 (m, 1H), 4.86-4.73 (m, 1H), 4.49 (s, 2H), 3.91-3.64 (m, 4H), 2.82 (s, 3H), 1.81 (s, 3H), 1.71 (s, 3H), 1.23 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 7.0 Hz).
  • TABLE 1-55
    structural
    No. formula salt 1H-NMR
    198
    Figure US20180319798A1-20181108-C00275
         		HCl 1H-NMR (DMSO-d6) δ: 8.88 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.70 (d, 1H, J = 13.0 Hz), 4.47 (s, 2H), 4.39-4.27 (m, 2H), 3.73-3.61 (m, 2H), 3.49-3.41 (m, 1H), 3.22 (s, 3H), 1.34 (d, 3H, J = 6.7 Hz), 1.26-1.13 (m, 1H), 0.69-0.60 (m, 1H), 0.54-0.45 (m, 1H), 0.42-0.27 (m, 2H).
    199
    Figure US20180319798A1-20181108-C00276
         		HCl 1H-NMR (DMSO-d6) δ: 12.87 (s, 1H), 8.56 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.48 (s, 2H), 4.21 (d, 1H, J = 13.9 Hz), 3.98 (d, 1H, J = 13.9 Hz), 3.53 (q, 2H, J = 7.0 Hz), 2.50 (s, 6H), 2.01 (s, 3H), 1.11 (t, 3H, J = 7.0 Hz).
    200
    Figure US20180319798A1-20181108-C00277
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.67 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.48 (s, 2H), 4.19 (d, 1H, J = 13.9 Hz), 3.96 (d, 1H, J = 13.9 Hz), 3.59-3.25 (br m, 3H), 3.53 (dq, 1H, J = 14.0, 7.0 Hz), 3.49 (dq, 1H, J = 14.0, 7.0 Hz), 3.12-2.96 (br m, 1H), 2.01 (s, 3H), 1.96-1.48 (m, 4H), 1.09 (t, 3H, J = 7.0 Hz).
    201
    Figure US20180319798A1-20181108-C00278
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.62 (s, 1H), 8.26 (t, 1H, J = 5.6 Hz), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.48 (s, 2H), 4.13 (d, 1H, J = 13.9 Hz), 4.01 (d, 1H, J = 13.9 Hz), 3.62 (dq, 1H, J = 14.2, 7.1 Hz), 3.36 (dq, 1H, J = 14.2, 7.1 Hz), 3.14-3.04 (m, 2H), 1.93 (s, 3H), 1.11 (t, 3H, J = 7.1 Hz), 1.00 (t, 3H, J = 7.1 Hz).
  • TABLE 1-56
    structural
    No. formula salt 1H-NMR
    202
    Figure US20180319798A1-20181108-C00279
         		HCl 1H-NMR (DMSO-d6) δ: 13.00 (br s, 1H), 8.57 (s, 1H), 7.45-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.72 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.18 (d, 1H, J = 14.4 Hz), 3.81 (d, 1H, J = 14.4 Hz), 3.64 (br s, 3H), 3.42 (t, 2H, J = 5.3 Hz), 3.20 (s, 3H), 3.05-2.92 (br m, 2H), 2.02 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.13 (d, 3H, J = 6.7 Hz).
    203
    Figure US20180319798A1-20181108-C00280
         		HCl 1H-NMR (DMSO-d6) δ: 13.06 (br s, 1H), 8.52 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.75 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.05 (d, 1H, J = 14.4 Hz), 3.84 (d, 1H, J = 14.4 Hz), 3.62-3.48 (br m, 8H), 1.98 (s, 3H), 1.18 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    204
    Figure US20180319798A1-20181108-C00281
         		HCl 1H-NMR (DMSO-d6) δ: 12.95 (br s, 1H), 8.68-8.61 (m, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.69 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.23-4.15 (br m, 1H), 4.11 (d, 1H, J = 13.9 Hz), 3.76 (d, 1H, J = 13.9 Hz), 3.69-3.59 (br m, 1H), 3.46-3.36 (br m, 2H), 3.30-2.88 (br m, 1H), 2.09-2.00 (m, 3H), 2.02-1.55 (br m, 2H), 1.21-1.06 (m, 6H).
    205
    Figure US20180319798A1-20181108-C00282
         		HCl 1H-NMR (DMSO-d6) δ: 12.91 (br s, 1H), 8.71-8.61 (m, 1H), 7.46-7.37 (m, 2H), 7.24-7.14 (m, 2H), 4.69 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.33-4.13 (br m, 2H), 4.08 (d, 1H, J = 13.9 Hz), 3.77 (d, 1H, J = 13.9 Hz), 3.51-3.15 (br m, 3H), 2.14-2.01 (m, 3H), 1.89-1.61 (br m, 2H), 1.21-1.02 (m, 6H).
  • TABLE 1-57
    structural
    No. formula salt 1H-NMR
    206
    Figure US20180319798A1-20181108-C00283
         		HCl 1H-NMR (DMSO-d6) δ: 8.87 (s, 1H), 7.44-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.72 (d, 1H, J = 12.3 Hz), 4.47 (s, 2H), 4.43-4.33 (m, 2H), 3.67-3.58 (m, 1H), 3.57-3.51 (m, 1H), 3.47-3.40 (m, 1H), 3.22 (s, 3H), 1.34 (d, 3H, J = 6.7 Hz), 1.31-1.21 (m, 1H), 0.68-0.59 (m, 1H), 0.54-0.46 (m, 1H), 0.44-0.36 (m, 1H), 0.32-0.24 (m, 1H).
    207
    Figure US20180319798A1-20181108-C00284
         		HCl 1H-NMR (DMSO-d6) δ: 13.31 (br s, 1H), 8.48 (s, 1H), 7.59-7.49 (m, 1H), 7.38-7.22 (m, 1H), 7.20-7.05 (m, 1H), 4.87-4.73 (m, 1H), 4.48 (s, 2H), 4.02-3.86 (m, 1H), 3.80 (d, 1H, J = 13.7 Hz), 3.71 (d, 1H, J = 13.7 Hz), 3.47-3.32 (m, 1H), 2.85 (s, 3H), 2.17-2.04 (m, 2H), 1.71 (s, 3H), 1.23 (d, 3H, J = 7.0 Hz), 1.17 (d, 3H, J = 7.0 Hz), 0.65 (t, 3H, J = 7.4 Hz).
    208
    Figure US20180319798A1-20181108-C00285
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (br s, 1H), 8.72 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.69 (sep, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.44-4.27 (br m, 2H), 4.11-3.82 (br m, 2H), 4.02 (d, 1H, J = 13.9 Hz), 3.72 (d, 1H, J = 13.9 Hz), 3.64-3.40 (br m, 1H), 1.99 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz).
  • TABLE 1-58
    structural
    No. formula salt 1H-NMR
    209
    Figure US20180319798A1-20181108-C00286
         		HCl 1H-NMR (DMSO-d6) δ: 12.89 (br s, 1H), 8.71 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.70 (sep, 1H, J = 6.8 Hz), 4.48 (s, 2H), 4.22-3.90 (br m, 4H), 4.00 (d, 1H, J = 13.9 Hz), 3.74-3.57 (br m, 1H), 3.74 (d, 1H, J = 13.9 Hz), 3.14 (s, 3H), 2.00 (s, 3H), 1.19-1.09 (m, 6H).
    210
    Figure US20180319798A1-20181108-C00287
         		HCl 1H-NMR (DMSO-d6) δ: 13.30 (s, 1H), 8.60 (s, 1H), 7.56-7.50 (m, 1H), 7.35-7.25 (m, 1H), 7.13-7.08 (m, 1H), 4.80-4.74 (m, 1H), 4.47 (s, 2H), 3.75 (s, 2H), 3.48-3.30 (m, 2H), 2.84 (s, 3H), 2.57 (s, 3H), 1.74 (s, 3H), 1.24 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz).
    211
    Figure US20180319798A1-20181108-C00288
         		HCl 1H-NMR (DMSO-d6) δ: 12.91 (s, 0.5H), 12.86 (s, 0.5H), 8.68 (s, 0.5H), 8.60 (s, 0.5H), 7.42-7.38 (m, 2H), 7.20-7.15 (m, 2H), 4.72-4.65 (m, 1H), 4.47 (s, 2H), 4.16 (d, 0.5H, J = 13.7 Hz), 4.08 (d, 0.5H, J = 13.7 Hz), 4.00-3.98 (m, 0.5H), 3.86-3.84 (m, 0.5H) 3.81-3.74 (m, 2H), 3.51-3.33 (m, 3H), 3.17 (s, 3H), 2.54-2.49 (m, 2H), 2.07 (s, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.05 (d, 3H, J = 6.7 Hz).
  • TABLE 1-59
    structural
    No. formula salt 1H-NMR
    212
    Figure US20180319798A1-20181108-C00289
         		HCl 1H-NMR (DMSO-d6) δ: 12.94 (s, 1H), 8.66 (s, 0.5H), 8.62 (s, 0.5H), 7.42-7.38 (m, 2H), 7.20-7.15 (m, 2H), 4.70-4.65 (m, 1H), 4.47 (s, 2H), 4.11-4.06 (m, 1H), 3.93-3.90 (m, 1H), 3.87-3.84 (m, 1H), 3.81-3.75 (m, 1H) 3.69-3.65 (m, 1H), 3.62-3.45 (m, 1H), 3.17 (s, 1.5H), 3.15 (s, 1.5H), 3.10-3.06 (m, 1H), 2.07 (s, 1.5H), 2.05 (s, 1.5H), 1.99-1.96 (m, 1H), 1.79-1.76 (m, 1H), 1.16 (d, 3H, J = 6.7 Hz), 1.06 (d, 3H, J = 6.7 Hz).
    213
    Figure US20180319798A1-20181108-C00290
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.55 (s, 0.5H), 8.48 (s, 0.5H), 7.67 (s, 1H), 7.34-7.29 (m, 2H), 7.17-7.11 (m, 2H), 4.71-4.65 (m, 1H), 4.25-4.04 (m, 1H), 4.20 (s, 2H), 3.98-3.86 (m, 0.5H), 3.85-3.84 (m, 0.5H), 3.78-3.68 (m, 2H), 3.50-3.25 (m, 2H), 3.17 (s, 1.5H), 3.15 (s, 1.5H), 2.54-2.49 (m, 1H), 2.02 (s, 3H), 1.91-1.85 (m, 1H), 1.78-1.71 (m, 1H), 1.15 (d, 3H, J = 6.7 Hz), 1.05 (d, 3H, J = 6.7 Hz).
    214
    Figure US20180319798A1-20181108-C00291
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.54 (s, 0.5H), 8.50 (s, 0.5H), 7.68 (s, 1H), 7.34-7.31 (m, 2H), 7.17-7.11 (m, 2H), 4.71-4.65 (m, 1H), 4.20 (s, 2H), 4.07 (dd, 1H, J = 13.9, 5.3 Hz), 3.90-3.85 (m, 1H), 3.75 (dd, 1H, J = 13.9, 7.4 Hz), 3.59-3.36 (m, 3H), 3.15 (s, 3H), 2.54-2.49 (m, 1H), 2.02 (s, 1.5H), 1.99 (s, 1.5H), 1.99-1.97 (m, 1H), 1.78-1.71 (m, 1H), 1.16 (d, 3H, J = 6.7 Hz), 1.08 (d, 3H, J = 6.7 Hz).
  • TABLE 1-60
    structural
    No. formula salt 1H-NMR
    215
    Figure US20180319798A1-20181108-C00292
         		HCl 1H-NMR (DMSO-d6) δ: 13.20 (br s, 1H), 8.44 (s, 1H), 7.67 (s, 1H), 7.35-7.31 (m, 2H), 7.16-7.11 (m, 2H), 4.81-4.74 (m, 1H), 4.19 (s, 2H), 3.79-3.65 (m, 3H), 3.57 (d, 1H, J = 14.4 Hz), 2.74 (s, 3H), 1.81 (s, 3H), 1.66 (s, 3H), 1.21 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz).
    216
    Figure US20180319798A1-20181108-C00293
         		HCl 1H-NMR (DMSO-d6) δ: 12.60 (br s, 1H), 8.63 (s, 1H), 7.66 (s, 1H), 7.35-7.30 (m, 2H), 7.17-7.11 (m, 2H), 4.89-4.85 (m, 1H), 4.19 (s, 2H), 4.08 (dd, 1H, J = 13.7, 4.2 Hz), 3.81 (d, 1H, J = 13.7 Hz), 3.57 (dd, 1H, J = 10.5, 5.7 Hz), 3.66 (dd, 1H, J = 10.5, 7.9 Hz), 3.56-3.39 (m, 3H), 3.33-3.27 (m, 3H), 3.10 (s, 3H), 1.10-1.04 (m, 1H), 0.55-0.46 (m, 2H), 0.36-0.26 (m, 2H).
    217
    Figure US20180319798A1-20181108-C00294
         		HCl 1H-NMR (DMSO-d6) δ: 12.30 (br s, 1H), 8.65 (s, 1H), 7.66 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.60 (d, 1H, J = 13.2 Hz), 4.42 (dd, 1H, J = 13.2, 3.9 Hz), 4.24-4.19 (m, 1H), 4.19 (s, 2H), 3.67 (dd, 1H, J = 14.2, 7.0 Hz), 3.55 (dd, 1H, J = 10.3, 4.8 Hz), 3.47 (dd, 1H, J = 10.3, 7.0 Hz), 3.20 (s, 3H), 3.19 (dd, 1H, J = 14.2, 7.4 Hz), 1.18-1.12 (m, 1H), 0.55-0.46 (m, 2H), 0.41-0.37 (m, 1H), 0.31-0.28 (m, 1H).
  • TABLE 1-61
    structural
    No. formula salt 1H-NMR
    218
    Figure US20180319798A1-20181108-C00295
         		HCl 1H-NMR (DMSO-d6) δ: 12.30 (br s, 1H), 8.65 (s, 1H), 7.66 (s, 1H), 7.34-7.31 (m, 2H), 7.16-7.11 (m, 2H), 4.61 (d, 1H, J = 13.5 Hz), 4.42 (dd, 1H, J = 13.5, 4.2 Hz), 4.24-4.19 (m, 1H), 4.19 (s, 2H), 3.67 (dd, 1H, J = 14.0, 7.1 Hz), 3.60 (dd, 1H, J = 10.3, 4.2 Hz), 3.52 (dd, 1H, J = 10.3, 6.4 Hz), 3.42-3.30 (m, 2H), 3.20 (dd, 1H, J = 14.0, 7.0 Hz), 1.16-1.11 (m, 1H), 0.95 (t, 3H, J = 7.0 Hz), 0.56-0.46 (m, 2H), 0.41-0.37 (m, 1H), 0.31-0.27 (m, 1H).
    219
    Figure US20180319798A1-20181108-C00296
         		HCl 1H-NMR (DMSO-d6) δ : 12.79 (br s, 1H), 8.78 (s, 1H), 7.35 (dd, 1H, J = 8.4, 7.0 Hz), 6.93 (dd, 1H, J = 11.4, 2.6 Hz), 6.74 (td, 1H, J = 8.4, 2.6 Hz), 4.97-4.93 (m, 1H), 4.79-4.72 (m, 1H), 4.33 (s, 2H), 406 (q, 2H, J = 7.0 Hz), 3.79-3.65 (m, 2H), 3.61 (dd, 1H, J = 10.3, 5.7 Hz), 3.55 (dd, 1H, J = 10.3, 7.7 Hz), 3.23 (s, 3H), 1.31 (t, 3H, J = 7.0 Hz), 1.15 (d, 3H, J = 2.3 Hz), 1.14 (d, 3H, J = 2.3 Hz).
    220
    Figure US20180319798A1-20181108-C00297
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.76 (s, 1H), 6.93-6.87 (m, 2H), 4.97-4.93 (m, 1H), 4.79-4.72 (m, 1H), 4.33 (s, 2H), 3.85 (s, 3H), 3.84-3.72 (m, 2H), 3.61 (dd, 1H, J = 10.3, 5.7 Hz), 3.55 (dd, 1H, J = 10.3, 7.8 Hz), 3.23 (s, 3H), 1.15 (d, 3H, J = 2.3 Hz), 1.14 (d, 3H, J = 2.3 Hz).
  • TABLE 1-62
    structural
    No. formula salt 1H-NMR
    221
    Figure US20180319798A1-20181108-C00298
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 9.02 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.76 (d, 1H, J = 13.3 Hz), 4.47 (s, 2H), 4.30 (dd, 1H, J = 13.3, 4.6 Hz), 4.21-4.14 (m, 1H), 3.83 (br t, 1H, J = 4.6 Hz), 2.04-1.99 (m, 1H), 1.39 (d, 3H, J = 6.9 Hz), 1.35 (d, 3H, J = 6.9 Hz), 1.05 (d, 3H, J = 6.9 Hz), 0.64 (d, 3H, J = 6.9 Hz).
    222
    Figure US20180319798A1-20181108-C00299
         		HCl 1H-NMR (DMSO-d6) δ: 12.30 (br s, 1H), 8.65 (s, 1H), 7.67 (s, 1H), 7.35-7.31 (m, 2H), 7.18-7.13 (m, 2H), 4.59 (br d, 1H, J = 13.3 Hz), 4.41 (dd, 1H, J = 13.3, 4.1 Hz), 4.20 (s, 2H), 4.12-4.09 (m, 1H), 3.89-3.84 (m, 1H), 3.58-3.50 (m, 2H), 3.41-3.34 (m, 2H), 3.29-3.24 (m, 1H), 1.20 (t, 3H, J = 7.2 Hz), 0.97 (t, 3H, J = 7.0 Hz).
    223
    Figure US20180319798A1-20181108-C00300
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (m, 1H), 8.59 (s, 1H), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.17-7.11 (m, 2H), 4.72-4.65 (m, 1H), 4.20 (s, 2H), 4.20-4.13 (m, 1H), 4.00 (d, 1H, J = 13.5 Hz), 3.86-3.80 (m, 2H), 3.75-3.66 (m, 2H), 2.12-2.03 (m, 2H), 1.93 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz).
    224
    Figure US20180319798A1-20181108-C00301
         		HCl 1H-NMR (DMSO-d6) δ: 12.55 (br s, 1H), 9.02 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.76 (d, 1H, J = 13.3 Hz), 4.47 (s, 2H), 4.30 (dd, 1H, J = 13.3, 4.6 Hz), 4.21-4.14 (m, 1H), 3.83 (br t, 1H, J = 4.6 Hz), 2.04-1.99 (m, 1H), 1.39 (d, 3H, J = 6.9 Hz), 1.35 (d, 3H, J = 6.9 Hz), 1.05 (d, 3H, J = 6.9 Hz), 0.64 (d, 3H, J = 6.9 Hz).
  • TABLE 1-63
    structural
    No. formula salt 1H-NMR
    225
    Figure US20180319798A1-20181108-C00302
         		HCl 1H-NMR (DMSO-d6) ι: 12.78 (s, 1H), 8.52 (s, 1H), 7.67 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.12 (m, 2H), 4.72-4.66 (m, 1H), 4.19 (s, 2H), 4.11 (d, 1H, J = 13.9 Hz), 3.74 (d, 1H, J = 13.9 Hz), 3.41-3.25 (m, 1H), 3.13-3.06 (m, 1H), 3.81-3.74 (m, 2H), 2.00 (s, 3H), 1.92-1.84 (m, 1H), 1.75-1.61 (m, 3H), 1.15 (d, 3H, J = 6.7 Hz), 1.07 (d, 3H, J = 6.7 Hz).
    226
    Figure US20180319798A1-20181108-C00303
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.51 (s, 1H), 8.20 (br t, 1H, J = 5.5 Hz), 7.67 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.73-4.66 (m, 1H), 4.20 (s, 2H), 4.11 (d, 1H, J = 13.7 Hz), 3.77 (d, 1H, J = 13.7 Hz), 3.13-2.99 (m, 2H), 1.92 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.10 (d, 3H, J = 6.7 Hz), 0.99 (t, 3H, J = 7.2 Hz).
    227
    Figure US20180319798A1-20181108-C00304
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.54 (s, 1H), 8.22 (d, 1H, J = 4.4 Hz), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.12 (m, 2H), 4.73-4.66 (m, 1H), 4.20 (s, 2H), 4.13 (d, 1H, J = 13.7 Hz), 3.78 (d, 1H, J = 13.7 Hz), 2.57 (d, 3H, J = 4.4 Hz), 1.93 (s, 3H), 1.13 (d, 3H, J = 7.0 Hz), 1.08 (d, 3H, J = 7.0 Hz).
  • TABLE 1-64
    structural
    No. formula salt 1H-NMR
    228
    Figure US20180319798A1-20181108-C00305
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.81 (s, 1H), 7.48-7.46 (m, 1H), 7.42-7.33 (m, 3H), 4.98-4.96 (m, 1H), 4.80-4.73 (m, 1H), 4.50 (s, 2H), 3.84 (dd, 1H, J = 13.8, 4.1 Hz), 3.75 (br d, 1H, J = 13.8 Hz), 3.63 (dd, 1H, J = 10.4, 5.7 Hz), 3.57 (dd, 1H, J = 10.4, 7.5 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
    229
    Figure US20180319798A1-20181108-C00306
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.80 (s, 1H), 7.51 (t, 1H, J = 8.3 Hz), 7.48 (dd, 1H, J = 8.3, 2.0 Hz), 7.32 (dd, 1H, J = 8.3, 2.0 Hz), 5.00-4.95 (m, 1H), 4.80-4.74 (m, 1H), 4.50 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (dd, 1H, J = 13.7, 1.6 Hz), 3.62 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
    230
    Figure US20180319798A1-20181108-C00307
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.79 (s, 1H), 7.66 (dd, 1H, J = 8.7, 2.6 Hz), 7.61 (dd, 1H, J = 8.7, 6.0 Hz), 7.32 (td, 1H, J = 8.7, 2.6 Hz), 4.99-4.95 (m, 1H), 4.80-4.74 (m, 1H), 4.57 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (dd, 1H, J = 13.7, 1.6 Hz), 3.62 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
  • TABLE 1-65
    structural
    No. formula salt 1H-NMR
    231
    Figure US20180319798A1-20181108-C00308
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.79 (s, 1H), 7.37 (dd, 1H, J = 8.5, 6.1 Hz), 7.10-7.01 (m, 2H), 4.99-4.95 (m, 1H), 4.80-4.74 (m, 1H), 4.45 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.1 Hz), 3.75 (br d, 1H, J = 13.7 Hz), 3.62 (dd, 1H, J = 10.4, 5.7 Hz), 3.57 (dd, 1H, J = 10.4, 7.6 Hz), 3.25 (s, 3H), 2.29 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
    232
    Figure US20180319798A1-20181108-C00309
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.56 (s, 1H), 7.42-7.38 (m, 2H), 7.20-7.16 (m, 2H), 4.66-4.64 (m, 1H), 4.47 (s, 2H), 4.45-4.40 (m, 1H), 4.08-4.05 (m, 1H), 3.56 (dd, 1H, J = 11.3, 3.2 Hz), 3.50 (dd, 1H, J = 11.3, 4.2 Hz), 3.11 (s, 3H), 1.75 (d, 3H, J = 6.5 Hz), 1.33 (d, 3H, J = 6.0 Hz), 1.32 (d, 3H, J = 6.0 Hz).
    233
    Figure US20180319798A1-20181108-C00310
         		HCl 1H-NMR (DMSO-d6) δ: 12.54 (br s, 1H), 8.85 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.62-4.53 (m, 1H), 4.51-4.44 (m, 3H), 4.32 (dd, 1H, J = 13.1, 3.4 Hz), 4.26-4.18 (m, 1H), 1.27 (d, 3H, J = 6.7 Hz), 1.26 (d, 3H, J = 6.7 Hz), 1.21 (d, 3H, J = 6.5 Hz).
    234
    Figure US20180319798A1-20181108-C00311
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (s, 1H), 8.43 (s, 1H), 7.69 (s, 1H), 7.37-7.29 (m, 2H), 7.19-7.11 (m, 2H), 4.73 (sep, 1H, J = 6.7 Hz), 4.21 (s, 2H), 4.12 (d, 1H, J = 14.1 Hz), 3.79 (d, 1H, J = 14.1 Hz), 2.93 (s, 6H), 1.98 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.11 (d, 3H, J = 6.7 Hz).
  • TABLE 1-66
    structural
    No. formula salt 1H-NMR
    235
    Figure US20180319798A1-20181108-C00312
         		HCl 1H-NMR (DMSO-d6) δ: 12.89 (br s, 1H), 8.46 (s, 1H), 7.69 (s, 1H), 7.34-7.31 (m, 2H), 7.16-7.12 (m, 2H), 4.74-4.68 (m, 1H), 4.20 (s, 2H), 4.15 (d, 1H, J = 14.2 Hz), 3.78 (d, 1H, J = 14.2 Hz), 3.60-3.53 (m, 1H), 3.40 (br t, 2H, J = 5.2 Hz), 3.36-3.28 (m, 1H), 3.18 (s, 3H), 2.95 (br s, 3H), 1.97 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz).
    236
    Figure US20180319798A1-20181108-C00313
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (m, 1H), 8.59 (s, 1H), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.17-7.11 (m, 2H), 4.72-4.65 (m, 1H), 4.20 (s, 2H), 4.20-4.13 (m, 1H), 4.00 (d, 1H, J = 13.5 Hz), 3.86-3.80 (m, 2H), 3.75-3.66 (m, 2H), 2.12-2.03 (m, 2H), 1.93 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.12 (d, 3H, J = 6.7 Hz).
    237
    Figure US20180319798A1-20181108-C00314
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.55 (s, 1H), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.17-7.11 (m, 2H), 4.72-4.66 (m, 1H), 4.20 (s, 2H), 4.17-3.96 (m, 4H), 3.73-3.53 (m, 3H), 3.12 (s, 3H), 2.95 (s, 3H), 1.18-1.07 (m, 6H).
    238
    Figure US20180319798A1-20181108-C00315
         		HCl 1H-NMR (DMSO-d6) δ: 1.280 (br s, 1H), 8.58-8.53 (m, 1H), 7.69-7.68 (m, 1H), 7.34-7.30 (m, 2H), 7.16-7.12 (m, 2H), 4.72-4.66 (m, 2H), 4.20 (s, 2H), 3.99-3.84 (m, 2H), 3.78-3.67 (m, 1H), 3.60-3.47 (m, 2H), 3.36-3.33 (m, 2H), 3.27-3.25 (m, 1H), 3.28-3.16 (m, 3H), 1.93 (s, 3H), 1.15-1.10 (m, 6H).
  • TABLE 1-67
    structural
    No. formula salt 1H-NMR
    239
    Figure US20180319798A1-20181108-C00316
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.51 (s, 1H), 8.20 (br t, 1H, J = 5.5 Hz), 7.67 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.73-4.66 (m, 1H), 4.20 (s, 2H), 4.11 (d, 1H, J = 13.7 Hz), 3.77 (d, 1H, J = 13.7 Hz), 3.13-2.99 (m, 2H), 1.92 (s, 3H), 1.14 (d, 3H, J = 6.7 Hz), 1.10 (d, 3H, J = 6.7 Hz), 0.99 (t, 3H, J = 7.2 Hz).
    240
    Figure US20180319798A1-20181108-C00317
         		HCl 1H-NMR (DMSO-d6) δ: 1.280 (br s, 1H), 8.80 (s, 1H), 7.29 (d, 2H, J = 8.9 Hz), 6.92 (d, 2H, J = 8.9 Hz), 4.99-4.94 (m, 1H), 4.80-4.73 (m, 1H), 4.39 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (d, 1H, J = 13.7 Hz), 3.74 (s, 3H), 3.62 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.4 Hz), 1.15 (d, 3H, J = 2.4 Hz).
    241
    Figure US20180319798A1-20181108-C00318
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.80 (s, 1H), 7.32 (dd, 2H, J = 8.5, 5.6 Hz), 7.11 (t, 2H, J = 8.5 Hz), 4.98-4.94 (m, 1H), 4.81-4.74 (m, 1H), 3.84 (dd, 1H, J = 13.9, 3.8 Hz), 3.76 (d, 1H, J = 13.9 Hz), 3.63 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.5 Hz), 3.41 (t, 2H, J = 7.7 Hz), 3.26 (s, 3H), 3.09 (t, 2H, J = 7.7 Hz), 1.17 (d, 3H, J = 1.6 Hz), 1.15 (d, 3H, J = 1.6 Hz).
  • TABLE 1-68
    structural
    No. formula salt 1H-NMR
    242
    Figure US20180319798A1-20181108-C00319
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.81 (s, 1H), 7.28 (dd, 2H, J = 8.5, 5.6 Hz), 7.11 (t, 2H, J = 8.5 Hz), 4.98-4.94 (m, 1H), 4.81-4.74 (m ,1H), 3.85 (dd, 1H, J = 13.9, 4.0 Hz), 3.76 (dd, 1H, J = 13.9, 1.4 Hz), 3.63 (dd, 1H, J = 10.3, 5.8 Hz), 3.58 (dd, 1H, J = 10.3, 7.7 Hz), 3.26 (s, 3H), 3.10 (t, 2H, J = 7.7 Hz), 2.68 (t, 2H, J = 7.7 Hz), 2.09-2.01 (m, 2H), 1.18 (d, 3H, J = 2.0 Hz), 1.16 (d, 3H, J = 2.0 Hz).
    243
    Figure US20180319798A1-20181108-C00320
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.81 (s, 1H), 7.65-7.63 (m, 1H), 7.41-7.39 (m, 2H), 5.00-4.95 (m, 1H), 4.80-4.74 (m, 1H), 4.50 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.76 (dd, 1H, J = 13.7, 1.6 Hz), 3.63 (dd, 1H, J = 10.1, 5.6 Hz), 3.57 (dd, 1H, J = 10.1, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
    244
    Figure US20180319798A1-20181108-C00321
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.81 (s, 1H), 7.73 (d, 2H, J = 8.1 Hz), 7.60 (d, 2H, J = 8.1 Hz), 4.99-4.94 (m, 1H), 4.80-4.73 (m, 1H), 4.61 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.76 (dd, 1H, J = 13.7, 1.6 Hz), 3.63 (dd, 1H, J = 10.1, 5.6 Hz), 3.57 (dd, 1H, J = 10.1, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
  • TABLE 1-69
    structural
    No. formula salt 1H-NMR
    245
    Figure US20180319798A1-20181108-C00322
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.48 (s, 1H), 8.34-8.33 (m, 1H), 7.67 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.12 (m, 2H), 4.73-4.67 (m, 1H), 4.20 (s, 2H), 4.06 (d, 1H, J = 13.7 Hz), 3.78 (d, 1H, J = 13.7 Hz), 3.61-3.44 (m, 1H), 1.90 (s, 3H), 1.13 (d, 3H, J = 6.7 Hz), 1.09 (d, 3H, J = 6.7 Hz), 0.62 (d, 2H, J = 7.4 Hz), 0.46-0.41 (m, 2H).
    246
    Figure US20180319798A1-20181108-C00323
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.51 (s, 1H), 8.28 (t, 1H, J = 5.5 Hz), 7.67 (s, 1H), 7.33-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.73-4.66 (m, 1H), 4.20 (s, 2H), 4.15 (d, 1H, J = 13.9 Hz), 3.78 (d, 1H, J = 13.9 Hz), 2.98-2.84 (m, 2H), 1.93 (s, 3H), 1.14 (d, 3H, J = 7.2 Hz), 1.12 (d, 3H, J = 7.2 Hz), 0.89-0.85 (m, 1H), 0.40-0.37 (m, 2H), 0.14-0.10 (m, 2H).
    247
    Figure US20180319798A1-20181108-C00324
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.51 (s, 1H), 7.71 (s, 1H), 7.34-7.30 (m, 2H), 7.18-7.12 (m, 2H), 4.64-4.62 (m, 1H), 4.45-4.49 (m, 1H), 4.21 (s, 2H), 4.06-4.02 (m, 1H), 3.53 (dd, 1H, J = 11.1, 3.4 Hz), 3.48 (dd, 1H, J = 11.1, 4.2 Hz), 3.11 (s, 3H), 1.72 (d, 3H, J = 6.5 Hz), 1.33 (d, 3H, J = 5.6 Hz), 1.31 (d, 3H, J = 5.6 Hz).
    248
    Figure US20180319798A1-20181108-C00325
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.44 (s, 1H), 7.68 (s, 1H), 7.37-7.29 (m, 2H), 7.16-7.11 (m, 2H), 4.20 (s, 2H), 4.19 (d, 1H, J = 14.1 Hz), 3.93 (d, 1H, J = 14.1 Hz), 3.56-3.44 (m, 2H), 2.90 (s, 6H), 1.94 (s, 3H), 1.10 (s, 3H, J = 7.2 Hz).
  • TABLE 1-70
    structural
    No. formula salt 1H-NMR
    249
    Figure US20180319798A1-20181108-C00326
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.50 (s, 1H), 8.20 (br t, 1H, J = 5.1 Hz), 7.67 (s, 1H), 7.33-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.20 (s, 2H), 4.09 (d, 1H, J = 13.7 Hz), 3.97 (d, 1H, J = 13.7 Hz), 3.64-3.55 (m, 1H), 3.38-3.32 (m, 1H), 3.11-3.04 (m, 2H), 1.88 (s, 3H), 1.10 (s, 3H, J = 7.2 Hz), 0.96 (s, 3H, J = 7.2 Hz).
    250
    Figure US20180319798A1-20181108-C00327
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.81 (s, 1H), 7.23-7.16 (m, 2H), 6.94-6.90 (m, 1H), 4.99-4.95 (m, 1H), 4.80-4,74 (m, 1H), 4.45 (s, 2H), 3.86-3.83 (m, 1H), 3.83 (s, 3H), 3.76 (dd, 1H, J = 13.9, 1.4 Hz), 3.63 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
    251
    Figure US20180319798A1-20181108-C00328
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.79 (s, 1H), 7.38 (dd, 1H, J = 8.5, 6.5 Hz), 7.02 (td, 1H, 8.5, 2.8 Hz), 6.81 (dd, 1H, J = 8.5, 2.8 Hz), 4.98-4.94 (m, 1H), 4.78-4.64 (m, 1H), 4.60 (s, 2H), 3.83 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (dd, 1H, J = 13.7, 1.4 Hz), 3.62 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 2.06-1.99 (m, 1H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz), 0.90-0.84 (m, 2H), 0.66-0.63 (m, 2H).
  • TABLE 1-71
    structural
    No. formula salt 1H-NMR
    252
    Figure US20180319798A1-20181108-C00329
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.52 (s, 1H), 8.09-8.05 (m, 1H), 7.65 (s, 1H), 7.34-7.29 (m, 2H), 7.16-7.10 (m, 2H), 4.67 (d, 1H, J = 13.5 Hz), 4.37 (d, 1H, J = 13.5 Hz), 4.19 (s, 2H), 3.76-3.68 (m, 1H), 3.38-3.29 (m, 1H), 2.54 (d, 3H, J = 4.4 Hz), 1.65 (s, 3H), 1.51 (t, 3H, J = 7.1 Hz).
    253
    Figure US20180319798A1-20181108-C00330
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.68 (s, 1H), 7.66 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.86 (d, 1H, J = 14.1 Hz), 4.46 (d, 1H, J = 14.1 Hz), 4.19 (s, 2H), 3.78-3.69 (m, 1H), 3.18-3.09 (m, 1H), 2.99 (br s, 6H), 1.71 (s, 3H), 1.19 (t, 3H, J = 7.1 Hz).
    254
    Figure US20180319798A1-20181108-C00331
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.69 (s, 1H), 7.65 (s, 1H), 7.34-7.29 (m, 2H), 7.16-7.11 (m, 2H), 4.86 (d, 1H, J = 13.9 Hz), 4.46 (d, 1H, J = 13.9 Hz), 4.30-4.03 (m, 1H), 4.19 (s, 2H), 3.78-3.68 (m, 2H), 3.46-3.17 (m, 3H), 1.98-1.78 (m, 4H), 1.73 (s, 3H), 1.17 (t, 3H, J = 7.1 Hz).
    255
    Figure US20180319798A1-20181108-C00332
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.61 (s, 1H), 7.70 (s, 1H), 7.35-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.21 (s, 2H), 4.21-4.17 (m, 1H), 4.11 (d, 1H, J = 13.7 Hz), 3.96 (d, 1H, J = 13.7 Hz), 3.89-3.82 (m, 2H), 3.78-3.73 (m, 1H), 3.46 (dd, 1H, J = 13.9, 6.9 Hz), 3.25 (dd, 1H, J = 13.9, 7.5 Hz), 2.14-2.06 (m, 2H), 1.94 (s, 3H), 1.09-1.03 (m, 1H), 0.52-0.49 (m, 1H), 0.34-0.31 (m, 2H).
  • TABLE 1-72
    structural
    No. formula salt 1H-NMR
    256
    Figure US20180319798A1-20181108-C00333
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.78 (s, 1H), 7.42-7.30 (m, 2H), 7.20-7.16 (m, 2H), 4.72-4.70 (m, 1H), 4.60-4.53 (m, 1H), 4.47 (s, 2H), 4.18-4.10 (m, 2H), 3.94 (dd, 1H, J = 11.9, 2.2 Hz), 3.46 (s, 3H), 1.29 (d, 3H, J = 6.9 Hz), 1.27 (d, 3H, J = 6.9 Hz), 1.05 (d, 3H, J = 6.5 Hz).
    257
    Figure US20180319798A1-20181108-C00334
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (br s, 1H), 8.62 (s, 1H), 7.42-7.38 (m, 2H), 7.20-7.16 (m, 2H), 4.77-4.74 (m, 1H), 4.47 (s, 2H), 4.19 (q, 1H, J = 4.0 Hz), 3.71 (dd, 1H, J = 14.1, 7.3 Hz), 3.62 (d, 2H, J = 4.4 Hz) 3.23 (dd, 1H, J = 14.1, 6.9 Hz), 3.16 (s, 3H), 1.69 (d, 3H, J = 6.9 Hz), 1.22-1.16 (m, 1H), 0.58-0.48 (m, 2H), 0.44-0.39 (m, 1H), 0.34-0.29 (m, 1H).
    258
    Figure US20180319798A1-20181108-C00335
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.72 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.84-4.79 (m, 1H), 4.47 (s, 2H), 4.26-4.21 (m, 1H), 3.89-3.76 (m, 3H), 3.33 (s, 3H), 3.33-3.26 (m, 1H), 1.24 (d, 3H, J = 6.9 Hz), 1.17 (t, 3H, J = 7.3 Hz).
    259
    Figure US20180319798A1-20181108-C00336
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.74 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.85-4.81 (m, 1H), 4.47 (s, 2H), 4.30-4.24 (m, 1H), 3.93 (dd, 1H, J = 11.5, 8.5 Hz), 3.85 (dd, 1H, J = 11.5, 3.0 Hz), 3.56 (dd, 1H, J = 14.1, 7.5 Hz), 3.37 (s, 3H), 3.30 (dd, 1H, J = 14.1, 6.9 Hz), 1.24 (d, 3H, J = 6.9 Hz), 1.15-1.09 (m, 1H), 0.58-0.48 (m, 2H), 0.41-0.30 (m, 2H).
  • TABLE 1-73
    structural
    No. formula salt 1H-NMR
    260
    Figure US20180319798A1-20181108-C00337
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.53 (s, 1H), 7.69 (s, 1H), 7.33-7.29 (m, 2H), 7.17-7.11 (m, 2H), 4.73-4.67 (m, 1H), 4.19 (s, 2H), 4.10 (q, 1H, J = 4.1 Hz), 3.90-3.83 (m, 1H), 3.56 (d, 2H, J = 4.6 Hz), 3.33-3.32 (m, 1H), 3.16 (s, 3H), 1.61 (d, 3H, J = 6.5 Hz), 1.20 (t, 3H, J = 7.1 Hz).
    261
    Figure US20180319798A1-20181108-C00338
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.59 (s, 1H), 7.67 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.79-4.75 (m, 1H), 4.22-4.19 (m, 1H), 4.19 (s, 2H), 3.85-3.73 (m, 3H), 3.31 (s, 3H), 3.31-3.24 (m, 1H), 1.22 (d, 3H, J = 6.7 Hz), 1.15 (t, 3H, J = 7.1 Hz).
    262
    Figure US20180319798A1-20181108-C00339
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.60 (s, 1H), 7.70 (s, 1H), 7.35-7.31 (m, 2H), 7.16-7.12 (m, 2H), 4.41-4.38 (m, 1H), 4.20 (s, 2H), 4.10-4.02 (m, 4H), 3.98 (d, 1H, J = 13.7 Hz), 3.68-3.59 (m, 1H), 3.43-3.35 (m, 1H), 3.32-3.26 (m, 1H), 3.13 (s, 3H), 1.94 (s, 3H), 1.07-1.00 (m, 1H), 0.53-0.45 (m, 2H), 0.34-0.28 (m, 2H).
    263
    Figure US20180319798A1-20181108-C00340
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.60 (s, 1H), 7.69 (s, 1H), 7.34-7.31 (m, 2H), 7.14 (br t, 2H, J = 8.8 Hz), 4.39-4.36 (m, 1H), 4.20 (s, 2H), 4.11-3.90 (m, 5H), 3.69-3.65 (m, 1H), 3.57-3.40 (m, 2H), 3.12 (s, 3H), 1.92 (s, 3H), 1.09 (t, 3H, J = 6.6 Hz).
  • TABLE 1-74
    structural
    No. formula salt 1H-NMR
    264
    Figure US20180319798A1-20181108-C00341
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.41 (s, 1H), 7.68 (s, 1H), 7.32 (dd, 2H, J = 8.2, 5.9 Hz), 7.16-7.13 (m, 2H), 4.19 (s, 2H), 4.18 (d, 1H, J = 13.9 Hz), 3.90 (d, 1H, J = 13.9 Hz), 3.05 (s, 3H), 2.88 (s, 6H), 1.91 (s, 3H).
    265
    Figure US20180319798A1-20181108-C00342
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.40 (s, 1H), 7.67 (s, 1H), 7.35-7.29 (m, 2H), 7.16-7.11 (m, 2H), 4.19 (s, 2H), 4.17 (d, 1H, J = 13.9 Hz), 3.89 (d, 1H, J = 13.9 Hz), 3.43-3.35 (m, 1H), 3.28-3.19 (m, 1H), 3.05 (s, 3H), 2.83 (s, 3H), 1.89 (s, 3H), 0.98 (t, 3H, J = 7.1 Hz).
    266
    Figure US20180319798A1-20181108-C00343
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.62 (s, 1H), 7.70 (s, 1H), 7.34-7.31 (m, 2H), 7.16-7.12 (m, 2H), 4.20 (s, 2H), 4.18-4.11 (m, 1H), 4.04-3.97 (m, 1H), 3.91-3.82 (m, 2H), 3.28-3.19 (m, 1H), 3.64-3.57 (m, 1H), 3.03 (s, 3H), 2.09-2.03 (m, 2H), 1.90 (s, 3H).
    267
    Figure US20180319798A1-20181108-C00344
         		HCl 1H-NMR (DMSO-d6) δ: 12.73 (br s, 1H), 8.50 (s, 1H), 8.18 (br t, 1H, J = 5.6 Hz), 7.67 (s, 1H), 7.34-7.29 (m, 2H), 7.17-7.11 (m, 2H), 4.20 (s, 2H), 3.99 (d, 1H, J = 13,7 Hz), 3.93 (d, 1H, J = 13.7 Hz), 3.08-3.01 (m, 2H), 2.87-2.84 (m, 1H), 1.87 (s, 3H), 0.96 (t, 3H, J = 7.2 Hz), 0.94-0.89 (m, 1H), 0.81-0.69 (m, 2H), 0.62-0.56 (m, 1H).
  • TABLE 1-75
    No. structural formula salt 1H-NMR
    268
    Figure US20180319798A1-20181108-C00345
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.61 (s, 1H), 7.69 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.20 (s, 2H), 4.07-4.01 (m, 1H), 3.92 (d, 1H, J = 13.2 Hz), 3.87-3.82 (m, 2H), 3.80 (d, 1H, J = 13.2 Hz), 3.50-3.42 (m, 1H), 2.89-2.84 (m, 1H), 2.08-2.00 (m, 2H), 1.89 (s, 3H), 0.91-0.85 (m, 1H), 0.82-0.73 (m, 2H), 0.67-0.61 (m, 1H).
    269
    Figure US20180319798A1-20181108-C00346
         		HCl 1H-NMR (DMSO-d6) δ: 13.18 (br s, 1H), 8.67 (s, 1H), 7.42-7.38 (m, 2H), 7.20-7.14 (m, 2H), 4.46 (s, 2H), 3.83 (d, 1H, J = 13.7 Hz), 3.74 (d, 1H, J = 13.7 Hz), 3.64 (d, 1H, J = 11.8 Hz), 3.62 (d, 1H, J = 11.8 Hz), 3.60-3.44 (m, 3H), 1.59 (s, 3H), 1.15 (t, 3H, J = 7.2 Hz).
    270
    Figure US20180319798A1-20181108-C00347
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.75 (s, 1H), 7.41-7.38 (m, 2H), 7.20-7.15 (m, 2H), 4.53 (d, 1H, J = 13.7 Hz), 4.46 (s, 2H), 4.30 (d, 1H, J = 13.7 Hz), 3.68-3.59 (m, 1H), 3.51 (d, 1H, J = 10.4 Hz), 3.48-3.43 (m, 2H), 3.20 (s, 3H), 1.35 (s, 3H), 1.19 (t, 3H, J = 7.1 Hz).
    271
    Figure US20180319798A1-20181108-C00348
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.61 (s, 1H), 7.69 (s, 1H), 7.34-7.31 (m, 2H), 7.16-7.12 (m, 2H), 4.20 (s, 2H), 4.17-4.15 (m, 1H), 4.02 (d, 1H, J = 13.5 Hz), 4.00-3.87 (m, 2H), 3.89 (d, 1H, J = 13.5 Hz), 3.65-3.63 (m, 1H), 3.54-3.44 (m, 2H), 2.10-2.06 (m, 2H), 1.91 (s, 3H), 1.10 (t, 3H, J = 7.1 Hz).
  • TABLE 1-76
    No. structural formula salt 1H-NMR
    272
    Figure US20180319798A1-20181108-C00349
         		HCl 1H-NMR (DMSO-d6) δ: 12.65 (br s, 1H), 8.66 (s, 1H), 7.64 (s, 1H), 7.47-7.41 (m, 1H), 7.24 (dt, 1H, J = 14.0, 5.0 Hz), 7.06 (td, 1H, J = 8.5, 2.3 Hz), 5.10-5.03 (m, 1H), 4.80-4.73 (m, 1H), 4.20 (s, 2H), 4.18-4.04 (m, 2H), 3.98-3.85 (m, 1H), 3.87-3.71 (m, 3H), 3.61-3.53 (m, 1H), 3.15 (s, 1.5H), 3.08 (s, 1.5H), 2.66-2.58 (m, 2H), 1.15-1.11 (m, 6H).
    273
    Figure US20180319798A1-20181108-C00350
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.59 (s, 1H), 7.70 (s, 1H), 7.35-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.21 (s, 2H), 4.21-4.17 (m, 1H), 4.14 (d, 1H, J = 13.7 Hz), 3.93-3.76 (m, 5H), 2.16-2.08 (m, 2H), 1.97 (s, 3H), 1.24 (d, 3H, J = 6.8 Hz), 1.13-1.10 (m, 1H), 0.64-0.58 (m, 1H), 0.43-0.38 (m, 2H), 0.20-0.15 (m, 1H).
    274
    Figure US20180319798A1-20181108-C00351
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.58 (s, 1H), 7.70 (s, 1H), 7.35-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.21 (s, 2H), 4.21-4.14 (m, 3H), 4.06-4.00 (m, 1H), 3.87-3.64 (m, 4H), 3.15 (s, 3H), 1.98 (s, 3H), 1.24 (d, 3H, J = 6.6 Hz), 1.13-1.09 (m, 1H), 0.61-0.57 (m, 1H), 0.49-0.36 (m, 2H), 0.15-0.07 (m, 1H).
  • TABLE 1-77
    No. structural formula salt 1H-NMR
    275
    Figure US20180319798A1-20181108-C00352
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.48 (s, 1H), 7.69 (s, 1H), 7.35-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.31 (d, 1H, J = 14.3 Hz), 4.21 (s, 2H), 3.93 (d, 1H, J = 14.3 Hz), 3.83-3.75 (m, 1H), 2.98 (br s, 6H), 2.05 (s, 3H), 1.25 (d, 3H, J = 6.8 Hz), 1.10-1.03 (m, 1H), 0.64-0.58 (m, 1H), 0.42-0.33 (m, 2H), 0.12-0.08 (m, 1H).
    276
    Figure US20180319798A1-20181108-C00353
         		HCl 1H-NMR (DMSO-d6) δ: 12.86 (br s, 1H), 8.52 (s, 1H), 8.21 (t, 1H, J = 5.4 Hz), 7.69 (s, 1H), 7.36-7.31 (m, 2H), 7.18-7.13 (m, 2H), 4.29 (d, 1H, J = 13.7 Hz), 4.21 (s, 2H), 3.87 (d, 1H, J = 13.7 Hz), 3.81-3.73 (m, 1H), 3.20-3.14 (m, 1H), 3.02-2.96 (m, 1H), 1.94 (s, 3H), 1.24 (d, 3H, J = 6.8 Hz), 1.13-1.07 (m, 1H), 1.01 (t, 3H, J = 7.2 Hz), 0.62-0.57 (m, 1H), 0.37-0.31 (m, 2H), 0.18-0.12 (m, 1H).
    277
    Figure US20180319798A1-20181108-C00354
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.80 (s, 1H), 7.38-7.32 (m, 2H), 4.99-4.97 (m, 1H), 4.80-4.74 (m, 1H), 4.46 (s, 2H), 3.84 (dd, 1H, J = 13.5, 4.2 Hz), 3.83 (s, 3H), 3.75 (dd, 1H, J = 13.5, 1.2 Hz), 3.63 (dd, 1H, J = 10.3, 5.8 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.25 (s, 3H), 1.17 (d, 3H, J = 2.0 Hz), 1.15 (d, 3H, J = 2.0 Hz).
  • TABLE 1-78
    No. structural formula salt 1H-NMR
    278
    Figure US20180319798A1-20181108-C00355
         		HCl 1H-NMR (DMSO-d6) δ: 12.45 (br s, 1H), 8.98 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.71-4.67 (m, 1H), 4.56-4.49 (m, 1H), 4.47 (s, 2H), 4.30-4.25 (m, 1H), 3.93-3.90 (m, 1H), 1.65-1.61 (m, 1H), 1.46-1.38 (m, 1H), 1.29 (d, 3H, J = 2.4 Hz), 1.27 (d, 3H, J = 2.0 Hz), 0.92 (t, 3H, J = 7.5 Hz).
    279
    Figure US20180319798A1-20181108-C00356
         		HCl 1H-NMR (DMSO-d6) δ: 12.60 (br s, 1H), 8.84 (s, 1H), 7.43-7.38 (m, 2H), 7.20-7.15 (m, 2H), 4.50-4.46 (m, 1H), 4.46 (s, 2H), 4.41 (dd, 1H, J = 13.1, 3.6 Hz), 4.20-4.17 (m, 1H), 3.57 (dd, 1H, J = 14.0, 7.1 Hz), 3.22 (dd, 1H, J = 14.0, 7.0 Hz), 1.24 (d, 3H, J = 6.5 Hz), 1.14-1.10 (m, 1H), 0.56-0.47 (m, 2H), 0.39-0.36 (m, 1H), 0.33-0.29 (m, 1H).
    280
    Figure US20180319798A1-20181108-C00357
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.61 (s, 1H), 7.70 (s, 1H), 7.35-7.32 (m, 2H), 7.18-7.13 (m, 2H), 4.21 (s, 2H), 4.21-4.13 (m, 2H), 3.86-3.73 (m, 5H), 2.14-2.06 (m, 2H), 1.96 (s, 3H), 1.20 (d, 3H, J = 6.6 Hz), 1.15-1.07 (m, 1H), 0.64-0.58 (m, 1H), 0.45-0.38 (m, 2H), 0.23-0.20 (m, 1H).
    281
    Figure US20180319798A1-20181108-C00358
         		HCl 1H-NMR (DMSO-d6) δ: 12.74 (br s, 1H), 8.60 (s, 1H), 7.70 (s, 1H), 7.36-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.21 (s, 2H), 4.15-4.04 (m, 4H), 3.89-3.78 (m, 2H), 3.68-3.58 (m, 2H), 3.15 (s, 1.5H), 3.14 (s, 1.5H), 1.98 (s, 3H), 1.19-1.11 (m, 4H), 0.61-0.57 (m, 1H), 0.49-0.38 (m, 2H), 0.22-0.19 (m, 1H).
  • TABLE 1-79
    No. structural formula salt 1H-NMR
    282
    Figure US20180319798A1-20181108-C00359
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.42 (s, 1H), 7.69 (s, 1H), 7.35-7.32 (m, 2H), 7.18-7.12 (m, 2H), 4.24 (d, 1H, J = 14.3 Hz), 4.21 (s, 2H), 3.93 (d, 1H, J = 14.3 Hz), 3.89-3.81 (m, 1H), 2.94 (br s, 6H), 1.99 (s, 3H), 1.19 (d, 3H, J = 6.6 Hz), 1.15-1.09 (m, 1H), 0.63-0.58 (m, 1H), 0.48-0.39 (m, 2H), 0.26-0.22 (m, 1H).
    283
    Figure US20180319798A1-20181108-C00360
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.53 (s, 1H), 8.25 (t, 1H, J = 5.4 Hz), 7.69 (s, 1H), 7.35-7.32 (m, 2H), 7.17-7.13 (m, 2H), 4.29 (d, 1H, J = 13.9 Hz), 4.21 (s, 2H), 3.92 (d, 1H, J = 13.9 Hz), 3.89-3.83 (m, 1H), 3.16-3.02 (m, 2H), 1.95 (s, 3H), 1.18 (d, 3H, J = 6.8 Hz), 1.03-1.01 (m, 1H), 1.01 (t, 3H, J = 7.2 Hz), 0.62-0.58 (m, 1H), 0.47-0.39 (m, 2H), 0.24-0.19 (m, 1H).
    284
    Figure US20180319798A1-20181108-C00361
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.82 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.83 (br t, 1H, J = 6.6 Hz), 4.48 (s, 2H), 4.04 (q, 1H, J = 6.2 Hz), 3.95-3.86 (m, 1H), 3.64 (dd, 1H, J = 10.4, 5.3 Hz), 3.53 (dd, 1H, J = 10.4, 7.9 Hz), 3.24 (s, 3H), 3.16-3.07 (m, 1H), 1.26 (d, 3H, J = 6.6 Hz), 1.16 (t, 3H, J = 7.1 Hz).
  • TABLE 1-80
    No. structural formula salt 1H-NMR
    285
    Figure US20180319798A1-20181108-C00362
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.82 (s, 1H), 7.43-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.82 (br t, 1H, J = 6.0 Hz), 4.65-4.58 (m, 1H), 4.48 (s, 2H), 4.16 (q, 1H, J = 6.5 Hz), 3.60 (dd, 1H, J = 10.3, 5.4 Hz), 3.49 (dd, 1H, J = 10.3, 7.9 Hz), 3.24 (s, 3H), 1.21 (d, 3H, J = 2.0 Hz), 1.26 (d, 3H, J = 2.0 Hz), 1.21 (t, 3H, J = 6.8 Hz).
    286
    Figure US20180319798A1-20181108-C00363
         		HCl 1H-NMR (DMSO-d6) δ: 12.53 (br s, 1H), 9.01 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.15 (m, 2H), 4.75 (d, 1H, J = 13.8 Hz), 4.47 (s, 2H), 4.34 (dd, 1H, J = 13.8, 4.3 Hz), 4.01 (td, 1H, J = 13.8, 6.9 Hz), 3.74 (br t, 1H, J = 5.0 Hz), 3.74 (td, 1H, J = 13.8, 6.9 Hz), 1.92 (td, 1H, J = 13.8, 6.9 Hz), 1.20 (t, 3H, J = 6.9 Hz), 0.99 (d, 3H, J = 6.9 Hz), 0.79 (d, 3H, J = 6.9 Hz).
    287
    Figure US20180319798A1-20181108-C00364
         		HCl 1H-NMR (DMSO-d6) δ: 12.53 (br s, 1H), 9.01 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.15 (m, 2H), 4.75 (d, 1H, J = 13.8 Hz), 4.47 (s, 2H), 4.34 (dd, 1H, J = 13.8, 4.3 Hz), 4.01 (td, 1H, J = 13.8, 6.9 Hz), 3.74 (br t, 1H, J = 5.0 Hz), 3.74 (td, 1H, J = 13.8, 6.9 Hz), 1.92 (td, 1H, J = 13.8, 6.9 Hz), 1.20 (t, 3H, J = 6.9 Hz), 0.99 (d, 3H, J = 6.9 Hz), 0.79 (d, 3H, J = 6.9 Hz).
  • TABLE 1-81
    No. structural formula salt 1H-NMR
    288
    Figure US20180319798A1-20181108-C00365
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.82 (s, 1H), 7.43-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.82 (br t, 1H, J = 6.0 Hz), 4.65-4.58 (m, 1H), 4.48 (s, 2H), 4.16 (q, 1H, J = 6.5 Hz), 3.60 (dd, 1H, J = 10.3, 5.4 Hz), 3.49 (dd, 1H, J = 10.3, 7.9 Hz), 3.24 (s, 3H), 1.27 (d, 3H, J = 2.0 Hz), 1.26 (d, 3H, J = 2.0 Hz), 1.21 (t, 3H, J = 6.8 Hz).
    289
    Figure US20180319798A1-20181108-C00366
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.82 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.83 (br t, 1H, J = 6.6 Hz), 4.48 (s, 2H), 4.04 (q, 1H, J = 6.2 Hz), 3.95-3.86 (m, 1H), 3.64 (dd, 1H, J =10.4, 5.3 Hz), 3.53 (dd, 1H, J = 10.4, 7.9 Hz), 3.24 (s, 3H), 3.16-3.07 (m, 1H), 1.26 (d, 3H, J = 6.6 Hz), 1.16 (t, 3H, J = 7.1 Hz).
    290
    Figure US20180319798A1-20181108-C00367
         		HCl 1H-NMR (DMSO-d6) δ: 12.86 (br s, 1H), 8.56 (s, 1H), 7.70 (s, 1H), 7.37-7.31 (m, 2H), 7.19-7.12 (m, 2H), 4.73-4.66 (m, 1H), 4.21 (s, 2H), 4.19-4.07 (m, 2H), 3.86-3.70 (m, 6H), 2.03 (s, 3H), 1.17 (d, 3H, J = 6.5 Hz), 1.10 (d, 3H, J = 6.5 Hz).
    291
    Figure US20180319798A1-20181108-C00368
         		HCl 1H-NMR (DMSO-d6) δ: 12.53 (br s, 1H), 8.96 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.65 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J = 13.5, 3.8 Hz), 3.92-3.84 (m, 2H), 3.24-3.16 (m, 1H), 1.72-1.66 (m, 1H), 1.51-1.41 (m, 1H), 1.20 (t, 3H, J = 7.3 Hz), 0.92 (t, 3H, J = 7.5 Hz).
  • TABLE 1-82
    No. structural formula salt 1H-NMR
    292
    Figure US20180319798A1-20181108-C00369
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.52 (s, 1H), 8.09-8.05 (m, 1H), 7.65 (s, 1H), 7.34-7.29 (m, 2H), 7.16-7.10 (m, 2H), 4.67 (d, 1H, J = 13.5 Hz), 4.37 (d, 1H, J = 13.5 Hz), 4.19 (s, 2H), 3.76-3.68 (m, 1H), 3.38-3.29 (m, 1H), 2.54 (d, 3H, J = 4.4 Hz), 1.65 (s, 3H), 1.51 (t, 3H, J = 7.1 Hz).
    293
    Figure US20180319798A1-20181108-C00370
         		HCl 1H-NMR (DMSO-d6) δ: 12.40 (br s, 1H), 8.68 (s, 1H), 7.66 (s, 1H), 7.34-7.30 (m, 2H), 7.16-7.11 (m, 2H), 4.86 (d, 1H, J = 14.1 Hz), 4.46 (d, 1H, J = 14.1 Hz), 4.19 (s, 2H), 3.78-3.69 (m, 1H), 3.18-3.09 (m, 1H), 2.99 (br s, 6H), 1.71 (s, 3H), 1.19 (t, 3H, J = 7.1 Hz).
    294
    Figure US20180319798A1-20181108-C00371
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.69 (s, 1H), 7.65 (s, 1H), 7.34-7.29 (m, 2H), 7.16-7.11 (m, 2H), 4.86 (d, 1H, J = 13.9 Hz), 4.46 (d, 1H, J = 13.9 Hz), 4.30-4.03 (m, 1H), 4.19 (s, 2H), 3.78-3.68 (m, 2H), 3.46-3.17 (m, 3H), 1.98-1.78 (m, 4H), 1.73 (s, 3H), 1.17 (t, 3H, J = 7.1 Hz).
    295
    Figure US20180319798A1-20181108-C00372
         		HCl 1H-NMR (DMSO-d6) δ: 12.46 (br s, 1H), 8.84 (s, 1H), 7.43-7.39 (m, 2H), 7.20-7.15 (m, 2H), 4.68 (d, 1H, J = 13.5 Hz), 4.46 (s, 2H), 4.36 (dd, 1H, J = 13.5, 3.7 Hz), 4.08-4.00 (m, 2H), 3.49 (dd, 1H, J = 10.2, 3.9 Hz), 3.41 (dd, 1H, J = 10.2, 7.0 Hz), 3.17 (s, 3H), 1.77-1.59 (m, 4H), 0.90 (t, 3H, J = 7.3 Hz), 0.85 (t, 3H, J = 7.3 Hz).
  • TABLE 1-83
    No. structural formula salt 1H-NMR
    296
    Figure US20180319798A1-20181108-C00373
         		HCl 1H-NMR (DMSO-d6) δ: 13.19 (br s, 1H), 8.71 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.47 (s, 2H), 3.86-3.76 (m, 3H), 3.70 (d, 1H, J = 10.4 Hz), 3.63-3.45 (m, 4H), 3.35-3.33 (m, 2H), 3.11 (s, 3H), 1.64 (s, 3H), 1.17 (t, 3H, J = 7.2 Hz).
    297
    Figure US20180319798A1-20181108-C00374
         		HCl 1H-NMR (DMSO-d6) δ: 13.21 (br s, 1H), 8.71 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.47 (s, 2H), 3.80-3.63 (m, 4H), 3.51-3.44 (m, 2H), 3.35-3.33 (m, 2H), 3.12 (s, 3H), 2.95-2.90 (m, 1H), 1.62 (s, 3H), 0.93-0.76 (m, 4H).
    298
    Figure US20180319798A1-20181108-C00375
         		HCl 1H-NMR (DMSO-d6) δ: 12.51 (br s, 1H), 8.93 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.91 (q, 1H, J = 6.8 Hz), 4.48 (s, 2H), 4.04-3.95 (m, 2H), 3.52 (dd, 1H, J = 10.3, 5.2 Hz), 3.46 (dd, 1H, J = 10.3, 6.5 Hz), 3.22 (s, 3H), 3.20-3.13 (m, 1H), 1.42 (d, 3H, J = 6.6 Hz), 1.19 (t, 3H, J = 7.1 Hz).
    299
    Figure US20180319798A1-20181108-C00376
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.95 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.95 (q, 1H, J = 6.5 Hz), 4.58-4.51 (m, 1H), 4.48 (s, 2H), 4.07-4.04 (m, 1H), 3.50 (dd, 1H, J = 10.5, 4.1 Hz), 3.36 (dd, 1H, J = 10.5, 7.9 Hz), 3.22 (s, 3H), 1.39 (d, 3H, J = 6.8 Hz), 1.29 (d, 3H, J = 5.0 Hz), 1.27 (d, 3H, J = 5.0 Hz).
  • TABLE 1-84
    No. structural formula salt 1H-NMR
    300
    Figure US20180319798A1-20181108-C00377
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.82 (s, 1H), 7.39 (dd, 1H, J = 15.3, 8.7 Hz), 7.22-7.16 (m, 1H), 7.02 (td, 1H, J = 8.7, 2.4 Hz), 4.63 (d, 1H, J = 13.3 Hz), 4.42 (dd, 1H, J = 13.3, 4.3 Hz), 4.17-4.13 (m, 1H), 3.87 (td, 1H, J = 14.0. 7.1 Hz), 3.56-3.49 (m, 2H), 3.40 (t, 2H, J = 7.5 Hz), 3.32-3.25 (m, 1H), 3.22 (s, 3H), 3.09 (t, 2H, J = 7.5 Hz), 1.21 (t, 3H, J = 7.1 Hz).
    301
    Figure US20180319798A1-20181108-C00378
         		HCl 1H-NMR (DMSO-d6) δ: 12.61 (br s, 1H), 8.78 (s, 1H), 7.42-7.39 (m, 2H), 7.20-7.16 (m, 2H), 4.51 (s, 2H), 4.47 (s, 2H), 3.65-3.53 (m, 6H), 3.26 (s, 6H), 1.19 (t, 3H, J = 7.1 Hz).
    302
    Figure US20180319798A1-20181108-C00379
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.80 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.15 (m, 2H), 4.99-4.95 (m, 1H), 4.46 (s, 2H), 3.99-3.84 (m, 3H), 3.63 (dd, 1H, J = 10.3, 5.7 Hz), 3.57 (dd, 1H, J = 10.3, 7.7 Hz), 3.24 (s, 3H), 1.22 (d, 3H, J = 7.0 Hz), 1.08-1.00 (m, 1H), 0.61-0.55 (m, 1H), 0.47-0.36 (m, 2H), 0.23-0.18 (m, 1H).
    303
    Figure US20180319798A1-20181108-C00380
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.97 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.69 (d, 1H, J = 13.3 Hz), 4.48 (s, 2H), 4.38 (dd, 1H, J = 13.3, 3.4 Hz), 3.95-3.93 (m, 1H), 3.69 (dd, 1H, J = 13.9, 7.1 Hz), 3.16 (dd, 1H, J = 13.9, 7.2 Hz), 1.79-1.72 (m, 1H), 1.48-1.40 (m, 1H), 1.19-1.12 (m, 1H), 0.93 (t, 3H, J = 7.4 Hz), 0.55-0.48 (m, 2H), 0.42-0.37 (m, 1H), 0.34-0.30 (m, 1H).
  • TABLE 1-85
    No. structural formula salt 1H-NMR
    304
    Figure US20180319798A1-20181108-C00381
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.95 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.95 (q, 1H, J = 6.5 Hz), 4.58-4.51 (m, 1H), 4.48 (s, 2H), 4.07-4.04 (m, 1H), 3.50 (dd, 1H, J = 10.5, 4.1 Hz), 3.36 (dd, 1H, J = 10.5, 7.9 Hz), 3.22 (s, 3H), 1.39 (d, 3H, J = 6.8 Hz), 1.29 (d, 3H, J = 5.0 Hz), 1.27 (d, 3H, J = 5.0 Hz).
    305
    Figure US20180319798A1-20181108-C00382
         		HCl 1H-NMR (DMSO-d6) δ: 12.51 (br s, 1H), 8.93 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.91 (q, 1H, J = 6.8 Hz), 4.48 (s, 2H), 4.04-3.95 (m, 2H), 3.52 (dd, 1H, J = 10.3, 5.2 Hz), 3.46 (dd, 1H, J = 10.3, 6.5 Hz), 3.22 (s, 3H), 3.20-3.13 (m, 1H), 1.42 (d, 3H, J = 6.6 Hz), 1.19 (t, 3H, J = 7.1 Hz).
    306
    Figure US20180319798A1-20181108-C00383
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.86 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.80 (d, 1H, J = 14.0 Hz), 4.49 (d, 1H, J = 14.0 Hz), 4.47 (s, 2H), 4.11-3.06 (m, 4H), 3.60 (sep, 1H, J = 6.6 Hz), 2.06-1.63 (m, 4H), 1.73 (s, 3H), 1.46 (d, 3H, J = 6.6 Hz), 1.43 (d, 3H, J = 6.6 Hz).
    307
    Figure US20180319798A1-20181108-C00384
         		HCl 1H-NMR (DMSO-d6) δ: 12.65 (br s, 1H), 8.74 (s, 1H), 8.31 (t, 1H, J = 5.5 Hz), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.58 (d, 1H, J = 13.5 Hz), 4.48 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 3.53 (sep, 1H, J = 6.6 Hz), 3.20-3.09 (m, 2H), 1.58 (s, 3H), 1.48 (d, 3H, J = 6.6 Hz), 1.41 (d, 3H, J = 6.6 Hz), 1.01 (t, 3H, J = 7.2 Hz).
  • TABLE 1-86
    No. structural formula salt 1H-NMR
    308
    Figure US20180319798A1-20181108-C00385
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.74 (s, 1H), 8.11 (d, 1H, J = 7.7 Hz), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.61 (d, 1H, J = 14.0 Hz), 4.49 (d, 1H, J = 14.0 Hz), 4.47 (s, 2H), 3.91 (sep, 1H, J = 6.6 Hz), 3.48 (sep, 1H, J = 6.6 Hz), 1.55 (s, 3H), 1.51 (d, 3H, J = 6.6 Hz), 1.41 (d, 3H, J = 6.6 Hz), 1.09 (d, 3H, J = 6.6 Hz), 1.06 (d, 3H, J = 6.6 Hz).
    309
    Figure US20180319798A1-20181108-C00386
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.75 (s, 1H), 7.77 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.67 (d, 1H, J = 13.5 Hz), 4.49 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 3.40 (sep, 1H, J = 6.7 Hz), 1.54 (d, 3H, J = 6.7 Hz), 1.50 (s, 3H), 1.41 (d, 3H, J = 6.7 Hz), 1.29 (s, 9H).
    310
    Figure US20180319798A1-20181108-C00387
         		HCl 1H-NMR (DMSO-d6) δ: 12.66 (br s, 1H), 8.85 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.68-3.76 (m, 4H), 4.64 (d, 1H, J = 13.9 Hz), 4.47 (s, 2H), 4.46 (d, 1H, J = 13.9 Hz), 3.69 (sep, 1H, J = 6.7 Hz), 2.28-2.15 (m, 2H), 1.66 (s, 3H), 1.44 (d, 3H, J = 6.7 Hz), 1.43 (d, 3H, J = 6.7 Hz).
    311
    Figure US20180319798A1-20181108-C00388
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.81 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.71 (d, 1H, J = 14.0 Hz), 4.58 (d, 1H, J = 14.0 Hz), 4.47 (s, 2H), 3.75-3.40 (m, 9H), 1.66 (s, 3H), 1.53 (d, 3H, J = 6.6 Hz), 1.42 (d, 3H, J = 6.6 Hz).
  • TABLE 1-87
    No. structural formula salt 1H-NMR
    312
    Figure US20180319798A1-20181108-C00389
         		HCl 1H-NMR (DMSO-d6) δ: 13.99 (br s, 1H), 12.50 (br s, 1H), 8.83 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.13 (m, 2H), 4.78 (d, 1H, J = 14.0 Hz), 4.49 (d, 1H, J = 14.0 Hz), 4.47 (s, 2H), 3.85 (sep, 1H, J = 6.8 Hz), 1.66 (s, 3H), 1.49 (d, 3H, J = 6.8 Hz), 1.45 (d, 3H, J = 6.8 Hz).
    313
    Figure US20180319798A1-20181108-C00390
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (br s, 1H), 8.55 (s, 1H), 7.45-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.48 (s, 2H), 4.21 (d, 1H, J = 14.0 Hz), 3.96 (d, 1H, J = 14.0 Hz), 3.07 (s, 3H), 2.91 (s, 6H), 1.98 (s, 3H).
    314
    Figure US20180319798A1-20181108-C00391
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.42 (s, 1H), 7.69 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.21 (s, 2H), 4.20 (d, 1H, J = 13.9 Hz), 3.91 (d, 1H, J = 13.9 Hz), 3.07 (s, 3H), 2.89 (s, 6H), 1.92 (s, 3H).
    315
    Figure US20180319798A1-20181108-C00392
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (br s, 1H), 8.84 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.16 (m, 2H), 4.80 (d, 1H, J = 13.9 Hz), 4.53 (d, 1H, J = 13.9 Hz), 4.47 (s, 2H), 3.45 (sep, 1H, J = 6.6 Hz), 3.08 (s, 6H), 1.05 (s, 3H), 1.49 (d, 3H, J = 6.6 Hz), 1.42 (d, 3H, J = 6.6 Hz).
  • TABLE 1-88
    No. structural formula salt 1H-NMR
    316
    Figure US20180319798A1-20181108-C00393
         		HCl 1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.80 (s, 1H), 7.45-7.39 (m, 2H), 7.23-7.15 (m, 2H), 5.06-4.97 (m, 1H), 4.48 (s, 2H), 3.94-3.91 (m, 2H), 3.90-3.80 (m, 1H), 3.72-3.58 (m, 2H), 3.26 (s, 3H), 1.23 (d, 3H, J = 6.8 Hz), 1.18-1.07 (m, 1H), 0.66-0.57 (m, 1H), 0.50-0.37 (m, 2H), 0.31-0.20 (m, 1H).
    317
    Figure US20180319798A1-20181108-C00394
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.84 (s, 1H), 7.44-7.36 (m, 1H), 7.23-7.15 (m, 1H), 7.06-6.98 (m, 1H), 4.66 (dd, 1H, J = 13.6, 1.4 Hz), 4.48 (sep, 1H, J = 6.8 Hz), 4.35 (dd, 1H, J = 13.6, 3.6 Hz), 4.24-4.17 (m, 1H), 3.50 (dd, 1H, J = 10.4, 4.2 Hz), 3.44-3.37 (m, 3H), 3.22 (s, 3H), 3.09 (t, 2H, J = 7.5 Hz), 1.30 (d, 3H, J = 6.8 Hz), 1.29 (d, 3H, J = 6.8 Hz).
    318
    Figure US20180319798A1-20181108-C00395
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.76 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.55 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 4.31 (d, 1H, J = 13.5 Hz), 3.71-3.59 (m, 1H), 3.56-3.42 (m, 3H), 3.21 (s, 3H), 1.37 (s, 3H), 1.20 (t, 3H, J = 7.1 Hz).
    319
    Figure US20180319798A1-20181108-C00396
         		HCl 1H-NMR (DMSO-d6) δ: 12.63 (br s, 1H), 8.77 (s, 1H), 7.58-7.48 (m, 1H), 7.33-7.25 (m, 1H), 7.16-7.08 (m, 1H), 4.52 (s, 2H), 4.49 (s, 2H), 3.63 (d, 2H, J = 10.6 Hz), 3.58 (q, 2H, J = 7.1 Hz), 3.54 (d, 2H, J = 10.6 Hz), 3.26 (s, 6H), 1.19 (t, 3H, J = 7.1 Hz).
  • TABLE 1-89
    No. structural formula salt 1H-NMR
    320
    Figure US20180319798A1-20181108-C00397
         		HCl 1H-NMR (DMSO-d6) δ: 12.74 (br s, 1H), 8.74 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.50 (s, 2H), 4.47 (s, 2H), 3.94 (sep, 1H, J = 6.6 Hz), 3.66 (d, 2H, J = 10.6 Hz), 3.51 (d, 2H, J = 10.6 Hz), 3.27 (s, 6H), 1.45 (d, 6H, J = 6.6 Hz).
    321
    Figure US20180319798A1-20181108-C00398
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.83 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.26 (m, 1H), 7.15-7.08 (m, 1H), 4.80 (d, 1H, J = 14.0 Hz), 4.54 (d, 1H, J = 14.0 Hz), 4.49 (s, 2H), 3.45 (sep, 1H, 6.7 Hz), 3.07 (s, 6H), 1.65 (s, 3H), 1.49 (d, 3H, J = 6.7 Hz), 1.42 (d, 3H, J = 6.7 Hz).
    322
    Figure US20180319798A1-20181108-C00399
         		HCl 1H-NMR (DMSO-d6) δ: 13.25 (br s, 1H), 8.71 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.79 (sep, 1H, J = 6.8 Hz), 4.47 (s, 2H), 3.80-3.73 (m, 2H), 3.71-3.64 (m, 2H), 3.55-3.43 (m, 2H), 3.37-3.31 (m, 2H), 3.11 (s, 3H), 1.65 (s, 3H), 1.18 (d, 3H, J = 6.8 Hz), 1.18 (d, 3H, J = 6.8 Hz).
    323
    Figure US20180319798A1-20181108-C00400
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.73 (s, 1H), 7.44-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.55 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 4.31 (d, 1H, J = 13.5 Hz), 3.71-3.46 (m, 4H), 3.46-3.42 (m, 2H), 3.29-3.24 (m, 2H), 3.07 (s, 3H), 1.37 (s, 3H), 1.20 (t, 3H, J = 7.1 Hz).
  • TABLE 1-90
    No. structural formula salt 1H-NMR
    324
    Figure US20180319798A1-20181108-C00401
         		HCl 1H-NMR (DMSO-d6) δ: 12.52 (br s, 1H), 8.91 (s, 1H), 7.44-7.36 (m, 2H), 7.22-7.14 (m, 2H), 4.82 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 4.35 (sep, 1H, J = 6.8 Hz), 4.30 (dd, 1H, J = 13.5, 4.5 Hz), 4.01-3.96 (m, 1H), 3.64-3.55 (m, 1H), 3.05 (s, 3H), 1.35 (d, 3H, J = 6.8 Hz), 1.33 (d, 3H, J = 6.8 Hz), 1.19 (d, 3H, J = 6.2 Hz).
    325
    Figure US20180319798A1-20181108-C00402
         		HCl 1H-NMR (DMSO-d6) δ: 12.64 (br s, 1H), 8.83 (s, 1H), 7.44-7.35 (m, 1H), 7.23-7.15 (m, 1H), 7.05-6.98 (m, 1H), 4.50-4.37 (m, 2H), 4.16-4.07 (m, 1H), 3.88-3.76 (m, 1H), 3.40 (t, 2H, J = 7.5 Hz), 3.30-3.19 (m, 1H), 3.10 (t, 2H, J = 7.5 Hz), 1.24 (d, 3H, J = 6.6 Hz), 1.20 (t, 3H, J = 7.2 Hz).
    326
    Figure US20180319798A1-20181108-C00403
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.91 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.80 (d, 1H, J = 13.5 Hz), 4.47 (s, 2H), 4.36 (dd, 1H, J = 13.5, 4.6 Hz), 4.00-3.87 (m, 2H), 3.66-3.58 (m, 1H), 3.31-3.18 (m, 1H), 3.08 (s, 3H), 1.21 (t, 3H, J = 7.1 Hz), 1.16 (d, 3H, J = 6.4 Hz).
    327
    Figure US20180319798A1-20181108-C00404
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.76 (s, 1H), 7.67 (s, 1H), 7.36-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.61 (d, 1H, J = 13.2 Hz), 4.33 (dd, 1H, J = 13.2, 3.7 Hz), 4.20 (s, 2H), 3.95-3.83 (m, 1H), 3.88-3.80 (m, 1H), 3.22-3.11 (m, 1H), 1.74-1.62 (m, 1H), 1.50-1.36 (m, 1H), 1.20 (t, 3H, J = 7.2 Hz), 0.91 (t, 3H, J = 7.4 Hz).
  • TABLE 1-91
    No. structural formula salt 1H-NMR
    328
    Figure US20180319798A1-20181108-C00405
         		HCl 1H-NMR (DMSO-d6) δ: 12.62 (br s, 1H), 8.84 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.49-4.35 (m, 2H), 4.47 (s, 2H), 4.15-4.07 (m, 1H), 3.87-3.75 (m, 1H), 3.31-3.18 (m, 1H), 1.26-1.14 (m, 6H).
    329
    Figure US20180319798A1-20181108-C00406
         		HCl 1H-NMR (DMSO-d6) δ: 12.33 (br s, 1H), 8.82 (s, 1H), 7.67 (s, 1H), 7.37-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.71 (d, 1H, J = 13.9 Hz), 4.32 (dd, 1H, J = 13.9, 4.4 Hz), 4.20 (s, 2H), 4.07-3.94 (m, 1H), 3.75-3.69 (m, 1H), 3.16-3.04 (m, 1H), 1.97-1.85 (m, 1H), 1.20 (t, 3H, J = 7.1 Hz), 0.98 (d, 3H, J = 6.8 Hz), 0.78 (d, 3H, J = 6.8 Hz).
    330
    Figure US20180319798A1-20181108-C00407
         		HCl 1H-NMR (DMSO-d6) δ: 12.52 (br s, 1H), 8.66 (s, 1H), 7.67 (s, 1H), 7.37-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.46-4.33 (m, 2H), 4.20 (s, 2H), 4.14-4.04 (m, 1H), 3.86-3.75 (m, 1H), 3.29-3.18 (m, 1H), 1.22 (d, 3H, J = 6.6 Hz), 1.19 (t, 3H, J = 7.2 Hz).
    331
    Figure US20180319798A1-20181108-C00408
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.83 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.77 (d, 1H, J = 13.7 Hz), 4.55 (d, 1H, J = 13.7 Hz), 4.47 (s, 2H), 4.16-3.03 (m, 5H), 3.44 (sep, 1H, J = 6.6 Hz), 1.63 (s, 3H), 1.49 (d, 3H, J = 6.6 Hz), 1.42 (d, 3H, J = 6.6 Hz), 1.09-1.00 (m, 3H).
  • TABLE 1-92
    No. structural formula salt 1H-NMR
    332
    Figure US20180319798A1-20181108-C00409
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.95 (s, 1H), 7.44-7.36 (m, 2H), 7.22-7.15 (m, 2H), 4.69 (dd, 1H, J = 14.0, 1.5 Hz), 4.47 (s, 2H), 4.39 (dd, 1H, J = 14.0, 4.2 Hz), 4.04-3.98 (m, 1H), 3.97-3.92 (m, 1H), 3.51-3.43 (m, 1H), 3.26-3.18 (m, 1H), 3.18 (s, 3H), 1.19 (t, 3H, J = 7.2 Hz), 1.10 (d, 3H, J = 6.2 Hz).
    333
    Figure US20180319798A1-20181108-C00410
         		HCl 1H-NMR (DMSO-d6) δ: 8.76 (s, 1H), 7.67 (s, 1H), 7.36-7.30 (m, 2H), 7.18-7.11 (m, 2H), 4.64 (dd, 1H, J = 13.6, 1.5 Hz), 4.37 (dd, 1H, J = 13.6, 4.0 Hz), 4.20 (s, 2H), 4.06-3.97 (m, 1H), 3.95-3.90 (m, 1H), 3.51-3.40 (m, 1H), 3.27-3.19 (m, 1H), 3.19 (s, 3H), 1.19 (t, 3H, J = 6.8 Hz), 1.08 (d, 3H, J = 6.4 Hz).
    334
    Figure US20180319798A1-20181108-C00411
         		HCl 1H-NMR (DMSO-d6) δ: 12.47 (br s, 1H), 8.96 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.68 (dd, 1H, J = 13.9, 1.3 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J = 13.9, 3.5 Hz), 4.14-4.06 (m, 1H), 3.98-3.93 (m, 1H), 3.41 (sep, 1H, J = 6.7 Hz), 3.24 (s, 3H), 1.39 (d, 3H, J = 6.7 Hz), 1.34 (d, 3H, J = 6.7 Hz), 1.02 (d, 3H, J = 6.3 Hz).
    335
    Figure US20180319798A1-20181108-C00412
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.54 (s, 1H), 7.58-7.50 (m, 1H), 7.33-7.25 (m, 1H), 7.15-7.08 (m, 1H), 4.49 (s, 2H), 4.21 (d, 1H, J = 13.9 Hz), 3.97 (d, 1H, J = 13.9 Hz), 3.07 (s, 3H), 2.91 (s, 6H), 1.97 (s, 3H).
  • TABLE 1-93
    No. structural formula salt 1H-NMR
    336
    Figure US20180319798A1-20181108-C00413
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.46 (s, 1H), 7.69 (s, 1H), 7.50-7.42 (m, 1H), 7.29-7.21 (m, 1H), 7.11-7.05 (m, 1H), 4.22 (s, 2H), 4.21 (d, 1H, J = 14.0 Hz), 3.93 (d, 1H, J = 14.0 Hz), 3.07 (s, 3H), 2.89 (s, 6H), 1.93 (s, 3H).
    337
    Figure US20180319798A1-20181108-C00414
         		HCl 1H-NMR (DMSO-d6) δ: 12.86 (br s, 1H), 8.83 (s, 1H), 7.45-7.39 (m, 2H), 7.23-7.16 (m, 2H), 5.02-4.94 (m, 1H), 4.47 (s, 2H), 4.40-4.29 (m, 1H), 3.83-3.56 (m, 4H), 3.26 (s, 3H), 1.64-1.43 (m, 4H), 0.92-0.78 (m, 6H).
  • TABLE 1-94
    No. structural formula salt 1H-NMR
    338
    Figure US20180319798A1-20181108-C00415
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.92 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.78 (quint, 1H, J = 6.9 Hz), 4.71 (ddd, 1H, J = 6.4, 4.0, 1.6 Hz), 4.47 (s, 2H), 3.87 (dd, 1H, J = 13.7, 1.6 Hz), 3.78 (dd, 1H, J = 13.7, 4.0 Hz), 3.58 (dq, 1H, J = 6.4, 6.0 Hz), 3.22 (s, 3H), 1.19 (d, 3H, J = 6.9 Hz), 1.17 (d, 3H, J = 6.9 Hz), 1.03 (d, 3H, J = 6.0 Hz).
    339
    Figure US20180319798A1-20181108-C00416
         		1H-NMR (DMSO-d6) δ: 8.21 (s, 1H), 7.42-7.39 (m, 2H), 7.20-7.16 (m, 2H), 4.85 (quint, 1H, J = 6.6 Hz), 4.71-4.65 (m, 1H), 4.41 (s, 2H), 3.58-3.53 (m, 3H), 3.48-3.44 (m, 1H), 3.24 (s, 3H), 1.09 (d, 6H, J = 6.6 Hz).
    340
    Figure US20180319798A1-20181108-C00417
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.72 (s, 1H), 7.44-7.41 (m, 2H), 7.21-7.17 (m, 2H), 4.77 (sep, 1H, J = 6.6 Hz), 4.65 (ddd, 1H, J = 8.2, 4.1, 0.9 Hz), 4.47 (s, 2H), 3.88 (dd, 1H, J = 14.0, 4.1 Hz), 3.76 (dd, 1H, J = 14.0, 0.9 Hz), 3.52 (dq, 1H, J = 8.2, 6.2 Hz), 3.03 (s, 3H), 1.21 (d, 3H, J = 6.2 Hz), 1.20 (d, 3H, J = 6.6 Hz), 1.17 (d, 3H, J = 6.6 Hz).
    341
    Figure US20180319798A1-20181108-C00418
         		HCl 1H-NMR (DMSO-d6) δ: 8.95 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.68 (dd, 1H, J = 13.8, 1.5 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J = 13.8, 3.9 Hz), 4.10 (quint, 1H, J = 6.6 Hz), 3.96 (ddd, 1H, J = 6.6, 3.9, 1.5 Hz), 3.41 (dq, 1H, J = 6.6, 6.4 Hz), 3.24 (s, 3H), 1.39 (d, 3H, J = 6.6 Hz), 1.34 (d, 3H, J = 6.6 Hz), 1.02 (d, 3H, J = 6.4 Hz).
    342
    Figure US20180319798A1-20181108-C00419
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8 72 (s, 1H), 7.45-7.41 (m, 3H), 7.22-7.17 (m, 2H), 4.77 (quint, 1H, J = 6.8 Hz), 4.60 (ddd, 1H, J = 8.4, 4.2, 0.9 Hz), 4.47 (s, 2H), 3.88 (dd, 1H, J = 14.3, 4.2 Hz), 3.74 (dd, 1H, J = 14.3, 0.9 Hz), 3.56 (dq, 1H, J = 8.4, 6.2 Hz), 3.41 (dq, 1H, J = 9.5, 7.1 Hz), 2.91 (dq, 1H, J = 9.5, 7.1 Hz), 1.22 (d, 3H, J = 6.2 Hz), 1.20 (d, 3H, J = 6.8 Hz), 1.17 (d, 3H, J = 6.8 Hz), 0.75 (t, 3H, J = 7.1 Hz).
  • TABLE 1-95
    No. structural formula salt 1H-NMR
    343
    Figure US20180319798A1-20181108-C00420
         		HCl 1H-NMR (DMSO-d6) δ: 8.85 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.15 (m, 2H), 4.66 (dd, 1H, J = 12.4, 1.5 Hz), 4.48 (sep, 1H, J = 6.6 Hz), 4.47 (s, 2H), 4.35 (dd, 1H, J = 13.2, 3.7 Hz), 4.20-4.16 (m, 1H), 3.54 (dd, 1H, J = 10.5, 4.1 Hz), 3.45-3.30 (m, 3H), 1.30 (d, 3H, J = 6.6 Hz), 1.28 (d, 3H, J = 6.6 Hz), 0.96 (t, 3H, J = 6.9 Hz).
    344
    Figure US20180319798A1-20181108-C00421
         		1H-NMR (DMSO-d6) δ: 12.81 (s, 1H), 8.80 (s, 1H), 7.44-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.99-4.95 (m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J = 13.7, 3.9 Hz), 3.75 (dd, 1H, J = 13.9, 1.6 Hz), 3.63 (dd, 1H, J = 10.2, 6.0 Hz), 3.57 (dd, 1H, J = 10.2, 7.7 Hz), 3.25 (s, 3H), 1.16 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    345
    Figure US20180319798A1-20181108-C00422
         		1H-NMR (DMSO-d6) δ: 8.10 (s, 1H), 7.41-7.36 (m, 2H), 7.20-7.14 (m, 2H), 4.83 (quint, 1H, J = 6.7 Hz), 4.62-4.57 (m, 1H), 4.38 (s, 2H), 3.57-3.44 (m, 4H), 3.25 (s, 3H), 1.05 (d, 6H, J = 6.7 Hz).
    346
    Figure US20180319798A1-20181108-C00423
         		1H-NMR (DMSO-d6) δ: 12.44 (br s, 1H), 8.85 (s, 1H), 7.44-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.70- 4.61 (m, 1H), 4.54-4.41 (m, 1H), 4.47 (s, 2H), 4.39-4.30 (m, 1H), 4.25-4.14 (m, 1H), 3.53-3.34 (m, 2H), 3.21 (s, 3H), 1.30 (d, 3H, J = 6.3 Hz), 1.28 (d, 3H, J = 6.3 Hz).
    347
    Figure US20180319798A1-20181108-C00424
         		1H-NMR (DMSO-d6) δ: 8.02 (br s, 1H), 7.42-7.33 (m, 2H), 7.21-7.13 (m, 2H), 4.73-4.59 (m, 1H), 4.38 (s, 2H), 4.34-4.22 (m, 1H), 4.07-3.96 (m, 1H), 3.89-3.78 (m, 1H), 3.30-3.05 (m, 2H), 3.24 (s, 3H), 1.13 (d, 3H, J = 7.0 Hz), 1.06 (d, 3H, J = 7.0 Hz).
  • TABLE 1-96
    No. structural formula salt 1H-NMR
    348
    Figure US20180319798A1-20181108-C00425
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.72 (s, 1H), 7.47-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.83- 4.71 (m, 1H), 4.69-4.60 (m, 1H), 4.47 (s, 2H), 3.88 (dd, 1H, J = 14.1, 3.7 Hz), 3.81-3.71 (m, 1H), 3.56-3.47 (m, 1H), 3.03 (s, 3H), 1.24-1.13 (m, 9H).
    349
    Figure US20180319798A1-20181108-C00426
         		HCl 1H-NMR (DMSO-d6) δ: 12.52 (s, 1H), 8.90 (s, 1H), 7.40 (dd, 2H, J = 8.3, 5.6 Hz), 7.17 (dd, 2H, J = 8.3, 8.4 Hz), 4.81 (d, 1H, J = 14.1 Hz), 4.46 (s, 2H), 4.38-4.27 (m, 2H), 3.98 (s, 1H), 3.62-3.56 (m, 1H), 3.04 (s, 3H), 1.33 (t, 6H, J = 6.0 Hz), 1.18 (d, 3H, J = 7.0 Hz).
    350
    Figure US20180319798A1-20181108-C00427
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.91 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.15 (m, 2H), 4.78 (quint, 1H, J = 6.9 Hz), 4.70 (dd, 1H, J = 6.4, 4.2 Hz), 4.47 (s, 2H), 3.86 (d, 1H, J = 13.7 Hz), 3.77 (dd, 1H, J = 13.7, 4.2 Hz), 3.58 (dq, 1H, J = 6.4, 6.0 Hz), 3.21 (s, 3H), 1.19 (d, 3H, J = 6.9 Hz), 1.17 (d, 3H, J = 6.9 Hz), 1.02 (d, 3H, J = 6.0 Hz).
    351
    Figure US20180319798A1-20181108-C00428
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.56 (s, 1H), 7.44-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.70- 4.60 (m, 1H), 4.50-4.38 (m, 1H), 4.47 (s, 2H), 4.08-4.02 (m, 1H), 3.61 (dd, 1H, J = 11.1, 3.7 Hz), 3.53 (dd, 1H, J = 11.1, 3.9 Hz), 3.27 (q, 2H, J = 7.4 Hz), 1.75 (d, 3H, J = 6.5 Hz), 1.32 (t, 6H, J = 7.0 Hz), 0.82 (t, 3H, J = 7.0 Hz).
    352
    Figure US20180319798A1-20181108-C00429
         		1H-NMR (DMSO-d6) δ: 12.79 (br s, 1H), 8.74 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 5.32- 5.23 (m, 1H), 4.81-4.65 (m, 2H), 4.47 (s, 2H), 3.86-3.64 (m, 3H), 3.60-3.51 (m, 1H), 1.16 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz).
  • TABLE 1-97
    No. structural formula salt 1H-NMR
    353
    Figure US20180319798A1-20181108-C00430
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.56 (s, 1H), 7.44-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.70- 4.59 (m, 1H), 4.49-4.37 (m, 1H), 4.47 (s, 2H), 4.11-4.03 (m, 1H), 3.59-3.46 (m, 2H), 3.11 (s, 3H), 1.75 (d, 3H, J = 6.5 Hz), 1.32 (t, 6H, J = 6.5 Hz).
    354
    Figure US20180319798A1-20181108-C00431
         		HBr 1H-NMR (DMSO-D6) δ: 8.80 (s, 1H), 7.43-7.37 (m, 2H), 7.21-7.14 (m, 2H), 4.70-4.64 (m, 1H), 4.55- 4.44 (m, 3H), 4.33 (dd, 1H, J = 13.3, 3.6 Hz), 3.99- 3.93 (m, 1H), 3.56 (dd, 1H, J = 11.4, 3.7 Hz), 3.35 (dd, 1H, J = 11.4, 8.1 Hz), 1.28 (d, 3H, J = 6.7 Hz), 1.27 (d, 3H, J = 6.7 Hz).
    355
    Figure US20180319798A1-20181108-C00432
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.76 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.47 (s, 2H), 4.34 (s, 2H), 3.55 (q, 2H, J = 7.1 Hz), 1.36 (s, 6H), 1.19 (t, 3H, J = 7.1 Hz).
    356
    Figure US20180319798A1-20181108-C00433
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (s, 1H), 8.77 (s, 1H), 7.42-7.36 (m, 2H), 7.21-7.14 (m, 2H), 4.71 (ddd, 1H, J = 8.0, 2.2, 2.0 Hz), 4.56 (quint, 1H, J = 6.9 Hz), 4.46 (s, 2H), 4.19-4.09 (m, 2H), 3.93 (dd, 1H, J = 11.7, 2.2 Hz), 3.45 (s, 3H), 1.29 (d, 3H, J = 6.9 Hz), 1.27 (d, 3H, J = 6.9 Hz), 1.04 (d, 3H, J = 6.5 Hz).
    357
    Figure US20180319798A1-20181108-C00434
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (s, 1H), 8.80 (s, 1H), 7.41 (tt, 2H, J = 8.7, 3.1 Hz), 7.18 (tt, 2H, J = 8.9, 2.5 Hz), 4.94-4.88 (m, 1H), 4.46 (s, 2H), 4.06 (dd, 1H, J = 13.8, 4.3 Hz), 3.73-3.67 (m, 2H), 3.64-3.52 (m, 2H), 3.49-3.27 (m, 3H), 1.63-1.53 (m, 2H), 1.01 (t, 3H, J = 7.0 Hz), 0.89 (t, 3H, J = 8.2 Hz).
  • TABLE 1-98
    No. structural formula salt 1H-NMR
    358
    Figure US20180319798A1-20181108-C00435
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (br s, 1H), 8.37 (s, 1H), 8.07 (s, 1H), 8.00 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.13 (m, 2H), 5.28-5.18 (m, 1H), 4.89-4.60 (m, 3H), 4.44 (s, 2H), 3.98-3.83 (m, 2H), 1.25 (d, 3H, J = 6.7 Hz), 1.18 (d, 3H, J = 6.7 Hz).
    359
    Figure US20180319798A1-20181108-C00436
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (br s, 1H), 8.99 (s, 1H), 8.20 (s, 1H), 7.46-7.37 (m, 2H), 7.24-7.14 (m, 2H), 5.48-5.38 (m, 1H), 5.37-5.19 (m, 2H), 4.84- 4.72 (m, 1H), 4.45 (s, 2H), 3.96 (d, 2H, J = 3.0 Hz), 1.25 (d, 3H, J = 6.7 Hz), 1.17 (d, 3H, J = 6.7 Hz).
    360
    Figure US20180319798A1-20181108-C00437
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.75 (s, 1H), 7.45-7.37 (m, 2H), 7.22-7.14 (m, 2H), 5.52- 5.41 (m, 1H), 4.81-4.71 (m, 1H), 4.47 (s, 2H), 3.98-3.81 (m, 2H), 3.66 (d, 2H, J = 7.0 Hz), 1.29 (s, 9H), 1.21 (d, 3H, J = 6.5 Hz), 1.15 (d, 3H, J = 6.5 Hz).
    361
    Figure US20180319798A1-20181108-C00438
         		HCl 1H-NMR (DMSO-d6) δ: 12.94 (s, 1H), 8.80 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.15 (m, 2H), 4.89-4.85 (m, 1H), 4.47 (s, 2H), 3.96 (dd, 1H, J = 14.0, 1.5 Hz), 3.87 (dd, 1H, J = 14.0, 3.0 Hz), 3.70 (dd, 1H, J = 10.2, 6.7 Hz), 3.62 (dd, 1H, J = 10.2, 7.5 Hz), 3.50-3.41 (m, 2H), 1.49 (s, 9H), 1.05 (t, 3H, J = 6.9 Hz).
    362
    Figure US20180319798A1-20181108-C00439
         		HCl 1H-NMR (DMSO-d6) δ: 8.80 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.94-4.89 (m, 1H), 4.47 (s, 2H), 4.06 (dd, 1H, J = 13.6, 4.3 Hz), 3.77-3.72 (m, 2H), 3.70-3.46 (m, 5H), 3.38-3.31 (m, 3H), 3.11 (s, 3H), 1.60-1.52 (m, 2H), 1.37-1.27 (m, 2H), 0.92 (t, 3H, J = 7.4 Hz).
  • TABLE 1-99
    No. structural formula salt 1H-NMR
    363
    Figure US20180319798A1-20181108-C00440
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.82 (s, 1H), 7.46-7.38 (m, 2H), 7.24-7.14 (m, 2H), 5.01- 4.91 (br m, 1H), 4.77 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 3.88-3.54 (m, 4H), 3.41-3.24 (m, 2H), 1.41 (td, 2H, J = 13.9, 7.2 Hz), 1.17 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz), 0.74 (t, 3H, J = 7.2 Hz).
    364
    Figure US20180319798A1-20181108-C00441
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.80 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.13 (m, 2H), 4.99- 4.89 (m, 1H), 4.76 (sep, 1H, J = 7.0), 4.46 (s, 2H), 3.88-3.52 (m, 4H), 3.43-3.24 (m, 2H), 1.40-1.29 (m, 2H), 1.22-1.09 (m, 8H), 0.69 (t, 3H, J = 7.3 Hz).
    365
    Figure US20180319798A1-20181108-C00442
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.83 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.94- 4.71 (m, 2H), 4.47 (s, 2H), 3.85-3.45 (m, 5H), 1.21-1.12 (m, 6H), 1.02 (d, 3H, J = 6.0 Hz), 0.96 (d, 3H, J = 6.3 Hz).
    366
    Figure US20180319798A1-20181108-C00443
         		1H-NMR (DMSO-d6) δ: 12.77 (s, 1H), 8.80 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.14 (m, 2H), 4.91-4.83 (m, 1H), 4.83-4.73 (m, 2H), 4.47 (s, 2H), 3.86 (dd, 1H, J = 14.1, 3.5 Hz), 3.76-3.67 (m, 1H), 3.54-3.43 (m, 1H), 1.96-1.71 (m, 2H), 1.19 (d, 3H, J = 7.0 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    367
    Figure US20180319798A1-20181108-C00444
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 8.84 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.69- 4.63 (m, 1H), 4.53-4.44 (m, 3H), 4.35 (dd, 1H, J = 13.3, 4.0 Hz), 4.18-4.11 (m, 1H), 3.55 (dd, 1H, J = 10.5, 3.6 Hz), 3.48-3.39 (m, 2H), 1.30 (d, 3H, J = 6.9 Hz), 1.28 (d, 3H, J = 6.9 Hz), 0.95-0.90 (m, 6H).
  • TABLE 1-100
    No. structural formula salt 1H-NMR
    368
    Figure US20180319798A1-20181108-C00445
         		HCl 1H-NMR (DMSO-d6) δ: 8.78 (s, 1H), 7.44-7.40 (m, 2H), 7.22-7.16 (m, 2H), 4.74-4.70 (m, 1H), 4.74 (quint, 1H, J = 7.1 Hz), 4.47 (s, 2H), 3.91-3.82 (m, 2H), 3.05 (s, 3H), 1.20 (d, 3H, J = 7.1 Hz), 1.19 (s, 3H), 1.18 (d, 3H, J = 7.1 Hz), 1.10 (s, 3H).
    369
    Figure US20180319798A1-20181108-C00446
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.81 (s, 1H), 7.44-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.95 (s, 1H), 4.80-4.73 (m, 1H), 4.47 (s, 2H), 3.85 (dd, 1H, J = 13.7, 4.0 Hz), 3.75 (d, 1H, J = 13.7 Hz), 3.67 (dd, 1H, J = 10.3, 5.4 Hz), 3.58 (dd, 1H, J = 10.3, 7.7 Hz), 3.45 (dt, 1H, J = 11.4, 4.6 Hz), 3.34 (dt, 1H, J = 11.4, 4.8 Hz), 3.20-3.13 (m, 2H), 3.00 (s, 3H), 1.64-1.58 (m, 2H), 1.16 (dd, 6H, J = 6.9, 2.4 Hz).
    370
    Figure US20180319798A1-20181108-C00447
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.72 (s, 1H), 7.46-7.38 (m, 2H), 7.24-7.15 (m, 2H), 4.91- 4.81 (m, 1H), 4.84-4.72 (m, 1H), 4.47 (s, 2H), 3.89-3.65 (m, 2H), 3.45-3.35 (m, 1H), 3.20-3.07 (m, 1H), 3.18 (s, 3H), 2.07-1.93 (m, 1H), 1.93-1.80 (m, 1H), 1.18 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    371
    Figure US20180319798A1-20181108-C00448
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.75 (s, 1H), 7.47-7.37 (m, 2H), 7.24-7.15 (m, 2H), 4.91- 4.73 (m, 2H), 4.47 (s, 2H), 3.90-3.63 (m, 2H), 3.58-3.01 (m, 4H), 2.11-1.79 (m, 2H), 1.19 (d, 3H, J = 7.2 Hz), 1.16 (d, 3H, J = 7.2 Hz), 1.03 (t, 3H, J = 7.2 Hz).
    372
    Figure US20180319798A1-20181108-C00449
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (br s, 1H), 8.80 (s, 1H), 7.44-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.93- 4.84 (m, 1H), 4.47 (s, 2H), 4.04 (dd, 1H, J = 13.7, 4.0 Hz), 3.69 (dd, 1H, J = 10.5, 5.6 Hz), 3.66-3.59 (m, 2H), 3.53-3.32 (m, 5H), 2.93-2.85 (m, 1H), 0.96-0.69 (m, 4H), 0.93 (d, 3H, J = 6.0 Hz), 0.90 (d, 3H, J = 6.0 Hz).
  • TABLE 1-101
    No. structural formula salt 1H-NMR
    373
    Figure US20180319798A1-20181108-C00450
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.80 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 5.00- 4.91 (m, 1H), 4.77 (sep, 1H, J = 6.9 Hz), 4.47 (s, 2H), 3.84 (dd, 1H, J = 13.7, 4.0 Hz), 3.80-3.74 (m, 1H), 3.71 (dd, 1H, J = 10.3, 5.8 Hz), 3.65 (dd, 1H, J = 10.3, 7.9 Hz), 3.54-3.32 (m, 5H), 1.17 (d, 3H, J = 6.9 Hz), 1.16 (d, 3H, J = 6.9 Hz), 0.92 (d, 3H, J = 6.0 Hz), 0.89 (d, 3H, J = 6.0 Hz).
    374
    Figure US20180319798A1-20181108-C00451
         		HCl 1H-NMR (DMSO-d6) δ: 8.89 (s, 1H), 7.70 (d, 1H, J = 2.2 Hz), 7.45 (d, 1H, J = 1.8 Hz), 7.44-7.39 (m, 2H), 7.22-7.16 (m, 2H), 6.20 (dd, 1H, J = 2.2, 1.8 Hz), 4.86-4.82 (m, 1H), 4.78 (quint, 1H, J = 7.1 Hz), 4.47 (s, 2H), 4.26-4.14 (m, 2H), 3.84 (dd, 1H, J = 13.6, 3.6 Hz), 3.68 (dd, 1H, J = 13.6, 0.9 Hz), 2.27-2.20 (m, 2H), 1.18 (d, 3H, J = 7.1 Hz), 1.14 (d, 3H, J = 7.1 Hz).
    375
    Figure US20180319798A1-20181108-C00452
         		HCl 1H-NMR (DMSO-d6) δ: 13.19 (br s, 1H), 8.41 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.14 (m, 2H), 4.80- 4.68 (m, 1H), 4.47 (s, 2H), 4.08 (d, 1H, J = 14.1 Hz), 3.81 (d, 1H, J = 14.1 Hz), 2.93 (s, 6H), 2.61- 2.11 (m, 2H), 1.19 (d, 3H, J = 7.0 Hz), 1.16 (d, 3H, J = 7.0 Hz), 0.91 (t, 3H, J = 7.2 Hz).
    376
    Figure US20180319798A1-20181108-C00453
         		HCl 1H-NMR (DMSO-d6) δ: 13.09 (br s, 1H), 8.30 (s, 1H), 7.70 (s, 1H), 7.38-7.28 (m, 2H), 7.19-7.10 (m, 2H), 4.80-4.69 (m, 1H), 4.20 (s, 2H), 4.06 (d, 1H, J = 14.1 Hz), 3.78 (d, 1H, J = 14.1 Hz), 2.91 (s, 6H), 2.47-2.07 (m, 2H), 1.22-1.12 (m, 6H), 0.87 (t, 3H, J = 7.2 Hz).
    377
    Figure US20180319798A1-20181108-C00454
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.96 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.87- 4.80 (m, 1H), 4.80 (quint, 1H, J = 6.6 Hz), 4.47 (s, 2H), 4.23 (t, 2H, J = 7.9 Hz), 3.87-3.82 (m, 1H), 3.76-3.73 (m, 1H), 3.57-3.46 (m, 2H), 3.33-3.25 (m, 1H), 3.19-3.11 (m, 1H), 1.95 (dt, 2H, J = 7.1, 7.9 Hz), 1.22 (d, 3H, J = 6.6 Hz), 1.16 (d, 3H, J = 6.6 Hz).
  • TABLE 1-102
    No. structural formula salt 1H-NMR
    378
    Figure US20180319798A1-20181108-C00455
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.75 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.88- 4.83 (m, 1H), 4.78 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 3.85 (dd, 1H, J = 13.6, 3.6 Hz), 3.73 (dd, 1H, J = 13.6, 0.9 Hz), 3.53-3.48 (m, 1H), 3.45-3.31 (m, 4H), 3.29-3.18 (m, 1H), 3.15 (s, 3H), 2.04-1.96 (m, 1H), 1.91-1.83 (m, 1H), 1.19 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    379
    Figure US20180319798A1-20181108-C00456
         		HCl 1H-NMR (DMSO-d6) δ: 12.78 (br s, 1H), 8.91 (s, 1H), 7.44-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.83- 4.81 (m, 1H), 4.79 (sep, 1H, J = 6.7 Hz), 4.47 (s, 2H), 3.83 (dd, 1H, J = 13.8, 3.6 Hz), 3.72 (dd, 1H, J = 13.8, 1.5 Hz), 3.35-3.22 (m, 2H), 3.18 (s, 3H), 1.81-1.71 (m, 1H), 1.70-1.58 (m, 2H), 1.37-1.33 (m, 1H), 1.18 (d, 3H, J = 6.7 Hz), 1.16 (d, 3H, J = 6.7 Hz).
    380
    Figure US20180319798A1-20181108-C00457
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.83 (s, 1H), 7.46-7.39 (m, 2H), 7.23-7.15 (m, 2H), 4.92- 4.83 (br m, 1H), 4.81-4.70 (m, 1H), 4.47 (s, 2H), 3.85-3.62 (m, 4H), 3.59-3.48 (m, 1H), 3.26-3.18 (m, 2H), 3.17 (s, 3H), 1.21-1.12 (m, 6H), 0.91 (d, 3H, J = 6.5 Hz).
    381
    Figure US20180319798A1-20181108-C00458
         		HCl 1H-NMR (DMSO-d6) δ: 12.85 (br s, 1H), 8.83 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.86- 4.76 (br m, 1H), 4.47 (s, 2H), 4.02 (dd, 1H, J = 13.4, 4.2 Hz), 3.77-3.58 (m, 3H), 3.57-3.48 (m, 1H), 3.26-3.19 (m, 2H), 3.18 (s, 3H), 2.93-2.84 (m, 1H), 0.92 (d, 3H, J = 6.3 Hz), 0.91-0.70 (m, 4H).
    382
    Figure US20180319798A1-20181108-C00459
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.71 (s, 1H), 7.44-7.42 (m, 2H), 7.21-7.17 (m, 2H), 4.78 (quint, 1H, J = 6.9 Hz), 4.70 (dd, 1H, J = 9.0, 3.7 Hz), 4.47 (s, 2H), 3.87 (dd, 1H, J = 14.5, 3.7 Hz), 3.74 (d, 1H, J = 14.5 Hz), 3.32 (ddd, 1H, J = 9.0, 3.6, 6.0 Hz), 2.96 (s, 3H), 1.79-1.70 (m, 1H), 1.54-1.43 (m, 1H), 1.19 (dd, 6H, J = 10.9, 6.9 Hz), 0.94 (t, 3H, J = 7.5 Hz).
  • TABLE 1-103
    No. structural formula salt 1H-NMR
    383
    Figure US20180319798A1-20181108-C00460
         		HCl 1H-NMR (DMSO-d6) δ: 12.88 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.86-4.82 (m, 1H), 4.77 (quint, 1H, J = 6.9 Hz), 4.47 (s, 2H), 3.83- 3.78 (m, 2H), 3.47-3.42 (m, 1H), 3.18 (s, 3H), 1.53-1.47 (m, 1H), 1.33-1.25 (m, 1H), 1.19 (d, 3H, J = 6.9 Hz), 1.17 (d, 3H, J = 6.9 Hz), 0.87 (t, 3H, J = 7.5 Hz).
    384
    Figure US20180319798A1-20181108-C00461
         		HCl 1H-NMR (DMSO-d6) δ: 12.82 (br s, 1H), 8.81 (s, 1H), 7.46-7.36 (m, 2H), 7.23-7.15 (m, 2H), 4.93- 4.86 (m, 1H), 4.47 (s, 2H), 4.04 (dd, 1H, J = 13.2, 4.2 Hz), 3.75-3.57 (m, 3H), 3.39-3.25 (m, 3H), 3.10 (s, 3H), 2.92-2.87 (m, 1H), 0.93 (d, 3H, J = 5.8 Hz), 0.91-0.67 (m, 4H).
    385
    Figure US20180319798A1-20181108-C00462
         		HCl 1H-NMR (DMSO-d6) δ: 12.84 (br s, 1H), 8.82 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.15 (m, 2H), 5.00- 4.92 (br m, 1H), 4.83-4.72 (m, 1H), 4.47 (s, 2H), 3.89-3.59 (m, 4H), 3.41-3.24 (m, 3H), 3.09 (s, 3H), 1.17 (d, 3H, J = 6.7 Hz), 1.15 (d, 3H, J = 6.7 Hz), 0.93 (d, 3H, J = 6.3 Hz).
    386
    Figure US20180319798A1-20181108-C00463
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.56 (s, 1H), 7.66 (s, 1H), 7.39-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.83-4.71 (m, 1H), 4.63-4.54 (m, 1H), 4.20 (s, 2H), 3.86 (dd, 1H, J = 14.1. 4.2 Hz), 3.78-3.70 (m, 1H), 3.55-3.45 (m, 1H), 3.02 (s, 3H), 1.23-1.14 (m, 9H).
    387
    Figure US20180319798A1-20181108-C00464
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.74 (s, 1H), 7.68 (s, 1H), 7.37-7.30 (m, 2H), 7.19-7.11 (m, 2H), 4.84-4.73 (m, 1H), 4.69-4.63 (m, 1H), 4.20 (s, 2H), 3.89-3.81 (m, 1H), 3.76 (dd, 1H, J = 13.7, 4.0 Hz), 3.60-3.52 (m, 1H), 3.22 (s, 3H), 1.21-1.15 (m, 6H), 1.00 (d, 3H, J = 6.0 Hz).
  • TABLE 1-104
    No. structural formula salt 1H-NMR
    388
    Figure US20180319798A1-20181108-C00465
         		HCl 1H-NMR (DMSO-d6) δ: 8.74 (s, 1H), 7.68 (s, 1H), 7.37-7.31 (m, 2H), 7.18-7.11 (m, 2H), 4.84-4.73 (m, 1H), 4.69-4.63 (m, 1H), 4.20 (s, 2H), 3.89-3.81 (m, 1H), 3.76 (dd, 1H, J = 13.7, 4.0 Hz), 3.60-3.51 (m, 1H), 3.22 (s, 3H), 1.21-1.14 (m, 6H), 1.00 (d, 3H, J = 6.0 Hz).
    389
    Figure US20180319798A1-20181108-C00466
         		HCl 1H-NMR (DMSO-d6) δ: 12.81 (s, 1H), 8.73 (s, 1H), 7.45-7.42 (m, 2H), 7.21-7.18 (m, 2H), 4.82- 4.75 (m, 1H), 4.65 (dd, 1H, J = 9.1, 2.6 Hz), 4.47 (s, 3H), 3.87 (dd, 1H, J = 13.3, 3.8 Hz), 3.74 (d, 1H, J = 13.3 Hz), 3.39-3.27 (m, 2H), 2.77-2.73 (m, 1H), 1.79-1.70 (m, 1H), 1.51-1.43 (m, 1H), 1.20 (d, 3H, J = 6.9 Hz), 1.17 (d, 3H, J = 6.9 Hz), 0.96 (t, 3H, J = 7.5 Hz), 0.74 (t, 3H, J = 6.9 Hz).
    390
    Figure US20180319798A1-20181108-C00467
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (s, 1H), 7.44-7.42 (m, 2H), 7.21-7.17 (m, 2H), 4.62 (d, 1H, J = 5.6 Hz), 4.47 (s, 2H), 4.05 (dd, 1H, J = 13.9, 3.8 Hz), 3.57 (d, 1H, J = 13.3 Hz), 3.47-3.45 (m, 1H), 3.34 (dd, 1H, J = 9.3, 6.9 Hz), 2.94 (dd, 1H, J = 7.7, 3.6 Hz), 2.86 (dd, 1H, J = 9.3, 7.3 Hz), 1.55-1.38 (m, 2H), 0.94 (t, 3H, J = 7.0 Hz), 0.78 (t, 3H, J = 6.5 Hz), 0.42-0.36 (m, 1H), 0.34-0.27 (m, 2H), 0.24- 0.20 (m, 1H).
    391
    Figure US20180319798A1-20181108-C00468
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (s, 1H), 8.86 (s, 1H), 7.47-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.81- 4.65 (m, 1H), 4.47 (s, 2H), 4.41 (d, 1H, J = 12.1 Hz), 4.25 (d, 1H, J = 12.1 Hz), 4.06 (d, 1H, J = 14.1 Hz), 3.81 (d, 1H, J = 14.1 Hz), 3.75-3.63 (m, 2H), 3.62-3.36 (m, 2H), 3.21 (s, 3H), 3.11-2.73 (m, 6H), 1.16 (d, 3H, J = 6.8 Hz), 1.10 (d, 3H, J = 6.8 Hz).
    392
    Figure US20180319798A1-20181108-C00469
         		HCl 1H-NMR (DMSO-d6) δ: 13.04 (s, 1H), 8.69 (s, 1H), 7.46-7.38 (m, 2H), 7.23-7.14 (m, 2H), 4.76-4.62 (m, 1H), 4.48 (s, 2H), 4.18-4.04 (m, 1H), 3.98 (d, 1H, J = 13.5 Hz), 3.94-3.82 (m, 2H), 3.78 (d, 1H, J = 13.5 Hz), 3.70-3.57 (m, 1H), 2.50-2.22 (m, 2H), 2.15-2.00 (m, 2H), 1.16 (t, 6H, J = 6.8 Hz), 1.03 (t, 3H, J = 7.5 Hz).
  • TABLE 1-105
    No. structural formula salt 1H-NMR
    393
    Figure US20180319798A1-20181108-C00470
         		HCl 1H-NMR (DMSO-d6) δ: 8.80 (s, 1H), 8.16 (t, 1H, J = 5.5 Hz), 7.67 (s, 1H), 7.38-7.28 (m, 2H), 7.19- 7.10 (m, 2H), 4.76-4.63 (m, 1H), 4.20 (s, 2H), 4.17 (d, 1H, J = 11.9 Hz), 4.12 (d, 1H, J = 11.9 Hz), 4.03 (d, 1H, J = 13.9 Hz), 3.76 (d, 1H, J = 13.9 Hz), 3.40 (s, 3H), 3.21-2.92 (m, 2H), 1.13 (d, 3H, J = 6.8 Hz), 1.10 (d, 3H, J = 6.8 Hz), 0.99 (t, 3H, J = 7.5 Hz).
    394
    Figure US20180319798A1-20181108-C00471
         		HCl 1H-NMR (DMSO-d6) δ: 8.88 (s, 1H), 8.17 (t, 1H, J = 5.1 Hz), 7.66 (s, 1H), 7.37-7.29 (m, 2H), 7.19- 7.10 (m, 2H), 4.76-4.64 (m, 1H), 4.33-4.16 (m, 2H), 4.20 (s, 2H), 4.04 (d, 1H, J = 13.9 Hz), 3.78 (d, 1H, J = 13.9 Hz), 3.72-3.66 (m, 2H), 3.57-3.50 (m, 2H), 3.25 (s, 3H), 3.20-2.96 (m, 2H), 1.14 (d, 3H, J = 6.8 Hz), 1.10 (d, 3H, J = 6.8 Hz), 1.04 (t, 3H, J = 7.3 Hz).
    395
    Figure US20180319798A1-20181108-C00472
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.95 (s, 1H), 7.44-7.36 (m, 2H), 7.22-7.15 (m, 2H), 4.69 (dd, 1H, J = 14.0, 1.5 Hz), 4.47 (s, 2H), 4.39 (dd, 1H, J = 14.0, 4.2 Hz), 4.04-3.98 (m, 1H), 3.97-3.92 (m, 1H), 3.51-3.43 (m, 1H), 3.26-3.18 (m, 1H), 3.18 (s, 3H), 1.19 (t, 3H, J = 7.2 Hz), 1.10 (d, 3H, J = 6.2 Hz).
    396
    Figure US20180319798A1-20181108-C00473
         		HCl 1H-NMR (DMSO-d6) δ: 12.92 (s, 1H), 8.77 (s, 1H), 7.47-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.79- 4.66 (m, 1H), 4.47 (s, 2H), 4.28 (d, 1H, J = 11.9 Hz), 4.12 (d, 1H, J = 11.9 Hz), 4.06 (d, 1H, J = 14.3 Hz), 3.82 (d, 1H, J = 14.3 Hz), 3.47-3.29 (m, 5H), 3.05-2.78 (m, 3H), 1.16 (d, 3H, J = 7.1 Hz), 1.12 (d, 3H, J = 7.1 Hz), 1.08-0.97 (m, 3H).
    397
    Figure US20180319798A1-20181108-C00474
         		HCl 1H-NMR (DMSO-d6) δ: 12.93 (s, 1H), 8.85 (s, 1H), 7.48-7.34 (m, 2H), 7.24-7.13 (m, 2H), 4.77- 4.65 (m, 1H), 4.47 (s, 2H), 4.38 (d, 1H, J = 11.9 Hz), 4.23 (d, 1H, J = 11.9 Hz), 4.06 (d, 1H, J = 14.3 Hz), 3.82 (d, 1H, J = 14.3 Hz), 3.73-3.24 (m, 6H), 3.19 (s, 3H), 3.06-2.84 (m, 3H), 1.16 (d, 3H, J = 6.6 Hz), 1.12 (d, 3H, J = 6.6 Hz), 1.07-0.94 (m, 3H).
  • TABLE 1-106
    No. structural formula salt 1H-NMR
    398
    Figure US20180319798A1-20181108-C00475
         		HCl 1H-NMR (DMSO-d6) δ: 12.69 (br s, 1H), 8.78 (s, 1H), 7.44-7.36 (m, 2H), 7.22-7.14 (m, 2H), 4.84- 4.79 (m, 1H), 4.47 (s, 2H), 4.46-4.37 (m, 1H), 4.22-4.13 (m, 2H), 4.01 (dd, 1H, J = 11.9, 2.2 Hz), 3.49-3.39 (m, 2H), 3.46 (s, 3H), 3.14 (s, 3H), 1.33 (d, 3H, J = 6.9 Hz), 1.30 (d, 3H, J = 6.9 Hz).
    399
    Figure US20180319798A1-20181108-C00476
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.73 (s, 1H), 7.47-7.39 (m, 2H), 7.23-7.15 (m, 2H), 4.60- 4.52 (m, 1H), 4.47 (s, 2H), 4.06 (dd, 1H, J = 14.1 4.0 Hz), 3.65-3.55 (m, 2H), 3.47-3.36 (m, 1H), 3.02-2.88 (m, 2H), 1.16 (d, 3H, J = 6.2 Hz), 0.94- 0.82 (m, 3H), 0.79 (t, 3H, J = 7.3 Hz), 0.75-0.64 (m, 1H).
    400
    Figure US20180319798A1-20181108-C00477
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (s, 1H), 8.72 (s, 1H), 7.47-7.39 (m, 2H), 7.24-7.15 (m, 2H), 4.84- 4.71 (m, 1H), 4.60 (dd, 1H, J = 8.6, 2.6 Hz), 4.47 (s, 2H), 3.88 (dd, 1H, J = 14.3, 4.0 Hz), 3.75 (d, 1H, J = 13.9 Hz), 3.58-3.53 (m, 1H), 3.46-3.34 (m, 1H), 2.97-2.85 (m, 1H), 1.26-1.14 (m, 9H), 0.75 (t, 3H, J = 6.9 Hz).
    401
    Figure US20180319798A1-20181108-C00478
         		HCl 1H-NMR (DMSO-d6) δ: 8.72 (s, 1H), 7.47-7.39 (m, 2H), 7.24-7.15 (m, 2H), 4.60-4.53 (m, 1H), 4.47 (s, 2H), 4.11 (dd, 1H, J = 14.1, 4.2 Hz), 3.75 (d, 1H, J = 13.5 Hz), 3.65-3.37 (m, 4H), 3.00-2.90 (m, 1H), 1.22 (d, 3H, J = 5.2 Hz), 1.16 (t, 3H, J = 7.1 Hz), 0.77 (t, 3H, J = 6.9 Hz).
    402
    Figure US20180319798A1-20181108-C00479
         		HCl 1H-NMR (DMSO-d6) δ: 12.90 (s, 1H), 8.32 (s, 1H), 7.44-7.40 (m, 2H), 7.22-7.17 (m, 2H), 4.81-4.74 (m, 1H), 4.71 (t, 1H, J = 4.8 Hz), 4.47 (s, 2H), 3.87 (d, 1H, J = 12.5 Hz), 3.78 (dd, 1H, J = 13.9, 4.2 Hz), 3.71-3.65 (m, 1H), 3.57-3.50 (m, 1H), 3.17- 3.10 (m, 1H), 1.19 (t, 6H, J = 7.0 Hz), 1.06 (d, 3H, J = 6.0 Hz), 1.02 (t, 3H, J = 6.9 Hz).
  • TABLE 1-107
    No. structural formula salt 1H-NMR
    403
    Figure US20180319798A1-20181108-C00480
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.91 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.69 (t, 1H, J = 4.6 Hz), 4.47 (s, 2H), 4.02 (dd, 1H, J = 14.1, 4.4 Hz), 3.84 (d, 1H, J = 13.7 Hz), 3.73-3.67 (m, 1H), 3.65-3.58 (m, 1H), 3.56-3.39 (m, 2H), 3.21- 3.15 (m, 1H), 1.16 (t, 3H, J = 7.1 Hz), 1.07 (d, 3H, J = 6.0 Hz), 1.01 (t, 3H, J = 6.9 Hz).
    404
    Figure US20180319798A1-20181108-C00481
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.90 (s, 1H), 7.43-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.66 (t, 1H, J = 4.4 Hz), 4.47 (s, 2H), 3.98 (dd, 1H, J = 13.9, 4.2 Hz), 3.74-3.65 (m, 2H), 3.56-3.48 (m, 1H), 3.20-3.14 (m, 1H), 2.92-2.87 (m, 1H), 1.04 (d, 3H, J = 7.0 Hz), 1.02 (t, 3H, J = 7.2 Hz), 0.94-0.89 (m, 1H), 0.87-0.80 (m, 2H), 0.75-0.70 (m, 1H).
    405
    Figure US20180319798A1-20181108-C00482
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.62 (s, 1H), 7.42-7.38 (m, 2H), 7.20-7.16 (m, 2H), 4.77- 4.71 (m, 1H), 4.47 (s, 2H), 4.14 (q, 1H, J = 4.0 Hz), 3.92-3.84 (m, 1H), 3.59 (d, 2H, J = 4.4 Hz), 3.33- 3.26 (m, 1H), 3.18 (s, 3H), 1.64 (d, 3H, J = 6.5 Hz), 1.21 (t, 3H, J = 7.1 Hz).
    406
    Figure US20180319798A1-20181108-C00483
         		HCl 1H-NMR (DMSO-d6) δ: 12.44 (br s, 1H), 8.89 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.66- 4.60 (m, 1H), 4.56-4.45 (m, 3H), 4.34-4.27 (m, 1H), 4.10-4.04 (m, 1H), 3.50-3.36 (m, 2H), 3.24 (s, 3H), 1.89-1.79 (m, 1H), 1.73-1.62 (m, 1H), 1.28 (d, 6H, J = 6.9 Hz).
    407
    Figure US20180319798A1-20181108-C00484
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.88 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.15 (m, 2H), 4.71- 4.66 (m, 1H), 4.62-4.52 (m, 1H), 4.47 (s, 2H), 4.21-4.07 (m, 2H), 3.99 (dd, 1H, J = 11.7, 2.0 Hz), 3.71-3.62 (m, 2H), 1.32-1.22 (m, 9H), 1.05 (d, 3H, J = 6.4 Hz).
  • TABLE 1-108
    No. structural formula salt 1H-NMR
    408
    Figure US20180319798A1-20181108-C00485
         		HCl 1H-NMR (DMSO-d6) δ: 12.73 (s, 1H), 8.72 (s, 1H), 7.44-7.40 (m, 2H), 7.22-7.16 (m, 2H), 4.64-4.55 (m, 1H), 4.47 (s, 2H), 4.06 (dd, 1H, J = 14.1, 4.2 Hz), 3.66-3.49 (m, 2H), 3.06 (s, 3H), 2.96-2.86 (m, 1H), 1.15 (d, 3H, J = 6.0 Hz), 0.96-0.78 (m, 3H), 0.75-0.63 (m, 1H).
    409
    Figure US20180319798A1-20181108-C00486
         		HCl 1H-NMR (DMSO-D6) δ: 12.73 (br s, 1H), 8.71 (s, 1H), 7.47-7.39 (m, 2H), 7.24-7.15 (m, 2H), 4.66- 4.56 (m, 1H), 4.47 (s, 2H), 4.11 (dd, 1H, J = 14.1, 4.2 Hz), 3.76 (d, 1H, J = 13.7 Hz), 3.66-3.42 (m, 3H), 3.06 (s, 3H), 1.21 (d, 3H, J = 5.7 Hz), 1.16 (t, 3H, J = 7.3 Hz).
    410
    Figure US20180319798A1-20181108-C00487
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.71 (s, 1H), 7.47-7.39 (m, 2H), 7.24-7.15 (m, 2H), 4.65- 4.57 (m, 1H), 4.47 (s, 2H), 4.10 (dd, 1H, J = 14.1 4.0 Hz), 3.77 (d, 1H, J = 14.8 Hz), 3.59-3.38 (m, 3H), 3.05 (s, 3H), 1.60 (dt, 2H, J = 7.4, 7.4 Hz), 1.21 (d, 3H, J = 6.2 Hz), 0.90 (t, 3H, J = 7.4 Hz).
    411
    Figure US20180319798A1-20181108-C00488
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (s, 1H), 8.83 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.14 (m, 2H), 4.81 (t, 1H, J = 6.3 Hz), 4.48 (s, 2H), 4.09-3.99 (m, 1H), 3.97- 3.85 (m, 1H), 3.68 (dd, 1H, J = 10.6, 5.7 Hz), 3.55 (dd, 1H, J = 10.6, 7.6 Hz), 3.51-3.30 (m, 2H), 3.19-3.06 (m, 1H), 1.27 (d, 3H, J = 6.6 Hz), 1.17 (t, 3H, J = 6.8 Hz), 1.01 (t, 3H, J = 7.3 Hz).
    412
    Figure US20180319798A1-20181108-C00489
         		HCl 1H-NMR (DMSO-d6) δ: 12.68 (br s, 1H), 8.83 (s, 1H), 7.46-7.37 (m, 2H), 7.23-7.15 (m, 2H), 4.85- 4.76 (m, 1H), 4.67-4.57 (m, 1H), 4.48 (s, 2H), 4.20-4.10 (m, 1H), 3.64 (dd, 1H, J = 10.5, 5.8 Hz), 3.56-3.32 (m, 3H), 1.31-1.18 (m, 9H), 1.02 (t, 3H, J = 7.1 Hz).
  • TABLE 1-109
    No. structural formula salt 1H-NMR
    413
    Figure US20180319798A1-20181108-C00490
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (s, 1H), 8.87 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.69 (t, 1H, J = 4.4 Hz), 4.47 (s, 2H), 4.09-4.04 (m, 1H), 3.76 (d, 1H, J = 12.9 Hz), 3.66-3.60 (m, 1H), 3.23 (s, 3H), 3.07 (s, 3H), 1.04 (d, 3H, J = 6.4 Hz).
    414
    Figure US20180319798A1-20181108-C00491
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (s, 1H), 8.90 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.17 (m, 2H), 4.69 (t, 1H, J = 4.4 Hz), 4.47 (s, 2H), 4.05-4.00 (m, 1H), 3.83 (d, 1H, J = 13.3 Hz), 3.67-3.59 (m, 2H), 3.45-3.39 (m, 1H), 3.23 (s, 3H), 1.16 (t, 3H, J = 7.1 Hz), 1.04 (d, 3H, J = 6.0 Hz).
    415
    Figure US20180319798A1-20181108-C00492
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.89 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.66 (t, 1H, J = 4.6 Hz), 4.47 (s, 2H), 3.98 (dd, 1H, J = 13.7, 4.0 Hz), 3.71 (d, 1H, J = 12.5 Hz), 3.59-3.53 (m, 1H), 3.22 (s, 3H), 2.94-2.88 (m, 1H), 1.02 (d, 3H, J = 6.0 Hz), 0.95-0.89 (m, 1H), 0.85-0.80 (m, 2H), 0.75-0.69 (m, 1H).
    416
    Figure US20180319798A1-20181108-C00493
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (s, 1H), 8.90 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.69 (t, 1H, J = 4.8 Hz), 4.47 (s, 2H), 4.01 (dd, 1H, J = 13.9, 4.2 Hz), 3.83 (d, 1H, J = 12.9 Hz), 3.64-3.58 (m, 1H), 3.55-3.48 (m, 1H), 3.41-3.34 (m, 1H), 3.21 (s, 3H), 1.63-1.58 (m, 2H), 1.05 (d, 3H, J = 6.0 Hz), 0.91 (t, 3H, J = 7.3 Hz).
    417
    Figure US20180319798A1-20181108-C00494
         		HCl 1H-NMR (DMSO-d6) δ: 8.86 (s, 1H), 7.44-7.35 (m, 2H), 7.19-7.09 (m, 2H), 4.86-4.68 (m, 2H), 4.45 (s, 2H), 3.90-3.80 (m, 1H), 3.76-3.67 (m, 1H), 3.46- 2.59 (m, 3H), 2.14-1.65 (m, 5H), 1.24 (d, 3H, J = 7.1 Hz), 1.19 (d, 3H, J = 7.1 Hz), 1.14-0.98 (m, 6H).
  • TABLE 1-110
    No. structural formula salt 1H-NMR
    418
    Figure US20180319798A1-20181108-C00495
         		HCl 1H-NMR (DMSO-d6) δ: 8.84 (s, 1H), 7.46-7.36 (m, 2H), 7.23-7.14 (m, 2H), 5.21-5.10 (m, 1H), 4.86- 4.73 (m, 1H), 4.47 (s, 2H), 3.84 (d, 2H, J = 2.2 Hz), 3.37-3.11 (m, 4H), 2.87 (d, 2H, J = 7.1 Hz), 1.13 (t, 6H, J = 7.3 Hz), 0.99 (t, 3H, J = 7.1 Hz), 0.95 (t, 3H, J = 7.1 Hz).
    419
    Figure US20180319798A1-20181108-C00496
         		HCl 1H-NMR (DMSO-d6) δ: 8.73 (s, 1H), 7.47-7.38 (m, 2H), 7.23-7.15 (m, 2H), 4.89-4.76 (m, 1H), 4.47 (s, 2H), 4.20-3.99 (m, 2H), 3.72-3.57 (m, 2H), 3.51- 3.32 (m, 2H), 3.18 (s, 3H), 2.15-1.83 (m, 2H), 1.16 (t, 3H, J = 7.3 Hz).
    420
    Figure US20180319798A1-20181108-C00497
         		HCl 1H-NMR (DMSO-d6) δ: 12.75 (br s, 1H), 8.64 (s, 1H), 7.46-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.77- 4.71 (m, 1H), 4.47 (s, 2H), 4.11 (dd, 1H, J = 13.7, 4.0 Hz), 3.77-3.71 (m, 1H), 3.64-3.44 (m, 5H), 3.33 (s, 3H), 3.10 (s, 3H), 1.20-1.13 (m, 3H).
    421
    Figure US20180319798A1-20181108-C00498
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.61 (s, 1H), 7.46-7.34 (m, 2H), 7.24-7.14 (m, 2H), 4.81- 4.69 (m, 1H), 4.47 (s, 2H), 4.15-4.08 (m, 1H), 3.90 (td, 1H, J = 13.9, 7.0 Hz), 3.64 (d, 2H, J = 4.2 Hz), 3.38-3.21 (m, 3H), 1.65 (d, 3H, J = 7.0 Hz), 1.22 (t, 3H, J = 7.3 Hz), 0.89 (t, 3H, J = 6.8 Hz).
    422
    Figure US20180319798A1-20181108-C00499
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (br s, 1H), 8.55 (s, 1H), 7.45-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.72- 4.61 (m, 1H), 4.49-4.38 (m, 1H), 4.47 (s, 2H), 4.09-4.02 (m, 1H), 3.61 (dd, 1H, J = 11.1, 3.0 Hz), 3.54 (dd, 1H, J = 11.1, 3.9 Hz), 3.27 (q, 2H, J = 7.0 Hz), 1.75 (d, 3H, J = 6.6 Hz), 1.32 (t, 6H, J = 6.8 Hz), 0.82 (t, 3H, J = 7.0 Hz).
  • TABLE 1-111
    No. structural formula salt 1H-NMR
    423
    Figure US20180319798A1-20181108-C00500
         		HCl 1H-NMR (DMSO-d6) δ: 8.83 (s, 1H), 7.44-7.35 (m, 2H), 7.18-7.09 (m, 2H), 4.84-4.66 (m, 2H), 4.45 (s, 2H), 3.90-3.79 (m, 1H), 3.77-3.64 (m, 1H), 3.48- 2.60 (m, 4H), 2.33-2.17 (m, 2H), 2.08-1.77 (m, 2H), 1.24 (d, 3H, J = 6.4 Hz), 1.19 (d, 3H, J = 6.6 Hz), 1.12-1.00 (m, 3H), 0.97 (t, 3H, J = 7.7 Hz).
    424
    Figure US20180319798A1-20181108-C00501
         		HCl 1H-NMR (DMSO-d6) δ: 9.02 (s, 0.25H), 8.94 (s, 0.75H), 7.46-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.95-4.66 (br m, 2H), 4.47 (s, 2H), 3.92-3.67 (m, 2H), 3.53-2.98 (br m, 4H), 2.87-2.53 (br m, 1H), 2.14-1.63 (br m, 2H), 1.29-0.86 (br m, 15H).
    425
    Figure US20180319798A1-20181108-C00502
         		HCl 1H-NMR (DMSO-d6) δ: 8.86 (s, 1H), 7.44-7.35 (m, 2H), 7.19-7.08 (m, 2H), 4.85-4.69 (m, 2H), 4.45 (s, 2H), 4.22-3.98 (m, 2H), 3.90-3.80 (m. 1H), 3.78- 3.68 (m, 1H), 3.13-3.00 (m, 1H), 2.35-2.15 (m, 2H), 2.09-1.93 (m, 1H), 1.87-1.71 (m, 1H), 1.24 (d, 3H, J = 6.6 Hz), 1.19 (d, 3H, J = 6.8 Hz), 1.07 (t, 6H, J = 6.4 Hz), 0.96 (t, 3H, J = 7.3 Hz).
    426
    Figure US20180319798A1-20181108-C00503
         		HCl 1H-NMR (DMSO-d6) δ: 12.49 (s, 1H), 8.91 (s, 1H), 7.42-7.39 (m, 2H), 7.20-7.16 (m, 2H), 4.80 (d, 1H, J = 13.3 Hz), 4.47 (s, 2H), 4.36 (dd, 1H, J = 13.7, 4.8 Hz), 3.96-3.89 (m, 2H), 3.65-3.60 (m, 1H), 3.28-3.20 (m, 1H), 3.08 (s, 3H), 1.21 (t, 3H, J = 7.1 Hz), 1.16 (d, 3H, J = 6.4 Hz).
    427
    Figure US20180319798A1-20181108-C00504
         		HCl 1H-NMR (DMSO-d6) δ: 8.65 (s, 1H), 7.44-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.88-4.84 (m, 1H), 4.46 (s, 2H), 4.08 (dd, 1H, J = 13.5, 3.8 Hz), 3.65-3.62 (m, 1H), 3.62 (dq, 1H, J = 13.7, 7.3 Hz), 3.45 (dq, 1H, J = 13.7, 7.3 Hz), 3.21 (s, 3H), 3.02-2.97 (m, 1H), 1.93-1.78 (m, 2H), 1.16 (t, 3H, J = 7.3 Hz), 1.04 (d, 3H, J = 6.0 Hz).
  • TABLE 1-112
    No. structural formula salt 1H-NMR
    428
    Figure US20180319798A1-20181108-C00505
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (s, 1H), 8.64 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.17 (m, 2H), 4.91-4.87 (m, 1H), 4.78 (sep, 1H, J = 6.8 Hz), 4.46 (s, 2H), 3.84 (dd, 1H, J = 13.5, 3.6 Hz), 3.68 (dd, 1H, J = 13.5, 1.3 Hz), 3.22 (s, 3H), 2.99-2.95 (m, 1H), 1.86 (ddd, 1H, J = 14.6, 9.9, 3.1 Hz), 1.77 (ddd, 1H, J = 14.6, 10.4, 4.9 Hz), 1.18 (d, 3H, J = 6.8 Hz), 1.15 (d, 3H, J = 6.8 Hz), 1.04 (d, 3H, J = 6.0 Hz).
    429
    Figure US20180319798A1-20181108-C00506
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (br s, 1H), 8.65 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.85- 4.80 (m, 1H), 4.46 (s, 2H), 4.02 (dd, 1H, J = 13.2, 3.7 Hz), 3.54 (dd, 1H, J = 13.2, 0.9 Hz), 3.21 (s, 3H), 3.03-2.96 (m, 1H), 2.97-2.91 (m, 1H), 1.85- 1.75 (m, 2H), 1.03 (d, 3H, J = 6.0 Hz), 0.95-0.72 (m, 4H).
    430
    Figure US20180319798A1-20181108-C00507
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.95 (s, 1H), 7.45-7.37 (m, 2H), 7.23-7.14 (m, 2H), 5.01- 4.90 (m, 1H), 4.56 (sep, 1H, J = 6.8 Hz), 4.48 (s, 2H), 4.08-4.01 (m, 1H), 3.55 (dd, 1H, J = 10.5, 3.9 Hz), 3.45-3.31 (m, 3H), 1.40 (d, 3H, J = 6.6 Hz), 1.29 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz), 0.98 (t, 3H, J = 6.9 Hz).
    431
    Figure US20180319798A1-20181108-C00508
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (br s, 1H), 8.93 (s, 1H), 7.45-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.92 (q, 1H, J = 6.7 Hz), 4.48 (s, 2H), 4.04-3.96 (m, 2H), 3.59-3.47 (m, 2H), 3.44-3.31 (m, 2H), 3.22- 3.09 (m, 1H), 1.42 (d, 3H, J = 6.7 Hz), 1.20 (t, 3H J = 7.1 Hz), 0.97 (t, 3H, J = 6.9 Hz).
    432
    Figure US20180319798A1-20181108-C00509
         		HCl 1H-NMR (DMSO-d6) δ: 8.80-8.74 (m, 1H), 7.68 (s, 1H), 7.38-7.29 (m, 2H), 7.20-7.10 (m, 2H), 4.97- 4.55 (m, 2H), 4.20 (s, 2H), 3.92-3.60 (m, 2H), 3.60-3.02 (m, 2H), 2.93 (s, 2H), 2.72 (s, 1H), 2.08- 1.59 (m, 5H), 1.22 (d, 3H, J = 7.1 Hz), 1.16 (d, 3H, J = 6.4 Hz).
  • TABLE 1-113
    No. structural formula salt 1H-NMR
    433
    Figure US20180319798A1-20181108-C00510
         		HCl 1H-NMR (DMSO-d6) δ: 8.66 (s, 1H), 7.61 (s, 1H), 7.36-7.27 (m, 2H), 7.16-7.04 (m, 2H), 4.84-4.56 (m, 2H), 4.19 (s, 2H), 3.88-3.76 (m, 1H), 3.75-3.63 (m, 1H), 3.52-3.14 (m, 2H), 3.03-2.70 (m, 3H), 2.33-2.17 (m, 2H), 2.06-1.76 (m, 2H), 1.24 (d, 3H, J = 6.6 Hz), 1.19 (d, 3H, J = 6.6 Hz), 0.96 (t, 3H, J = 7.5 Hz).
    434
    Figure US20180319798A1-20181108-C00511
         		HCl 1H-NMR (DMSO-d6) δ: 12.63 (br s, 1H), 8.73 (s, 1H), 7.44-7.41 (m, 2H), 7.21-7.17 (m, 2H), 4.60- 4.55 (m, 1H), 4.47 (s, 2H), 4.05 (dd, 1H, J = 13.9, 3.4 Hz), 3.78 (dd, 1H, J = 13.9, 1.1 Hz), 3.63 (dq, 1H, J = 13.5, 7.1 Hz), 3.48 (dq, 1H, J = 13.5, 7.1 Hz), 3.18 (dd, 1H, J = 9.9, 4.2 Hz), 3.02 (s, 3H), 2.88 (dd, 1H, J = 9.9, 3.4 Hz), 2.11-2.04 (m, 1H), 1.16 (t, 3H, J = 7.1 Hz), 1.07 (d, 3H, J = 6.8 Hz).
    435
    Figure US20180319798A1-20181108-C00512
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.75 (s, 1H), 7.44-7.41 (m, 2H), 7.22-7.17 (m, 2H), 4.79 (sep, 1H, J = 6.8 Hz), 4.60-4.57 (m, 1H), 4.46 (s, 2H), 3.82 (dd, 1H, J = 14.3, 3.5 Hz), 3.77 (dd, 1H, J = 14.3, 1.3 Hz), 3.16 (dd, 1H, J = 9.9, 4.1 Hz), 2.99 (s, 3H), 2.83 (dd, 1H, J = 9.9, 3.3 Hz), 2.06- 2.02 (m, 1H), 1.20 (d, 3H, J = 6.8 Hz), 1.19 (d, 3H, J = 6.8 Hz), 1.08 (d, 3H, J = 6.8 Hz).
    436
    Figure US20180319798A1-20181108-C00513
         		HCl 1H-NMR (DMSO-d6) δ: 12.64 (br s, 1H), 8.73 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.17 (m, 2H), 4.57- 4.54 (m, 1H), 4.46 (s, 2H), 4.01 (dd, 1H, J = 13.7, 3.6 Hz), 3.61 (dd, 1H, J = 13.7, 1.2 Hz), 3.17 (dd, 1H, J = 9.9, 4.4 Hz), 3.02 (s, 3H), 2.98-2.92 (m, 1H), 2.88 (dd, 1H, J = 9.9, 3.4 Hz), 2.07-1.99 (m, 1H), 1.03 (d, 3H, J = 6.9 Hz), 0.93-0.81 (m, 3H), 0.72-0.65 (m, 1H).
    437
    Figure US20180319798A1-20181108-C00514
         		HCl 1H-NMR (DMSO-d6) δ: 12.83 (br s, 1H), 8.65 (s, 1H), 7.46-7.40 (m, 2H), 7.22-7.16 (m, 2H), 4.83- 4.71 (m, 2H), 4.47 (s, 2H), 3.93-3.86 (m, 1H), 3.79-3.73 (m, 1H), 3.60-3.47 (m, 3H), 3.33 (s, 3H), 3.08 (s, 3H), 1.22 (d, 3H, J = 6.9 Hz), 1.18 (d, 3H, J = 6.9 Hz).
  • TABLE 1-114
    No. structural formula salt 1H-NMR
    438
    Figure US20180319798A1-20181108-C00515
         		HCl 1H-NMR (DMSO-d6) δ: 12.74 (br s, 1H), 8.64 (s, 1H), 7.46-7.39 (m, 2H), 7.22-7.15 (m, 2H), 4.76- 4.70 (m, 1H), 4.47 (s, 2H), 4.10-4.02 (m, 1H), 3.67-3.60 (m, 1H), 3.60-3.53 (m, 1H), 3.48 (dd, 1H, J = 10.9, 4.0 Hz), 3.43 (dd, 1H, J = 10.9, 5.2 Hz), 3.32 (s, 3H), 3.10 (s, 3H), 2.96-2.88 (m, 1H), 0.95-0.73 (m, 4H).
    439
    Figure US20180319798A1-20181108-C00516
         		HCl 1H-NMR (DMSO-d6) δ: 12.46 (br s, 1H), 8.87 (s, 1H), 7.45-7.36 (m, 2H), 7.23-7.14 (m, 2H), 4.65- 4.56 (m, 1H), 4.47 (s, 2H), 4.38 (dd, 1H, J = 13.7, 3.6 Hz), 4.07-3.98 (m, 1H), 3.91 (td, 1H, J = 13.9, 7.1 Hz), 3.48-3.33 (m, 2H), 3.23 (s, 3H), 3.11 (td, 1H, J = 13.9, 7.1 Hz), 1.91-1.79 (m, 1H), 1.79-1.67 (m, 1H), 1.20 (t, 3H, J = 7.1 Hz).
    440
    Figure US20180319798A1-20181108-C00517
         		HCl 1H-NMR (DMSO-d6) δ: 12.63 (s, 1H), 8.76 (s, 1H), 7.44-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.66 (dd, 1H, J = 9.7, 4.4 Hz), 4.47 (s, 2H), 3.97 (dd, 1H, J = 13.9, 6.2 Hz), 3.92-3.86 (m, 1H), 3.41-3.36 (m, 1H), 3.17-3.10 (m, 5H), 2.08-2.01 (m, 1H), 1.87- 1.80 (m, 1H), 1.24 (d, 3H, J = 6.4 Hz), 1.19 (t, 3H, J = 7.1 Hz).
    441
    Figure US20180319798A1-20181108-C00518
         		HCl 1H-NMR (DMSO-d6) δ: 12.77 (s, 1H), 8.64 (s, 1H), 7.44-7.40 (m, 2H), 7.22-7.17 (m, 2H). 4.71-4.67 (m, 1H), 4.47 (s, 2H), 4.33-4.27 (m, 1H), 3.76 (td, 1H, J = 14.1, 7.1 Hz), 3.43-3.36 (m, 2H), 3.15 (s, 3H), 3.12-3.05 (m, 1H), 2.09-2.02 (m, 1H), 1.94- 1.84 (m, 1H), 1.33 (d, 3H, J = 5.2 Hz), 1.14 (t, 3H, J = 7.1 Hz).
    442
    Figure US20180319798A1-20181108-C00519
         		HCl 1H-NMR (DMSO-d6) δ: 12.65 (s, 1H), 8.75 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.17 (m, 2H), 4.67-4.58 (m, 2H), 4.47 (s, 2H), 4.10-4.04 (m, 1H), 3.42-3.37 (m, 1H), 3.17 (s, 3H), 3.15-3.09 (m, 1H), 2.05-1.97 (m, 1H), 1.82-1.75 (m, 1H), 1.28-1.23 (m, 9H).
  • TABLE 1-115
    No. structural formula salt 1H-NMR
    443
    Figure US20180319798A1-20181108-C00520
         		HCl 1H-NMR (DMSO-d6) δ: 12.76 (s, 1H), 8.65 (s, 1H), 7.42-7.39 (m, 2H), 7.20-7.16 (m, 2H), 4.56-4.51 (m, 2H), 4.47 (s, 2H), 4.09-4.03 (m, 1H), 3.63-3.54 (m, 2H), 3.31 (s, 3H), 2.50-2.48 (m, 1H), 2.12-2.06 (m, 1H), 1.30 (d, 3H, J = 7.0 Hz), 1.28 (d, 3H, J = 7.0 Hz), 1.09 (d, 3H, J = 6.0 Hz).
    444
    Figure US20180319798A1-20181108-C00521
         		HCl 1H-NMR (DMSO-d6) δ: 12.48 (br s, 1H), 8.80 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.55 (dd, 1H, J = 13.2, 1.5 Hz), 4.47 (s, 2H), 4.38 (dd, 1H, J = 13.2, 3.5 Hz), 4.08-4.04 (m, 1H), 3.98 (dq, 1H, J = 13.5, 7.1 Hz), 3.42-3.37 (m, 1H), 3.20 (s, 3H), 3.06 (dq, 1H, J = 13.5, 7.1 Hz), 1.71-1.59 (m, 2H), 1.20 (t, 3H, J = 7.1 Hz), 1.06 (d, 3H, J = 6.2 Hz).
    445
    Figure US20180319798A1-20181108-C00522
         		HCl 1H-NMR (DMSO-d6) δ: 8.81 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.57 (dd, 1H, J = 13.2, 1.3 Hz), 4.47 (s, 2H), 4.45 (sep, 1H, J = 6.8 Hz), 4.31 (dd, 1H, J = 13.2, 3.3 Hz), 4.11-4.06 (m, 1H), 3.50-3.45 (m, 1H), 3.19 (s, 3H), 1.68-1.57 (m, 2H), 1.31 (d, 3H, J = 6.8 Hz), 1.28 (d, 3H, J = 6.8 Hz), 1.08 (d, 3H, J = 6.2 Hz).
    446
    Figure US20180319798A1-20181108-C00523
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.75 (s, 1H), 7.45-7.39 (m, 2H), 7.22-7.16 (m, 2H), 4.86- 4.75 (m, 2H), 4.47 (s, 2H), 3.86-3.80 (m, 1H), 3.76 (dd, 1H, J = 13.3, 3.6 Hz), 3.61 (dd, 1H, J = 11.7, 2.8 Hz), 3.58-3.51 (m, 1H), 3.30 (s, 3H), 3.18 (s, 3H), 2.97 (dd, 1H, J = 11.7, 2.8 Hz), 1.20 (d, 3H, J = 6.9 Hz), 1.17 (d, 3H, J = 6.9 Hz).
    447
    Figure US20180319798A1-20181108-C00524
         		HCl 1H-NMR (DMSO-d6) δ: 12.47 (br s, 1H), 8.99 (s, 1H), 7.44-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.73 (d, 1H, J = 13.7 Hz), 4.47 (s, 2H), 4.34 (dd, 1H, J = 13.7, 4.4 Hz), 4.23-4.14 (m, 1H), 4.05-4.00 (m, 1H), 3.46 (dd, 1H, J = 9.7, 8.1 Hz), 3.37 (dd, 1H, J = 9.7, 5.2 Hz), 3.30 (s, 3H), 2.22-2.11 (m, 1H), 1.38 (d, 3H, J = 6.9 Hz), 1.34 (d, 3H, J = 6.9 Hz), 0.60 (d, 3H, J = 7.3 Hz).
  • TABLE 1-116
    No. structural formula salt 1H-NMR
    448
    Figure US20180319798A1-20181108-C00525
         		HCl 1H-NMR (DMSO-d6) δ: 12.42 (br s, 1H), 9.00 (s, 1H), 7.44-7.37 (m, 2H), 7.22-7.14 (m, 2H), 4.76- 4.68 (m, 1H), 4.47 (s, 2H), 4.37 (dd, 1H, J = 14.1, 4.0 Hz), 4.07-3.96 (m, 1H), 3.93-3.86 (m, 1H), 3.38-3.28 (m, 2H), 3.26 (s, 3H), 3.11-2.99 (m, 1H), 2.05-1.95 (m, 1H), 1.19 (t, 3H, J = 7.1 Hz), 0.81 (d, 3H, J = 6.9 Hz).
    449
    Figure US20180319798A1-20181108-C00526
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (s, 1H), 8.57 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.65-4.59 (m, 1H), 4.47 (s, 2H), 4.30-4.24 (m, 1H), 4.01-3.96 (m, 1H), 3.33-3.24 (m, 2H), 3.11 (s, 3H), 1.92-1.86 (m, 1H), 1.70 (d, 3H, J = 6.4 Hz), 1.66-1.59 (m, 1H), 1.38 (d, 3H, J = 6.9 Hz), 1.33 (d, 3H, J = 6.9 Hz).
    450
    Figure US20180319798A1-20181108-C00527
         		HCl 1H-NMR (DMSO-d6) δ: 12.52 (s, 1H), 8.93 (s, 1H), 7.43-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.88-4.84 (m, 1H), 4.48 (s, 2H), 4.08-4.02 (m, 1H), 3.83 (t, 1H, J = 7.1 Hz), 3.44-3.37 (m, 2H), 3.23 (s, 3H), 3.04-2.96 (m, 1H), 1.84-1.73 (m, 2H), 1.41 (d, 3H, J = 6.9 Hz), 1.19 (t, 3H, J = 7.0 Hz).
    451
    Figure US20180319798A1-20181108-C00528
         		HCl 1H-NMR (DMSO-d6) δ: 12.50 (s, 1H), 8.95 (s, 1H), 7.42-7.38 (m, 2H), 7.21-7.16 (m, 2H), 4.91 (dd, 1H, J = 12.7, 5.8 Hz), 4.61-4.54 (m, 1H), 4.48 (s, 2H), 3.88 (d, 1H, J = 8.9 Hz), 3.50-3.39 (m, 2H), 3.24 (s, 3H), 1.91-1.85 (m, 1H), 1.69-1.61 (m, 1H), 1.39 (d, 3H, J = 6.9 Hz), 1.28 (d, 3H, J = 6.4 Hz), 1.26 (d, 3H, J = 6.4 Hz).
    452
    Figure US20180319798A1-20181108-C00529
         		HCl 1H-NMR (DMSO-d6) δ: 12.70 (s, 1H), 8.65 (s, 1H), 7.42-7.38 (m, 2H), 7.22-7.15 (m, 2H), 4.75-4.70 (m, 1H), 4.47 (s, 2H), 4.08-3.96 (m, 2H), 3.37-3.31 (m, 2H), 3.20 (s, 3H), 3.15-3.07 (m, 1H), 1.94-1.87 (m, 1H), 1.68-1.58 (m, 4H), 1.20 (t, 3H, J = 7.1 Hz).
  • TABLE 1-117
    No. structural formula salt 1H-NMR
    453
    Figure US20180319798A1-20181108-C00530
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (br s, 1H), 8.81 (s, 1H), 7.45-7.39 (m, 2H), 7.23-7.15 (m, 2H), 4.95- 4.88 (m, 1H), 4.78 (sep, 1H, J = 6.9 Hz), 4.47 (s, 2H), 3.81 (dd, 1H, J = 13.5, 3.4 Hz), 3.74-3.65 (m, 1H), 3.58-3.48 (m, 1H), 3.03 (s, 3H), 1.88-1.80 (m, 1H), 1.78-1.68 (m, 1H), 1.19 (d, 3H, J = 6.9 Hz), 1.16 (d, 3H, J = 6.9 Hz), 1.07 (d, 3H, J = 6.0 Hz).
    454
    Figure US20180319798A1-20181108-C00531
         		HCl 1H-NMR (DMSO-d6) δ: 12.67 (br s, 1H), 8.82 (s, 1H), 7.45-7.38 (m, 2H), 7.23-7.14 (m, 2H), 4.93- 4.83 (m, 1H), 4.47 (s, 2H), 4.05 (dd, 1H, J = 13.5, 3.8 Hz), 3.71-3.42 (m, 4H), 3.05 (s, 3H), 1.95-1.86 (m, 1H), 1.82-1.71 (m, 1H), 1.16 (t, 3H, J = 7.1 Hz), 1.09 (d, 3H, J = 6.0 Hz).
    455
    Figure US20180319798A1-20181108-C00532
         		HCl 1H-NMR (DMSO-d6) δ: 8.82 (s, 1H), 7.43-7.40 (m, 2H), 7.21-7.16 (m, 2H), 4.88-4.83 (m, 1H), 4.46 (s, 2H), 3.98 (dd, 1H, J = 13.3, 3.6 Hz), 3.53 (dd, 1H, J = 13.3, 1.8 Hz), 3.52-3.46 (m, 1H), 3.02 (s, 3H), 2.98-2.93 (m, 1H), 1.86 (ddd, 1H, J = 14.3, 6.2, 2.6 Hz), 1.71 (ddd, 1H, J = 14.3, 8.8, 7.9 Hz), 1.08 (d, 3H, J = 6.0 Hz), 0.94-0.79 (m, 3H), 0.75-0.70 (m, 1H).
    456
    Figure US20180319798A1-20181108-C00533
         		HCl 1H-NMR (DMSO-d6) δ: 8.66 (s, 0.7H), 8.50 (s, 0.3H), 7.70-7.64 (m, 1.0H), 7.37-7.30 (m, 2.0H), 7.19-7.11 (m, 2.0H), 4.70-4.62 (m, 0.3H), 4.59- 4.51 (m, 0.7H), 4.44-4.34 (m, 0.7H), 4.20 (s, 2.0H), 4.08-3.99 (m, 1.0H), 3.80-3.70 (m, 0.3H), 3.69-3.47 (m, 3.0H), 2.80 (s, 2.1H), 2.69 (s, 0.9H), 2.12-1.86 (m, 4.3H), 1.83-1.73 (m, 0.7H), 1.22- 1.12 (m, 3.0H), 1.05 (d, 0.9H, J = 6.4 Hz), 1.00 (d, 2.1H, J = 6.4 Hz).
    457
    Figure US20180319798A1-20181108-C00534
         		HCl 1H-NMR (DMSO-d6) δ: 12.80 (br s, 1H), 8.82 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.77 (sep, 1H, J = 6.9 Hz), 4.69-4.65 (m, 1H), 4.47 (s, 2H), 3.86 (d, 2H, J = 2.8 Hz), 3.37 (d, 2H, J = 5.2 Hz), 3.28 (s, 3H), 2.22-2.15 (m, 1H), 1.21 (d, 3H, J = 6.9 Hz), 1.18 (d, 3H, J = 6.9 Hz), 0.66 (d, 3H, J = 6.9 Hz).
  • TABLE 1-118
    No. structural formula salt 1H-NMR
    458
    Figure US20180319798A1-20181108-C00535
         		HCl 1H-NMR (DMSO-d6) δ: 8.63 (s, 0.67H), 8.46 (s, 0.33H), 7.71-7.61 (m, 1H), 7.39-7.28 (m, 2H), 7.21-7.10 (m, 2H), 4.67-4.31 (m, 2H), 4.26-4.16 (m, 2H), 4.07-3.42 (br m, 2H), 3.03-2.56 (br m, 4H), 2.14-1.59 (m, 5H), 1.28-0.60 (m, 7H).
    459
    Figure US20180319798A1-20181108-C00536
         		HCl 1H-NMR (DMSO-d6) δ: 9.18-8.08 (m, 1H), 7.49- 7.10 (m, 4H), 5.28-3.81 (m, 6H), 3.07-2.45 (m, 4H), 2.36-1.64 (m, 5H), 1.38-0.32 (m, 7H).
    460
    Figure US20180319798A1-20181108-C00537
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (br s, 1H), 8.92-8.63 (m, 1H), 7.47-7.37 (m, 2H), 7.24-7.13 (m, 2H), 4.80-4.19 (m, 4H), 4.10-3.39 (m, 2H), 3.04-2.48 (m, 4H), 2.15-1.61 (m, 5H), 1.18-0.59 (m, 7H).
    461
    Figure US20180319798A1-20181108-C00538
         		HCl 1H-NMR (DMSO-d6) δ: 8.63 (s, 1H), 7.68 (s, 1H), 7.37-7.29 (m, 2H), 7.19-7.10 (m, 2H), 4.90-4.65 (m, 2H), 4.61-4.45 (m, 1H), 4.20 (s, 2H), 3.89-3.55 (m, 2H), 2.81 (s, 3H), 2.00 (s, 3H), 1.95-1.76 (m, 2H), 1.29-1.11 (br m, 6H), 1.02 (d, 3H, J = 7.1 Hz).
  • TABLE 1-119
    No. structural formula salt 1H-NMR
    462
    Figure US20180319798A1-20181108-C00539
         		HCl 1H-NMR (DMSO-d6) δ: 8.63 (s, 0.75H), 8.44 (s, 0.25H), 7.69-7.63 (m, 1H), 7.39-7.29 (m, 2H), 7.19-7.10 (m, 2H), 4.85-3.97 (m, 3H), 4.20 (s, 2H), 3.85-3.54 (m, 2H), 2.81 (s, 2.25H), 2.72 (s, 0.75H), 2.06-1.61 (m, 5H), 1.33-1.08 (m, 6H), 1.08-0.93 (m, 3H).
    463
    Figure US20180319798A1-20181108-C00540
         		HCl 1H-NMR (DMSO-d6) δ: 12.58 (br s, 1.0H), 8.62 (s, 0.9H), 8.58 (s, 0.1H), 7.68 (s, 0.9H), 7.67 (s, 0.1H), 7.36-7.30 (m, 2.0H), 7.18-7.11 (m, 2.0H), 4.76-4.65 (m, 1.0H), 4.57-4.49 (m, 1.0H), 4.20 (s, 2.0H), 3.99-3.93 (m, 1.0H), 3.75-3.59 (m, 1.9H), 3.59-3.38 (m, 1.1H), 2.80 (s, 2.7H), 2.58 (s, 0.3H), 1.98 (s, 2.7H), 1.92-1.83 (m, 2.3H), 1.22-1.13 (m, 3.3H), 1.03 (d, 2.7H, J = 6.9 Hz).
    464
    Figure US20180319798A1-20181108-C00541
         		HCl 1H-NMR (DMSO-d6) δ: 12.72 (br s, 1H), 8.81 (s, 1H), 7.44-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.65- 4.62 (m, 1H), 4.47 (s, 2H), 4.09 (dd, 1H, J = 13.7, 4.0 Hz), 3.82 (dd, 1H, J = 13.7, 0.8 Hz), 3.58 (dq, 1H, J = 13.3, 7.3 Hz), 3.53 (dq, 1H, J = 13.3, 7.3 Hz), 3.37 (dd, 1H, J = 9.7, 4.8 Hz), 3.32 (dd, 1H, J = 9.7, 6.4 Hz), 3.26 (s, 3H), 2.24-2.17 (m, 1H), 1.17 (t, 3H, J = 7.3 Hz), 0.72 (d, 3H, J = 6.9 Hz).
    465
    Figure US20180319798A1-20181108-C00542
         		HCl 1H-NMR (DMSO-d6) δ: 12.71 (br s, 1H), 8.81 (s, 1H), 7.43-7.39 (m, 2H), 7.21-7.16 (m, 2H), 4.64- 4.61 (m, 1H), 4.47 (s, 2H), 4.01 (dd, 1H, J = 13.7, 4.0 Hz), 3.72 (dd, 1H, J = 13.7, 1.2 Hz), 3.34-3.29 (m, 2H), 3.27 (s, 3H), 2.98-2.92 (m, 1H), 2.20-2.14 (m, 1H), 0.90-0.79 (m, 4H), 0.67 (d, 3H, J = 6.9 Hz).
    • Experimental Example 1
  • The following explains evaluation methods of the HIV integrase inhibitory activity of the compound of the present invention.
    • (i) Construction of Recombinant Integrase Gene Expression System
  • A full-length gene sequence (Accession No.: M19921) of HIV-1 pNL4-3 integrase was inserted into restriction enzyme Nde I and Xho I sites of plasmid pET21a(+) (manufactured by Novagen) to construct an integrase expression vector pET21a-IN-Wild type.
    • (ii) Production and Purification of Integrase Protein
  • Escherichia coli recombinant BL21(DE3) transformed with plasmid pET21a-IN-Wild type obtained in (i) was shake cultured at 30° C. in a liquid medium containing ampicillin. When the culture reached the logarithmic growth phase, isopropyl-β-D-thiogalactopyranoside was added to promote expression of integrase gene. The culture was continued for 5 hr to promote accumulation of the integrase protein. The recombinant E. coli was collected in pellets by centrifugal separation and preserved at −80° C.
  • This Escherichia coli was suspended in Lysis buffer (50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 5 mM DTT), and disrupted by repeating treatments of pressurization and depressurization, and insoluble fraction was collected by centrifugation at 4° C., 18,000 rpm for 60 min. This was suspended in Lysis buffer containing a protease inhibitor, 1.25 mM sodium chloride and 10 mM CHAPS were added, and the mixture was stirred at 4° C. for 30 min. Water-soluble fraction was collected by centrifugation at 4° C., 9,000 rpm for 30 min. The obtained fraction was diluted with a column buffer (50 mM Tris-HCl (pH 7.6), 1 mM DTT, 10% Glycerol, 10 mM CHAPS) to 5-fold, and the mixture was applied to heparin column (HiPrep 16/10 Heparin FF column: manufactured by GE Healthcare Bio-Sciences). Using a column buffer containing 1M NaCl, a protein was eluted with 0-1M NaCl concentration gradient, and an eluted fraction containing an integrase protein was collected. The obtained fraction was diluted 5-fold with a column buffer (50 mM Tris-HCl (pH 7.6), 1 mM DTT, 10% Glycerol, 10 mM CHAPS), and the mixture was applied to cation exchange column (Mono-S column: manufactured by GE Healthcare Bio-Sciences). Using a column buffer containing 1M NaCl, a protein was eluted with 0-1M NaCl concentration gradient, and an eluted fraction containing an integrase protein was collected. The obtained fractions of the integrase protein were collected, and preserved at −80° C.
  • (iii) Preparation of DNA Solution
  • The following DNA synthesized by FASMAC was dissolved in TE buffer (10 mM Tris-hydrochloric acid (pH 8.0), 1 mM EDTA) and mixed with donor DNA, target DNA, and each complementary strand (+ and − strands) to 1 μM. The mixture was heated at 95° C. for 5 min, 80° C. for 10 min, 70° C. for 10 min, 60° C. for 10 min, 50° C. for 10 min and 40° C. for 10 min and kept at 25° C. to give a double stranded DNA, which was used for the test.
  • Donor DNA (+ strand having biotin attached to
    the 5′ terminal)
    Donor + strand:
    (SEQ ID NO: 1)
    5′-Biotin-ACC CTT TTA GTC AGT GTG GAA AAT CTC
    TAG CA-3′
    Donor − strand:
    (SEQ ID NO: 2)
    5′-ACT GCT AGA GAT TTT CCA CAC TGA CTA AAA G-3′
    Target DNA (+, − strands both having digoxigenin
    attached to the 3′ terminal)
    Target + strand:
    (SEQ ID NO: 3)
    5′-TGA CCA AGG GCT AAT TCA CT-Dig-3′
    Target − strand:
    (SEQ ID NO: 4)
    5′-AGT GAA TTA GCC CTT GGT CA-Dig-3′
    • (iv) Determination of Enzyme (HIV Integrase) Inhibitory Activity
  • The donor DNA was diluted with TE buffer to 20 nM, of which 50 μL was added to each well of streptavidin-coated black plate (manufactured by PIAS Corporation) and allowed to adsorb at 37° C. for 20 min. The plate was washed with phosphate buffer (Dulbecco's PBS, Sanko Junyaku Co., Ltd.) containing 0.1% Tween 20 and phosphate buffer. Then, an enzyme reaction mixture (70 μL), a test substance (10 μL) diluted with the enzyme reaction mixture and 0.75 μM integrase protein (10 μL) were added to each well and the mixture was reacted at 37° C. for 60 min. composition of enzyme reaction mixture: 30 mM MOPS (3-morpholinopropanesulfonic acid), 5 mM magnesium chloride, 3 mM DTT (dithiothreitol), 0.1 mg/mL BSA (bovine serum albumin), 5% glycerol, 10% DMSO (dimethyl sulfoxide), 0.01% Tween 20.
  • Then, 25 nM target DNA (10 μL) was added, and the mixture was reacted at 37° C. for 20 min and washed with phosphate buffer containing 0.1% Tween 20 to stop the reaction.
  • Then, 100 mU/mL peroxidase labeled anti-digoxigenin antibody solution (Roche, 100 μL) was added, and the mixture was reacted at 37° C. for 60 min, followed by washing with phosphate buffer containing 0.1% Tween 20.
  • Then, peroxidase fluorescence substrate solution (manufactured by PIAS Corporation, 100 μL) was added, and the mixture was reacted at room temperature for 20 min to 30 min. A reaction quenching liquid (manufactured by PIAS Corporation, 100 μL) was added to discontinue the reaction, and fluorescence intensity at excitation wavelength 325 nm/fluorescence wavelength 420 nm was measured.
  • The HIV integrase inhibitory activity (IC50) of the compound of the present invention was calculated from the inhibition rate according to the following formula:

  • inhibition rate(%)=[1−(Object-Blank)/(Control-Blank)]×100
    • Object: fluorescence intensity of well in the presence of test compound
    • Control: fluorescence intensity of well in the absence of test compound
    • Blank: fluorescence intensity of well in the absence of test compound and integrase protein
  • The results are shown in the following Tables.
  • TABLE 2-1
    inhibitory
    Example activity
    No. IC50 (μM)
    2 0.013
    3 0.0085
    4 0.01
    5 0.0074
    6 0.0056
    7 0.013
    8 0.0089
    9 0.0091
    10 0.0088
    11 0.0064
    12 0.0073
    13 0.0064
    14 0.01
    15 0.013
    16 0.02
    17 0.0079
    18 0.0082
    19 0.0081
    20 0.017
  • TABLE 2-2
    inhibitory
    Example activity
    No. IC50 (μM)
    21 0.0094
    22 0.007
    23 0.012
    24 0.023
    25 0.011
    26 0.0076
    27 0.01
    28 0.015
    29 0.01
    30 0.009
    31 0.0083
    32 0.0077
    33 0.0062
    34 0.0082
    35 0.0067
    36 0.013
    37 0.0063
    38 0.012
    39 0.01
    40 0.013
  • TABLE 2-3
    inhibitory
    Example activity
    No. IC50 (μM)
    41 0.0072
    42 0.0034
    43 0.0046
    44 0.0081
    45 0.011
    46 0.011
    47 0.012
    48 0.0069
    49 0.0051
    50 0.0064
    51 0.0057
    52 0.013
    53 0.01
    54 0.0075
    55 0.021
    56 0.01
    57 0.011
    58 0.017
    59 0.012
    60 0.017
  • TABLE 2-4
    inhibitory
    Example activity
    No. IC50 (μM)
    61 0.0066
    62 0.0092
    63 0.0083
    64 0.0061
    65 0.013
    66 0.0064
    67 0.0076
    68 0.0098
    69 0.013
    70 0.0089
    71 0.011
    72 0.011
    73 0.0077
    74 0.0057
    75 0.0091
    76 0.0083
    77 0.011
    78 0.0089
    79 0.0064
    80 0.0098
  • TABLE 2-5
    inhibitory
    Example activity
    No. IC50 (μM)
    81 0.0075
    82 0.0049
    83 0.0071
    84 0.011
    85 0.0075
    86 0.0095
    87 0.0077
    88 0.0087
    89 0.008
    90 0.0067
    92 0.0087
    93 0.0078
    94 0.0088
    95 0.0095
    96 0.0067
    97 0.0066
    98 0.0075
    99 0.0061
    100 0.0081
    101 0.0064
  • TABLE 2-6
    inhibitory
    Example activity
    No. IC50 (μM)
    102 0.0071
    103 0.018
    104 0.015
    105 0.017
    106 0.02
    107 0.019
    108 0.018
    109 0.021
    110 0.023
    111 0.02
    112 0.019
    113 0.013
    114 0.0081
    115 0.012
    116 0.0096
    117 0.0094
    118 0.013
    119 0.011
    120 0.015
    121 0.016
  • TABLE 2-7
    inhibitory
    Example activity
    No. IC50 (μM)
    122 0.019
    123 0.027
    124 0.015
    125 0.011
    126 0.0073
    127 0.014
    128 0.019
    129 0.012
    130 0.013
    131 0.013
    132 0.0091
    133 0.0074
    134 0.016
    135 0.012
    136 0.011
    137 0.0086
    138 0.011
    139 0.012
    140 0.0058
    141 0.008
  • TABLE 2-8
    inhibitory
    Example activity
    No. IC50 (μM)
    142 0.0064
    143 0.0069
    144 0.0077
    145 0.0056
    146 0.0059
    147 0.0083
    148 0.0098
    149 0.0059
    150 0.0061
    151 0.0054
    152 0.0059
    153 0.0058
    154 0.0073
    155 0.01
    156 0.0046
    157 0.029
    158 0.0054
    159 0.0066
    160 0.0061
    161 0.0078
  • TABLE 2-9
    inhibitory
    Example activity
    No. IC50 (μM)
    162 0.0071
    163 0.0077
    164 0.0065
    165 0.0074
    166 0.012
    167 0.01
    168 0.0058
    169 0.012
    170 0.012
    171 0.016
    172 0.014
    173 0.016
    174 0.014
    175 0.0095
    176 0.0085
    177 0.017
    178 0.02
    179 0.019
    180 0.01
    181 0.014
  • TABLE 2-10
    inhibitory
    Example activity
    No. IC50 (μM)
    182 0.0097
    183 0.01
    184 0.006
    185 0.015
    186 0.018
    187 0.019
    188 0.018
    189 0.02
    190 0.011
    191 0.012
    192 0.015
    193 0.011
    194 0.0082
    195 0.0059
    196 0.0067
    197 0.014
    198 0.0057
    199 0.0084
    200 0.0096
    201 0.0095
  • TABLE 2-11
    inhibitory
    Example activity
    No. IC50 (μM)
    202 0.013
    203 0.013
    204 0.013
    205 0.013
    206 0.0059
    207 0.024
    208 0.012
    209 0.012
    210 0.023
    211 0.016
    212 0.014
    213 0.015
    214 0.016
    217 0.0053
    218 0.0065
    219 0.015
    220 0.0068
    221 0.0084
    222 0.0065
    223 0.012
  • TABLE 2-12
    inhibitory
    Example activity
    No. IC50 (μM)
    224 0.0073
    225 0.018
    226 0.013
    227 0.013
    228 0.011
    229 0.012
    230 0.069
    231 0.011
    232 0.015
    233 0.0064
    234 0.018
    235 0.016
    236 0.013
    237 0.013
    238 0.018
    239 0.016
    240 0.052
    241 0.014
    242 0.013
    243 0.0076
  • TABLE 2-13
    inhibitory
    Example activity
    No. IC50 (μM)
    244 0.074
    245 0.0081
    246 0.0084
    247 0.01
    248 0.014
    249 0.012
    250 0.017
    251 0.011
    252 0.0092
    253 0.0077
    254 0.0076
    255 0.009
    256 0.0082
    257 0.0091
    258 0.0093
    259 0.009
    260 0.012
    261 0.011
    262 0.01
    263 0.009
  • TABLE 2-14
    inhibitory
    Example activity
    No. IC50 (μM)
    264 0.0085
    265 0.0093
    266 0.011
    267 0.011
    268 0.015
    269 0.0094
    270 0.0095
    271 0.011
    272 0.0089
    273 0.014
    274 0.012
    275 0.014
    276 0.016
    277 0.012
    278 0.0099
    279 0.0063
    280 0.016
    281 0.016
    282 0.015
    283 0.018
  • TABLE 2-15
    inhibitory
    Example activity
    No. IC50 (μM)
    284 0.011
    285 0.011
    286 0.0078
    287 0.008
    288 0.0088
    289 0.01
    290 0.014
    291 0.0087
    292 0.0073
    293 0.0096
    294 0.011
    295 0.012
    296 0.019
  • TABLE 2-16
    inhibitory
    Example activity
    No. IC50 (μM)
    297 0.02
    298 0.009
    299 0.0098
    300 0.009
    301 0.008
    302 0.0099
    303 0.0058
    304 0.0091
    305 0.0095
    306 0.01
    307 0.011
    308 0.013
    309 0.0088
    310 0.0099
    311 0.0097
    312 0.012
    313 0.0097
    314 0.0079
    315 0.0088
  • TABLE 2-17
    inhibitory
    Example activity
    No. IC50 (μM)
    316 0.012
    317 0.0098
    318 0.0065
    319 0.0058
    320 0.0094
    321 0.007
    323 0.014
  • TABLE 2-18
    inhibitory
    Example activity
    No. IC50 (μM)
    327 0.0059
    328 0.0071
    329 0.0061
    330 0.0064
    331 0.0093
    332 0.012
    333 0.0075
    334 0.0091
    335 0.0098
    336 0.0072
    337 0.017
    338 0.0071
    353 0.013
    354 0.0080
    355 0.0066
    356 0.0089
    357 0.0073
    358 0.012
    359 0.0048
    360 0.011
  • TABLE 2-19
    inhibitory
    Example activity
    No. IC50 (μM)
    361 0.015
    362 0.010
    363 0.0087
    364 0.010
    365 0.012
    382 0.0087
    383 0.0079
    384 0.012
    385 0.0082
    386 0.015
    387 0.011
    388 0.0086
    389 0.014
    391 0.024
    392 0.011
    393 0.015
    394 0.014
    395 0.010
    396 0.015
    397 0.019
    • Experimental Example 2 Evaluation of Antiviral Activity
  • The effect of combined use of the compound of the present invention and existent anti-HIV agents can be determined in the following manner.
  • For example, the effect of combined use of two agents from existent nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, tenofovir), non-nucleoside reverse transcriptase inhibitors (efavirenz) or protease inhibitors (indinavir, nelfinavir) and test substance A and the like are evaluated using CEM-SS cells infected with HIV-1 IIIB by XTT method.
  • In addition, the effect of combined use of three agents of test substance A, zidovudine and lamivudine, or test substance A, tenofovir and lamivudine, and the like is evaluated.
  • Prior to the combined use test, IC50 and CC50 of each medicament alone are measured. 5 concentrates of medicament A and 9 concentrates of medicament B, determined based on these results, are combined to evaluate the effect of combined use of two agents. For combined use of three agents, a high concentrated medicament B and a medicament C are mixed and medicament A and concentration thereof are combined for evaluation.
  • The test results of the test substance and concomitant drug alone or in combination thereof are analyzed based on the programs of Prichard and Shipman MacSynergy II version 2.01 and Deltagraph version 1.5d. A three-dimensional plot is drawn from % inhibition at the concentrations of each combined medicament, the obtained from 3 times of tests, with 95% (or 68%, 99%) confidence limits, and the effect of the combined use is evaluated based on the numerical values of μM2% calculated therefrom. The criteria of evaluation are shown in the following.
  • Definition of interaction μM2 %
    Strong synergistic action >100
    Slight synergistic action +51-+100
    Additive action +50-−50 
    Slight antagonistic action −51-−100
    Strong antagonistic action <−100
    • Experimental Example 3 Metabolism Stability Test Metabolism Stability Test in Liver Microsome
  • Liver microsome of human or animal species (rat or monkey) (manufactured by Xenotech LLC (Lenexa, Kans., USA), 20 mg protein/mL) (2.5 μL) and NADPH-generating system coenzyme solution (β-nicotinamide adenine dinucleotide phosphate: 5.2 mM, D-glucose-6-phosphate: 13.2 mM, magnesium chloride: 13.2 mM, glucose-6-phosphate dehydrogenase: 1.8 U/mL) (50 μL) are suspended in 100 mM potassium phosphate buffer (pH 7.4, 147.5 μL), and mixed with a test substance (2 μL) dissolved in acetonitrile containing 0.5% DMSO. After incubation at 37° C. for 0, 10 and 60 min, acetonitrile containing formic acid (final concentrated 0.1%) is added and the mixture is centrifuged. The test substance (unchanged form) in the supernatant is measured by high performance liquid chromatography/Mass Spectrometry (LC/MS). The residual ratio (%) is calculated from the obtained measurement values according to the following formula. residual ratio (%)=amount of test substance after incubation (0, 10 or 60 min)/amount of test substance at incubation 0 min×100
  • Preferred as the compound of the present invention is a compound with a residual ratio at 60 min later of not less than 40%, more preferably not less than 60%, further preferably not less than 80%.
  • Formulation Example is given below. This example is merely for the exemplification purpose and does not limit the invention.
    • Formulation Example
  • (a) compound of Example 1 10 g
    (b) lactose 50 g
    (c) corn starch 15 g
    (d) sodium carboxymethylcellulose 44 g
    (e) magnesium stearate  1 g
  • The entire amounts of (a), (b) and (c) and 30 g of (d) are kneaded with water, dried in vacuo and granulated. The obtained granules are mixed with 14 g of (d) and 1 g of (e) and processed into tablets with a tableting machine to give 1000 tablets each containing 10 mg of (a).
    • INDUSTRIAL APPLICABILITY
  • The compounds of the present invention show a high inhibitory activity against HIV integrase.
  • Therefore, these compounds can be medicaments effective for, for example, the prophylaxis or treatment of AIDS, as integrase inhibitors, antiviral agents, anti-HIV agents and the like, having an HIV integrase inhibitory activity. In addition, by a combined use with other anti-HIV agent(s) such as protease inhibitor, reverse transcriptase inhibitor and the like, they can be more effective anti-HIV agents. Furthermore, having high inhibitory activity specific for integrase, they can be medicaments safe for human body with a fewer side effects.
    • SEQUENCE LISTING FREE TEXT
    • SEQ ID NO: 1: Donor+ chain for HIV integrase activity measurement
    • SEQ ID NO: 2: Donor− chain for HIV integrase activity measurement
    • SEQ ID NO: 3: Target+ chain for HIV integrase activity measurement
    • SEQ ID NO: 4: Target− chain for HIV integrase activity measurement

Claims (43)

1. A compound represented by the following formula [I]or a pharmaceutically acceptable salt thereof, or a solvate thereof:
Figure US20180319798A1-20181108-C00543
wherein
R1 is
(1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
(i) a C3-8 cycloalkyl group, and
(ii) a C1-6 alkoxy group,
(2) a C3-8 cycloalkyl group, or
(3) a saturated monocyclic heterocyclic group containing, besides carbon atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom,
R2, R3, R4 and R5 are the same or different and each is
(1) a hydrogen atom,
(2) a carboxyl group,
(3) —CO—NRaRb wherein Ra and Rb are the same or different and each is
(i) a hydrogen atom,
(ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, or
(iii) a C3-8 cycloalkyl group, or
Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
(4) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group A, or
(5) a cyano group, or
R2 and R3, or R4 and R5 optionally form, together with the carbon atom bonded thereto,
i) C3-8 cycloalkane, or
ii) a saturated monocyclic hetero ring containing, besides carbon atom, 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom,
wherein R2, R3, R4 and R5 are not hydrogen atoms at the same time,
R6 is
(1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 halogen atoms,
(2) a C1-6 alkoxy group,
(3) a halogen atom, or
(4) a C3-8 cycloalkyl group,
Y is
a nitrogen atom,
m is an integer of 1 to 5, and when m is an integer of 2 to 5, then each R6 may be the same or different, and
n is an integer of 1 to 3,
and wherein group A is selected from
(a) —CO—NRA1RA2
wherein RA1 and RA2 are the same or different and each is
(i) a hydrogen atom,
(ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, or
(iii) a C3-8 cycloalkyl group, or
RA1 and RA2 optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 3 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from the following group B,
(b) a hydroxyl group,
(c) a C1-6 alkoxy group,
(d) a C1-6 alkoxy-C1-6 alkoxy group,
(e) a cyano group,
(f) —NRA3RA4
wherein RA3 and RA4 are the same or different and each is
(i) a hydrogen atom,
(ii) a C1-6 alkyl group,
(iii) a C1-6 alkyl-carbonyl group, or
(iv) a C1-6 alkyl-sulfonyl group, or
RA3 and RA4 optionally form, together with the nitrogen atom bonded thereto, a hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by 1 or 2 oxo groups,
(g) a carboxyl group,
(h) a C1-6 alkyl-sulfonyl group, and
(i) a C1-6 alkyl-carbonyl group;
and group B is selected from
(a) a hydroxyl group,
(b) a C1-6 alkoxy group,
(c) a C1-6 alkoxy-C1-6 alkyl group
(d) a C3-8 cycloalkyl group, and
(e) an oxo group.
2. The compound according to claim 1, wherein R1 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
(i) a C3-8 cycloalkyl group, and
(ii) a C1-6 alkoxy group,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
3. The compound according to claim 2, wherein R1 is a C1-6 alkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
4. The compound according to claim 2, wherein R1 is a C1-6 alkyl group substituted by a C3-8 cycloalkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
5. The compound according to claim 1, wherein R1 is a C3-8 cycloalkyl group, or a pharmaceutically acceptable salt thereof, or a solvate thereof,
6. The compound according to claim 1, wherein one of R2, R3, R4 and R5 is —CO—NRaRb
wherein Ra and Rb are the same or different and each is
(i) a hydrogen atom,
(ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B, or
(iii) a C3-8 cycloalkyl group, or
Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
7. The compound according to claim 1, wherein one of R2, R3, R4 and R5 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
8. The compound according to claim 1, wherein R6 is a halogen atom, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
9. (canceled)
10. (canceled)
11. The compound according to claim 1, wherein m is 1 or 2, or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 1, wherein n is 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
13. The compound according to claim 1, which is represented by the following formula [I-1], or a pharmaceutically acceptable salt thereof, or a solvate thereof:
Figure US20180319798A1-20181108-C00544
wherein
R11 is
(1) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from
(i) a C3-8 cycloalkyl group, and
(ii) a C1-6 alkoxy group, or
(2) a C3-8 cycloalkyl group,
R21, R31, R41 and R51 are the same or different and each is
(1) a hydrogen atom,
(2) —CO—NRaRb wherein Ra and Rb are the same or different and each is
(i) a hydrogen atom,
(ii) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group B, or
(iii) a C3-8 cycloalkyl group, or
Ra and Rb optionally form, together with the nitrogen atom bonded thereto, a saturated monocyclic hetero ring optionally containing, besides carbon atom and one nitrogen atom, 1 to 5 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and optionally substituted by the same or different 1 to 5 substituents selected from group B, or
(3) a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A,
wherein R21, R31, R41 and R51 are not hydrogen atoms at the same time,
R61 is a halogen atom, and
R62 is a hydrogen atom or a halogen atom.
14. The compound according to claim 13, wherein R21 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, and
R31, R41 and R51 are each a hydrogen atom,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
15. The compound according to claim 13, wherein R21 is a C1-6 alkyl group, and
R31, R41 and R51 are each a hydrogen atom,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
16. The compound according to claim 13, wherein R41 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A, and
R21, R31 and R51 are each a hydrogen atom,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
17. The compound according to claim 13, wherein R21 is a C1-6 alkyl group optionally substituted by the same or different 1 to 5 substituents selected from group A,
R41 is a C1-6 alkyl group, and
R31 and R51 are each a hydrogen atom,
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
18. (canceled)
19. (canceled)
20. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00545
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
21. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00546
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
22. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00547
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
23. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00548
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
24. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00549
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
25. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00550
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
26. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00551
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
27. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00552
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
28. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00553
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
29. The compound according to claim 1, which is represented by the formula:
Figure US20180319798A1-20181108-C00554
or a pharmaceutically acceptable salt thereof, or a solvate thereof.
30. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
31. An anti-HIV agent comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.
32. An HIV integrase inhibitor comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient.
33. An anti-HIV agent comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, in combination with one or more other kinds of anti-HIV active substances.
34. (canceled)
35. (canceled)
36. A method for the prophylaxis or treatment of an HIV infectious disease in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
37. The method according to claim 36, which further comprises administering an effective amount of one or more other kinds of anti-HIV active substances to the mammal.
38. A method for inhibiting HIV integrase in a mammal, which comprises administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, to said mammal.
39. An anti-HIV composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
40. A pharmaceutical composition for inhibiting HIV integrase, comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier.
41. A commercial package comprising the pharmaceutical composition according to claim 30 and a written matter associated therewith, which states that the pharmaceutical composition can or should be used for treating HIV,
42. A kit comprising the pharmaceutical composition according to claim 30 and a written matter associated therewith, which states that the pharmaceutical composition can or should be used for treating HIV.
43. A pharmaceutical composition according to claim 30, which further comprises one or more other anti-HIV active substances.
US16/045,594 2010-02-26 2018-07-25 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor Abandoned US20180319798A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/045,594 US20180319798A1 (en) 2010-02-26 2018-07-25 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010043567 2010-02-26
JP2010-043567 2010-02-26
US33972910P 2010-03-09 2010-03-09
US13/034,866 US10065950B2 (en) 2010-02-26 2011-02-25 Substituted thiazoles as HIV integrase inhibitors
US16/045,594 US20180319798A1 (en) 2010-02-26 2018-07-25 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/034,866 Division US10065950B2 (en) 2010-02-26 2011-02-25 Substituted thiazoles as HIV integrase inhibitors

Publications (1)

Publication Number Publication Date
US20180319798A1 true US20180319798A1 (en) 2018-11-08

Family

ID=44506987

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/034,866 Expired - Fee Related US10065950B2 (en) 2010-02-26 2011-02-25 Substituted thiazoles as HIV integrase inhibitors
US16/045,594 Abandoned US20180319798A1 (en) 2010-02-26 2018-07-25 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/034,866 Expired - Fee Related US10065950B2 (en) 2010-02-26 2011-02-25 Substituted thiazoles as HIV integrase inhibitors

Country Status (19)

Country Link
US (2) US10065950B2 (en)
EP (1) EP2540720B1 (en)
JP (1) JP5765965B2 (en)
KR (1) KR20120130185A (en)
CN (1) CN102858771A (en)
AR (1) AR080314A1 (en)
AU (1) AU2011221037A1 (en)
BR (1) BR112012021595A2 (en)
CA (1) CA2789457A1 (en)
CL (1) CL2012002355A1 (en)
CO (1) CO6571861A2 (en)
MX (1) MX2012009869A (en)
NZ (1) NZ601847A (en)
PE (1) PE20130010A1 (en)
PH (1) PH12012501689A1 (en)
RU (1) RU2012140961A (en)
SG (1) SG183484A1 (en)
TW (1) TW201139437A (en)
WO (1) WO2011105590A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10065950B2 (en) * 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
KR20140090197A (en) * 2011-10-12 2014-07-16 시오노기세야쿠 가부시키가이샤 Polycyclic pyridone derivative having integrase-inhibiting activity
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (en) * 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2997033B1 (en) 2013-05-17 2017-11-15 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015006731A1 (en) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (en) 2013-07-12 2018-07-21
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN103736081A (en) * 2013-12-18 2014-04-23 首都医科大学附属北京佑安医院 Application of ONTAK in preparing medicine for eliminating latent HIV (Human Immunodeficiency Virus)
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
NO2717902T3 (en) 2014-06-20 2018-06-23
JPWO2016027879A1 (en) 2014-08-22 2017-06-01 塩野義製薬株式会社 Polycyclic pyridone derivatives having integrase inhibitory activity
WO2016094198A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (en) 2014-12-23 2020-06-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2972366C (en) * 2014-12-24 2020-04-21 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
BR112017020837A2 (en) 2015-04-02 2018-07-03 Gilead Sciences, Inc. polycyclic carbamoylpyridone compounds and their pharmaceutical use
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
EP3377065B1 (en) * 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
JOP20190130A1 (en) 2016-12-02 2019-06-02 Merck Sharp & Dohme Tetracyclic heterocyclic compounds useful as integrated enzyme inhibitors for human immunodeficiency virus (HIV)
WO2019070059A1 (en) 2017-10-06 2019-04-11 塩野義製薬株式会社 Method for stereoselectively producing substituted polycyclic pyridone derivative
US11453669B2 (en) 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
WO2019230858A1 (en) 2018-05-31 2019-12-05 塩野義製薬株式会社 Polycyclic carbamoylpyridone derivative
HUE059677T2 (en) 2019-03-22 2022-12-28 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical application
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN112574155A (en) * 2020-11-25 2021-03-30 南京杰运医药科技有限公司 Synthetic method of 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid
PE20231297A1 (en) 2021-01-19 2023-08-22 Gilead Sciences Inc SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES OF THESE
TW202446773A (en) 2022-04-06 2024-12-01 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN116969940B (en) * 2023-08-03 2025-08-12 浙江大学 3-Hydroxypyridone-5-amide compounds and their medical uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789457A1 (en) * 2010-02-26 2011-09-01 Susumu Miyazaki 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc 1,6-DIONED DIHYDROXYPYRIDOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF HIV INTEGRASE
ATE404563T1 (en) 2002-09-11 2008-08-15 Merck & Co Inc 8-HYDROXY-1-OXOTETRAHYDROPYRROLOPYRAZINE COMPOUNDS ACTIVE AS INHIBITORS OF HIV INTEGRASE
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7435735B2 (en) 2003-10-20 2008-10-14 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
WO2005092099A1 (en) 2004-03-09 2005-10-06 Merck & Co., Inc. Hiv integrase inhibitors
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
WO2005110414A2 (en) 2004-05-07 2005-11-24 Merck & Co., Inc. Hiv integrase inhibitors
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
LT3372281T (en) 2005-04-28 2021-12-10 Viiv Healthcare Company POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE WITH HIV INTEGRATION INHIBITOR ACTIVITY
CN101346376A (en) * 2005-10-27 2009-01-14 盐野义制药株式会社 Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
CA2625673A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. Hiv integrase inhibitors
BRPI0617842A2 (en) * 2005-10-27 2011-08-09 Shionogi & Co compound or a pharmaceutically acceptable salt or solvate thereof, and, pharmaceutical composition
WO2010000031A1 (en) 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones and uses thereof
MX2011000149A (en) 2008-07-02 2011-02-24 Avexa Ltd Compounds having antiviral properties.
PL2247601T3 (en) 2008-07-02 2013-09-30 Avexa Ltd Thiazopyrimidinones and uses thereof
AU2011219764A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
JP5575274B2 (en) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4- [Cycloalkyloxy (hetero) arylamino] thieno "2,3-D] pyrimidines having MNKL / MNK2 inhibitory activity for pharmaceutical compositions
JP5766690B2 (en) 2010-04-12 2015-08-19 塩野義製薬株式会社 Pyridone derivatives having integrase inhibitory activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789457A1 (en) * 2010-02-26 2011-09-01 Susumu Miyazaki 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. *
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18. *

Also Published As

Publication number Publication date
WO2011105590A1 (en) 2011-09-01
CN102858771A (en) 2013-01-02
EP2540720A4 (en) 2013-07-31
NZ601847A (en) 2014-03-28
AU2011221037A1 (en) 2012-09-06
CA2789457A1 (en) 2011-09-01
EP2540720B1 (en) 2015-04-15
CL2012002355A1 (en) 2013-01-25
US10065950B2 (en) 2018-09-04
JP5765965B2 (en) 2015-08-19
MX2012009869A (en) 2012-09-12
KR20120130185A (en) 2012-11-29
US20120108564A1 (en) 2012-05-03
SG183484A1 (en) 2012-09-27
BR112012021595A2 (en) 2017-02-21
RU2012140961A (en) 2014-04-10
TW201139437A (en) 2011-11-16
AR080314A1 (en) 2012-03-28
JP2011195585A (en) 2011-10-06
EP2540720A1 (en) 2013-01-02
CO6571861A2 (en) 2012-11-30
PE20130010A1 (en) 2013-02-05
PH12012501689A1 (en) 2012-11-05

Similar Documents

Publication Publication Date Title
US10065950B2 (en) Substituted thiazoles as HIV integrase inhibitors
US10087178B2 (en) Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
US11161847B2 (en) KRAS mutant protein inhibitors
US11986531B2 (en) Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
JP2023521698A (en) Compounds and methods for targeted degradation of KRAS
US20080161311A1 (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US20100105661A1 (en) Condensed pyridine compound
KR20240028539A (en) Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US7872004B2 (en) 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US20120034250A1 (en) Condensed pyrrolopyridine derivative
US20230103494A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2021214136A1 (en) Rsv inhibiting 3-substituted quinoline and cinnoline derivatives
KR20060114374A (en) Therapeutic Combinations
HK1179615A (en) 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
RU2830173C2 (en) Polycyclic compounds and methods for targeted degradation of polypeptides of fast accelerated fibrosarcoma
KR20060127939A (en) Composition comprising HIB protease inhibitor and cytochrome P450 enzyme activity inhibitor
HK1237783B (en) 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION